Using B-type natriuretic peptide and whole body contrast enhanced magnetic resonance imaging to detect asymptomatic cardiovascular disease and improve prediction of risk of cardiovascular disease:the TASCFORCE Study by Lambert, Matthew Alexander
Using B-type natriuretic peptide and whole body 
contrast enhanced magnetic resonance 
imaging to detect asymptomatic cardiovascular 
disease and improve prediction of risk of 
cardiovascular disease: the TASCFORCE 
Study 
 
 
Matthew Alexander Lambert 
 
 
 
 
Degree of Doctor of Medicine 
University of Dundee 
March 2016 
 
  
  
 
2 
TABLE OF CONTENTS 
List of figures 6 
List of tables 9 
List of appendices 14 
Abbreviations 15 
Acknowledgements 18 
Declaration 21 
Summary 22 
1. Literature review 
1.1. Cardiovascular disease 
1.1.1. The burden of cardiovascular disease 
1.1.2. Pathophysiology of atherosclerosis 
1.1.3. Reducing risk of cardiovascular disease 
Statins 
Antihypertensives 
Antiplatelets 
 
25 
25 
26 
29 
29 
32 
32 
1.2. Assessing cardiovascular risk 
1.2.1. Background 
1.2.2. Existing risk scores and charts 
1.2.3. B type natriuretic peptide (BNP) 
BNP and vascular abnormalities and function 
BNP and subclinical arterial disease 
BNP and cardiac function and structure 
BNP and cardiovascular events and mortality 
BNP and traditional cardiovascular risk factors 
Incremental benefit of adding BNP 
What is the role for BNP? 
1.2.4. Other candidate tests 
1.2.5. Imaging to predict cardiovascular disease 
Magnetic resonance cardiac imaging 
Magnetic Resonance Angiography (MRA) 
Other imaging techniques 
1.3. Summary – is the future screening rather than risk estimation? 
33 
33 
35 
41 
41 
43 
44 
44 
46 
48 
48 
50 
52 
52 
56 
58 
59 
  
 
3 
2. Methods: The TASCFORCE study-screening for asymptomatic 
cardiovascular disease 
2.1. Study design 
2.2. Recruitment 
2.3. Assessments 
2.3.1. The Assessment algorithm 
2.3.2. Screening visit 
2.3.3. Cardiovascular risk estimation 
2.3.4. BNP measurement and allocation to MRI group 
2.3.5. MRI acquisition technique 
2.3.6. MRI left ventricular quantification 
2.3.7. MRI angiogram scoring technique 
2.3.8. MRI angiogram interpretation validation 
2.3.9. MRI incidental findings 
2.4. Follow up 
2.4.1. Health Informatics Centre data linkage 
2.4.2. Outcome measures 
2.5. Data entry and management 
2.6. Statistical analysis 
2.6.1. Missing data 
2.6.2. Sample size 
2.6.3. Baseline data analysis 
2.6.4. Screen fail population 
Baseline data 
Prescribing data 
2.6.5. Assessment of outcomes 
 
 
 
62 
63 
65 
65 
66 
70 
71 
72 
77 
79 
81 
81 
82 
82 
82 
90 
92 
92 
93 
94 
97 
97 
97 
98 
3. Results part 1 – study participants 
3.1. Recruitment and eligibility 
3.2. Cardiovascular risk incidental findings 
3.3. Baseline characteristics of eligible participants 
3.3.1. Demographics and baseline cardiovascular risk factors 
3.3.2. BNP results 
3.3.3. Comparison of estimated cardiovascular risk using 
ASSIGN and ATPIII algorithms 
Effect on reclassification 
Eligible population 
Potential participants who failed screening due to 
 
100 
102 
104 
104 
110 
113 
 
114 
117 
120 
  
 
4 
high cardiovascular risk 
3.3.4. Correlation of BNP with baseline cardiovascular risk 
factors 
 
 
122 
4. Results part 2 – MRI results 
4.1. Participant acceptability of MRI scan 
4.2. Incidental findings on MRI scan 
4.3. MRI derived left ventricular results 
4.3.1. Left ventricular measures 
4.3.2. Correlation of left ventricular measures with BNP 
4.3.3. Correlation of left ventricular measures with 
cardiovascular risk factors 
4.3.4. Multivariable analysis of left ventricular measures and 
risk factors and BNP 
4.4. Whole body MRI angiogram results 
4.4.1. Angiogram results 
4.4.2. Correlation of angiogram results with risk factors and 
BNP 
4.4.3. Correlation of angiogram results with left ventricular 
measures 
4.5. MRI angiogram analysis reproducibility 
4.5.1. Inter-observer reproducibility 
4.5.2. Intra-observer reproducibility 
 
 
128 
130 
132 
132 
143 
149 
 
155 
 
162 
162 
170 
 
176 
 
181 
181 
183 
5. Results part 3 – 2-year follow up 
5.1. CVD endpoints in eligible population 
5.2. CVD endpoints in screen fail population 
5.3. Prescribing changes following screening 
Medication prescribed before screening visit 
Medication prescribed after screening visit 
Effect of medication prescription on CV event rate 
 
 
184 
189 
191 
191 
195 
202 
6. Discussion 
6.1. Summary of main findings 
6.2. Trial methodology 
6.2.1. Recruitment 
6.2.2. Ensuring representation of cross section Scottish 
 
203 
207 
207 
209 
  
 
5 
population 
6.2.3. Screening method 
6.2.4. Imaging method 
6.2.5. Strengths and limitations 
6.3. Usefulness of screening for incidental findings 
6.3.1. Increased cardiovascular risk 
6.3.2. Non-cardiovascular findings 
6.4. Baseline results 
6.4.1. Risk factors and BNP 
6.4.2. Cardiac imaging baseline results 
6.4.3. MRA baseline results 
6.5. Primary outcome – ability of BNP and left ventricular mass to 
predict cardiovascular events and death 
6.6. Ability of whole body MRI angiogram to predict cardiovascular 
events 
6.7. Conclusions 
 
 
212 
218 
228 
236 
236 
238 
239 
239 
244 
253 
256 
 
258 
 
259 
7. Further work 
7.1. Further follow up to 20 years 
7.2. Health economics of the technique as a screening programme 
7.3. A “Scottish Framingham” 
 
 
262 
263 
263 
8. Publications and Presentations 
8.1. Publications 
8.2. Oral presentations 
 
 
264 
264 
9. References 
 
265 
10. Appendices 299 
  
  
 
6 
List of figures 
Figure 1.1: Deaths by cause in Europe (men top, women bottom) taken from European 
Cardiovascular disease statistics 2012 
Figure 1.2: The continuum of atherosclerosis 
Figure 1.3: Whole body magnetic resonance angiogram 
Figure 2.1: Flowchart giving overview of study design 
Figure 2.2: Participant undergoing whole body CE-MRI scan 
Figure 2.3: MRI stations/fields of view (FOV) 
Figure 2.4: Defining endocardial border and epicardial border at end of diastole and 
end of systole 
Figure 3.1: CONSORT diagram showing participant flow through study 
Figure 3.2: Distribution of age in the eligible population 
Figure 3.3: Distribution of CHD risk scores calculated using ATPIII algorithm in the BNP 
and MRI/BNP populations 
Figure 3.4: Spread of Scottish Index of Multiple Deprivation (SIMD) scores in eligible 
population 
Figure 3.5: Distribution of TASCFORCE participants by SIMD decile compared with 
Tayside working population and Tayside total population 
Figure 3.6: Distribution of BNP results for men and women 
Figure 3.7: Distributions of ASSIGN risk scores and risk score estimated using ATPIII 
algorithm for all participants eligible to enter the TASCFORCE study 
Figure 3.8: Correlation between ASSIGN and ATPIII risk scores 
Figure 3.9: Distribution of difference between ATPIII derived CHD risk score and 
ASSIGN derived CV risk score for participants eligible to enter the TASCFORCE study 
based on their ATPIII score 
Figure 3.10: Distribution of ASSIGN scores in participants ineligible to enter 
TASCFORCE study due to high predicted cardiovascular risk using ATPIII guidelines 
  
 
7 
Figure 3.11: Distribution of difference between ATPIII derived CHD risk score and 
ASSIGN derived CV risk score in participants ineligible to enter TASCFORCE study 
due to high predicted CHD risk using ATPIII guidelines 
Figure 3.12: Age and gender specific BNP median, 75th percentile and 90th percentiles 
Figure 4.1: A left lung mass (probably malignant) seen on a post contrast MRI scan in 
a female TASCFORCE participant 
Figure 4.2: Scatterplots of left ventricular mass and height, weight, body mass index, 
body surface area for both men and women 
Figure 4.3: Scatterplots of left ventricular mass and height, weight, body mass index, 
body surface area for men 
Figure 4.4: Scatterplots of left ventricular mass and height, weight, body mass index, 
body surface area for women 
Figure 4.5: Boxplots of distribution of left ventricular mass and left ventricular mass 
index (LVMI) for men and women: LVM, LVMI (height), LVMI (height1.7), LVMI 
(height2.7), LVMI (BSA using Dubois calculation), LVMI (BSA using Mosteller 
calculation) and LVM/end diastolic volume ratio 
Figure 4.6: Example of bilateral carotid stenoses detected by WB CE-MRA in a 47 year 
old woman 
Figure 4.7: Distribution of abnormalities at arterial segment level 
Figure 4.8: Number of segments affected per individual participant (if coeliac artery 
included) 
Figure 4.9: Number of segments affected per individual participant (if coeliac artery 
excluded) 
Figure 4.10: Distribution of standardised atheroma scores with coeliac excluded and 
included 
Figure 4.11: Distribution of regional atheroma scores 
Figure 5.1: Kaplan-Meier plot of survival to first cardiovascular event/procedure 
  
 
8 
Figure 5.2: Kaplan-Meier plot of survival from CV events or all-cause death for those 
who failed screening due to high predicted cardiovascular risk, those who failed due to 
hypertension and the eligible study population 
Figure 5.3: Time to prescription analysis for those who failed screening due to high 
predicted CHD risk or hypertension and those eligible for the study (including aspirin) 
Figure 5.4: Time to prescription analysis for those who failed screening due to high 
predicted CHD risk or hypertension and those eligible for the study (excluding aspirin) 
  
  
 
9 
List of Tables 
Table 1.1: Risk factors for developing cardiovascular disease 
Table 1.2: Summary of cardiovascular risk charts and scores 
Table 2.1: Imaging parameters for all sequences run within the combined CMR and 
MRA protocol 
Table 2.2: Coding and scoring for WB CE-MRA arterial segments 
Table 2.3: ICD-10 end point codes 
Table 2.4: OPCS-4 codes 
Table 2.5: Cardiovascular medication of interest at follow up 
Table 2.6: Summary of missing data of visit 1 variables 
Table 3.1: Characteristics of subjects excluded due to presence of cardiovascular risk 
Table 3.2: Baseline characteristics of participants eligible for the TASCFORCE study 
Table 3.3: B-type natriuretic peptide (BNP) results for eligible participants 
Table 3.4: Percentiles of BNP results for each gender 
Table 3.5: Differences between ATPIII and ASSIGN scores 
Table 3.6: Reclassification of risk categories using the ASSIGN score instead of the 
ATPIII derived score 
Table 3.7: Characteristics of participants with ASSIGN score ≥20 
Table 3.8: Baseline characteristics of male participants according to BNP level 
Table 3.9: Baseline characteristics of female participants according to BNP level 
Table 3.10: Association of baseline cardiovascular risk factors with log10 BNP levels: 
linear stepwise multivariable regression analysis 
Table 3.11: Age and sex specific BNP median, 75th and 90th percentiles 
Table 4.1: Characteristics of those who had an MRI scan and those who declined or 
were unable to complete a scan 
Table 4.2: Summary of MRI incidental findings requiring clinical review and/or further 
investigation 
Table 4.3: Activity arising as a result of MRI incidental findings 
  
 
10 
Table 4.4: Descriptive characteristics of participants who underwent cardiac MRI 
imaging 
Table 4.5: Left ventricular characteristics by gender 
Table 4.6: Left ventricular mass index (LVMI) by height, height1.7, height2.7, and body 
surface area (BSA) using DuBois and Mosteller formulae 
Table 4.7: Correlations between left ventricular mass index and measures of body size 
Table 4.8: Means and standard deviations of left ventricular measurements indexed for 
height, height1.7, height2.7, BSA (using Dubois formula) and BSA (using Mosteller 
formula) 
Table 4.9: Correlations between BNP and MRI derived measures of left ventricular 
function and size 
Table 4.10: Comparison of left ventricular measures in different quartiles of BNP 
Table 4.11: Comparison of LV measures above and below 90th percentiles of BNP 
Table 4.12: Comparison of LV measures above and below 95th percentiles of BNP 
Table 4.13: Median BNP values for those with and without LVH 
Table 4.14: Median BNP values for those with and without concentric LVH 
Table 4.15: Univariate analysis of correlations between left ventricular mass and 
baseline variables in men 
Table 4.16: Univariate analysis of correlations between left ventricular mass and 
baseline variables in women 
Table 4.17: Univariate analysis of correlations between left ventricular measures and 
baseline variables in men 
Table 4.18: Univariate analysis of correlations between left ventricular measures and 
baseline variables in women  
Table 4.19: Multivariable analysis of traditional cardiovascular risk factors, socio-
demographic factors and BNP in relation to left ventricular mass and left ventricular 
mass index in men 
  
 
11 
Table 4.20: Multivariable analysis of traditional cardiovascular risk factors, socio-
demographic factors and BNP in relation to left ventricular mass and left ventricular 
mass index in women 
Table 4.21: Multivariable analysis of traditional cardiovascular risk factors, socio-
demographic factors and BNP in relation to other left ventricular measures in men 
Table 4.22: Multivariable analysis of traditional cardiovascular risk factors, socio-
demographic factors and BNP in relation to other left ventricular measures in women 
Table 4.23: Individual arterial segment scores obtained from WB CE-MRA images 
Table 4.24: Regional standardised atheroma scores 
Table 4.25: Standardised atheroma scores for men and women 
Table 4.26: Univariate analysis of correlations between baseline factors and 
standardised whole body atheroma score 
Table 4.27: Multivariable analysis of traditional cardiovascular risk factors, socio-
demographic factors and BNP in relation to standardised atheroma score 
Table 4.28: Baseline variables and BNP comparison between those with standardised 
atheroma score greater and less than 80th centile 
Table 4.29: Univariate correlations between percentage of arterial segments with any 
degree of stenosis or aneurysm and baseline risk factors 
Table 4.30: Comparison of baseline characteristics between those with no atheroma 
and those with any atheroma 
Table 4.31: BNP levels in men and women with and without arterial abnormality on 
MRA 
Table 4.32: Univariate correlations between standardised atheroma score and left 
ventricular measures 
Table 4.33: Univariate correlations between percentage of arterial segments affected 
and left ventricular measures 
Table 4.34: Comparison of left ventricular measures in those with standardised 
atheroma scores above and below 80th centile 
  
 
12 
Table 4.35: Comparison of left ventricular measures between those with and without 
any abnormality on whole body angiography 
Table 4.36: Number of abnormal arterial assessments within the cohort (from a possible 
n=48 for each location) identified by a consensus of four observers with cardiovascular 
MRI experience  
Table 5.1: Cardiovascular events in the eligible population at 2 year follow up (following 
end of recruitment) 
Table 5.2: Combined cardiovascular event and all-cause mortality rates in those with 
upper and lower gender specific quartiles of LVM, LVMI and LVM/LVEDV 
Table 5.3: Combined cardiovascular event and all-cause mortality rates in those with 
LVM, LVMI and LVM/LVEDV above and below gender specific median 
Table 5.4: CV events in the population who failed screening due to high cardiovascular 
risk or hypertension at 2 year follow up 
Table 5.5: Time from last prescription of cardiovascular medication to screening visit 
for participants who failed screening who had previously been prescribed medication 
Table 5.6: Drug classes prescribed prior to screening visit 
Table 5.7: Time from last prescription of cardiovascular medication to screening visit 
for participants who were eligible for the study but who had previously been prescribed 
medication 
Table 5.8: Drug classes prescribed to the eligible population prior to screening visit 
Table 5.9: Time to first prescription of cardiovascular medication from time of screening 
visit for those who failed screening due to high cardiovascular risk, hypertension or 
dyslipidaemia and were prescribed medication after screening visit 
Table 5.10: Time to first prescription of cardiovascular medication from time of 
recruitment for those who were eligible to enter the study and were prescribed 
medication after recruitment 
Table 5.11: Drug classes prescribed after screening visit to those who failed screening 
Table 5.12: Drug classes prescribed after screening visit to those who were eligible for 
the study 
  
 
13 
Table 6.1: Whole body atheroma scores reported in the literature 
Table 6.2: Criteria for screening programme and how TASCFORCE fits these 
  
  
 
14 
List of Appendices 
1. TASCFORCE recruitment leaflet 
2. Participant information sheet (Cardiovascular risk assessment by BNP) 
3. Participant consent form (BNP study) 
4. Case report form (CRF) 
5. Participant information leaflet (MRI scan) 
6. Participant consent form (MRI scan) 
  
  
 
15 
Abbreviations 
AF = atrial fibrillation 
ANP = atrial (A-type) natriuretic peptide 
ASSIGN = Assessing cardiovascular risk using SIGN guidelines to assign preventive 
treatment 
ATPIII = adult treatment panel III 
AUC = area under the curve 
BHS = British Hypertension Society 
BMI = Body Mass Index 
BNF = British National Formulary 
BNP = B-type natriuretic peptide 
BP = Blood Pressure 
BSA = Body Surface Area 
CAD = Coronary Artery Disease 
CHD = Coronary Heart Disease 
CHI = Community Health Index 
CI = Confidence Interval 
C-IMT = Carotid Intima Media Thickness 
CMR = Cardiac Magnetic Resonance Imaging 
CRF = Case Report Form 
CRP = C-reactive protein 
CT = Computed Tomography 
CV = Cardiovascular 
CVD = Cardiovascular Disease 
DBP = Diastolic Blood Pressure 
DE-MRI = Delayed Enhancement Magnetic Resonance Imaging 
ECG = Electrocardiogram 
FLASH = Fast low-angle shot 
FOV = Field of View 
GP = General Practice 
  
 
16 
GRAPPA = Generalised Autocalibrating Partially Parallel Acquisition 
GRO = General Registrar Office 
HDL = High Density Lipoprotein 
HIC = Health Informatics Centre 
hs = high sensitivity 
ICD-10 = International Classification of Diseases version 10 
IQR = Inter-quartile Range 
ISD = Information and Statistics Division 
LDL = Low Density Lipoprotein 
LGE = Late Gadolinium Enhancement 
LV = Left Ventricular 
LVEF = Left Ventricular Ejection Fraction 
LVEDV = Left Ventricular End Diastolic Volume 
LVESF = Left Ventricular End Systolic Volume 
LVM = Left Ventricular Mass 
LVMI = Indexed Left Ventricular Mass 
LVH = Left Ventricular Hypertrophy 
MI = Myocardial Infarction 
MIP = Maximum Intensity Projections 
ML = Matthew Lambert 
MMSE = Mini Mental State Examination 
MPR = Multiplanar Reconstructions 
MRI = Magnetic Resonance Imaging 
MRA = Magnetic Resonance Angiography 
NICE = National Institute of Health and Care Excellence 
NT-proBNP = N-terminal proBNP 
OPCS-4 = Office of Population, Censuses and Surveys Classification of Surgical 
Operations and Procedures (4th revision) 
OR = Odds Ratio 
PAD = Peripheral Arterial Disease 
  
 
17 
PSIR = Phase-Sensitive Inversion Recovery 
QOF = Quality and Outcomes Framework 
RANKL/OPG = Receptor activator of nuclear factor kappa-B ligand/osteoprotegerin 
ROC = Receiver Operating Characteristic 
ROI = Region of Interest 
RR = Risk Ratio 
SAS = Standardised Atheroma Score 
SBP = Systolic Blood Pressure 
SD = Standard Deviation 
SIGN = Scottish Intercollegiate Guidelines Network 
SIMD = Scottish Index of Multiple Deprivation 
SSFP = Steady State Free Precision 
TGE = Turbo Gradient Echo 
TrueFISP = True fast imaging with steady state precision 
WBAS = Whole Body Atheroma Score 
WB CE-MRA = Whole Body Contrast Enhanced Magnetic Resonance Angiography 
WB CE-MRI = Whole Body Contrast Enhanced Magnetic Resonance Imaging 
  
  
 
18 
Acknowledgments 
I would like to thank all those who have helped me with my thesis. In particular I would 
like to thank: 
 
Professor Jill Belch for introducing me to research, designing the study, giving me the 
opportunity to become involved in such a large study and providing feedback and 
guidance as my supervisor for this MD. Her expert advice and encouragement have 
been invaluable. 
 
Professor Graeme Houston for co-supervising this MD, providing timely feedback, 
encouragement and for his expert advice particularly on the imaging aspects of this 
thesis. Also for his work with analysing the whole body MRI images. 
 
Dr Roberta Littleford for introducing and explaining the background to the study and the 
activity in the study before I became involved. Also for her ongoing support during the 
write up and analysis of the thesis as well as her part in recruiting the study 
participants. 
 
Daniel Levin for his support with the statistical analysis of the study data. 
 
Professor Allan Struthers for his support and advice in the writing up of papers related 
to the study and for his expert knowledge about B-type natriuretic peptide and left 
ventricular mass. 
 
Professor Frank Sullivan as co-investigator for his work laying the foundation and 
recruitment for the study in Primary Care. 
 
  
 
19 
Dr Stephen Gandy and the team of medical physicists for analysing the cardiac images 
and providing me with the data for inclusion for analysis. Also for answering my 
incessant questions about the MRI methodology. 
 
Pat Martin and the staff in the clinical research centre, Dundee for scanning the study 
participants. 
 
Janice Rowland and Anita Hutcheon for their work recruiting and screening the study 
participants. 
 
Elsie Greenhill for her administrative support. 
 
Professor Marion McMurdo, Professor Brian Lipworth and Dr Jacob George, my thesis 
monitoring committee, for giving me timely independent advice and giving me 
important encouragement to push forward with my thesis. 
 
Dr Stephen McSwiggan for his enthusiasm, support and advice particularly around the 
areas of ethics and the research approvals process. 
 
Dr Miles Witham for his enthusiasm for research and his informal advice and support 
throughout my MD. 
 
Dr John Dick and Dr Colin Baines for advising me to become involved in research and 
persuading me to apply for the clinical lecturer post. 
 
All the study participants who gave up their valuable time to take part in the study. 
 
  
 
20 
And my family, particularly my fantastic and beloved wife, Kathryn, for supporting me 
throughout my MD and for putting up with me when I was working hard on my thesis 
including some long days and late nights.   
  
 
21 
Declaration 
 
I hereby declare that I am the author of this thesis, that all references cited have been 
consulted by me, and that I have carried out the work described in this thesis. The work 
described in this thesis has not been previously accepted for a higher degree and I 
have defined the nature of my contribution to the work within the project described in 
the thesis. 
 
I contributed to the study design, was key in the running of the study, and designed the 
amendments to the study to improve its quality. I designed the statistical package, in 
collaboration with the study statistician. I analysed the data, again in collaboration with 
the study statistician, and I drew the study conclusions. I was responsible for the data 
linkage concept through the Health Informatics Centre and for the comparison of 
different risk scores. I checked the database for accuracy and corrected data entry 
errors in the database using the CRFs where required. I was lead author of the 
baseline paper (The Tayside Screening For Cardiac Events (TASCFORCE) Study: A 
Prospective Cardiovascular Risk Screening Study. Study aims, design and baseline 
characteristics) and have been co-author for a number of further papers which have 
been submitted for publication. 
 
The work contained within this was carried out during my appointment as a Clinical 
lecturer in the Division of Cardiovascular and Diabetes Medicine, Medical Research 
Institute, University of Dundee, between September 2010 and August 2015. 
 
Signed:…………………………………………………………..   
 
Dated:…………………………  
  
 
22 
Summary 
Cardiovascular disease remains a leading a cause of mortality and morbidity. Primary 
prevention is known to reduce the incidence of cardiovascular disease. The use of 
medication is currently targeted at those at increased predicted risk of cardiovascular 
disease using risk prediction tools developed from large epidemiological studies. 
However these have poor external validity particularly for those at low or intermediate 
risk: a significant number of cardiovascular events still occurs in these groups. We 
hypothesised that screening for asymptomatic pre-clinical cardiovascular disease using 
B-type natriuretic peptide (BNP) and whole body contrast enhanced magnetic 
resonance imaging (MRI) could identify those at low/intermediate risk or disease who 
will develop clinical disease and thus facilitate improved targeting of primary prevention 
at those most likely to benefit. 
 
The Tayside Screening for Cardiac Events (TASCFORCE) study is a prospective 
normal volunteer cohort study. Men and women aged 40 years or older free from 
cardiovascular disease and with a predicted 10-year coronary heart disease risk less 
than 20% were recruited. All had comprehensive baseline cardiovascular risk 
information and a BNP level measured. If the BNP level was greater than the median 
for their gender participants were invited to attend for a whole body contrast enhanced 
MRI scan comprising cardiac imaging and whole body angiography. The images were 
analysed to measure left ventricular mass (LVM), left ventricular volumes and left 
ventricular function. These were indexed for body size using height, height1.7, height2.7 
and body surface area. Angiogram images were analysed for the presence and degree 
of intraluminal stenosis. All participants are being followed up using anonymised 
electronic data linkage for incident cardiovascular disease and death. 
 
4423 participants (39.3% male) were recruited between November 2007 and February 
2013. Median age was 51.2 years. The median 10-year coronary heart disease (CHD) 
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risk was 2% and 13.6% had a CHD risk of 10-19.9% (intermediate risk). The median 
BNP results for men and women were 7.5 and 15.3 pg/ml respectively. Age, female 
sex and high density lipoprotein were independently associated with BNP level. Heart 
rate, total cholesterol and ex-smoking status were independently inversely associated 
with BNP level. 1528 (74.8% of those invited) underwent an MRI scan. Mean left 
ventricular mass was 129.2g and 87.0g for men and women respectively. LVM and left 
ventricular mass index (LVMI) were significantly higher in men than women. The vast 
majority (94.6%) of arterial segments analysed were normal and 50.6% of individuals 
had no evidence of luminal stenosis. From follow up data obtained 2 years after the 
end of recruitment 18,364 person years at risk were analysed. 17 cardiovascular 
events and no deaths occurred in those not invited for an MRI scan based on their 
BNP result and 16 events and 1 death occurred in those invited for an MRI scan. There 
was no significant difference in event rates between those with above and below 
median BNP levels, between those with higher or lower LVM or LVMI or between those 
with and without the presence of stenosis on angiography. 
 
As expected we have not demonstrated the ability of LVM, LVMI or stenosis burden 
determined using magnetic resonance imaging to predict cardiovascular disease in a 
population at low or intermediate risk of CHD. We have also not demonstrated the 
ability of BNP to identify those at low or intermediate risk of CHD who will develop 
clinical CV disease. However it is the pre-planned longer-term follow up where 
difference might be expected. The low number of events at this early stage in follow up 
mean that it is difficult to draw firm conclusions. As follow up continues and further 
events accumulate we hope to determine if these measures will be shown to predict 
cardiovascular events in future analyses. We have characterised the normal values 
and distribution of a range of left ventricular structural and functional parameters 
derived using a steady state free precision sequence MRI in a population at low or 
intermediate risk of CHD which will provide a useful reference for normal values that 
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are different to other imaging modalities including echocardiography and other 
protocols of MRI scanning.  
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1. Literature review 
 
1.1. Cardiovascular disease 
 
1.1.1. The burden of cardiovascular disease 
Cardiovascular disease (CVD) is a leading cause of mortality and morbidity in 
developed societies. It causes 47% of all deaths in Europe and 40% in the European 
Union (figure 1.1).[1] In Scotland myocardial infarction, stroke and peripheral arterial 
disease combined are responsible for more than 18500 deaths annually.[2] 
 
Figure 1.1: Deaths by cause in Europe (men top, women bottom). Taken from 
European Cardiovascular disease statistics 2012.[1] 
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It is also a major cause of morbidity. Advances in medical therapy mean that many who 
would previously have died from cardiovascular events such as myocardial infarction or 
stroke now survive but live with either the effects of their acute event or live with 
chronic cardiovascular disease such as angina, peripheral arterial disease or heart 
failure. These produce a burden on both health and social care services. CVD is 
estimated to cost the European Union about €196 billion per year with 54% due to 
healthcare costs, 24% due to productivity losses and 22% for informal care for people 
with CVD.[1] As survival improves more people are also surviving long enough to 
develop other cardiovascular diseases such as vascular dementia increasing the 
demands on the health and social care systems further. It is estimated that over 
815,000 people in the UK are currently living with dementia 17% (approx. 139,000) of 
whom have vascular dementia and 10% (approx. 81,000) have mixed dementia.[3] The 
total cost of all dementia to society in the UK (of which vascular dementia is a 
significant proportion) is estimated to be £26.3 billion of which £4.3 billion is for 
healthcare, £10.3 billion is for social care and £11.6 billion is contributed by unpaid 
carers of people with dementia.[3] 
 
Therefore any steps to reduce the incidence of the range of cardiovascular diseases 
has the potential to reduce demand on the health and social care systems. 
 
1.1.2. Pathophysiology of atherosclerosis 
Atherosclerosis is a degenerative inflammatory disease of the arteries in which 
atheroma develops in the arterial wall. If the endothelium sustains damage low density 
lipoproteins enter the intima layer which are then taken up by macrophages. As the 
process continues lipid also accumulates outside the macrophages and the 
macrophages stimulate the production of collagen making the plaque more fibrous. 
This causes narrowing of the arteries, which in turn impedes blood flow to organs and 
tissues supplied by the affected artery. Usually atherosclerosis only becomes apparent 
when it produces symptoms. This occurs either when the blood flow through the 
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narrowed artery is unable to meet the demand of the tissues it supplies causing 
ischaemia, or when the atheromatous plaque ruptures (due to weakening of endothelial 
wall) exposing thrombogenic material beneath to the blood. This initiates platelet 
aggregation and the clotting cascade causing sudden occlusion of the artery or 
embolization of the clot to the distal arterial bed. The first of these processes causes 
clinical conditions such as angina (coronary arteries) or intermittent claudication 
(peripheral arteries) and the second process commonly causes myocardial infarction 
(coronary arteries), cerebral infarction (stroke) or acute limb ischaemia. 
 
Figure 1.2: The continuum of atherosclerosis 
 
Illustration courtesy of JJF Belch. 
 
The lesions take a number of years to develop (see figure 1.2) therefore subclinical 
atheroma will be present and developing insidiously in many people before they reach 
a stage where they produce clinically apparent disease. Atherosclerosis is a complex 
process involving inflammation and cellular proliferation in the arterial wall. Many 
epidemiological studies have demonstrated a number of risk factors that are 
associated with an increased risk of developing atherosclerosis and its clinical 
consequences (see table 1.1). Many of these are related to lifestyle in modern 
industrialised areas and include cigarette smoking, a high serum total cholesterol and 
low density lipoprotein, hypertension, and diabetes mellitus. Some risk factors are 
modifiable whereas others are not. The presence or absence of these risk factors is 
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used to estimate an individual’s risk of developing cardiovascular disease (see section 
1.2 below). 
 
Table 1.1: Risk factors for developing cardiovascular disease 
Risk Factor Association with cardiovascular risk 
Non-modifiable risk factors 
Age Risk increases with age 
Gender Higher in males 
Rheumatoid 
arthritis 
Increased risk in those with rheumatoid arthritis. 
Family history of 
CVD 
Increased risk if there is a family history of CVD at a young age 
(less than 60) in one 1st degree or 2 or more 2nd degree relatives. 
Ethnicity Increased risk in some ethnic groups such as those of South Asian 
or African origin. 
Apolipoprotein E 
(APOE) gene 
Carrying at least one copy of e4 allele associated with increased 
risk. e2 allele associated with hyperlipoproteinaemia type III. 
Modifiable risk factors 
Blood pressure Hypertension associated with increased risk 
Total cholesterol Increased level associated with increased risk 
Low density 
lipoprotein 
Increased level associated with increased risk 
High density 
lipoprotein 
Low level associated with increased risk 
Triglycerides Increased level associated with increased risk 
Tobacco smoking Use is associated with increased risk. Increased smoking level is 
associated with increased risk. This includes passive smoking. 
Social Deprivation Living in an area of deprivation is associated with increased risk. 
Diabetes mellitus Increased risk in those with diabetes. 
Diet “Healthy” diet including more fruit and vegetables and less 
saturated fat and sugar associated with lower risk. 
Exercise Low levels of physical exercise associated with increased risk. 
Obesity Obesity associated with increased risk. 
Alcohol intake Low level intake (one or 2 units per day) associated with decreased 
risk but higher levels of intake associated with increased risk. 
Chronic renal 
failure 
Presence of chronic renal disease associated with increased risk. 
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1.1.3. Reducing risk of cardiovascular disease 
A number of interventions, both lifestyle and medication based, have been shown to 
reduce the risk of developing atherosclerotic cardiovascular disease and mortality both 
in a primary and secondary prevention context. Guidelines have been produced 
describing the evidence base for a variety of interventions to reduce the risk of 
cardiovascular disease for both primary and secondary prevention, the latter including 
secondary prevention after coronary heart disease, stroke and peripheral arterial 
disease.[4-10] Lifestyle modification to reduce the prevalence of adverse behaviours 
such as smoking, diet, sedentary lifestyle and stress forms the cornerstone of 
cardiovascular risk reduction. Interventions that increase physical activity for example 
can lead to weight loss, lowered blood pressure, improved lipid profile and decreased 
insulin resistance. Detrimental behaviours are often seeded in childhood or 
adolescence but are maintained or even augmented by social environments. For this 
reason they are the target of public health measures. These aim to both alter the social 
environment and drivers of lifestyle choices and work in addition to advice and support 
aimed at individuals.  
 
In addition to lifestyle and environmental interventions a number of medications have 
been shown to be effective in reducing CVD risk. 
 
Statins 
3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors (statins) are known to 
reduce coronary events, a variety of coronary and cerebrovascular outcomes and 
mortality in those with known cardiovascular disease.[11-14] As a result their use has 
become an accepted and routine part of secondary prevention and is advised in a 
range of clinical guidelines for coronary artery disease, stroke and peripheral arterial 
disease. 
 
  
 
30 
Their benefit in primary prevention has also been demonstrated. A meta-analysis of the 
use of statins in primary prevention published in 2006 showed they reduce the risk of 
major coronary events, major cerebrovascular events, non-fatal myocardial infarction 
and revascularisations but not coronary heart disease death or all-cause death.[15] 
The relative risk reduction occurred whatever the baseline (low density lipoprotein) LDL 
level was and regardless of what risk factors were present and the relative risk 
reductions demonstrated were similar to those demonstrated in secondary prevention 
trials. The benefit in terms of absolute risk reduction was therefore greatest in those at 
highest risk of cardiovascular disease. Further trials were published following that 
review and a meta-analysis of trials of statins for primary prevention in people at low 
risk of cardiovascular disease (<20% in 10 years) demonstrated that statins brought 
about a statistically significant relative risk reduction for all-cause mortality (10% 
reduction), myocardial infarction, non-fatal myocardial infarction, stroke, unstable 
angina and revascularisation.[16] The effect on all-cause mortality, fatal or non-fatal 
myocardial infarction and stroke was similar for high and low potency statins. The 
baseline cholesterol level or change in lipid level during the trial did not modify the 
effects suggesting that statins have a benefit on relative risk reduction irrespective of 
the lipid profile. This may be due to anti-inflammatory effects of statins (that reduce the 
vessel wall inflammation which leads to atherosclerosis or instability of plaques that 
already exist), improved endothelial function and/or reduced thrombus formation. Other 
potential actions of statins include decreased oxidative stress, inhibition of myocardial 
hypertrophy, up regulation of endothelium derived nitric oxide, attenuation of P-selectin 
expression and leucocyte adhesion and mobilisation of endothelial progenitor cells all 
of which could have protective or healing qualities for CVD.[17] The benefit of statins at 
all levels of cardiovascular risk is reflected in recent guidelines from the National 
Institute for Health and Care Excellence (NICE) and the American College of 
Cardiology/American Heart Association which recommend offering treatment to those 
at lower risk than in previous guidelines.[6, 9] 
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A further meta-analysis of individual patient data from trials both looking at patients at 
low risk of cardiovascular disease and low risk patients from other trials but including 
some people with pre-existing cardiovascular disease (i.e. secondary prevention) 
demonstrated that statins reduced the risk of major vascular events by 21% per 
1.0mmol/L LDL cholesterol.[18] The relative risk reduction was still observed in those 
estimated to be at very low risk of CVD (<5% 5 year risk) and in those with no history of 
cardiovascular disease. 
 
A systematic review and meta-analysis of the use of statins for primary prevention from 
Cochrane demonstrated reductions in all-cause mortality (odds ratio (OR) 0.86, 95% CI 
0.79 to 0.94), fatal coronary heart disease (CHD) events (risk ratio (RR) 0.82, 95% CI 
0.70-0.96), non-fatal CHD events (RR 0.67, 95% CI 0.59-0.76), fatal (RR 0.83, 95% CI 
0.72-0.96) and non-fatal (RR 0.77, 95% CI 0.62-0.96) CVD events, combined fatal and 
non-fatal stroke events (RR 0.78, 95% CI 0.68-0.89), combined fatal and non-fatal 
CHD, CVD and stroke events (RR 0.65, 95% CI 0.58-0.73) and revascularisations (RR 
0.62, 95% CI 0.54-0.72).[19] One concern about the use of statins is that of adverse 
events and side effects. The Cochrane review of statins for primary prevention found 
that there was no significant increase in risk of all adverse events combined (cancer 
incidence, myalgia, rhabdomyolysis or haemorrhagic stroke) or in the number of trial 
participants stopping medication due to adverse events.[19] There was a slight 
increased risk of incidence of type 2 diabetes mellitus (RR 1.18, 95% CI 1.01-1.39) that 
was driven by the results of the JUPITER trial which used higher statin doses. The 
AFACPS/TexCAPS trial used lower doses of statins and showed no effect on diabetes 
incidence. There is no reliable data on quality of life in patients taking statins for 
primary prevention. 
 
In summary the use of statins for primary prevention is efficacious in reducing the risk 
of a range of cardiovascular outcomes and death whatever an individual’s baseline risk 
is. However the biggest absolute risk reduction will be in those at highest baseline risk. 
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Their benefit needs to be balanced with the risk of adverse effects when deciding with 
individuals whether they wish to take them. 
 
Antihypertensives 
Many randomised controlled trials have demonstrated that blood pressure reduction 
with antihypertensive drugs in hypertensive people reduces morbidity and mortality 
from CVD. Therefore current UK guidelines from the British Hypertension Society and 
NICE[10] and from the Joint British Societies[20] recommend initiating antihypertensive 
treatment in those under 80 years old with stage 1 hypertension (clinic reading ≥ 
140/90mmHg and ambulatory monitoring daytime average ≥135/85mmHg) and either 
target organ damage, established cardiovascular disease, renal disease, diabetes, or a 
10-year CVD risk ≥20%, or in people of any age with stage 2 hypertension (clinic 
reading ≥160/100mmHg and ambulatory daytime average ≥150/95mmHg). This is 
more stringent than the recommendations in the European Cardiology Society 
guidelines.[4] Evidence suggests that treatment with antihypertensives is beneficial at 
all ages including those aged >80 years.[21] It has long been known that blood 
pressure lowering therapy in those with hypertension can reduce left ventricular 
hypertrophy[22, 23] and a meta-analysis has shown that beta-blockers induce less 
regression and angiotensin receptor blockers may induce larger regression than other 
classes of antihypertensives.[24] Regression of left ventricular mass during 
antihypertensive treatment is also independently associated with a better 
prognosis.[25] 
 
Antiplatelet agents 
A meta-analysis of use of aspirin for both primary and secondary prevention of 
vascular disease has been published.[26] As the focus of this thesis is on primary 
prevention I discuss only the use of aspirin in this context here. The review reported 
that in the primary prevention trials aspirin was associated with a reduction in serious 
vascular events (0.51% aspirin v 0.57% control per year, p=0.001) driven mainly by a 
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reduction in non-fatal myocardial infarction. There was no significant net effect on 
stroke (0.20% v 0.21% per year, p=0.4) or vascular mortality (0.19% v 0.19% per year, 
p=0.7). However aspirin allocation for primary prevention increased major gastro-
intestinal and extracranial bleeds (0.10% v 0.07% per year, p<0.0001). Therefore the 
benefit of aspirin in primary prevention is uncertain as the reduction in CV events may 
be outweighed by increased haemorrhage. 
 
1.2. Assessing cardiovascular risk 
 
1.2.1. Background 
The evidence for reducing risk of cardiovascular disease with statins and other 
therapies outlined above could imply that we should offer statins to the entire 
population. However this approach brings a number of economic and ethical 
questions.[27, 28] 
 
Drugs cost money so more widespread use would lead to an increase in prescription 
costs despite the reducing cost of drugs to each individual as patents expire. However 
the economic effect is complex: if people live longer due to the preventive medication 
the lifetime cost per individual could increase as they will take medication for longer, 
and survival may be associated with older age with frailty, comorbidity and increased 
health and care costs compared to a sudden death from a myocardial infarction. 
Recent systematic reviews of the cost-effectiveness of the use of statins for primary 
prevention have attempted to address this complicated economic question. One review 
concluded that as statins become cheaper their cost-effectiveness increases and 
advocated more aggressive use of statins in primary prevention.[29] However this 
analysis used American healthcare costs which may not be generalizable to other 
countries with different healthcare systems. A second review concluded that the 
evidence on cost effectiveness is mixed and if other treatment options (such as 
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smoking cessation) are taken into account the cost-effectiveness is less positive.[30] 
Therefore with the changing costs of drugs it is currently not clear what the health 
economic impact would be of such a strategy in the United Kingdom healthcare system 
for example. 
 
Even if such a strategy was cost effective this does not necessarily mean it is the right 
thing to do. A blanket or more widespread policy of statin use would involve exposing a 
large number of people to a drug that is going to bring them no personal benefit thus 
“medicalising” a significant proportion of the population who are in fact healthy. It has 
been estimated that the number needed to treat to prevent a single death from any 
cause among people at low risk of CVD would be 239 and to prevent a single non-fatal 
myocardial infarction would be 153.[16] Despite the apparent absence of increased risk 
of adverse events such as myalgia, rhabdomyolysis, cancer and haemorrhagic stroke 
with statins compared to control in the meta-analysis of use in primary prevention[19] 
any medication brings the potential for increased harm and interaction with other 
medications. Balances of benefits of risk from the meta-analysis are based on 
population averages and risks, which should be considered when advocating their use 
at the individual person level. Many people may not be prepared to be exposed to 
potential side effects if their individual probability of benefit is low: individual preference 
needs to be considered in decisions. The effect of lifelong statin therapy on quality of 
life is also not known. Others have argued[27] that identifying a larger population to 
start statin treatment may deflect attention from high risk groups where the absolute 
benefit is higher but where underuse of statins has been shown to be a problem.[31] 
 
For these reasons there is an ongoing debate about whether statins should be offered 
more widely[28] and a number of guidelines have recently been updated and advise 
offering statin treatment more widely. Currently clinical guidelines from the Scottish 
intercollegiate guidelines network (SIGN)[5] and Europe[4] all recommend statins be 
prescribed for individuals predicted to be at high risk of developing disease (usually 
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defined as a 10 year risk >20%). However the recent update to the guidelines from the 
National Institute for Health and Care Excellence (NICE) advise offering statins to 
those with a predicted 10 year risk ≥10%[9] and those from the United States to those 
with a predicted 10-year risk of 7.5% or even 5%[6] reflecting the much debated lower 
threshold. A number of risk estimation methods are available to determine individuals’ 
risk and decide on primary prevention in clinical practice. The derivation, role and 
limitations of these scores are discussed below. 
 
1.2.2. Existing risk scores and charts 
Results from observational studies have been used to generate a variety of predictive 
models that incorporate various markers of increased cardiovascular risk to estimate 
the absolute risk of developing clinically overt cardiovascular disease. Various cohorts 
of people from different backgrounds have been used to generate risk charts and 
scores to predict an individual’s absolute risk of developing cardiovascular disease. 
Most of the earlier tools [32-36] used data from the Framingham cohort,[37, 38] while 
other groups have studied different populations to produce tools such as PROCAM[39], 
SCORE[40], ASSIGN[41], Seven Countries Study[42], QRISK[43] and CUORE.[44] 
However the different tools and scores are not directly comparable with each other. 
Some scores (such as some Framingham based tools, Seven Countries and 
PROCAM) use just cardiac disease as an outcome whereas others predict a wider 
range of cardiovascular disease. Some scores look just at mortality as an outcome 
whereas others also look at non-fatal events. Others have developed models looking 
purely at the outcome of stroke incidence.[45] Different groups have included different 
variables in their risk algorithms based on observed influence of different factors on the 
risk of cardiovascular disease to optimise their accuracy. Table 1.2 summarises 
commonly used risk scores/tools along with their end points and variables that are 
included. 
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Table 1.2: Summary of cardiovascular risk charts and scores 
Scoring system End points Time 
(years) 
Variables included 
ASSIGN • Death from 
cardiovascular causes 
• Coronary heart disease 
• Cerebrovascular disease 
• Coronary artery 
interventions 
10 • Age 
• Sex 
• Family history of CHD/stroke 
• Diabetes 
• Rheumatoid arthritis 
• Smoking habit 
• Systolic BP 
• Total cholesterol 
• HDL cholesterol 
• Social deprivation 
Framingham 
(1998) 
• Acute myocardial 
infarction 
• Coronary heart death 
(sudden or not) 
• Angina pectoris 
• Heart failure 
10 • Age 
• Systolic/diastolic BP 
• Total cholesterol 
• Diabetes 
• Smoking habit 
• HDL cholesterol 
• Antihypertensive treatment 
PROCAM • Non-fatal myocardial 
infarction 
• Fatal myocardial 
infarction 
• Sudden death 
10 • Age 
• Systolic BP 
• LDL cholesterol 
• HDL cholesterol 
• Triglycerides 
• Smoking habit 
• Diabetes 
• Family history of MI 
• Angina pectoris 
QRISK2 • Coronary heart disease 
• Stroke 
• Transient ischaemic 
attack 
10 • Ethnicity 
• Age 
• Sex 
• Smoking status 
• Systolic BP 
• Total cholesterol:HDL ratio 
• BMI 
• Family history of CVD 
• Deprivation 
• Treated hypertension 
• Type 2 diabetes 
• Renal disease 
• Atrial fibrillation 
• Rheumatoid arthritis 
Seven Countries 
Study (Italia) 
• Coronary heart death 
• Fatal myocardial 
infarction 
• Non-fatal MI 
• Angina pectoris 
10 • Age 
• Systolic BP 
• Total Cholesterol 
• Smoking habit (number of 
cigarettes) 
SCORE • Cardiovascular mortality 
• Ischaemic heart disease 
• Sudden death 
10 • Systolic BP 
• Total cholesterol 
• Ratio total/HDL cholesterol 
• Smoking habit 
CUORE • Fatal/non-fatal major 
coronary events 
• Fatal/non-fatal major 
cerebrovascular events 
• Coronary and carotid 
revascularisation 
treatment 
• Sudden death 
10 • Age 
• Systolic BP 
• Total cholesterol 
• Smoking habit 
• Diabetes 
  
 
37 
Clinical risk stratification models are measured in three domains: calibration, 
discrimination and reclassification. Calibration refers to how well a prediction model 
derived estimate of absolute risk agrees with the observed risk in a population. 
Discrimination refers to the ability of a model to distinguish between cases and non-
cases. Reclassification refers to the ability of a model to correctly reclassify individuals 
into different risk categories and therefore whether a model will alter clinical decision 
making. 
 
Evaluation of the various risk models in different population groups has found disparity 
between the predicted and observed event rates (i.e. calibration). In a representative 
British population the Framingham score gave a relative overestimation of 47% of 
death from coronary heart disease and 57% of a non-fatal coronary heart disease 
event.[46] Similar degrees of overestimation of risk were found in Augsberg and 
Munster in Germany.[47] Both the Framingham and PROCAM scores also 
overestimated the absolute risk in populations in France and Belfast in the PRIME 
cohorts[48] and in a Spanish non-diabetic population the Framingham and the SCORE 
systems over predicted the risk by 64% and 40% respectively.[49] A study of the 
predictive accuracy of the SCORE system in Austria found that it over predicted 
mortality in the group as a whole.[50] Interestingly a study of Framingham risk scores 
in socioeconomically deprived individuals found the converse of the studies described 
above; the score underestimated the observed incidence of disease by 31% in non-
manual workers and 48% in manual workers.[51] 
 
These observed discrepancies between predicted and actual events have led 
researchers to further adapt many of the tools to reflect the population group in which 
they are to be used.[52-55] For example different versions of the SCORE system have 
been devised to be used in areas with high and low incidence of cardiovascular 
disease by recalibrating the scores to reflect the underlying incidence of cardiovascular 
disease. In addition country specific versions for countries such as the Netherlands and 
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Belgium have been developed.[54, 56] Others have incorporated additional clinical and 
socioeconomic features to the traditional risk factors to improve predictive 
accuracy.[41, 43, 57, 58]  
 
As might be expected with a large numbers of risk assessment tools available there 
are clinical implications in terms of decisions on whether to treat individuals. For 
reasons explained above this can vary greatly depending on which risk assessment 
method is used, which guidelines are followed or the underlying risk of cardiovascular 
disease in the area.[59-63] Despite refinements and recalibrations there are still 
limitations of these risk assessment tools in terms of their external validity and the tools 
cannot necessarily be directly transferred for use in populations from which they were 
not derived. 
 
The difficulties in developing an accurate risk assessment tool reflect the complex 
nature of atherosclerotic disease. Relatively simple prediction tools can never expect to 
capture this complexity. 
 
Firstly the risk scores look at the risk factor profile at a specific moment in time. Many 
of the factors however are dynamic and fluctuate over time so risk measured at these 
cross sections in time is likely to increase and decrease over a patient’s lifetime. As 
atherosclerosis develops over a prolonged time period exposure to risk factors earlier 
in life may not necessarily be detected by “snapshot” risk assessment tools. Some 
studies have looked at the effect of treatment on changes to risk scores and have 
demonstrated that application of risk stratification and subsequent treatment of 
modifiable risk factors can reduce the mean risk estimation using the scoring methods 
described above.[64-66] However using this outcome measure may not necessarily 
always translate into a better clinical outcome because the disease process of 
atherosclerosis may have begun previously when the risk profile was less favourable. 
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The improved estimated risk may not be accurate after treatment because it will not 
reflect past vascular damage. 
 
Secondly some individuals are more susceptible to environmental risk factors than 
others. This is likely to be due to genetic differences, differing inflammatory processes, 
differences in endothelial function, or other processes which can vary in the presence 
of the same environmental factors that are known to increase risk. This will lead to a 
degree of unpredictable distribution and behaviour of atherosclerotic plaques. As 
scores do not, and realistically never will, incorporate every individual factor that leads 
to cardiovascular disease we cannot expect them to accurately predict event rates 
even if they are recalibrated for different populations and levels of underlying disease. 
 
Calibration is only part of the accuracy of a score. Their main use as advocated in 
guidelines[4, 5, 9] is that of discrimination between future cases and non-cases to 
determine who should be prioritised for preventive treatment. It has been argued that 
discrimination is the more important function of the scores rather than absolute risk 
prediction.[67] A number of studies looking at the discriminatory ability of a variety of 
scores applied to an English and Welsh population found that they all had similar ability 
as assessed by area under the receiver operating characteristic ROC curve analysis 
(c-statistics ranged from 0.740 to 0.792).[68, 69] The nature of the risk scores as 
described previously means that they will not be 100% sensitive or specific and a 
trade-off has to be reached when selecting what is classified as high risk. Many people 
who are assessed as being “low” risk go onto develop or die from myocardial 
infarctions, strokes or peripheral arterial disease as although their risk is lower the 
group is more numerous. Conversely many who are assessed as being “high” risk 
never develop such diseases even though their risk is higher. One could argue they 
are therefore taking primary preventive medication without any benefit but with all the 
potential risks of side effects and expense. The threshold for treating could be reduced 
which would increase the sensitivity of the test to those who will have events but at the 
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expense of specificity as we treat more people who will not develop disease. Only by 
increasing then area under the ROC curve by improving the risk estimation itself will 
risk discrimination be improved. 
 
The presence of events in those assessed as low risk by risk estimation tools is 
supported by evidence that such individuals have evidence of atherosclerotic disease 
that puts them at increased risk of cardiovascular disease.[70-72] The extent of plaque 
progression is associated with increased estimated risk of clinical events as assessed 
by Framingham, PROCAM and SCORE algorithms.[73] It could therefore be argued 
effectively that if individuals have evidence of subclinical vascular damage they may 
benefit from primary preventative medication and treatment, which they are currently 
denied by current guidelines which use risk estimation alone without assessing for 
subclinical disease. 
 
These shortcomings maybe one reason why the use of the tools in clinical practice is 
low in a variety of European, North American and South American settings.[74-78] 
Lack of time, perception that scores oversimplify risk or lead to medication overuse and 
poor patient compliance are also quoted as being reasons for the low level of use.[79] 
Some have suggested that a simple measure of waist circumference rather than use of 
a risk scoring tool may be a quicker screening tool for those with higher cardiovascular 
risk who merit further work-up.[80] Therefore despite the presence of tools, and 
evidence based treatment guidelines for primary prevention cardiovascular risk 
remains high.[81] 
 
A range of biomarkers to either improve or enhance risk stratification models that use 
“traditional” risk factors or screen for asymptomatic cardiovascular disease have been 
investigated. The aim is to improve calibration or discrimination of risk scores. 
Biomarkers investigated include blood tests, imaging techniques and physiological 
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examinations. The potential new biomarkers relate either to susceptibility to vascular 
damage, inflammation or evidence of end organ damage. 
 
1.2.3. B-type natriuretic peptide (BNP) 
B-type natriuretic peptide (BNP) is a hormone that regulates loss of water (diuresis) 
and sodium (natriuresis) by the kidneys. It belongs to a family of peptides that also 
includes atrial (A-type) natriuretic peptide (ANP). BNP is co-expressed with ANP in 
secretory vesicles and its secretion is increased in response to pressure and volume 
overload in the atria and ventricles.[82] BNP is produced initially as pre-prohormone 
BNP before being processed to proBNP. This is then cleaved to the biologically active 
BNP and the non-biologically inactive N-terminal proBNP (NT-proBNP).[83] Both of 
these substances can be detected in the bloodstream and assays are available to 
quantify them. A large number of studies have been performed using both these 
markers and their association with cardiovascular disease and physiology. However 
BNP and NT-proBNP have different half lives so they are not directly interchangeable. 
The following discussion includes studies of both BNP and NT-proBNP and specifies 
which marker was studied in each case. 
 
The use of BNP or NT-proBNP in the diagnosis of heart failure has become well 
established and is now included in the NICE[84] and SIGN[85] guidelines on the 
subject. However BNP or NT-proBNP may have a role in detecting poor cardiovascular 
health or pre-clinical disease, and predicting cardiovascular disease and death in 
patients without heart failure, both with and without pre-existing CVD and whether or 
not they have cardiovascular risk markers.[86]  
 
BNP and vascular abnormalities and function 
Elevated levels of BNP and NT-proBNP have been linked with various abnormalities of 
vascular function which in turn have been associated with overt clinical cardiovascular 
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disease. A few studies have reported an association between elevated natriuretic 
peptides and markers of vascular stiffness. One studied BNP levels in patients with 
type 2 diabetes but no evidence of frank left ventricular dysfunction.[87] The 
researchers found that an increased augmentation index reflecting aortic stiffness is an 
independent predictor of BNP level even when the BNP level is within the “normal” 
range. This is supported by the findings of a study of hypertensive patients which found 
that higher plasma NT-proBNP tertiles were associated with a variety of markers of 
impaired aortic elasticity (larger systolic and diastolic aorta diameters, longer 
deceleration time of E wave velocity and isovolumic relaxation time).[88] This study 
also found that NT-proBNP levels were higher in the hypertensive subjects than 
normotensive controls supporting the idea that levels may reflect cardiovascular stress. 
Even in “healthy” men stiffening of arteries, as measured by pulse wave velocity and 
pulse pressure, is significantly correlated with BNP levels.[89] Further evidence of an 
association with impaired endovascular function is provided by a study that 
demonstrates that BNP is independently related to endothelium-dependent 
vasodilatation as assessed by an invasive acetylcholine induced forearm vasodilation 
technique.[90] The study included both patients with and without cardiovascular risk 
factors. 
 
In a study of patients with rheumatoid arthritis but no clinical coronary artery disease, 
hypertension, diabetes or advanced chronic kidney disease elevated NT-proBNP levels 
were associated with increased carotid intima media thickness (C-IMT) which indicates 
subclinical atherosclerotic disease.[91] In a large study (n=2445) of patients without 
heart failure or renal insufficiency higher log NT-proBNP were independently 
associated with higher coronary artery calcium scores derived from electron beam 
computed tomography (CT) scans.[92] This association remained when patients with 
low left ventricular (LV) ejection fractions, LV hypertrophy, angina or previous 
myocardial infarction were excluded. A study of patients with peripheral arterial disease 
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found that NT-proBNP levels are 2.5 fold higher in those with poorly compressible (i.e. 
calcified) peripheral arteries.[93] 
 
BNP and subclinical arterial disease 
Log NT-proBNP has been shown to be an independent predictor of the presence of 
silent myocardial ischemia (stenosis of >50% detected by angiography) in patients with 
diabetes.[94] The authors reported a high negative predictive value for NT-proBNP 
(94.3%) however this study was only small (n=40). A larger study of high risk diabetic 
patients without heart failure reported that an NT-proBNP ≥38pg/ml was a significant 
predictor of silent coronary artery disease (CAD) detected using stress myocardial 
scintigraphy and subsequent angiography.[95] A meta-analysis of studies investigating 
the association of BNP with inducible myocardial ischaemia found that an increased 
BNP level can identify inducible ischaemia with an AUROC of 0.71.[96] This meta-
analysis included populations with suspected or known coronary artery disease in 
addition to those without disease however a study of patients with type 2 diabetes 
found that BNP was an independent predictor of an abnormal exercise tolerance test 
even in a subgroup with no history of ischaemic heart disease or heart failure.[97] The 
use of exercise induced changes in BNP may also be helpful detecting CAD. In a study 
of patients referred with chest pain and LV ejection fraction >50% and no previous 
history of CAD a 1.3 fold increase in BNP after exercise (Bruce protocol exercise 
tolerance test) was associated with an 11 times greater odds of having 
angiographically proven CAD.[98] This threshold produced a sensitivity of 81.8% and 
specificity of 71.8%. The presence of silent myocardial infarctions (MI) detected by 
delayed-enhancement magnetic resonance imaging (DE-MRI) is associated with 
higher levels of NT-proBNP than in those who had no evidence or history of MI.[99] A 
study of asymptomatic patients with type 2 diabetes found that NT-proBNP was 
associated with the presence of coronary, carotid or peripheral atherosclerosis but this 
association did not persist when the data was adjusted for conventional cardiac risk 
factors.[100] 
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BNP and cardiac function and structure 
BNP levels correlate with increased left ventricular mass and subtly lower left 
ventricular ejection fraction in those with no clinical evidence of heart failure.[87] This is 
supported by the findings of another study of patients with preserved systolic function 
which showed that more severe left ventricular hypertrophy and impaired diastolic 
function were independent predictors of higher BNP.[101]  
 
BNP and cardiovascular events and mortality 
Associations between BNP/NT-proBNP levels and a variety of clinical outcomes have 
been reported. Increased NT-proBNP[102, 103] and BNP [103, 104] levels are 
associated with increased cardiovascular mortality, heart failure and stroke in patients 
with stable CAD. Elevated levels of NT-proBNP are also independently associated with 
the risk of stroke in patients with atrial fibrillation (AF)[105] and NT-proBNP and BNP 
levels can predict cardiovascular events following vascular surgery.[106] In patients 
who have had a stroke but have no clinical evidence of previous cardiac ischaemia NT-
proBNP independently predicts future MI[107] and BNP correlates with reversible 
cardiac ischaemia.[108] 
 
In population studies of patients unselected on the basis of the presence or absence of 
pre-existing CVD increased levels of NT-proBNP have been associated with higher 
rates of all-cause mortality, cardiovascular events, coronary events and incidence of 
AF.[109-115] A higher level of BNP is associated with CV events, cardiovascular 
mortality, all-cause mortality, heart failure, stroke and AF but not CHD events in a 
similar population.[116] An evaluation of BNP as part of a bank of other biomarkers in 
the Framingham Heart study found that BNP predicted the risk of death and first 
cardiovascular event however the use of the bank of biomarkers only added 
moderately to the prediction of risk in individuals.[117] In a population of patients with 
diabetes (and mixed history of absence/presence of CVD) NT-proBNP <125pg/mL has 
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been shown to have a good negative predictive value for CV events within 12 
months.[118] 
 
A systematic review and meta-analysis of prospective studies examining the 
association of BNP and NT-proBNP with CVD reported that after adjustment for 
conventional risk factors the relative risk of CV events in those in the highest tertile of 
BNP or NT-proBNP compared with those in the lowest tertile was 2.68 (95% CI, 2.07-
3.47) for general populations.[86] Increased NT-proBNP is associated with increased 5 
year risk of stroke (both ischaemic stroke and intracerebral haemorrhage) in a 
population with no prior evidence of cerebrovascular disease.[119] The association of 
NT-proBNP with new onset heart failure and CV death has been demonstrated in those 
aged 70 and over[120] and it may be that the association of NT-proBNP with CV 
endpoints increases with age but may not be significant in younger age groups.[121] 
 
The association between natriuretic peptides and other vascular diseases has also 
been studied. Elevated NT-proBNP is associated with poorer cognitive performance in 
community dwelling older adults.[122] The development of dementia and the decline in 
Mini Mental State Examination (MMSE) also appear to be associated with elevated 
BNP which remains significant when corrected for baseline MMSE.[123] In those with 
known cerebrovascular disease an independent relationship between log transformed 
BNP levels and dementia severity as measured using the Dementia Rating Scale has 
been demonstrated.[124] In a small case control study BNP levels were found to be 
significantly higher in patients with subcortical vascular dementia than in those with 
Alzheimer’s dementia and healthy controls.[125] However it is not clear if the results 
were adjusted for vascular risk factors so the higher levels of BNP may reflect the 
higher vascular risk factor burden in those with vascular dementia rather than the 
presence of vascular dementia itself. An association between increased NT-proBNP 
and incident disability in older adults has been described.[126] 
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However is the prognostic ability described above also demonstrable in populations 
with no pre-existing evidence of CVD? A number of studies of asymptomatic 
populations have demonstrated that BNP[127-130] and NT-proBNP[127, 131, 132] 
predict mortality and CV events. The hazard ratios for death range from 1.3 to 5.7 and 
those for cardiovascular events range from 1.3 to 13.8. For both outcomes the larger 
studies quote figures that are lower suggesting the association may only be slight. It is 
unclear whether the association with BNP is continuous or whether there is a threshold 
effect as different studies have used different cut offs and methods. 
 
A study of healthy normal people defined as the absence of traditional clinical CV risk 
factors and no echocardiographic structural cardiac abnormalities found that NT-
proBNP was not predictive of either death or CV events.[133] This may suggest that in 
a truly low risk population NT-proBNP may not be useful for further risk stratification. 
However the same study found that NT-proBNP levels above age and sex specific 80th 
percentiles were associated with increased risk of death, heart failure, stroke, and MI 
after adjustment for clinical risk factors and structural cardiac abnormalities in a 
population free of symptomatic heart failure but with either CV risk factors or impaired 
cardiac function demonstrated on echocardiogram. A greater proportion of this 
population had an NT-proBNP level greater than their age and sex specific 80th 
percentile than the healthy population. Therefore even in a population who may appear 
to be healthy it is possible that higher natriuretic peptide levels may help recognise 
those with a subclinical CVD. 
 
BNP and traditional cardiovascular risk factors 
The correlation of natriuretic peptide levels with existing risk estimation tools has also 
been evaluated. In patients with type 2 diabetes but no pre-existing coronary artery 
disease or stroke log BNP level correlates with the 10-year risk for CHD and stroke as 
assessed with the Framingham risk score.[134] BNP levels are also significantly higher 
in those with a high cardiovascular risk as assessed by the New Zealand Risk 
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Score.[134] There is evidence to support this correlation in a general (not exclusively 
diabetic) population. In one study ROC analysis showed the area under the curve was 
comparable to that for the Framingham Risk Score when cut offs for BNP of 37pg/ml 
and 55pg/ml were used in men and women respectively.[135] A further comparison of 
existing risk scores and natriuretic peptides found that NT-proBNP correlated less with 
Framingham Risk Score and SCORE risk estimation algorithms than the alternative 
NT-proANP.[136] However no actual cardiovascular endpoints were measured so it is 
not possible to say whether the NT-proBNP or existing clinical risk scores were more 
effective at predicting actual events. 
 
In patients with established cardiovascular disease (i.e. secondary prevention) the 
addition of NT-proBNP levels to clinical assessment of traditional cardiovascular risk 
factors and or echocardiographic parameters appears to improve prediction of future 
cardiovascular events and cardiovascular death.[137, 138] However the use of risk 
factor modification and secondary preventative medication is already known to be 
beneficial in this population so the additional prognostic information provided by NT-
proBNP has limited clinical usefulness (i.e. has limited reclassification use). 
 
Importantly many studies have found that BNP[139-141]  and NT-proBNP[92, 140] 
levels are significantly higher in women compared to men. The reasons for the 
difference in BNP level have been investigated in a population free from cardiovascular 
disease or cardiovascular medication in who LV failure had been excluded by 
echocardiogram.[139] The higher levels were not explained by gender related 
differences in blood pressure, renal function or cardiac structure but may be related to 
oestrogen status. As a higher level is seen in women who have a lower cardiovascular 
risk than men gender specific references ranges are likely to be needed for each 
gender. 
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Incremental benefit of adding BNP 
Large prospective studies have found that adding NT-proBNP levels to a Framingham 
Risk Score based model improves the accuracy of risk predictions[142-144] and can 
result in a net reclassification improvement of between 8.2% and 13.3%[143, 144] in a 
population of asymptomatic individuals (i.e. primary prevention). This effect persists in 
those older than 55 years of age.[144] Further evidence of a possible supplementary 
role of natriuretic peptides is provided by studies that used BNP[117, 145, 146] or NT-
proBNP[117, 146, 147] markers in combination with other biomarkers to improve the 
accuracy of event prediction however the effect of the addition of biomarkers is often 
only small. A systematic review reported the effect of the addition of BNP or NT-
proBNP to risk models on their discriminatory ability: improvements in area under the 
ROC curve were only small in the studies looking at general populations (increases in 
the c statistic range 0.007-0.03).[86] Also not all studies of the ability to improve event 
prediction are positive. A case control study found that the addition of NT-proBNP to a 
Framingham Risk Model did not improve calibration of a prediction model or result in 
reclassification of individuals’ risk.[148] A smaller study of patients with rheumatoid 
arthritis but no cardiovascular disease did not demonstrate an improvement over 
Framingham Risk Score alone when NT-proBNP was added.[149] One other large 
prospective study reported that incorporation of NT-proBNP into a risk prediction model 
did not significantly improve c statistics of the model.[150] It is unclear which model 
was used in this study so direct comparison with models in use in clinical practice is 
difficult. 
 
What is the role of BNP? 
BNP or NT-proBNP are associated with impaired vascular function, calcification, 
presence of subclinical disease, and increased estimated and actual cardiovascular 
risk in a variety of populations. Although evidence about their ability to improve 
calibration, discrimination or reclassification beyond traditional risk factor models is 
mixed, possibly due in part to heterogeneity in study design particularly in identifying 
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the study population, it appears that BNP/NT-proBNP levels reflect an increase of 
stress on the cardiovascular system and they are likely to be a common end point for a 
number of cardiovascular abnormalities. It therefore follows that an elevated BNP level 
could conceivably be used to screen for atherosclerotic disease or target organ 
disease that requires further characterisation and phenotyping.  
 
In a study examining the usefulness of natriuretic peptides for screening for increased 
left ventricular mass and left ventricular systolic dysfunction in a community based 
study as part of the Framingham Study BNP the area under the curve (AUC) was at or 
below 0.75 for increased LV mass and LV systolic dysfunction (except moderate to 
severe systolic dysfunction).[151] This was true when all participants, participants aged 
60 years or older, those with hypertension, those with prevalent cardiovascular disease 
and those with 2 or more high risk features were analysed separately. The authors 
suggested that the use of BNP for detection of elevated LV mass and left ventricular 
systolic dysfunction was suboptimal and therefore of limited usefulness as a mass 
screening tool. However a study of people receiving primary prevention for 
cardiovascular risk factors found that the BNP was able to more accurately predict 
cardiac target organ damage (left ventricular hypertrophy, left ventricular diastolic 
dysfunction, left atrial enlargement, left ventricular systolic dysfunction or cardiac 
ischaemia).[152] The AUC for BNP (0.78) was similar to other screening tests used 
clinically such as prostatic specific antigen (PSA) for prostate cancer (AUC 0.68-
0.78)[153, 154] and mammography for breast cancer (AUC 0.78).[155] BNP performed 
better than high sensitivity troponin T, microalbuminurea, estimated glomerular filtration 
rate, uric acid and abnormalities on a 12 lead ECG. It therefore appears that BNP may 
have a role in screening for a range of abnormalities but then require follow up with 
further evaluation to determine the nature of any abnormality in each individual. 
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1.2.4. Other candidate tests 
Other tests have been investigated to see if they add any additional predictive ability to 
identify those at risk of CVD. C-reactive protein (CRP) has attracted a great deal of 
research attention as a marker of inflammation that plays a key part in formation of 
atherosclerosis. This has been furthered with the emergence of high sensitivity 
assays.[156, 157] CRP is an independent predictor of death.[117] High sensitivity CRP 
(hsCRP) has been shown to correlate with the calculated 10 year Framingham 
Coronary Heart Disease risk in men and women.[158] The results of this study could 
reflect hsCRP being a marker of vascular risk however others have shown hsCRP to 
be an independent predictor of future myocardial infarction and ischaemic stroke.[159] 
The Reynolds risk score was developed by adding hsCRP and parenteral history of MI 
before the age of 60 years to the usual risk factors used in the Framingham score.[160] 
This score was reported to be more accurate in predicting cardiovascular disease 
when compared to the Framingham Risk Score particularly where people are classed 
as being at “intermediate risk”.[160, 161] Using cut offs of levels of hsCRP of <1.0mg/l, 
1.0-3.0mg/l and >3.0mg/l to reflect low intermediate and high risk respectively, 
predicted risk in those previously assessed to be at intermediate risk as calculated by 
Framingham Risk Score was adjusted in 66% of patients.[162] However there may be 
limitations to the use of hsCRP. The number of intermediate risk individuals reclassified 
as high risk when using hsCRP depends on the cut off level used and the 
demographics of the individuals being screened.[163] In this way the limitations are 
similar to those of the original risk stratification models. 
 
Soluble P-selectin was shown to be positively and independently associated with 
Framingham Risk Score and presence of atherosclerotic plaques.[164] Non-high-
density lipoprotein cholesterol was found in one study to be more strongly associated 
with subclinical atherosclerosis, as measured by coronary artery calcification, than 
conventional lipid values.[165] Receptor activator of nuclear factor kappa-B 
ligand/osteoprotegerin (RANKL/OPG) has been suggested as a possible marker of 
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vascular vulnerability.[166] Homocysteine and renin levels have also been shown to 
predict death and urinary albumin to creatinine ratio predicted death and first major 
cardiovascular events although their use in a panel of biomarkers only moderately 
improved prediction above the use of traditional risk factors.[117] 
 
The level of troponin T detected using a highly sensitive assay (hsTnT) in a population 
based cohort was associated with left ventricular hypertrophy, left ventricular systolic 
dysfunction and all-cause mortality.[167] The troponin T level remained independently 
associated with mortality when adjusted for traditional cardiovascular risk factors, CRP, 
chronic kidney disease and NT-proBNP. HsTnT levels are also associated with 
cardiovascular risk as estimated by Framingham Risk Score.[168] Increasing hsTnT 
levels on serial measurements have also been shown to be associated with 
cardiovascular events.[169] As discussed previously in a population receiving 
treatment for primary prevention of cardiovascular disease hsTnT was an independent 
predictor of cardiac target organ damage when corrected for age, sex, and estimated 
glomerular filtration rate.[152] However it did not perform as well as BNP. The use of a 
supersensivity troponin I assay led to an improvement in net reclassification for major 
adverse cardiac events in people at intermediate risk.[170] In the Framingham study 
the addition of a biomarker panel including high sensitivity troponin I improved 
prediction (improved c statistic and net reclassification improvement over using 
standard risk factors).[171] 
 
Some have used exercise tests to improve risk estimation or detect subclinical 
atherosclerosis. A positive exercise tolerance test (defined as ST-segment depression 
during or following exercise) when added to conventional risk factors improved the 
positive predictive value in one cohort study.[172]  
 
A series of systematic reviews published in 2009 investigated the ability of a range of 
biomarkers and tests to successfully reclassify those at intermediate risk of CVD as 
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assessed by Framingham Risk Scores.[173] Based on these results available at that 
time it was advised that the evidence for using CRP, lipoprotein, homocysteine, 
leukocyte count, fasting glucose concentration, presence of periodontal disease and 
ankle brachial index was insufficient to recommend their use in assessment of CHD 
risk. This review did not include any studies on high sensitivity troponin and I found no 
published reviews of troponin in healthy populations to date. 
 
1.2.5. Imaging to predict cardiovascular disease 
The evidence suggests that BNP is able to identify those who have subclinical silent 
cardiovascular disease. However, as with most screening tests, the test is not 100% 
specific and therefore further characterisation or phenotyping of any underlying 
abnormality is desirable. A variety of imaging techniques including echocardiography, 
CT, nuclear medicine perfusion scanning, ultrasonography and magnetic resonance 
imaging have been developed which can be used to detect abnormalities which in turn 
have been associated with clinical outcomes. As this study used MRI this modality is 
reviewed in most detail below. 
 
Magnetic resonance cardiac imaging 
The development and improvement in magnetic resonance imaging has allowed the 
modality to be used to assess cardiac mass, function and detect cardiac disease. A 
few large epidemiological cohorts and some smaller studies have used MRI to assess 
left ventricular mass (LVM) or other cardiac parameters. These have allowed 
characterisation of “normal” MRI derived parameters and have shown associations with 
a variety of risk factors and cardiovascular outcomes.[174-178] 
 
The Multi-Ethnic Study of Atherosclerosis (MESA) recruited 6500 men and women 
aged 45-84 years and free from established cardiovascular disease from different 
ethnic backgrounds in the United States.[174] Participants underwent cardiac MRI 
imaging to determine LVM and LV function as well as coronary calcium assessment 
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using CT, measurement of brachial artery endothelial dilatation, C-IMT and carotid 
artery distensibility using ultrasound, ankle-brachial blood pressure index in addition to 
“traditional” cardiovascular risk factors, socioeconomic, lifestyle factors and 
psychosocial factors. Participants have been followed up for CV events and mortality. 
The aims of the study included to determine characteristics that relate to progression of 
subclinical disease to clinical CVD and determine the incremental value above 
traditional risk factors of new factors in predicting CVD. 
 
The Dallas Heart study imaged almost 3000 participants using thoracic MRI to 
measure LVM, LV function and aortic distensibility.[175] The study population was 
aimed to represent the population of the United States so recruited people from various 
ethnic backgrounds. It did not exclude people with established or increased risk of 
cardiovascular disease. It aims to produce population estimates of biological and social 
variables that identify ethnic differences in cardiovascular health and produce 
hypotheses on underlying mechanisms for these differences. 
 
1794 participants of the Framingham Heart Study Offspring cohort have undergone LV 
short-axis orientated contiguous multislice MR of the left ventricle. A healthy subgroup 
of 852 participants free from clinical cardiac disease, hypertension and treatment for 
hypertension have been studied to produce normal LV parameters for this 
population.[177] 
 
Cardiac parameters appear to be different in men and women and in different ethnic 
groups. LVM derived from MRI has consistently been shown to be lower in women 
compared to men.[177, 179-183] The Dallas Heart study found that African Americans 
have increased LVM compared with White-Americans even when adjusted for fat 
mass, fat-free mass, systolic blood pressure, age, gender and markers of 
socioeconomic status.[184] However African Americans do not have a higher 
prevalence of reduced left ventricular ejection fraction (LVEF).[180] Another analysis 
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from the Dallas Heart study found that LVEF was higher in women compared to men 
secondary to a higher stroke volume when adjusted for end diastolic volume and other 
potential confounders.[185] A subpopulation of the MESA study excluding smokers, 
those with hypertension (>140/90mmhg), increased fasting glucose, increased 
cholesterol and decreased HDL was investigated to determine normal MRI derived 
cardiovascular values by age, sex and ethnicity.[182] LV volumes except end systolic 
volume were inversely associated with age in both sexes. LVM indexed for body 
surface area was not associated with age for either sex (although unindexed LVM was 
in men). LVM was largest in African Americans and smallest in Asian Americans. A 
similar study of a subpopulation of the Framingham Heart study offspring cohort free of 
hypertension or cardiovascular disease found LV volume measures corrected for body 
surface area were greater in men compared to women but there were no differences in 
LVEF.[183] 
 
Cardiac MRI parameters are associated with CV risk and outcomes. In those aged 30-
50 years old concentric left ventricular hypertrophy (LVH) was associated with a high 
lifetime predicted risk of CVD even in those without detectable coronary artery calcium 
in the Dallas heart study.[186] In a multivariable linear regression analysis the MESA 
study demonstrated an association of higher systolic blood pressure and body mass 
index (BMI) with larger LVM and LV volumes after correction for socioeconomic 
variables and height.[187] Current smoking and diabetes were also associated with a 
greater LVM and lower stroke volume and ejection fraction. Increased LVM indexed for 
fat free mass was associated with subclinical atherosclerosis (detected by coronary 
artery calcification).[188] However LVM has also been associated with a high ankle-
brachial pressure index (indicating stiff arteries) which persisted after correction for 
measures of atherosclerosis in the coronary and carotid arteries (assessed using 
coronary artery calcification and carotid intimal media thickness respectively)[189] 
suggesting that increased LVM may not be entirely caused by detectable sub-clinical 
atherosclerosis. LVM was associated with endothelial dysfunction assessed by brachial 
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flow mediated dilation independent of age, gender, race, systolic BP, diabetes, 
smoking, weight, statin use, HDL and LDL.[190] 
 
These associations between markers of vascular health and predicted risk also 
translate into clinical outcomes. Increased LV mass to LV end diastolic volume ratio (a 
marker of concentric ventricular remodelling) was positively associated with incident 
coronary heart disease and stroke in a Cox proportional hazard model as part of the 
MESA study.[191] This association persisted after adjustment for baseline 
cardiovascular risk factors (age, sex, ethnicity, diabetes, cigarette smoking, total 
cholesterol, HDL, use of antihypertensive or lipid lowering medication and systolic and 
diastolic blood pressure). LVM and LVM/volume ratio were also associated with the 
combined endpoint of coronary artery disease, stroke and heart failure when adjusted 
for traditional risk factors.[181] The same study found that risk prediction for heart 
failure was improved significantly by adding LVM to traditional risk factors. 
 
Beyond left ventricular mass and volume assessment the use of delayed myocardial 
enhancement to detect myocardial infarction has been evaluated. The Age, 
Gene/Environment Susceptibility-Reykjavik (AGES-Reykjavik) Study used gadolinium 
enhanced cardiac MRI in a subset of 1000 participants to look for myocardial infarction 
and determine cardiac output and assess wall motion.[176] This study population was 
drawn from an established population study cohort of people who were born between 
1907 and 1935 and thus has an older population than some other studies. It included 
people with existing cardiovascular disease. It is aiming to comprehensively study 
ageing by assessing a range of phenotypic variables and relate these to earlier life risk 
factor assessments and genetic information. Presence of clinically unrecognised MI 
detected by contrast enhanced cardiac MRI was associated with increased mortality 
when adjusted for age, sex, diabetes and recognised MI (from ECG).[192] This 
supports evidence from a smaller study of patients with diabetes which found late 
gadolinium enhancement detected MIs in those with no previous clinical diagnosis of 
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MI was associated with increased rate of cardiac events and death.[193] In a sub-study 
of participants of the PIVUS study not all late-enhancement detected MIs were 
associated with atheroma detected by MRI angiography or carotid ultrasound, or with 
cardiovascular risk factors.[194] The authors suggested that this could be because 
unrecognised MIs either have a non-atheromatous aetiology or they manifest at an 
earlier stage of disease. These findings suggest a possible incremental benefit of 
identifying subclinical infarcts as part of a screening process. 
 
Magnetic Resonance Angiography (MRA) 
Atheroma develops over a period of time and is likely to be present subclinically for 
some time before clinical disease becomes apparent potentially offering a window to 
intervene to prevent clinical disease. This is supported by evidence from the 
Framingham Offspring study where T2 weighted black-blood thoracoabdominal aortic 
imaging found evidence of atheroma in 38% and 41% of women and men respectively 
free of cardiovascular disease.[195] The presence of plaque correlated with the 
Framingham coronary risk score for all women and for men after adjustment for age. 
Mean aortic wall thickness of the abdominal aorta was associated with an increased 
risk of cardiovascular events and increasing aortic plaque burden was associated with 
an increased risk of non-fatal non-cardiac vascular events in the Dallas Heart 
Study.[196] 
 
Recently there has been a growing interest in and development of the technique for 
whole body contrast enhanced MRI angiography (WB CE-MRA).[197-203] As scanners 
have improved and scanning protocols have evolved the time required for scans (often 
combined with cardiac or other solid organ imaging) has reduced. WB CE-MRA has 
shown to have a good sensitivity and specificity for significant stenosis when compared 
to digital subtraction angiography albeit in populations with peripheral arterial 
disease.[201, 204, 205] In a population free from clinical disease a validation study 
found that findings of arterial stenosis or previous MI agreed with findings from other 
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tests (Doppler ultrasound for peripheral arteries and cardiac angioplasty, ECG, stress 
testing or echocardiography for cardiac disease including previous MIs).[198] 
 
In addition to the diagnostic accuracy of the technique patient acceptance of WB CE-
MRA is important especially if it is to be used as a screening tool. A prospective study 
of patients with peripheral arterial disease who underwent both WB CE-MRA and 
digital subtraction angiography found that WB CE-MRA was the preferred 
technique.[206] 
 
Various groups have developed a variety of slightly different scoring systems to 
quantify whole body atheroma burden by quantifying luminal narrowing.[207-209] 
These scores have been correlated with various cardiovascular risk factors and 
presence of disease in other vascular beds. In a study of 50 people suspected of 
having coronary artery disease but no history of extra-cardiac atherosclerosis those 
with significant coronary artery disease shown on coronary angiography had a higher 
atheroma burden on MRA.[209] The same study also found the whole body atheroma 
burden was associated with predicted coronary risk using both the PROCAM and 
Framingham Risk Scores.  
 
A subpopulation of 306 70 year olds from the PIVUS study cohort in Sweden, some of 
whom had a history of cardiovascular disease, underwent a WB CE-MRA using 
gadodiamide contrast which was used to give a total atheroma score. This score was 
associated with traditional cardiovascular risk factors (male sex, systolic blood 
pressure, cigarette pack years and HDL) as well as the Framingham Risk Score.[208] 
Even in those without evident CVD 26% had significant vascular abnormalities.[210] 
Importantly prospective follow up of the cohort found that the total atheroma score was 
associated with the combined end point of cardiac death, MI, stroke or coronary 
revascularisation when adjusted for multiple risk factors and improved discrimination 
and reclassification when added to the Framingham Risk Score.[211] 
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A WB CE-MRA derived atheroma score was also associated with predicted 10 year 
risk for CHD, fatal CHD and stroke and was significantly higher in those with features 
of metabolic syndrome in patients with longstanding diabetes.[207]  
 
Figure 1.3: Whole body magnetic resonance angiogram 
 
Courtesy of Prof Jill JF Belch and Prof J Graeme Houston 
 
Other imaging techniques 
Other imaging modalities and techniques have also been evaluated. Coronary artery 
calcification can be determined by electron beam CT. This has been described as both 
a marker of susceptibility to vascular damage and as a marker of subclinical damage. 
A meta-analysis of 4 cohort studies found that a coronary artery calcium score derived 
by electron beam CT in asymptomatic individuals is an independent predictor of CHD 
events.[212] This is the case in both younger (aged <40 years) [213] and older 
patients[213, 214] with no baseline coronary heart disease risk factors. Coronary artery 
calcification improves prediction of coronary events[214, 215] and this may be 
particularly useful in those with intermediate risk in whom it can be difficult to decide on 
the need for treatment.[216] It is also an independent predictor of all-cause mortality 
and can improve prediction of this end point.[217, 218]. A study of combined CT and 
PET using 18F-sodium fluoride (18F-NaF) showed that the technique was able to 
identify and localise ruptured and high risk coronary artery plaques.[219] Although this 
study was performed in a population of people with myocardial infarction or stable 
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angina it is conceivable that the methodology could be used to detect preclinical 
disease in an asymptomatic population. The risk derived from exposure to ionising 
radiation, however, needs to be considered if using CT as a screening tool. For this 
reason MRI may be more acceptable. 
 
Exercise thallium perfusion scans in healthy siblings of individuals with young onset 
coronary heart disease was shown to be helpful in predicting future cardiac events[220] 
and has been shown to identify subclinical atherosclerosis in such high risk 
individuals.[221] 
 
Evidence of vascular disease has been detected by increased carotid intima-media 
thickness (C-IMT) in those with a low Framingham Risk Score.[222] Framingham 
based risk prediction of coronary events has been improved by adding C-IMT in a 
number of studies[172, 223-225] although its role in predicting stroke is less clear.[226] 
A meta-analysis of common C-IMT thickness measurements in cardiovascular risk 
prediction concluded that the addition of the measurement to Framingham Risk Score 
improved the 10 year risk prediction of first time MI or stroke but only by a small 
amount.[227] The c statistic for predictive models with and without C-IMT were similar 
but there was a net classification improvement of 0.8% (95% CI 0.1-1.6%) with the 
addition of C-IMT. This was slightly better for those at intermediate risk (3.6%, 95% CI 
2.7-4.6%) however this small improvement is unlikely to be of clinical importance. 
 
1.3. Summary – is the future screening rather than risk estimation? 
In summary, there is a desire to improve how we assess individuals’ risk of developing 
cardiovascular disease to allow targeting of primary preventative measures including 
costly and potentially side effect inducing medication to those most likely to benefit. 
Current risk prediction tools based on observational population data are limited in their 
ability to accurately predict risk at the individual level. Therefore many individuals either 
do not receive medication from which they could benefit or receive medication that has 
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no benefit. This makes it difficult to give accurate information to individual patients 
(rather than at a population level) about the benefits of interventions such as statins 
and allow them to make an informed decision. A number of novel biomarkers have 
been studied to improve risk prediction. Many of these have shown varying success 
possibly reflecting the complex interaction of factors that lead to atherosclerotic 
disease. An emerging approach is to detect developing preclinical disease before it 
becomes clinically apparent allowing interventions to be started earlier. This is an 
approach that has worked effectively in the area of cancer for a number of years and 
allows early treatment of detected disease. A variety of methods of detecting preclinical 
disease have been suggested and researched to differing degrees. There is evidence 
that natriuretic peptides are able to identify those with a variety of cardiovascular 
abnormalities including subclinical or silent cardiovascular disease and that increased 
levels are associated with cardiovascular mortality. However BNP is a very non-
specific marker of cardiovascular abnormality so is not sufficient on its own to identify 
those at increased risk of cardiovascular disease. Cardiac and whole body magnetic 
resonance imaging is able to detect subclinical disease however imaging everybody for 
screening would be expensive and poor use of resources. Therefore “pre-screening” 
using a relatively low cost and widely available blood marker (BNP) could exclude 
those truly at low risk with a normal cardiovascular system and facilitate targeted more 
detailed phenotyping using more expensive and invasive whole-body contrast 
enhanced magnetic resonance imaging to detect a range of cardiovascular 
abnormalities (arterial disease, left ventricular hypertrophy, silent infarcts) that are 
associated with future clinical disease. This could potentially prevent future disease by 
facilitating targeted and individualised advice and treatment. The ability of a 
combination of these techniques to predict future clinical CVD in a large population of 
individuals at low or intermediate risk of CVD has not so far been assessed. 
 
The Tayside Screening for Cardiac Events (TASCFORCE) study is investigating the 
ability of a screening programme using BNP and whole body contrast enhanced 
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magnetic resonance imaging comprising cardiac imaging and whole body angiography 
to detect subclinical cardiovascular disease and predict future clinical cardiovascular 
disease in a population at low or intermediate (<20% in 10 year) predicted risk of CVD. 
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2. Methods: The TASCFORCE study-screening for asymptomatic cardiovascular 
disease 
 
2.1. Study design 
The TAyside SCreening FOR Cardiac Events (TASCFORCE) study is a prospective 
normal volunteer cardiovascular risk screening study (ISRCTN number: 
ISRCTN38976321). The protocol was approved by the Tayside Committee of Medical 
Research Ethics and can be accessed at http://www.controlled-
trials.com/ISRCTN38976321/TASCFORCE.  All study procedures were performed in 
accordance with Good Clinical Practice. Written informed consent for the study was 
obtained from each participant prior to enrollment in the study (appendix 3). 
 
Men and women aged 40 years or older living in Tayside or Fife, Scotland, were 
eligible for participation. 
 
Exclusion criteria were: 
• known atherosclerotic disease, 
• predicted increased risk of CVD requiring statin treatment, according to the 
Scottish Intercollegiate Guideline Network (SIGN) 97 Guideline[5] (≥20% in 10 
years) 
• BP greater than 145/90mmHg 
• other accepted indication for statin therapy according to the investigators’ 
current clinical practice (including familial hyperlipidaemia requiring drug 
therapy and known diabetes), any illness which in the doctor’s opinion meant 
that the subject was unable to give informed consent. 
 
Additionally a number of additional exclusion criteria were included to produce a 
population that could participate in a potential future statin intervention trial. These 
were: 
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• known primary muscle disease, 
• significant biochemical abnormalities (such as acute liver disease or hepatic 
dysfunction with aspartate transaminase (AST) or alanine transaminase (ALT) 
greater than two times the upper limit of normal, 
• other serious illness or significant abnormalities that may compromise the 
participant's safety or successful participation in the study, 
• known alcohol abuse,  
• participation in a clinical trial other than observational trials or registries 
concurrently or within 30 days prior to screening for entry to the study, 
• pregnancy, 
• breast-feeding, 
• women of child-bearing potential not using adequate contraception. 
 
Patients were also excluded if they were taking any of the following medications: 
• over the counter statins, 
• drugs known to be associated with rhabdomyolysis in combination with 3-
hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, 
• drugs known to affect lipid levels, 
• lipid-regulating drugs (probucol, fibrates and derivatives, bile acid sequestering 
resins).   
 
2.2. Recruitment 
Potential participants were recruited from a variety of sources. Ethically approved 
TASCFORCE leaflets (appendix 1) were handed out by research staff at appropriate 
public gatherings and events and were provided for members of the public to pick up at 
a range of sites throughout the region. Publicity campaigns, via press and radio 
coverage, and letters to subjects who had already agreed (and given written consent) 
to be contacted for such trials further raised awareness of the study. Participants were 
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also recruited from General Practice (GP) surgeries and large local employers. 
Potential participants were asked to use the contact details provided on the leaflets or 
letters to register their interest with the study team. Interested subjects were then 
contacted by study staff by telephone to answer questions about demographic details 
and the presence of any exclusion criteria. This allowed selection to be made of 
potentially eligible subjects who were sent an information sheet (see appendix) about 
the study and invited for screening visit 1. 
 
During the recruitment process pre-agreed 6-monthly checks were made of Scottish 
Index of Multiple Deprivation (SIMD), gender and age profile of the recruits so that 
future recruitment could be targeted to reflect the population from where they were 
drawn, i.e. Tayside. It is recognised that such screening trials may over recruit in the 
higher SIMD groups; by recruiting from GP surgeries within lower SIMD codes and 
from certain employers recruitment could be targeted to ensure under-represented 
groups were recruited pro-rata for the Tayside population. This aimed to produce a 
study population that represented the local regional population as a whole as closely 
as possible and included individuals from lower socio-economic status who are both 
frequently under-represented in clinical trials and often have poor engagement with 
health screening programmes.  
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2.3. Assessments 
 
2.3.1. The Assessment for Eligibility 
An overview of the flow of participants and activity at each stage is summarised in 
figure 2.1. 
Figure 2.1: Flowchart giving overview of study design. 
 
BNP=B-type natriuretic peptide, MRI=magnetic resonance imaging, ISD=Information and 
Statistics Division, Scotland, GP=General practice, ECG=electrocardiogram, BP=blood 
pressure. 
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2.3.2. Screening visit 
Potentially eligible participants were assessed at visit 1. This visit was either at the 
Clinical Research Centre at Ninewells Hospital and Medical School, Dundee or for 
those who worked at one of the large local employers at their workplace. A formal 
assessment of inclusion and exclusion criteria was made (except for cardiovascular 
risk, BP and lipid profile which were checked after consent was given during the initial 
assessment – see below). If the subject was potentially suitable for inclusion 
explanations of the procedures were given along with the participant information sheet 
(appendix 2) and written informed consent (appendix 3) was obtained at this point. 
 
The following information was obtained and documented on a case report form (CRF – 
see appendix 4): medical history, lifestyle risk factors (diet/exercise), risk perception 
question, family history of cardiovascular disease, smoking status, and concomitant 
medication. Exercise was classified as either none, 1-2 times per week, moderate 3-4 
times per week or strenuous 5-7 times per week along with a qualitative description of 
the type of exercise. Diet was qualitatively described. The risk perception question was 
“compared with a person of your own age and sex, how would you rate your risk of 
having a heart attack or stroke in the next 10 years?” Participants were asked to 
answer either “much lower than average”, “lower than average”, “average”, “higher 
than average” or “much higher than average”. A family history of cardiovascular 
disease was defined as disease in a female first degree relative aged less than 65 
years or male first degree aged less than 55 years. Smoking status was classified as 
either “never smoked”, “ex-smoker” or “current smoker”. If participants were ex-
smokers or current smokers their average number of cigarettes, cigars or pipes 
smoked per day along with the number of years smoked was recorded. To convert 
other tobacco types to equivalent smoking of cigarettes 1 pipe was counted as 2.5 
cigarettes, 1 Hamlet (or equivalent size) as 2.5 cigarettes, 1 Havana (or equivalent 
size) as 4 cigarettes and 1 café crème cigar (or equivalent size) as 1.5 cigarettes. 
Using participants’ postcodes their decile of Scottish Index of Multiple Deprivation 
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(SIMD) was determined. SIMD is a tool used by the Scottish government to identify 
areas where individuals may experience multiple deprivation (not for identifying 
individuals who are deprived). Postcodes can be used to determine if someone lives in 
an area of increased risk of deprivation which has been shown to be associated with 
cardiovascular risk.[228]  
 
Participants were examined to obtain their height, weight, waist circumference and 
blood pressure. Height and weight were measured using a vertical measuring stick and 
calibrated scales respectively. These measurements were used to calculate body mass 
index (BMI) by dividing weight in kilograms by height in metres squared. Waist 
circumference was measured using a flexible plastic measuring tape which were 
replaced at regular intervals to avoid stretching of the plastic. Participants were asked 
to lift their clothing to expose the abdominal area while standing. The narrowest waist 
level, or if this was not apparent, at the midpoint between the lowest rib and top of the 
iliac crest, was measured with the tape measure lying flat on the skin. This 
measurement was taken once for each participant. A 12 lead electrocardiogram (ECG) 
was recorded for each subject using ECG machines that were calibrated annually. 
Blood pressure was measured using a manual sphygmomanometer and stethoscope 
after the participant had been at rest for at least 15 minutes. It was measured in the left 
arm with the arm rested on a table at heart level. If the initial reading was greater than 
145mmHg (systolic) or 90mmHg (diastolic) a second reading was taken. If this 
remained elevated a third reading was taken. If this was still elevated the participant 
was excluded from the study and referred to their GP for follow up an appropriate 
clinical management. If more than one reading was taken the lowest reading was used 
for calculations and data analysis. Those excluded due to hypertension did not have 
their full cardiovascular risk assessed. 
 
Blood was obtained by venepuncture for analysis of lipid profile, glucose and B-type 
natriuretic peptide (BNP). Blood was collected in BD vacutainer tubes (Becton, 
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Dickinson and Company, Franklin Lakes, New Jersey, USA). Samples for the lipid and 
glucose assay were collected in a serum SST tube (silicone coated interior with clot 
activator and gel for serum separation) and for BNP in ethylenediaminetetraacetic acid 
(EDTA) tube. Glucose measurement was only started halfway through recruitment so 
blood glucose results are not available for all participants.  
 
The lipid profile (random total cholesterol, low density lipoprotein (LDL) cholesterol, 
high density lipoprotein (HDL) cholesterol and triglycerides – mmol/L) and glucose 
(mmol/L) were measured using the Alere Cholestech LDX analyser (Alere, Waltham, 
Massachusetts, USA). This machine also calculated the estimated 10 year coronary 
heart disease (CHD) risk using the National Cholesterol Education Program (NCEP) 
Adult Treatment Panel III (ATP III) guidelines.[229] The method of lipid and glucose 
determination is explained in detail in product literature.[230] The inter-assay bias limits  
from the product literature were -1%, -2%, 0% and 0% for total cholesterol, HDL 
cholesterol, triglycerides and glucose respectively. The intra-assay coefficients of 
variation were 2.5%, 3.4%, 1.6% and 6.2% for total cholesterol, HDL cholesterol, 
triglycerides and glucose respectively.[230] The cassette separates the plasma from 
blood cells. A portion of the plasma then flowed to one side of the cassette where low 
and very low density lipoproteins were precipitated with dextran sulphate and 
magnesium acetate. The filtrate from that process were then passed to the glucose 
and HDL cholesterol reaction pads. Another portion of the plasma flowed to the total 
cholesterol and triglyceride reaction pads. Cholesterol esterase hydrolysed the 
cholesterol esters to free cholesterol and the corresponding fatty acid. Cholesterol 
oxidase, in the presence of oxygen, oxidized free cholesterol to cholest-4-ene-3-one 
and hydrogen peroxide. In a reaction catalyzed by horseradish peroxidase, the 
peroxide reacted with 4-aminoantipyrine and N-ethyl-N-sulfohydroxypropyl-m-toluidine, 
sodium salt (TOOS) to form a purple-coloured quinoneimine dye proportional to the 
total cholesterol and HDL cholesterol concentrations of the sample. Triglycerides were 
measured by an enzymatic method based on the hydrolysis of triglycerides by lipase to 
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glycerol and free fatty acids. Glycerol, in a reaction catalyzed by glycerol kinase, was 
converted to glycerol-3-phosphate. In a third reaction, glycerol-3-phosphate was 
oxidized by glycerol phosphate oxidase to dihydroxyacetone phosphate and hydrogen 
peroxide. The colour reaction utilizing horseradish peroxidase was the same as for the 
total cholesterol and HDL cholesterol. LDL cholesterol level is calculated using the 
Friedewald calculation (LDL= Total cholesterol – HDL – triglycerides/2.17).[231] Levels 
of triglycerides lower than 0.51mmol/l could not be determined by the assay and levels 
above 4.51mmol/l can result in inaccurate estimation of LDL levels. Therefore if the 
triglycerides fell outside this range the machine was unable to calculate the LDL level. 
Glucose was measured by an enzymatic method that used glucose oxidase to catalyse 
the oxidation of glucose to gluconolactone and hydrogen peroxide. The colour reaction 
utilizing horseradish peroxidase was again the same as that for total cholesterol, HDL 
cholesterol and triglycerides. The resultant colour in all of the reactions was measured 
by reflectance photometry. 
 
BNP levels (pg/ml) were measured using the Alere Triage BNP assay (Beckman 
Coulter, Inc, Brea, California, USA) with an Alere Triage MeterPro (Alere, Waltham, 
Massachusetts, USA). The BNP assay was a two-site immunoenzymatic assay using 
mouse monoclonal anti-human BNP antibody-alkaline phosphatase conjugate and 
paramagnetic particles coated with mouse omniclonal anti-human BNP antibody. 
Following incubation materials bound to the solid phase were held in a magnetic field 
and unbound materials were washed away. The machine then used a luminometer to 
measure light generated (directly proportional to the concentration of BNP) by a 
reaction from addition of a chemiluminescent substrate. The test used plasma using 
ethylenediaminetetraacetic acid (EDTA) as the anticoagulant. The machine was 
calibrated as advised by the product literature. The intra-assay coefficient of variation 
for low level BNP (as in the TASCFORCE study) from the product literature was 
9.2%.[232]  
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Blood was also obtained for storage in the Tayside Tissue biobank for later analysis of 
endothelial and vascular markers. For those subjects who consented to participate in a 
genetic sub-study further blood was obtained for DNA analysis in EDTA tubes. These 
samples were frozen for analysis at a later date. 
 
2.3.3. Cardiovascular risk estimation 
Subjects found to have a CHD risk of greater than or equal to 20% over 10 years as 
assessed by the near patient testing equipment using the National Cholesterol 
Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines[229] and 
who were therefore potentially eligible for statin treatment under current guidelines, 
were ineligible to continue in the study. Subjects were also ineligible to proceed if they 
had a blood pressure greater than 145/90 mmHg (after at least three readings), if blood 
was impossible to obtain by venepuncture or if the bedside machine was unable to 
calculate their risk score (i.e. it was very high). These subjects were then asked for 
written informed consent to have their records electronically tagged to be followed up in 
the same way as participants in the main study (see below). Ineligible subjects were 
informed of their indication for risk factor management by the study nurse/doctor, given 
a copy of their results and asked to attend their General Practitioner for formal review. 
The GP was informed of any risk factor(s) using a standard letter e.g. all subjects found 
to be hypertensive (BP<145/90mmHg) or who had a predicted coronary heart disease 
risk of ≥20% over 10 years. Those with estimated risk levels below that recommended 
for treatment and with a BP<145/90mmHg were enrolled to the study. In line with local 
clinical guidelines those with a random blood glucose level >7mmol/l (including those 
with a level .11mmol/l) were advised of the need to have this followed up with a repeat 
fasting sample at their GP surgery to determine if they had diabetes. Such participants’ 
GPs were also informed of their random blood glucose result. Because glucose testing 
was not offered to about half the participants (it was introduced partway through 
recruitment) an increased level was not used to exclude people from the study. 
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All participants (both those who were eligible and those not eligible due to increased 
CHD risk or hypertension) received counselling on modifiable risk factors. This took the 
form of general information about blood pressure and cholesterol supplemented by 
individualised information based on smoking history and cholesterol results. Verbal 
information was supplemented by written material about smoking, healthy diet and 
blood pressure prepared by the British Heart Foundation. All participants’ GPs were 
informed about their blood results, blood pressure and BMI results and whether repeat 
samples and/or clinical review by the GP was advised. 
 
ASSIGN scores[41] were calculated for all eligible participants by using the 
demographic and cardiovascular risk variables collected and inputting them in the 
ASSIGN score algorithm. This was performed retrospectively after all participants had 
been recruited and not at the time of recruitment. 
 
2.3.4. BNP measurement and allocation to MRI group 
Once 200 subjects had been recruited the median BNP result (16.5pg/ml) was 
calculated for these 200 subjects. Those with a BNP greater than this median were 
allocated to the MRI/BNP group and invited to attend for an MRI scan at visit 2 (see 
below). The subjects not in the MRI/BNP group were called the BNP population. A 
further planned assessment was performed after 1000 participants had been recruited 
and on this occasion it was observed that the median BNP was higher for women than 
men (16.4pg/ml v 8.2pg/ml) resulting in very few men being allocated to the MRI/BNP 
group. The trial steering committee therefore decided to allocate subjects based on 
their gender specific median BNP value and the protocol was amended accordingly. 
Those subjects recruited early who were allocated to the BNP group but would be 
eligible for an MRI based on their gender specific median were recalled and asked to 
undergo MRI scanning. If the delay to this was greater than three months they had 
their BP, BNP, lipid profile and glucose rechecked to ensure continued eligibility and 
also had their height and weight remeasured. Hypertension is more prevalent with 
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increasing age and lipid profiles and BMI can change over time due to changes in 
dietary intake and exercise profile. Natriuretic peptide levels increase with age[141] 
and have also been shown to change over time and can reflect dynamic changes in 
cardiovascular risk.[169] 
 
A number of participants were also initially excluded from having an MRI scan on the 
basis of a metal in situ e.g. previous penetrative eye injury or exposure to metal 
fragments but would otherwise have been deemed eligible as per their BNP level. After 
consideration by the trial steering committee it was decided that such subjects should 
be recalled, as their risk during MRI was low. If interested in proceeding with an MRI 
scan research staff re-established their eligibility and MRI safety status if necessary by 
having an orbital x-ray. As with the recalled patients above, where the duration 
between Visit 1 and the proposed Visit 2 was greater than 3 months, subjects had their 
cholesterol, glucose and BNP levels and BP reassessed to ensure continued eligibility. 
Height and weight was re-measured. 
Also recruited was a substudy of participants of South Asian ethnicity which was 
incorporated in the protocol to examine potential differences in risk and subclinical 
disease in this ethnic group compared to a Caucasian population. This also ensured 
representation of this group within the whole study population. South Asians enrolled in 
this substudy were invited for an MRI scan regardless of their BNP result. 
 
2.3.5. MRI acquisition technique 
Subjects allocated to the MRI/BNP group had a whole body contrast enhanced MRI 
scan (WB CE-MRI) comprising cardiac (CMR) and whole body MRI angiogram (MRA) 
performed at visit 2 at the clinical research centre at Ninewells Hospital and Medical 
School, Dundee. The validation of the technique has been described in detail in an 
earlier paper.[233] The scans were performed in an integrated examination on a 32-
channel 3.0 Tesla Magnetom Trio scanner (Siemens, Erlangen, Germany). Patients 
were positioned head first in a supine position. Six sets of surface coils were used to 
  
 
73 
cover the body: head matrix coil (12 elements), neck matrix coil (4 elements), 2x body 
matrix coils (each with 6 elements), peripheral angiography coil (16 elements), and 
spine matrix coil (up to 24 elements depending on patient size) (see figure 2.7). Initial 
three-plane “localiser” scout images were acquired for the MRA using 500 mm field-of-
view (FOV) gradient echo fast low-angle shot (FLASH) sequence in the coronal, 
sagittal, and transverse planes from head to foot. This provided 4 anatomical stations: 
head and chest, abdomen, upper legs and lower legs (figure 2.8). Localizer images 
were positioned with an “overlap” between each FOV of at least 75 mm but adjustable 
according to patient height. Localizer TurboFLASH images of the heart in the two-
chamber, four-chamber and short axis (SA) orientations were also acquired. All 3D 
acquisitions were then planned using these scout images. 
 
Figure 2.2: Participant undergoing whole body CE-MRI scan. 
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Figure 2.3: MRI stations/fields of view (FOV) 
 
Station 1 and 4 images are acquired after the first injection of contrast agent.  Station 2 and 3 
images are acquired after the second injection of contrast agent. Overlap between stations was 
at least 75mm but varied with participant height. 
 
Protocol section 1-cine imaging and cardiac MRI and LV function 
ECG-gated segmented breath-hold cine true fast imaging with steady state precision 
(TrueFISP) images were acquired in the LV 4 chamber and 2 chamber orientations. A 
stack of short axis images from the atrioventricular ring to the left ventricular apex were 
then acquired using 2D ECG-gated breath-hold segmented CINE TrueFISP sequence 
with retrospective gating. The imaging parameters included repetition time 
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3.4milliseconds, echo time of 1.5milliseconds and flip angle 50°. Each slice was 6mm 
thick with a 4mm gap. Two slices were taken per breath hold of less than 15 seconds 
and scan time was minimized using parallel imaging generalised autocalibrating 
partially parallel acquisition (GRAPPA) factor of two. Imaging parameters for all the 
scan protocol stages are summarised in table 2.1. 
 
Table 2.1: Imaging parameters for all sequences run within the combined CMR and 
MRA protocol. 
Protocol 
Section 1 1 2 2 3 3 4 4 
Description CINE CINE WB-MRA WB-MRA TI-Scout PSIR WB-MRA WB-MRA 
Location Heart Heart LV Station 1 Station 4 Heart LV Heart LV Station 2 Station 3 
Sequence 2D TFi 2D TFi 3D TFl 3D TFl 2D TFi 2D PSIR 3D TFl 3D TFl 
Cardiac Phases 25 25 - - Variable - - - 
ECG Gating Retro Retro - - Pro Pro - - 
Lines/segment 14 26 - - 9 25 - - 
Orientation 4ch & 2ch SA Coronal Coronal SA SA Coronal Coronal 
TR/TE (ms) 3.37/1.48 3.37/1.48 2.68/1.00 2.61/0.96 3.11/1.99 5.21/1.99 2.60/0.96 3.47/1.21 
FA (o) >50 >50 19 22 35 20 16 37 
FOV (mm) >360 >360 360x500 360x500 >360 >360 344x500 344x500 
Phase FOV (%) 84.4 84.4 71.9 68.8 81.3 75.0 68.8 71.9 
Slice thickness 
(mm) 6 6 1.1 1 8 6 1.3 1.4 
Number Slices 1 2 96 80 1 2 96 96 
Resolution 
(pixels) 216x256 173x256 313x512 277x448 78x192 144x256 264x512 242x448 
Voxel Size (mm) Variable Variable 
1.1x1.0x1.
1 
1.2x1.1x1.
0 Variable Variable 
1.3x1.0x1.
3 
1.5x1.1x1.
4 
i-PAT x2 x2 x3 x3 - x2 x3 x3 
K-space Linear Linear 3D centric 3D centric Centric Linear 3D centric 3D centric 
BW (Hz/pix) 930 930 700 700 965 287 700 740 
Scan time (s) <20 <20 18 14 <20 <20 14 16 
LV = left ventricle, TFi = TrueFISP, TFl = TurboFLASH, PSIR = phase sensitive inversion 
recovery, Retro = Retrospective, Pro = Prospective, 4ch = Four Chamber, 2ch = Two Chamber, 
SA = Short Axis, TR = Repetition Time, TE = Echo Time, FA = Flip Angle, FOV = Field of View, 
i-PAT = integrated Parallel Acquisition Technique, BW = Bandwidth. 	
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Protocol section 2-WB-MRA stations 1 and 4 
The technique for whole body contrast enhanced magnetic resonance angiography 
(WB CE-MRA) has been optimised and validated by the TASCFORCE research group 
and is described in detail in an earlier publication.[203] Unenhanced CE-MRA “mask” 
data were acquired for each station using a 3D TurboFLASH sequence, and the 
scanner table was preset to move at a rate of 50 cm/s. 10 ml of 0.05 mmol/ml gadoteric 
acid (Dotarem, Guerbet, France) followed by 20 ml saline flush was delivered at the left 
or right antecubital fossa using a Spectris Solaris power injector (MedRad, Pittsburgh, 
PA, USA) at a rate of 1.5 ml/s. While standard contrast doses were used as part of the 
protocol, average patient weights in each group were used to calculate a contrast 
agent dose per weight for each group. Timing was controlled by a coronal 2D Care 
Bolus acquisition (MR fluoroscopy), and the contrast-enhanced acquisition for station 1 
commenced when contrast agent arrival was noted at the top of the aortic arch. Post-
contrast data for station 4 were acquired immediately after completion of station 1, and 
these were acquired three times consecutively to account for variable arterial transit 
times to the distal leg vessels. 
 
Protocol section 3-cardiac MRI of myocardial viability with phase-sensitive inversion 
recovery (PSIR) 
An ECG-gated segmented breath-hold 2D inversion-recovery prepared CINE TrueFISP 
“TI-Scout” sequence was implemented (in a central short-axis position) 8-10 min after 
initial contrast medium injection in order to identify the null point inversion time for the 
myocardium. Subsequently, at a mean of 11 min post-contrast medium administration 
(range 9-16 minutes) a short-axis stack of ECG-gated segmented 2D PSIR images 
were acquired in order to highlight any late gadolinium enhancement (LGE) within the 
myocardium. The mean inversion time used was 376ms (range 300-450 ms). 
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Protocol section 4-WB-MRA stations 2 and 3 
Unenhanced 3D Turbo-FLASH “mask” data were acquired for each station. The 
second contrast agent dose of 15ml was infused at 1.5 ml/s followed by a 20 ml saline 
flush using the same equipment as in protocol section 1. Timing was again controlled 
by 2D Care Bolus (coronal plane abdominal aorta), and post-contrast scans for station 
2 were triggered when the bolus could be seen arriving in the abdominal aorta. Due to 
the presence of contrast from the first injection, the arrival of the contrast bolus in the 
abdominal aorta was not always obvious at the second injection. Therefore, the timing 
information from the first injection was used in conjunction with MR fluoroscopy to start 
the post-contrast acquisitions of stations 2 and 3, after the mask images had been 
acquired. The timing was used to identify when contrast was expected in the 
abdominal aorta and the scan was started as a brighter ‘‘blush’’ was seen on the 
fluoroscopic acquisition. Post-contrast data for station 3 were acquired immediately 
after completion of the station 2 sequence. The average time between first and second 
contrast agent injections was 19 min (range 15-34 min). Finally, the pre- and post-
contrast WB-MRA data were subtracted and the resulting images were stitched using a 
multi-modality work platform (MMWP; Composing, Siemens, Erlangen, Germany). 
Multiplanar reconstructions (MPR) and maximum intensity projections (MIP) were also 
generated for further radiological interpretation. 
 
2.3.6. MRI left ventricular quantification 
CMR images were analysed offline by one of six blinded observers using commercial 
software (‘Argus’, Siemens Multi-modality Work Platform, version VB 15 and VB 17).  
Electronic region of interest (ROI) contours were placed manually around endocardial 
and epicardial left ventricular borders on all CMR image slices at end-diastole and end-
systole that were identified to contain 50% or more full-thickness myocardium (see 
figure 2.9).  Papillary muscles were included in the LV mass if the muscle structure was 
indistinguishable from the myocardial wall, but otherwise assigned to the left ventricular 
blood pool.  All myocardium (whether normal or displaying delayed gadolinium 
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enhancement) was included. The process of contour placement was repeated such 
that every patient dataset at both time-points was analysed twice in order to optimize 
the measurement precision (no participants were imaged more than once to check 
reproducibility of image acquisition). From these contours, quantitative measurement of 
the areas of the left ventricular muscle and left ventricular blood pool were calculated. 
These areas were then multiplied by the slice thickness and the slices summed to 
derive the left ventricular muscle and left ventricular blood pool volumes. These were 
then used to calculate end-diastolic volume, end-systolic volume, stroke volume and 
ejection fraction. Cardiac output was calculated by multiplying stroke volume by heart 
rate and LVM was calculated by multiplying the left ventricular muscle volume at end 
diastole by the specific gravity of myocardium (1.05g/ml).  
 
Figure 2.4: Defining endocardial border (red) and epicardial border (green) at end of 
diastole (left) and end of systole (right) 
 
The LVM was indexed (LVMI) to account for body size using a selection of techniques 
reported in the literature. This was performed by dividing LVM by the index value. The 
index values used were body surface area (BSA) calculated using the Dubois formula, 
BSA calculated using the Mosteller formula, height, height1.7 and height2.7. 
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The detection of gadolinium enhanced infarcts was performed manually on standard 
image analysis workstations (using Carestream PACS v10.1 on Barco 3MP monitors) 
based on an established myocardial segmentation and nomenclature using a 17 
segment model.[234] 
 
2.3.7. MRI angiogram scoring technique 
WB CE-MRA images were analysed by one of four blinded observers on standard 
image analysis workstations (using Carestream PACS v10.1 on Barco 3MP monitors) 
using the original source (3D FLASH post-contrast) images, along with subtracted 
MPRs and MIPs. The MRI whole-body arterial tree for every patient was divided 
anatomically into 31 segments: right and left internal carotid arteries, right and left 
vertebral arteries, right and left common carotid arteries, innominate artery, right and 
left subclavian arteries, aortic arch, thoracic aorta, abdominal aorta, coeliac artery, 
superior mesenteric artery, inferior mesenteric artery, right and left renal arteries, right 
and left iliac arteries, right and left femoral arteries, right & left profunda femoris 
arteries, right and left popliteal arteries, right and left anterior tibial arteries, right and 
left common peroneal arteries, and right and left posterior tibial arteries. Each arterial 
segment was assessed for the presence of luminal stenosis and/or aneurysm and 
allocated a code in a spreadsheet (table 2.2). If any arterial segment contained more 
than one luminal abnormality then the more severe abnormality was scored. 
Aneurysms were counted if they were greater than 50% wider than the proximal normal 
artery. A score was then allocated for each arterial segment (see table 2.2) based on 
the severity of any stenosis and/or aneurysm. This score reflected the degree of 
stenosis with an extra point being given for the presence of aneurysm. If a segment 
was uninterpretable because of poor image quality or if it was not included in the scan 
because of stopping of the scan before completion (e.g. due to claustrophobia) it was 
not allocated a numeric score. The scores for each arterial segment were then added 
together to give a total whole body atheroma score (WBAS). To account for 
uninterpretable segments the total score was divided by the number of interpretable 
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segments to produce a normalised whole body atheroma score. A standardised 
atheroma score (SAS) was calculated using the following equation where n is the 
number of interpretable segments: 
 
Regional standardised atheroma scores were also calculated to reflect possible 
different disease distributions. The regions were: head and neck (internal carotid, 
vertebral, innominate, common carotid, and subclavian arteries), aorta (aortic arch, 
thoracic aorta, abdominal aorta), abdominal (coeliac trunk, superior and inferior 
mesenteric and renal arteries), ileofemoral (common, external and internal iliac 
arteries, common and superficial femoral arteries and profunda femoris arteries) and 
run off arteries (popliteal, anterior tibial, posterior tibial and peroneal arteries). 
 
Table 2.2: Coding and scoring for WB CE-MRA arterial segments. 
Abnormality Code  Score ascribed to 
contribute to whole body 
atheroma score 
Normal 0 0 
<50% stenosis 1 1 
51-70% stenosis 2 2 
71-99% stenosis 3 3 
Occluded segment 4 4 
Aneurysm but no stenosis 5 1 
Aneurysm and <50% stenosis 6 2 
Aneurysm and 51-70% stenosis 7 3 
Aneurysm and 71-99% stenosis 8 4 
Aneurysm and occlusion 9 5 
1 100
4
score
SAS
n
⎡ ⎤⎛ ⎞
= × ×⎢ ⎥⎜ ⎟⎜ ⎟⎢ ⎥⎝ ⎠⎣ ⎦
∑
  
 
81 
2.3.8. MRI angiogram interpretation validation 
The angiograms were assessed by one of four observers so it was important that inter-
observer reproducibility was assessed to ensure that scoring was not dependent on 
individual observers. Intra-observer reproducibility was also assessed to further 
validate the technique. To achieve this 48 scans were randomly selected by a trial 
statistician. These 48 scans were all assessed by all four WB CE-MRA observers to 
allow assessment of inter-observer reproducibility. A consensus score was determined 
for each segment based on the most common score if there was disagreement 
between observers. If there was no clear consensus from the initial assessments a 
further review by at least 2 of the observers produced a “consensus score” for that 
segment. 
 
Each observer also assessed a subset of 12 scans twice to assess intra-observer 
reproducibility. The second assessment was performed at least 1 month after the first 
assessment to reduce the impact of learning.  
 
2.3.9. MRI incidental findings 
As would be expected when scanning a large number of individuals some MRI scans 
revealed incidental findings ranging from congenital anatomical abnormalities to 
previously undiagnosed pathology such as potential tumours. All scans were reported 
by a trained radiologist shortly after being acquired. When an abnormality was found, 
which in the opinion of the radiologist merited further clinical assessment or 
investigation, the incidental finding was reviewed by one of the study doctors. 
Depending on the nature of the finding the participant was either invited to have a 
further clinical assessment by one of the study doctors or referred to their GP for 
further review. The participant was informed of this by a telephone call. Further 
investigation and management was then arranged as appropriate. Summaries of the 
radiological incidental findings found are summarised along with the further clinical 
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activity (clinical reviews, medication commencement, further imaging) required as a 
result of the findings. 
 
 
2.4. Follow up 
 
2.4.1. Health Informatics Centre data linkage 
Participants’ health records (both those who failed screening and those who were 
eligible for the study) have been electronically tagged with the Scottish Office’s 
Information Services Division (ISD) via the Health Informatics Centre (HIC) at the 
University of Dundee as well as at their local hospital Trusts’ Medical Information 
departments. Using anonymised data linkage by HIC follow up data on a variety of 
clinical outcomes was planned to be obtained 2 years after recruitment initially then at 
regular intervals for up to 20 years. Ethical approval for this was obtained and this was 
explicit in the participant information sheet. Data obtained comprised: 
• all details of hospital admissions including the diagnoses made  and procedures 
performed during the admissions, 
• all details of prescriptions issued by the participants general practitioners, 
• all details of deaths registered with the general registrar office (GRO) including 
details of cause of death. 
 
2.4.2. Outcome measures 
The primary predefined aim of the study was the ability of increased left ventricular 
mass, as assessed by contrast enhanced MRI, to predict future CV events. It is 
recognised that less than half of the total study population were imaged as their 
selection was based on BNP level however the trial steering committee felt that this 
measure had the best existing evidence base and was most likely to be predictive of 
future events. 
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Secondary aims of the study were: 
1. the ability to predict future CV events and disease using whole body contrast 
enhanced magnetic resonance angiography (WB CE-MRA) in the MRI/BNP 
group; 
2. the ability to predict future CV events and disease using a combination of BNP 
levels and WB CE-MRA; 
3. the ability to predict future CV events and disease using BNP and other 
biomarkers in both the MRI/BNP and BNP groups. 
 
Using record linkage as described above the incidence of a number of endpoints were 
determined for both the study population and those who failed screening initially at 2 
years from end of study recruitment and regularly thereafter. The time since 
recruitment that these events occur was determined. The endpoints were determined 
using (international classification of disease version 10 (ICD-10) codes and procedures 
using Office of Population, Censuses and Surveys Classification of Surgical Operations 
and Procedures (4th revision) (OPCS-4) codes. These are codes used by hospitals to 
record all diagnoses (ICD) and procedures or operations (OPCS) that are relevant to 
an individual during a hospital visit. Endpoints of interest were myocardial infarction 
(fatal and non-fatal), hospitalisation for angina, requirement for any endovascular 
procedure (e.g. angioplasty, stent, by-pass grafting), stroke, sudden death and all-
cause mortality. The ICD-10 codes of interest are summarised in table 2.3 and the 
OPCS-4 codes in table 2.4. Analyses were performed separately including and 
excluding peripheral arterial disease (PAD) diagnoses and procedures. Those codes 
for PAD are highlighted in grey. 
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Table 2.3: ICD-10 end point codes 
Code Diagnosis 
I20.0 Unstable angina 
I20.8 Other forms of angina pectoris 
I20.9 Angina pectoris, unspecified 
I21 (including all 
subdivisions) 
Acute myocardial infarction 
I24.0 Coronary artery thrombosis not resulting in myocardial infarction 
I24.8  Other forms of acute ischaemic heart disease 
I24.9 Acute ischaemic heart disease, unspecified 
I25.0 Atherosclerotic cardiovascular disease, so described 
I25.1 Atherosclerotic heart disease 
I25.6 Silent myocardial ischaemia 
I46.1 Sudden cardiac death, so described 
I61 (including all 
subdivisions) 
Intracerebral haemorrhage 
I63.0 Cerebral infarction due to thrombosis of precerebral arteries 
I63.1 Cerebral infarction due to embolism of precerebral arteries 
I63.2 Cerebral infarction due to unspecified occlusion or stenosis of 
precerebral arteries 
I63.3 Cerebral infarction due to thrombosis of cerebral arteries 
I63.4 Cerebral infarction due to embolism of cerebral arteries 
I63.5 Cerebral infarction due to unspecified occlusion or stenosis of 
cerebral arteries 
I63.8 Other cerebral infarction 
I63.9 Cerebral infarction, unspecified 
I64 Stroke, not specified as haemorrhage or infarction 
I70 (including all 
subdivisions) 
Atherosclerosis 
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Table 2.4: OPCS-4 codes 
Code Procedure 
K23.4 Revascularisation of wall of heart 
K40 (all 
subdivisions) 
Saphenous vein graft replacement of coronary artery 
K41 (all 
subdivisions) 
Other autograft replacement of coronary artery 
K42 (all 
subdivisions) 
Allograft replacement of coronary artery 
K43 (all 
subdivisions) 
Prosthetic replacement of coronary artery 
K44 (all 
subdivisions) 
Other replacement of coronary artery 
K45 (all 
subdivisions) 
Connection of thoracic artery to coronary artery 
K46.1 Double implantation of mammary arteries into heart 
K46.2 Double implantation of thoracic arteries into heart NEC 
K46.3 Implantation of mammary artery into heart NEC 
K46.4 Implantation of thoracic artery into heart NEC 
K46.5 Revision of implantation of thoracic artery into heart 
K46.8 Other specified other bypass of coronary artery 
K46.9 Unspecified other bypass of coronary artery 
K47.1 Endarterectomy of coronary artery 
K48.3 Open angioplasty of coronary artery 
K48.4 Exploration of coronary artery 
K48.8 Other specified other open operations on coronary artery 
K48.9 Unspecified other open operations on coronary artery 
K49 (all 
subdivisions) 
Transluminal balloon angioplasty of coronary artery 
K50.1 Percutaneous transluminal laser coronary angioplasty 
K50.2 Percutaneous transluminal coronary thrombolysis using streptokinase 
K50.4 Percutaneous transluminal atherectomy of coronary artery 
K50.8 Other specified other therapeutic transluminal operations on coronary artery 
K50.9 Unspecified other therapeutic transluminal operations on coronary artery 
K75 (all 
subdivisions) 
Percutaneous transluminal balloon angioplasty and insertion of stent into  
coronary artery 
L26.1 Percutaneous transluminal balloon angioplasty of aorta 
L26.2 Percutaneous transluminal angioplasty of aorta NEC 
Continued on next page 
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Table 2.4 continued 
L26.5 Percutaneous transluminal insertion of stent into aorta 
L26.6 Transluminal aortic stent graft with fenestration NEC 
L26.7 Transluminal aortic branched stent graft NEC 
L29 Reconstruction of carotid artery 
L29.1 Replacement of carotid artery using graft 
L29.2 Intracranial bypass to carotid artery NEC 
L29.3 Bypass to carotid artery NEC 
L29.4 Endarterectomy of carotid artery and patch repair of carotid artery 
L29.5 Endarterectomy of carotid artery NEC 
L29.6 
High-flow interposition extracranial to intracranial bypass from external carotid 
artery to middle cerebral artery 
L29.7 
Bypass of carotid artery by anastomosis of superficial temporal artery to middle 
cerebral artery 
L29.8 Other specified reconstruction of carotid artery 
L29.9 Unspecified reconstruction of carotid artery 
L30.1 Repair of carotid artery NEC 
L30.3 Open embolectomy of carotid artery 
L30.8 Other specified other open operations on carotid artery 
L30.9 Unspecified other open operations on carotid artery 
L31.1 Percutaneous transluminal angioplasty of carotid artery 
L31.3 Endovascular repair of carotid artery 
L31.4 Percutaneous transluminal insertion of stent into carotid artery 
L31.8 Other specified transluminal operations on carotid artery 
L31.9 Unspecified transluminal operations on carotid artery 
L34.3 Open embolectomy of cerebral artery 
L35.3 Percutaneous transluminal insertion of stent into cerebral artery 
L35.8 Other specified transluminal operations on cerebral artery 
L35.9 Unspecified transluminal operations on cerebral artery 
L37 Reconstruction of subclavian artery 
L37.1 Bypass of subclavian artery NEC 
L37.2 Endarterectomy of vertebral artery 
L37.3 Endarterectomy of subclavian artery and patch repair of subclavian artery 
L37.4 Endarterectomy of subclavian artery NEC 
L37.8 Other specified reconstruction of subclavian artery 
L37.9 Unspecified reconstruction of subclavian artery 
L38.3 Open embolectomy of subclavian artery 
Continued on next page 
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Table 2.4 continued 
L39.1 Percutaneous transluminal angioplasty of subclavian artery 
L39.2 Percutaneous transluminal embolectomy of subclavian artery 
L39.5 Percutaneous transluminal insertion of stent into subclavian artery 
L39.8 Other specified transluminal operations on subclavian artery 
L39.9 Unspecified transluminal operations on subclavian artery 
L41.2 Bypass of renal artery 
L41.3 Replantation of renal artery 
L41.4 Endarterectomy of renal artery 
L41.5 Translocation of branch of renal artery 
L41.6 Patch angioplasty of renal artery 
L41.8 Other specified reconstruction of renal artery 
L41.9 Unspecified reconstruction of renal artery 
L42.1 Open embolectomy of renal artery 
L43.1 Percutaneous transluminal angioplasty of renal artery 
L43.2 Percutaneous transluminal embolectomy of renal artery 
L43.5 Percutaneous transluminal insertion of stent into renal artery 
L43.8 Other specified transluminal operations on renal artery 
L43.9 Unspecified transluminal operations on renal artery 
L45 (all 
subdivisions) 
Reconstruction of other visceral branch of abdominal aorta 
L46.1 Open embolectomy of visceral branch of abdominal aorta NEC 
L47.1 
Percutaneous transluminal angioplasty of visceral branch of abdominal aorta 
NEC 
L47.4 
Percutaneous transluminal insertion of stent into visceral branch of abdominal 
aorta NEC 
L47.8 
Other specified transluminal operations on other visceral branch of abdominal 
aorta 
L47.9 Unspecified transluminal operations on other visceral branch of abdominal aorta 
L50 (all 
subdivisions) 
Other emergency bypass of iliac artery 
L51 (all 
subdivisions) 
Other bypass of iliac artery 
L52.1 Endarterectomy of iliac artery and patch repair of iliac artery 
L52.2 Endarterectomy of iliac artery NEC 
L53.2 Open embolectomy of iliac artery 
L54.1 Percutaneous transluminal angioplasty of iliac artery 
L54.2 Percutaneous transluminal embolectomy of iliac artery 
L54.4 Percutaneous transluminal insertion of stent into iliac artery 
Continued on next page 
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Table 2.4 continued 
L54.8 Other specified transluminal operations on iliac artery 
L54.9 Unspecified transluminal operations of iliac artery 
L58 (all 
subdivisions) 
Other emergency bypass of femoral artery 
L59 (all 
subdivisions) 
Other bypass of femoral artery 
L60 (all 
subdivisions 
Reconstruction of femoral artery 
L62.2 Open embolectomy of femoral artery 
L63.1 Percutaneous transluminal angioplasty of femoral artery 
L63.2 Percutaneous transluminal embolectomy of femoral artery 
L63.5 Percutaneous transluminal insertion of stent into femoral artery 
L63.8 Other specified transluminal operations on femoral artery 
L63.9 Unspecified transluminal operations on femoral artery 
L66.1 Percutaneous transluminal arterial thrombolysis and reconstruction 
L66.2 Percutaneous transluminal stent reconstruction of artery 
L66.5 Percutaneous transluminal balloon angioplasty of artery 
L66.7 Percutaneous transluminal placement of peripheral stent in artery 
L66.8 Other specified other therapeutic transluminal operations on artery 
L66.9 Unspecified other therapeutic transluminal operations on artery 
L68.1 Endarterectomy and patch repair of artery NEC 
L68.2 Endarterectomy NEC 
L70.1 Open embolectomy of artery NEC 
L71.1 Percutaneous transluminal angioplasty of artery 
L71.2 Percutaneous transluminal embolectomy of artery 
L71.5 Percutaneous transluminal dilation of artery 
L71.6 Percutaneous transluminal thrombolysis of artery 
L71.7 Percutaneous transluminal atherectomy 
L71.8 Other specified therapeutic transluminal operations on other artery 
L71.9 Unspecified therapeutic transluminal operations on other artery 
L76 (all 
subdivisions) 
Endovascular placement of stent 
L89 (all 
subdivisions) 
Other endovascular placement of stent 
 
 
 
  
 
89 
For those who died during follow up underlying cause of death, as recorded on death 
certificates, was provided by HIC/ISD supplemented by information from hospital 
records, including post-mortem examinations, if performed.  
 
Data on prescribing was also obtained from GP records (via HIC) to determine if and 
when preventative cardiovascular medication was prescribed for both the eligible 
population and screen fail population. These were identified by British National 
Formulary (BNF) codes. The codes of interest are shown in table 2.5. 
 
Table 2.5: Cardiovascular medication of interest at follow up 
BNF code Drug 
2.1.1 Digoxin 
2.2.1 Thiazides and related diuretics 
2.2.2 Loop diuretics 
2.2.3 Potassium sparing diuretics and aldosterone 
antagonists 
2.2.4 Potassium sparing diuretics with other diuretics 
2.2.8 Diuretics with potassium 
2.4 Beta-adrenoceptor blocking drugs 
2.5.2 Centrally acting antihypertensive drugs 
2.5.4 Alpha-adrenoceptor blocking drugs 
2.5.5 (including subgroups 
2.5.5.1, 2.5.5.2, 2.5.5.3) 
Drugs affecting the renin angiotensin system 
2.6.1 Nitrates 
2.6.2 Calcium-channel blockers 
2.6.3 Other antianginal drugs 
2.6.4 Peripheral vasodilators and related drugs 
2.8.2 Oral anticoagulants 
2.9 Antiplatelet drugs* 
2.12 Lipid regulating drugs 
BNF = British National Formulary. *Analysis was performed with and without aspirin as this is 
used for many non-cardiovascular indications. 
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2.5. Data entry and management 
Data from the screening visit was entered on the CRF and transcribed to a password 
protected Access database (Microsoft Corporation, Redmond, USA). Data for the left 
ventricular assessments and WB CE-MRAs were entered on separate password-
protected Excel spreadsheets (Microsoft Corporation, Redmond, USA) as the images 
were assessed. Once all image analysis had been completed demographic, risk factor 
and imaging data was merged in a single password protected Excel spreadsheet which 
was securely sent to the Health Informatics Centre (HIC) for follow up data linkage. 
HIC anonymised the data by ascribing a unique identifier (prochi) to each participant 
and rounding their date of birth to the nearest three months. The same prochi 
identifiers were used for the follow up data provided by HIC. This allowed linkage of the 
various pieces of data to allow statistical analysis to be performed. The anonymised 
data was placed in a secure server within HIC (Safehaven) where linkage and 
analyses were performed. 
 
Before statistical analysis and data linkage was performed the data in the databases 
was cleansed to ensure it was accurate and as complete as possible. This was 
performed by ML and took a period of approximately 6 months although as analysis 
began further inaccuracies in the data were discovered requiring cross-checking and 
correction. Where inaccuracies, suspected inaccuracies or previously unidentified 
missing data were discovered the appropriate source documents or case report forms 
were consulted and corrections to the database were made as required. All corrections 
were logged so that changes could be audited. Accurate Community Health Index 
(CHI) numbers were required to ensure correct data linkage. These were checked by 
cross-checking them with dates of birth (the first 6 digits of CHIs correspond to 
individuals DOB). Several dates of birth were found to be inaccurate resulting in 
incorrect ages being calculated. All variables were summarised for maximum and 
minimum to identify significant outliers potentially due to typing errors (e.g. systolic BP 
1300). The gender variable was cross-checked between the study database and the 
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screening log and also with the demographic data obtained via the data linkage to find 
cases where the gender had been miscoded. 
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2.6. Statistical analysis 
Statistical analyses were performed using computer software (R 3.1 (R Foundation for 
Statistical Computing, Vienna, Austria) and SPSS v 21 (IBM, New York, USA)). A 2-
sided p value of <0.05 was taken to be significant for analyses. The statistical analysis 
plan was predetermined before data analyses. 
 
2.6.1. Missing data 
Missing data was quantified by ML in terms of number and percentage of data cases 
with missing data for each variable. Table 2.6 shows details of missing data from visit 1 
data. 
 
Where missing data accounted for less than 5% of the total cases missing data was 
treated as missing completely at random and the mean value for that variable was 
imputed. The only variable in the visit 1 data with 5% or more of cases missing was 
LDL cholesterol. This variable is calculated using the triglyceride, total cholesterol and 
HDL levels using the Friedewald equation. However if the triglyceride level is below the 
lower limit of the assay (0.51mmol/l) or above 4.51mmol/l the LDL level cannot be 
accurately estimated. The vast majority of cases of missing data for LDL were for this 
reason. Where the LDL measurement was missing cases were excluded from 
analyses. 
 
  
  
 
93 
Table 2.6: Summary of missing data of visit 1 variables 
Variable Number 
missing 
% missing How missing data dealt 
with/notes 
Age 0 0 NA 
Systolic BP 0 0 NA 
Diastolic BP 0 0 NA 
Heart rate 19 0.4 Mean value imputed 
Total Cholesterol 1 <0.01 Mean value imputed 
HDL cholesterol 2 <0.01 Mean value imputed 
LDL cholesterol 323 7.3 Cases excluded from 
analysis 
Triglycerides 3 0.1 Mean value imputed 
Glucose 2391 54.1 Not included in analyses or 
summarised in this report* 
ATPIII 10 year cardiovascular 
risk 
9 0.2 Mean value imputed 
ASSIGN score 44 1.0 Mean value imputed 
Height 5 0.1 Mean value imputed 
Waist circumference 27 0.6 Mean value imputed 
Family history of CVD 0 0 NA 
SIMD decile 11 0.2  
BNP 2 <0.01 Mean value imputed 
Weight 4 0.1 Mean value imputed 
Sex 0 0 NA 
Smoking status 8 0.2  
BP=blood pressure, HDL=high density lipoprotein, LDL=low density lipoprotein, ATPIII= Adult 
Treatment Panel III, CVD=cardiovascular disease, SIMD=Scottish Index of Multiple deprivation, 
BNP= B-type natriuretic peptide. *Glucose measurement was only introduced after over half the 
study participants were recruited so over 50% have data missing. Therefore it has not been 
included in any analyses in this report. 
 
 
2.6.2. Sample Size 
The study aimed to recruit a total of 5000 subjects. Sub-division into the MRI group or 
BNP group was dependent upon the measured BNP level at the Visit 1. 
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The incidence of CV events was compared between the total MRI/BNP population and 
the BNP group. With 2 groups of 2500, one would have 80% power to distinguish rates 
of e.g. 2.7% v 1.5% ; RR= 1.8. The MRI/BNP groups were further divided into 
MRI/BNP1 and MRI/BNP2  depending on whether their BNP was above their gender 
specific 75th percentile (i.e. splitting the MRI/BNP group in 2) to reflect those likely to 
have higher and lower left ventricular masses as per our hypothesis.  In the 2 years 
follow-up we would expect the cumulative incidence in MRI/BNP1 and MRI/BNP2 to be 
1.6% and 3.6% (8%/5 years and 18%/5 years). With 1250 in each group the power to 
detect this difference is 85%. 
 
2.6.3. Baseline data analysis 
Baseline cardiovascular risk factor, demographic and BNP data were summarised for 
the study population as a whole and for the BNP and MRI/BNP groups separately. The 
distributions of variables were assessed by plotting histograms of the variables. For 
normally distributed variables mean and standard deviation were calculated. For 
variables with a skewed distribution median and interquartile range were calculated. 
For categorical variables numbers and percentages were calculated. Differences in 
variables between BNP and MRI/BNP groups were compared using independent 
samples t-test for variables with a normal distribution Mann-Whitney tests for variables 
with a skewed distribution and chi square test for categorical variables. BNP results 
were calculated separately for men and women. Summaries of baseline characteristics 
were also calculated for gender specific quartiles of participants based on their BNP 
result. Differences in these variables between the top and bottom quartiles of BNP 
(gender specific) were assessed using independent samples t-tests for normally 
distributed variables, Mann-Whitney tests for variables with a skewed distribution and 
chi square test for categorical variables. Gender specific medians, 75th and 90th 
percentiles were calculated for age groups 40-44, 45-49, 50-54, 55-59, 60-64, 65-69 
and 70+. Multivariable linear regression analyses were used to identify variables that 
were independently associated with BNP levels from among age, gender, smoking 
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status, systolic BP, diastolic BP, heart rate, total cholesterol, HDL cholesterol, LDL 
cholesterol, triglycerides, glucose, BMI, waist circumference, family history of 
cardiovascular disease and SIMD decile. BNP was log10 transformed for this analysis 
to normalise its distribution. 
 
The ASSIGN scores[41] were compared with the CHD risk scores calculated using the 
ATPIII guidelines[229] (that had been used to screen for eligibility for the study). The 
number and cardiovascular characteristics of those who would be reclassified using 
ASSIGN from low or intermediate risk to high risk were calculated. Similarly ASSIGN 
scores were calculated for those who failed screening for inclusion in the study based 
on a high predicted cardiovascular risk (using ATPIII). The number and characteristics 
of those who would be reclassified as intermediate or low risk and therefore may have 
been included in the study if ASSIGN score had been used to determine eligibility are 
presented. The mean difference between the ASSIGN and ATPIII scores for each 
individual was also calculated. 
 
Descriptive demographic and cardiovascular risk statistics of the population who 
underwent MRI scans were calculated and presented as means and standard 
deviations for variables with a normal distribution, medians and interquartile ranges for 
those with a skewed distribution and as frequencies and percentages for those with 
categorical outcomes. Left ventricular measures were summarised for men and women 
separately. The nature of the distribution of the left ventricular variables was assessed 
by plotting histograms of the variables. Left ventricular mass was indexed using a 
variety of methods reported in the literature (by dividing by height, height1.7, height2.7, 
body surface area calculated using the Dubois formula[235] and body surface area 
calculated using the Mosteller formula[236]). Differences in the measures between the 
2 genders were compared using independent samples t-tests. Correlations between 
BNP and LV measures were assessed using Spearman rank correlation tests. Mean 
LV parameters were compared between those with BNP levels above and below 
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gender specific 75th, 90th and 95th percentiles using independent samples t-tests. 
Gender specific univariate analyses of baseline cardiovascular and demographic risk 
factors with LV results were performed using Spearman rank correlations. Multivariable 
linear regression analysis was performed to identify variables that were associated with 
the various LV measures. The models included age, systolic BP, diastolic BP, heart 
rate, HDL cholesterol, LDL cholesterol, triglycerides, BMI, waist circumference, 
smoking status, family history of CVD, SIMD decile and BNP. Age, heart rate, 
triglycerides, BMI and BNP were log transformed to normalise the distribution of the 
variables as were all the left ventricular measures except stroke volume (which already 
had a normal distribution). 
 
Standardised atheroma scores (SAS) derived from the whole body angiography were 
presented as medians, 80th percentile and 90th percentile as the variable was very 
strongly positively skewed. Total population and gender specific univariate analyses 
were performed using Spearman rank correlation to investigate associations between 
SAS and baseline cardiovascular risk factors and BNP, and between the percentage of 
arterial segments with any stenosis and baseline cardiovascular risk factors and BNP. 
Multivariable linear regression analysis was performed to identify variables that 
predicted the SAS. The initial model included age, gender, smoking status, systolic BP, 
diastolic BP, heart rate, total cholesterol, HDL cholesterol, LDL cholesterol, 
triglycerides, BMI, waist circumference, family history of cardiovascular disease, SIMD 
decile and BNP level. Differences in baseline variables were compared between those 
with SAS below and above 80th percentile and between those with any arterial stenosis 
and those with none (SAS = 0 v. SAS >0). Independent samples t-test was used for 
variables with a normal distribution and Mann-Whitney test for variables with a skewed 
distribution. Correlations between LV measures and SAS and between LV measures 
and percentage of arterial segments with any stenosis were analysed using Spearman 
rank correlation. Mean left ventricular measurements were compared between those 
with an SAS greater and less than the gender specific 80th percentile and between 
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those with and without any arterial stenosis (SAS = 0 v. SAS>0) using independent 
samples t tests. 
 
2.6.4. Screen fail population 
Baseline data 
Baseline cardiovascular risk factor, demographic and BNP data were summarised for 
the participants who failed screening due to predicted cardiovascular risk ≥20% or 
hypertension. Figures were calculated separately for the 2 groups (hypertension and 
high CV risk). For normally distributed variables mean and standard deviation were 
calculated. For variables with a skewed distribution median and interquartile range 
were calculated. For categorical variables numbers and percentages were calculated. 
 
Prescribing data 
Those who failed screening due to either hypertension, high CV risk or dyslipidaemia 
and who had been prescribed a cardiovascular drug of interest indicated by the BNF 
codes described earlier in section 2.4.2 were identified. Minimum, maximum, and 
quartiles of time since last prescription until time of screening was calculated for the 
population as a whole and for the hypertensive and high cardiovascular risk groups 
separately. 
 
For participants who failed screening due to hypertension, high CHD risk or 
dyslipidaemia and who had not received a prescription of interest in the 6 months prior 
to screening (to exclude those who were already on or had recently received drugs of 
interest) take up rates of post-screening cardiovascular drugs of interest were 
calculated, with each person’s follow-up time calculated from screening date to earliest 
of first drug of interest prescription, death or end of study date. Rates of prescription 
were calculated per 1000 patient years at risk. For analysis of time to first prescription, 
Kaplan Meier analysis was performed comparing time to first prescription between 
those who failed screening due to hypertension and high cardiovascular risk. 
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The effect of CV medication prescription on event rates in those who had failed 
screening due to hypertension, high CHD risk or dyslipidaemia and who had not 
received a prescription of interest in the 6 months prior to screening was investigated. 
Each person’s follow up was split into 56 day intervals. At the start of each 
interval binary exposure statuses were recorded (1 if prescription issued in previous 56 
days, 0 otherwise), along with current age. A time-updated Cox proportional hazard 
survival model including current exposure status, current age and sex was used to 
assess the effect of current exposure on CV event hazard.	
 
2.6.5. Assessment of Outcomes 
Participants in the MRI/BNP Group were withdrawn (censored) from the time to event 
analysis once they had experienced a cardiovascular event or procedure indicated by 
the ICD10 or OPCS4 codes described earlier in section 2.4.2. If ICD10 or OPCS4 
codes belonged to the specified codes and the date was after the recruitment date, the 
time to event or hospital admission was calculated as the difference between 
admission date and recruitment date. Where a subject had no events/admissions, time 
at risk was calculated as the difference between the date the participant was last 
known to be alive and recruitment date. For analysis of time to first admission, life table 
analysis was used, by 1-year intervals. From GRO death data, we determined the date 
of death where available. Survival time in days was calculated by subtracting the 
recruitment date from date of death. For subjects still alive, the time of follow-up was 
found from the time between recruitment and date of latest update or date withdrawn 
from study, whichever was earlier. 
 
Time to first admission for any of the ICD/OPCS ranges or death were calculated 
(primary outcome). It was planned to analyse separately for outcomes of MI, angina, 
stroke and sudden death but at the early stage of follow up reported in this thesis only 
a very small number of events had occurred so this sub analysis has not been 
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performed. It is planned to do this for further follow up analyses in the future when 
more events are expected to occur. 
 
Cumulative incidence of events and death was compared between BNP groups, with 
95% CI. Relative risk (hazard ratio) with 95% CI for high versus low BNP were 
calculated from a Cox regression model. 
 
It was planned to analyse incidence rates of death at follow up using life table analysis 
of all-cause mortality by BNP level (high versus low) to determine cumulative mortality 
rates at 2 years. Death from MI, angina, stroke and sudden death were to be analysed 
separately. However at the stage of follow up reported in these thesis (mean follow up 
per participant 4.03 and 4.33 years for BNP and MRI/BNP groups respectively) only 2 
deaths had occurred so this analysis was not performed. It is planned to do this for 
further follow up analyses at 5, 10, 15 and 20 years. 
 
Event rates and 95% confidence intervals (combined death and cardiovascular events) 
were calculated for those with LVM, LVMIs (using each of the indexing methods) in the 
top and bottom quartiles for their gender. The difference in rates were deemed as 
significant if the CIs did not overlap.  
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3. Results part 1 – study participants 
 
3.1. Recruitment and eligibility 
5015 people attended the CRC at Ninewells Hospital (n=2066, 41.2% male) for 
screening between 26th November 2007 and 6th February 2013. 64 (n=21, 32.8% male) 
were found not to meet the inclusion or met exclusion criteria for a variety of reasons 
shown in the figure. A further 90 people (n=34, 37.8% male) were excluded as either 
they lived outside the recruitment area (n=4, all male) or it was not possible to calculate 
a cardiovascular risk score because either blood was not obtained (n=52, 9 male), the 
sample could not be analysed or HDL too low or high for the algorithm to calculate the 
score (n=30, 21 male). 
 
291 (137 47.1% male)  were failed at the screening phase due to hypertension, defined 
as a BP >145/90mmHg. A further 146 (142, 97.3% men) were then excluded due to a  
predicted cardiovascular risk score ≥20% and 1 (woman) was excluded due to marked 
dyslipidaemia. The characteristics of those who failed screening  are described in 
section 3.2. 
 
4423 (1740, 39.3% male) participants were therefore eligible to be allocated to either 
the BNP or BNP/MRI groups depending on their BNP result. 
 
The CONSORT diagram (figure 3.1) summarises the flow of participants through the 
TASCFORCE study including those who were excluded at the screening visit. 
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Figure 3.1 CONSORT diagram showing participant flow through study 
 
MRI=magnetic resonance imaging, BNP=B-type natriuretic peptide, CV=cardiovascular 
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3.2. Cardiovascular risk incidental findings 
438 participants (8.7% of those screened) were found to have either an estimated 10 
year cardiovascular risk of >20%, hypertension or dyslipidaemia requiring treatment 
under current guidelines. The characteristics of these groups of participants are 
summarised in table 3.1.  
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Table 3.1: Characteristics of subjects excluded due to presence of cardiovascular risk 
(characteristics of the eligible population are included for comparison) 
Variable 
Screen fail population Eligible population 
(n=4423) Hypertensive (BP> 
145/90 mmHg) 
(n=291) 
10 year CHD risk 
≥20% (n=146) 
Median (IQR) age (years) 58.2 (12.2) 58.7 (15.2) 51.2 (11.8) 
No (%) men 138 (47.4) 142 (97.3) 1740 (39.3) 
No (%) current smokers 34 (11.7) 85 (58.2) 572 (12.9) 
No (%) former smokers 65 (22.3) 24 (16.4) 1226 (27.7) 
No (%) never smokers 151 (51.9) (N/A41) 37 (25.3) 2617 (59.2) 
Mean (SD) systolic BP(mmHg)   156.5 (9.8) 132.2 (10.9) 122.4 (11.9) 
Mean (SD) diastolic BP(mmHg)   88.9 (9.7) 77.3 (9.5) 73.4 (9.3) 
Medan (IQR) heart rate (beats per 
min) 
72 (16) (N/A215) 68 (14) (N/A11) 65 (12) 
Mean (SD) total cholesterol (mmol/L) 5.69 (1.03) (N/A55) 6.07 (1.02) 5.48 (1.00) 
Mean (SD) high density lipoprotein 
(mmol/l) 
1.42 (0.48) (N/A58) 0.89 (0.24) 1.38 (0.43) 
Mean (SD) low density lipoprotein 
(mmol/l) 
3.34 (0.92) (N/A71) 3.93 (0.93) (N/A17) 3.40 (0.90) 
Median (IQR) triglycerides (mmol/l) 1.82 (1.38) (N/A55) 2.50 (1.93) 1.34 (1.09) 
Median (IQR) Body mass index 
(kg/m2) 
27.5 (5.5) (N/A202) 28.3 (4.7) (N/A6) 26.5 (5.58) 
Median (IQR) weight (kg) 82.0 (18.6) (N/A202) 83.6 (17.3) (N/A6) 74.7 (20.7) 
Mean (SD) height (cm) 168.5 (8.2) (N/A202) 173.4 (7.5) (N/A6) 167.4 (9.2) 
Mean (SD) waist circumference (cm) 91.1 (13.4) (N/A216) 97.0 (12.9) (N/A10) 87.5 (13.3) 
Median (IQR) 10 year CHD event risk 
estimation (%) 
5.0 (9.0) (N/A72) 20.0 (5.0) 2.0 (5.0) 
No (%) with family history of CVD 49 (16.8) (N/A96) 35 (23.2) (N/A9) 1075 (24.3) 
SIMD Number (%) 1 12 (4.1) 8 (5.5) 217 (4.9) 
2 19 (6.5) 11 (7.5) 251 (5.7) 
3 29 (10.0) 20 (13.7) 357 (8.1) 
4 19 (6.5) 10 (6.8) 250 (5.7) 
5 14 (4.8) 10 (6.8) 269 (6.1) 
6 21 (7.2) 14 (9.6) 424 (9.6) 
7 45 (15.5) 22 (15.1) 683 (15.4) 
8 51 (17.5) 22 (15.1) 843 (19.1) 
9 61 (21.0) 24 (16.4) 799 (18.1) 
10 18 (6.2) 4 (2.7) 319 (7.2) 
N/A 2 (0.7) 1 (0.7) 11 (0.2) 
Mean and standard deviation are given for variables with a normal distribution and median and 
interquartile range for those with a skewed distribution. SD=standard deviation. 
IQR=interquartile range. BP=blood pressure. CHD=coronary heart disease, 
CVD=cardiovascular disease, SIMD=Scottish Index of Multiple Deprivation. Full data was not 
collected for all screen-failed participants: the number of participants with missing data is 
indicated in italics. Only one subject was excluded due to dyslipidaemia so summary figures are 
not given for this person. N/A=not available. 
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3.3. Baseline characteristics of eligible participants 
 
3.3.1. Demographics and baseline cardiovascular risk factors 
4423 participants were eligible to enter the main part of the study. 2376 people (937 
male) were allocated to the BNP group and 2047 (803 male) were allocated to the 
MRI/BNP group based on their BNP result. The characteristics of the participants in 
each of these groups and the eligible population as a whole are summarised in table 
3.2. Compared to the BNP group the MRI/BNP group was older, contained less current 
smokers and more never smokers, had a slightly higher systolic blood pressure, lower 
resting heart rate, higher high density lipoprotein (HDL), lower triglycerides, slightly 
lower BMI and lower waist circumference. They had a higher predicted risk using both 
the ATPIII and ASSIGN algorithms and contained more people with an intermediate 
predicted risk (10-19.9%). 
 
The distribution of age is illustrated in figure 3.2. The distribution of CHD risk scores for 
the BNP and the MRI/BNP populations are illustrated in figure 3.3. Both these 
distributions were positively skewed. 
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Table 3.2: Baseline characteristics of participants eligible for the TASCFORCE study 
Baseline characteristics Eligible 
population 
(n=4423) 
BNP group 
(n=2376) 
MRI/BNP 
group 
(n=2047) 
Difference 
between BNP 
and MRI/BNP 
groups* 
Median (IQR) age (years) 51.2 (11.8) 49.5 (10.6) 53.4 (12.5) p<0.001 
No (%) men 1740 (39.3) 937 (39.4) 803 (39.3) p=0.94 
No (%) current smokers 572 (12.9) 351 (14.8) 221 (10.8) p<0.001 
No (%) former smokers 1226 (27.7) 663 (27.9) 563 (27.5) p=0.81 
No (%) never smokers 2617 (59.2) 1361 (57.3) 1256 (61.4) p=0.004 
Mean (SD) systolic BP(mmHg)   122.4 (11.9) 122.1 (11.7) 122.9 (12.0) p=0.027 
Mean (SD) diastolic BP(mmHg)   73.4 (9.3) 73.6 (9.4) 73.1 (9.2) p=0.06 
Median (IQR) heart rate (bpm) 65 (12) 67 (14) 63 (12) p<0.001 
Mean (SD) total cholesterol (mmol/L) 5.48 (1.00) 5.47 (1.02) 5.48 (0.99) p=0.79 
Mean (SD) high density lipoprotein 
(mmol/l) 
1.38 (0.43) 1.34 (0.44) 1.43 (0.42) p<0.001 
Mean (SD) low density lipoprotein 
(mmol/l) 
3.40 (0.90) 3.41 (0.92) 3.40 (0.42) p=0.84 
Median (IQR) triglycerides (mmol/l) 1.34 (1.09) 1.38 (1.18) 1.29 (1.02) p<0.001 
Median (IQR) body mass index 
(kg/m2) 
26.5 (5.6) 26.7 (5.8) 26.2 (5.4) p<0.001 
Median (IQR) weight (kg) 74.7 (20.7) 75.0 (21.2) 74.1 (20.0) p=0.08 
Mean (SD) height (cm) 167.4 (9.2) 167.1 (9.1) 167.7 (9.3) p=0.041 
Mean (SD) waist circumference (cm) 87.5 (13.3) 88.0 (13.6) 86.9 (13.0) p=0.006 
Median (IQR) 10 year CHD event risk 
estimation using ATPIII algorithm (%) 
2.0 (5.0) 2.0 (5.0) 2.0 (5.0)↑ p<0.001 
Median (IQR) 10 year cardiovascular 
event estimation using ASSIGN 
algorithm (%) 
7.0 (7.3) 6.6 (6.7) 7.6 (6.7) p<0.001 
No (%) with 10 year CHD risk 10-
19.9% (using ATPIII algorithm) 
602 (13.6) 286 (12.0) 316 (15.4) p=0.001 
No (%) with family history of CV 
disease 
1075 (24.3) 561 (23.6) 514 (25.1) p=0.25 
SIMD Number (%) 1 217 (4.9) 132 (5.6) 85 (4.2) p=0.054 
2 251 (5.7) 145 (6.1) 106 (5.2) 
3 357 (8.1) 208 (8.8) 149 (7.3) 
4 250 (5.7) 134 (5.6) 116 (5.7) 
5 269 (6.1) 143 (6.0) 126 (6.2) 
6 424 (9.6) 218 (9.2) 206 (10.1) 
7 683 (15.4) 349 (14.7) 334 (16.3) 
8 843 (19.1) 442 (18.6) 401 (19.6) 
9 799 (18.1) 428 (18.0) 371 (18.1) 
10 319 (7.2) 169 (7.1) 150 (7.3) 
N/A 11 (0.2) 8 (0.3) 3 (0.1) - 
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[Notes for table 3.2] 
IQR=inter-quartile range, SD=standard deviation, SIMD = Scottish Index of Multiple Deprivation, 
ATPIII=Adult Treatment Panel III. 
For variables with a normal distribution mean and standard deviation are given. For those with a 
skewed distribution median and interquartile range are given. *Comparisons for continuous 
variables with normal distributions are independent samples unpaired t-tests and for skewed 
distribution and ranked scores (i.e. SIMD) the Wilcoxan Mann-Whitney test. Chi-square tests 
were used for binomial variables. 
 
 
Figure 3.2: Distribution of age in the eligible population 
 
 
BNP = B-type natriuretic peptide. BNP group = those with BNP less than their gender median. 
MRI/BNP group = those with BNP less than their gender median. Frequency scale is number of 
participants. 
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Figure 3.3: Distribution of CHD risk scores calculated using ATPIII algorithm in the 
BNP and MRI/BNP populations 
 
 
BNP=B-type natriuretic peptide. BNP group=those with BNP less than their gender median. 
MRI/BNP group=those with BNP less than their gender median. Frequency scale is number of 
participants. 
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The spread of participants from deciles of the Scottish Index of Multiple Deprivation 
(SIMD) is illustrated in figure 3.4. The distribution of TASCFORCE participants by 
SIMD decile is compared with the Tayside entire and working populations in figure 3.5. 
Those from areas of less deprivation were slightly overrepresented compared to those 
from areas of greater deprivation. The distributions of SIMD deciles were similar for 
both the BNP and MRI/BNP groups. 
 
Figure 3.4: Spread of Scottish Index of Multiple Deprivation (SIMD) scores in eligible 
population 
 
Lower deciles of SIMD indicate living in an area of increased multiple deprivation. 
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Figure 3.5: Distribution of TASCFORCE participants by SIMD decile compared with 
Tayside working population (left) and Tayside total population (right) 
 
Tayside population data from 2006 SIMD data for Dundee City, Angus and Perth and Kinross 
local authority areas.[237] Lower deciles of SIMD indicate living in an area of increased multiple 
deprivation. SIMD = Scottish Index of Multiple Deprivation. 
 
4282 (1685 men) consented to having their blood samples retained to enter the genetic 
substudy. It is planned to genotype these samples to look for genetic variations that 
may be associated with cardiovascular disease. 
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3.3.2. BNP results 
The B-type natriuretic peptide (BNP) results for eligible participants are summarised in 
table 3.3. The distribution of BNP results is illustrated in the histograms (figure 3.6). 
The median BNP results were higher for women compared to men. For comparison the 
cut off BNP value for allocating participants to the BNP or MRI/BNP groups (the gender 
specific median after recruitment of 2000 people) is given to allow comparison of the 
final study population with this cut off. BNP results were strongly positively skewed for 
both men and women. 
 
Table 3.3: B-type natriuretic peptide (BNP) results for eligible participants 
 Median (IQR) pg/ml Cut off used for BNP v. 
MRI/BNP allocation 
All eligible participants 11.8 (14.6) N/A 
Men 7.5 (8.9) 8.2 
Women 15.3 (16.7) 16.4 
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Figure 3.6: Distribution of BNP results for men and women 
 
Values below the detection limit (5.0pg/ml) are reported as 4.9pg/ml. Frequency scale is 
number of participants. 
 
 
BNP results for men and women were compared using a Mann-Whitney test and 
demonstrated a significant difference for the results between the genders (p<0.001). 
Because the BNP results were positively skewed and mostly within a “normal” clinical 
range (e.g. below that for diagnosing heart failure) the values for 50th, 75th, 90th, 95th, 
97.5th and 99th percentiles have been calculated for each gender and are summarised 
in table 3.4.  
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Table 3.4: Percentiles of BNP results for each gender 
 Median 75th 
percentile 
90th 
percentile 
95th 
percentile 
97.5th 
percentile 
99th 
percentile 
Men 7.50 13.80 23.10 30.60 44.30 59.72 
Women 15.30 25.30 39.40 53.36 65.16 83.19 
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3.3.3. Comparison of estimated cardiovascular risk using ASSIGN and ATPIII 
algorithms 
The study used the ATPIII algorithm for deriving the predicted cardiovascular risk score 
however now local guidelines in Tayside advise the use of the ASSIGN risk score, 
which has been derived from a Scottish population. Therefore differences in the scores 
obtained for each participant using the two different scores were analysed. Table 3.5 
summarises the differences between the two risk prediction tools. 
 
Table 3.5: Differences between ATPIII and ASSIGN scores 
Scoring system End points Time 
point 
(years) 
Variables included 
ASSIGN[41] • Death from 
cardiovascular causes 
• Coronary heart 
disease 
• Cerebrovascular 
disease 
• Coronary artery 
interventions 
10 • Age 
• Gender 
• Family history of coronary 
heart disease/stroke 
• Diabetes 
• Rheumatoid arthritis 
• Smoking habit 
• Systolic blood pressure 
• Total cholesterol 
• High density lipoprotein 
• Social deprivation 
Adult Treatment 
Panel III[229] 
• Acute myocardial 
infarction 
• Coronary heart death 
(sudden or not) 
10 • Age 
• Gender 
• Systolic BP 
• Treatment for 
hypertension 
• Total cholesterol 
• High density lipoprotein 
• Smoking 
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Effect on reclassification 
The study population, including those who failed screening due to high predicted 
cardiovascular risk, were categorised according to their estimated 10 year 
cardiovascular risk: <10% were classified as low risk, 10-19.9% intermediate risk and 
>20% as high risk. Using the ASSIGN score resulted in the reclassification of 1105 
(24.7%) of participants with both ATPIII and ASSIGN scores available. Of these 992 
(22.1%) were “up-classified” to a higher risk category and 113 (2.5%) were “down-
classified”. Table 3.6 shows the breakdown of reclassification. 
 
Table 3.6: Reclassification of risk categories using the ASSIGN score instead of the 
ATPIII derived score (percentages reflect those reclassified from the given ATPIII 
derived category) 
Risk Category using 
ATPIII algorithm 
Risk category using ASSIGN score 
Low risk 
(<10%) 
Intermediate risk 
(10-19.9%) 
High risk 
(≥20%) 
Low risk (<10%) - 734 (19.3%) 109 (2.9%) 
Intermediate risk (10-
19.9%) 
61 (10.1%) - 149 (24.8%) 
High risk (>20%) 5 (3.4%) 47 (32.2%) - 
 
 
53 (36.3%) of participants found to be ineligible for the study due to a high ATPIII 
derived CHD risk score had an ASSIGN score <20 indicating that they may have been 
eligible for the study if this score had been used to determine eligibility. Those with an 
ASSIGN score less than 20 had a mean age of 51.9 years (SD 5.48), mean systolic BP 
of 125.7 mmHg (SD 11.10), mean diastolic BP 75.8 mmHg (SD 9.74), mean heart rate 
58.6 beats per minute (SD 40.6), mean total cholesterol 6.14 mmol/l (SD 0.98), mean 
HDL 0.90 mmol/l (SD 0.26), mean LDL 3.92 mmol/l (SD 0.91), median triglycerides 
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2.77 mmol/l (IQR 2) and median BMI 28.4 kg/m2 (IQR 5). 50 (94.3%) were male, 4 
(7.5%) were never smokers, 1 (1.9%) was an ex-smoker, 48 (90.6%) were current 
smokers and 10 (18.9%) had a family history of CV disease. 
 
258 (5.8%) participants found to be eligible for the study based on their ATPIII score 
had an ASSIGN score ≥20 (indicating a 10 year cardiovascular risk of ≥20% using the 
ASSIGN algorithm). Those with an ASSIGN score ≥20 had a mean age of 66.4 years 
(SD 9.66), mean systolic BP 130.7 mmHg (SD 9.53), mean diastolic BP 75.1 (SD 
8.84), mean heart rate 66.3 bpm (SD 9.66), mean total cholesterol 6.02 mmol/l (SD 
1.04), mean HDL 1.21 mmol/l (SD 0.40), mean LDL 3.88 mmol/l (SD 0.96), median 
triglycerides (1.83 mmol/l (IQR 1.33) and median BMI 27.0 kg/m2 (IQR 5.38). 140 
(54.3%) were male, 114 (44.2%) were never smokers, 98 (38.0%) were ex-smokers, 
46 (17.8%) were current smokers and 100 (38.8%) had a family history of CV disease. 
These characteristics and the distribution by SIMD deciles are summarised in table 3.7.  
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Table 3.7: Characteristics of participants with ASSIGN score ≥20. The figures for the 
entire eligible population (including those with ASSIGN score ≥20) are given for 
comparison 
Baseline characteristics ASSIGN score ≥20 
(n=258) 
Median (IQR) age (years) 66.4 (9.4) 
No (%) men 140 (54.3) 
No (%) current smokers 46 (17.8) 
No (%) former smokers 98 (38.0) 
No (%) never smokers 114 (44.2) 
Mean (SD) systolic BP(mmHg)   130.7 (9.5) 
Mean (SD) diastolic BP(mmHg)   75.1 (8.8) 
Median (IQR) heart rate beats per min 65 (14) 
Mean (SD) total serum cholesterol (mmol/L) 6.02 (1.04) 
Mean (SD) high density lipoprotein (mmol/l) 1.21 (0.40) 
Mean (SD) low density lipoprotein (mmol/l) 3.88 (0.96) 
Median (IQR) triglycerides (mmol/l) 1.83 (1.33) 
Median (IQR) body mass index 27.0 (5.4) 
No (%) with family history of CV disease 100 (38.8) 
Scottish Index of multiple deprivation 
(SIMD) Number (%) 
1 19 (7.4) 
2 23 (9.9) 
3 32 (12.4) 
4 18 (7.0) 
5 14 (5.4) 
6 24 (9.3) 
7 36 (14.0) 
8 44 (17.1) 
9 35 (13.6) 
10 13 (5.0) 
N/A 0 (0.0) 
BP= Blood pressure, IQR=interquartile range, SD=standard deviation,CV=cardiovascular, N/A= 
data not available (number indicates number of participants with no data). 
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Eligible population 
The distribution of estimated 10-year cardiovascular risk using both the ATP III 
guidelines and the ASSIGN score for those participants eligible to enter the study are 
illustrated in figure 3.7. The distributions of both of the scores were positively skewed. 
 
Figure 3.7: Distributions of ASSIGN risk scores (top) and risk score estimated using 
ATPIII algorithm (bottom) for all participants eligible to enter the TASCFORCE study 
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The correlation between the ATPIII risk score and ASSIGN score is shown in figure 
3.8. Using a Spearman rank correlation test the correlation between the 2 scores was 
very good (ρ=0.796, p<0.001). 
 
Figure 3.8: Correlation between ASSIGN and ATPIII risk scores 
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The difference between the predicted risk scores calculated using the ATPIII algorithm 
and those calculated using the ASSIGN algorithm is illustrated in figure 3.9. The mean 
difference between the scores was 4.72 with a maximum of 44.1 (a positive result 
indicating ASSIGN score greater than ATPIII score) and minimum -9.7 (a negative 
result indicating ASSIGN score less than ATPIII score). Most people had an ASSIGN 
score greater than their ATPIII score. 
 
Figure 3.9: Distribution of difference between ATPIII derived CHD risk score and 
ASSIGN derived CV risk score for participants eligible to enter the TASCFORCE study 
based on their ATPIII score 
 
Difference calculated by subtracting ATPIII score from ASSIGN score for each participant. 
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Potential participants who failed screening due to high cardiovascular risk 
The distribution of ASSIGN scores for those found to be ineligible for the TASCFORCE 
study at screening because of a high predicted CHD risk (using ATPIII guidelines) is 
illustrated in figure 3.10. The distribution of difference between ATPIII derived score 
and ASSIGN score is illustrated in figure 3.11. The mean difference between ATPIII 
derived score and ASSIGN score in this group was 2.23 (SD 10.34). As with the 
eligible population more people had an ASSIGN score that was greater than their 
ATPIII score. 
 
Figure 3.10: Distribution of ASSIGN scores in participants ineligible to enter 
TASCFORCE study due to high predicted cardiovascular risk using ATPIII guidelines 
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Figure 3.11: Distribution of difference between ATPIII derived CHD risk score and 
ASSIGN derived CV risk score in participants ineligible to enter TASCFORCE study 
due to high predicted CHD risk using ATPIII guidelines 
 
Difference calculated by subtracting ATPIII score from ASSIGN score for each participant. 
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3.3.4. Correlation of BNP with baseline cardiovascular risk factors 
Baseline characteristics are described for the 4 quartiles of participants based on BNP 
level for men in table 3.8 and for women in table 3.9. For men the 25th percentile was 
4.9 pg/ml, the median was 7.5 pg/ml and the 75th percentile was 13.8 pg/ml. Compared 
to men with a BNP in the lowest quartile those with a BNP in the top quartile were 
older, had a lower diastolic blood pressure, lower resting heart rate, higher HDL, lower 
triglycerides, slightly lower BMI and were less likely to come from areas of multiple 
deprivation. They also had a slightly higher predicted CHD risk. The differences in lipid 
levels, blood pressure and BMI were all small and within “normal” clinical ranges.  For 
women the 25th percentile was 8.5 pg/ml, the median was 15.3 pg/ml and the 75th 
percentile was 25.2 pg/ml. Compared to women with a BNP in the lowest quartile those 
with a BNP in the top quartile were also older, had a lower resting heart rate, 
triglycerides, and higher HDL but also had a slightly higher systolic blood pressure. 
They also had a slightly higher predicted 10 year CHD risk but this difference was less 
than in the men. 
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Table 3.8: Baseline characteristics of male participants according to BNP level 
Baseline characteristics 1st quartile 
(n= 523) 
2nd quartile 
(n= 352) 
3rd quartile 
(n= 433) 
4th quartile 
(n= 432) 
p value* 
Median (IQR) age (years) 47.4 (9.0) 50.6 (10.4) 51.8 (11.7) 54.6 (12.9) <0.001 
No (%) current smokers 67 (12.8) 31 (8.8) 42 (9.7) 46 (10.6) 0.30 
No (%) former smokers 132 (25.3) 121 (34.4) 124 (28.6) 126 (29.1) 0.18 
No (%) never smokers 323 (61.9) 199 (56.5) 266 (61.4) 260 (60.0) 0.59 
Mean (SD) systolic BP(mmHg)   124.7 (10.4) 124.8 (10.8) 125.3 (10.7) 125.1 (11.3) 0.541 
Mean (SD) diastolic BP(mmHg)   76.4 (8.8) 76.0 (9.3) 75.6 (8.7) 74.6 (8.8) 0.001 
Mean (SD) pulse pressure 
(mmHg) 
48.2 (9.6) 48.8 (9.7) 49.7 (9.6) 50.5 (9.7) <0.001 
Median (IQR) heart rate (beats 
per min) 
66.0 (14) 64.0 (14) 62.0 (11) 60.0 (13) <0.001 
Mean (SD) total cholesterol 
(mmol/L) 
5.46 (0.96) 5.52 (1.00) 5.45 (0.96) 5.40 (0.96) 0.30 
Mean (SD) high density 
lipoprotein (mmol/l) 
1.10 (0.37) 1.15 (0.36) 1.23 (0.38) 1.28 (0.39) <0.001 
Mean (SD) low density lipoprotein 
(mmol/l) 
3.46 (0.87) 3.51 (0.96) 3.43 (0.87) 3.39 (0.87) 0.24 
Median (IQR) triglycerides 
(mmol/l) 
1.70 (1.50) 1.73 (1.38) 1.49 (1.27) 1.51 (5.67) <0.001 
Median (IQR) body mass index 
(kg/m2) 
27.7 (4.9) 27.2 (4.8) 26.7 (4.4) 26.5 (4.9) <0.001 
Median (IQR) weight (kg) 85.0 (18.8) 84.0 (17.6) 83.0 (17.9) 82.9 (16.2) 0.009 
Mean (SD) height (cm) 175.4 (6.4) 175.4 (6.5) 175.6 (6.7) 176.1 (6.3) 0.10 
Mean (SD) waist circumference 
(cm) 
94.3 (11.4) 94.5 (11.4) 92.0 (10.9) 92.7 (12.4) 0.04 
Median (IQR) 10 year CHD event 
risk estimation using ATPIII 
algorithm (%) 
6.0 (5.0) 6.0 (6.0) 6.0 (6.0) 8.0 (8.0) <0.001 
No (%) with family history of CVD 99 (19.0) 63 (18.0) 93 (21.5) 98 (22.6) 0.16 
SIMD, Number (%) 1 28 (5.4) 17 (4.9) 22 (5.1) 14 (3.2) 0.047 
2 31 (5.9) 14 (4.0) 24 (5.5) 17 (3.9) 
3 47 (9.0) 35 (9.9) 28 (6.5) 32 (7.4) 
4 27 (5.2) 21 (6.0) 23 (5.3) 27 (6.2) 
5 30 (5.7) 16 (4.5) 29 (6.7) 24 (5.5) 
6 52 (10.0) 26 (7.4) 40 (9.2) 48 (11.1) 
7 81 (15.5) 59 (16.8) 58 (13.4) 72 (16.7) 
8 98 (18.8) 78 (22.2) 97 (22.4) 75 (17.3) 
9 92 (17.6) 62 (17.6) 77 (17.8) 82 (18.9) 
10 34 (6.5) 23 (6.5) 34 (7.9) 42 (9.7) 
SD=standard deviation, IQR=inter-quartile range, SIMD=Scottish Index of Multiple Deprivation, 
CV=cardiovascular.*comparison of 4th quartile with 1st quartile. Unpaired t-test was used for 
normally distributed variables, Mann-Whitney test for skewed and ranked variables and Chi-
square test for binomial variables. SIMD was treated as a continuous variable for the purpose of 
analysis. 25th percentile=4.9 pg/ml, median=7.5 pg/ml and 75th percentile=13.8 pg/ml. 
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Table 3.9: Baseline characteristics of female participants according to BNP level. 
Baseline characteristics 1st quartile 
(n= 671) 
2nd quartile 
(n= 679) 
3rd quartile 
(n= 661) 
4th quartile 
(n= 672) 
P value* 
Median (IQR) age (years) 49.5 (9.8) 50.9 (11.7) 52.4 (12.3) 54.4 (13.6) <0.001 
No (%) current smokers 131 (19.5) 95 (14.0) 80 (12.1) 80 (11.9) <0.001 
No (%) former smokers 188 (28.0) 183 (27.0) 180 (27.2) 172 (25.7) 0.38 
No (%) never smokers 353 (52.5) 401 (59.1) 401 (60.1) 414 (62.0) <0.001 
Mean (SD) systolic BP(mmHg)   120.2 (12.4) 120.6 (12.0) 120.5 (12.2) 121.9 (12.3) 0.010 
Mean (SD) diastolic BP(mmHg)   71.9 (9.5) 71.9 (9.0) 72.0 (9.1) 71.6 (9.4) 0.53 
Mean (SD) pulse pressure 
(mmHg) 
48.3 (9.7) 48.8 (9.5) 48.5 (9.7) 50.3 (9.9) <0.001 
Median (IQR) heart rate (beats 
per min) 
69.0 (13) 66.0 (12) 65.0 (11) 63.0 (12) <0.001 
Mean (SD) total cholesterol 
(mmol/L) 
5.43 (1.03) 5.51 (1.05) 5.53 (1.01) 5.50 (1.01) 0.20 
Mean (SD) high density 
lipoprotein (mmol/l) 
1.44 (0.42) 1.52 (0.42) 1.53 (0.41) 1.56 (0.40) <0.001 
Mean (SD) low density lipoprotein 
(mmol/l) 
3.32 (0.90) 3.40 (0.95) 3.42 (0.88) 3.35 (0.93) 0.54 
Median (IQR) triglycerides 
(mmol/l) 
1.28 (1.09) 1.21 (0.93) 1.17 (0.87) 1.17 (0.92) 0.005 
Median (IQR) body mass index 26.2 (6.0) 25.7 (6.1) 25.9 (6.0) 25.7 (5.8) 0.15 
Median (IQR) weight (kg) 68.2 (16.3) 68.0 (17.1) 68.0 (16.4) 68.9 (16.0) 0.75 
Mean (SD) height (cm) 161.4 (6.2) 162.0 (6.1) 162.5 (6.4) 162.2 (6.5) 0.034 
Mean (SD) waist circumference 
(cm) 
84.6 (12.8) 83.2 (13.0) 83.8 (12.5) 82.9 (12.8) 0.016 
Median (IQR) 10 year CHD event 
risk estimation using ATPIII 
algorithm (%) 
1.0 (2.0) 1.0 (2.0) 1.0 (2.0) 1.0 (2.0)↑ 0.001 
No (%) with family history of CVD 172 (25.6) 194 (28.6) 184 (27.8) 172 (25.7) 0.97 
SIMD, Number (%) 1 38 (5.7) 36 (5.3) 25 (3.8) 37 (5.5) 0.401 
2 48 (7.1) 43 (6.3) 32 (4.8) 42 (6.3) 
3 61 (9.1) 51 (7.5) 60 (9.1) 43 (6.4) 
4 38 (5.7) 43 (6.3) 36 (5.4) 35 (5.2) 
5 43 (6.4) 45 (6.6) 42 (6.3) 40 (6.0) 
6 57 (8.5) 71 (10.5) 70 (10.6) 60 (9.0) 
7 106 (15.8) 90 (13.3) 105 (15.9) 112 (16.7) 
8 110 (16.4) 127 (18.7) 125 (18.9) 133 (19.9) 
9 105 (15.6) 135 (19.9) 117 (17.7) 129 (19.3) 
10 64 (9.5) 36 (5.3) 50 (7.6) 36 (5.4) 
SD=standard deviation, IQR=inter-quartile range, SIMD=Scottish Index of Multiple Deprivation, 
CV=cardiovascular. 
*comparison of 4th quartile with 1st quartile. Unpaired t-test was used for normally distributed 
variables, Mann-Whitney test for skewed and ranked variables and Chi-square test for binomial 
variables. SIMD was treated as a continuous variable for the purpose of analysis. 25th 
percentile=8.5 pg/ml, median=15.3 pg/ml and 75th percentile=25.2 pg/ml. 
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Linear stepwise multiple regression modelling demonstrated that age, female sex, 
absence of ex-smoking status (but not current smoking status), lower heart rate, higher 
HDL and lower total cholesterol were associated with higher log10 serum BNP levels 
(table 3.10). The original model included age, gender, smoking status, systolic BP, 
diastolic BP, heart rate, total cholesterol, HDL cholesterol, LDL cholesterol, 
triglycerides, glucose, BMI, waist circumference, family history of cardiovascular 
disease, SIMD and predicted cardiovascular risk score. 
 
Table 3.10: Association of baseline cardiovascular risk factors with log10 BNP levels: 
linear stepwise multivariable regression analysis 
Variable Coefficient (95% CI) p value 
Age (years) 0.010 (0.009, 0.011) <0.001 
Male sex -0.211 (-0.230, -0.192) <0.001 
Ex-smoker -0.026 (-0.045, -0.006) 0.01 
Current smoker -0.009 (-0.036, 0.017) 0.49 
Heart rate (bpm) -0.006 (-0.007, -0.005) <0.001 
Total cholesterol (mmol/l) -0.020 (-0.028, -0.011) <0.001 
HDL (mmol/l) 0.055 (0.033, 0.076) <0.001 
HDL=high density lipoprotein, bpm = beats per minute, CI=confidence interval. 
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As age and gender have a large effect on BNP age and sex specific BNP median, 75th 
and 80th percentiles are summarised in table 3.11 and graphically illustrated in figure 
3.12. 
 
Table 3.11: Age and sex specific BNP median, 75th and 90th percentiles 
Age 
(years) 
Men Women 
n Median 75th 
percentile 
90th 
percentile 
n Median 75th 
percentile 
90th 
percentile 
40-44 402 5.6 10.2 17.8 536 12.5 21.2 33.2 
45-49 430 6.3 11.7 19.5 617 13.8 22.9 33.9 
50-54 348 8.1 13.8 21.8 554 14.7 24.3 39.4 
55-59 279 8.9 16.4 27.1 451 16.1 25.6 38.6 
60-64 175 11.6 17.3 30.1 307 19.2 28.4 42.4 
65-69 68 10.3 19.8 37.9 132 21.1 35.3 60.4 
70+ 34 27.1 43.5 62.1 78 32.9 59.5 84.4 
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Figure 3.12: Age and gender specific BNP median (top), 75th percentile (middle) and 
90th percentiles (bottom) 
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4. Results part 2 – MRI results 
 
4.1. Participant acceptability of MRI scan 
17 of those found to be eligible based on their original BNP result were found to be no 
longer eligible for scanning when their BNP was rechecked (the BNP cut off was 
changed after 200 people had been screened as described above). A substudy of 
participants of South Asian ethnicity was recruited to ensure diversity comparable with 
the UK population statistics. All recruits in this substudy were offered an MRI scan 
regardless of their BNP result. 30 South Asian participants were offered a scan 20 of 
whom had a BNP below their gender cut off. This resulted in 2050 participants being 
invited for an MRI scan. 
 
Of the 2050 participants eligible for or offered an MRI scan 373 (18.2%) did not 
consent for a scan and 12 (0.6%) failed to attend for their MRI scan appointment. 
 
1528 (74.8% of those invited) completed or partially completed the scan protocol. Of 
these 26 (1.3%) only partially completed the scan before it was abandoned due to 
claustrophobia. Any images obtained before the scan was abandoned were used for 
analysis where suitable. 
 
101 participants (4.9%) had their scan abandoned completely. In the majority of cases 
(83) this was due to claustrophobia. Other scans were abandoned due to large body 
habitus (3), inability to gain IV access (7), becoming unwell during cannulation (4), 
tissuing of intravenous access (2) or other technical issues (2). 34 (1.7%) were not safe 
to scan due to presence of metalwork. The characteristics of those who did not 
complete scanning and those who did have a scan are summarised in table 4.1. More 
were men, had a slightly higher blood pressure and resting heart rate, and slightly 
lower HDL. 
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Table 4.1: Characteristics of those who had an MRI scan and those who declined or 
were unable to complete a scan 
Variable Underwent MRI scan 
(n=1528) 
Unable/declined to 
have MRI scan 
(n=538) 
*p value 
No (%)  men 579 (37.9) 233 (43.3) 0.03 
Median (IQR) age (years) 53.5 (12.2) 52.6 (13.3) 0.57 
No (%) current smokers 165 (10.8) 57 (10.6) 0.88 
No (%) former smokers 417 (27.3) 150 (27.9) 0.81 
No (%) never smokers 940 (61.5) 330 (61.3) 0.90 
Mean (SD) systolic BP(mmHg)   122.4 (12.1) 123.7 (11.7) 0.046 
Mean (SD) diastolic BP(mmHg)   72.8 (9.2) 73.8 (9.3) 0.02 
Median (IQR) heart rate (beats per 
min) 
62 (12) 64 (11) <0.001 
Mean (SD) total cholesterol 
(mmol/l) 
5.51 (0.96) 5.51 (1.02) 0.89 
Mean (SD) high density lipoprotein 
(mmol/l)  
1.43 (0.42) 1.38 (0.39) 0.04 
Mean (SD) low density lipoprotein 
(mmol/l) 
3.39 (0.87) 3.41 (0.93) 0.78 
Median (IQR) triglycerides (mmol/l) 1.33 (0.98) 1.41 (0.98) 0.09 
Median (IQR) body mass index 26.1 (5.3) 26.3 (6.0) 0.15 
Mean (SD) waist circumference 
(cm) 
86.0 (16.0) 87.0 (17.0) 0.10 
Median (IQR) CHD risk score 2 (5) 3 (5) 0.19 
Median (IQR) ASSIGN score 7.4 (7.9) 7.8 (8.8) 0.18 
Number (%) with family history of 
CV disease 
392 (25.7) 128 (23.8) 0.39 
SIMD Number (%) 1 65 (4.3) 23 (4.3) 0.14 
 2 79 (5.2) 29 (5.4) 
 3 101 (6.6) 50 (9.3) 
 4 77 (5.0) 39 (7.2) 
 5 95 (6.2) 31 (5.8) 
 6 167 (10.9) 40( 7.4) 
 7 248 (16.2) 91 (16.9) 
 8 297 (19.4) 107 (19.9) 
 9 279 (18.3) 92 (17.1) 
 10 117 (7.7) 35 (6.5) 
SD=standard deviation, IQR=inter-quartile range, SIMD=Scottish Index of Multiple Deprivation, 
CV=cardiovascular, CHD=coronary artery disease, MRI=magnetic resonance imaging. 
*Unpaired t-test was used for normally distributed variables, Mann-Whitney test for skewed and 
ranked variables and Chi-square test for binomial variables. SIMD was treated as a continuous 
variable for the purpose of analysis. 
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4.2. Incidental findings on MRI scan 
All scans were reviewed by a radiologist for the presence of incidental findings needing 
further review or investigation. 32 participants (2.1% participants scanned) had an 
incidental finding on their MRI scan. The nature of the incidental findings are 
summarised in table 4.2. They have been categorised based on the abnormality. 
Structural cardiac abnormalities included cardiomyopathies, septal defects and 
enlargement of cardiac chambers. Benign masses include abnormalities seen on MRI 
suggesting a possible mass-some of these turned out to be not present on further 
imaging. Peripheral arterial abnormalities included significant occlusions, aneurysms or 
decreased flow suggesting a possible stenosis. 
 
Depending on the nature of the radiological incidental finding review by the trial 
medical team, GP, further investigations, referral to an appropriate specialist or 
initiation of medication were arranged as appropriate. Table 4.3 summarises the 
activity arising as a result of the incidental findings. All MRI incidental finding reports 
were reviewed by the trial team. Due to patient confidentiality the final outcome and 
diagnosis of those referred for specialist review is not known. 
 
Table 4.2: Summary of MRI incidental findings requiring clinical review and/or further 
investigation 
Nature of finding Frequency 
Myocardial infarct detected by delayed enhancement 1 
Structural cardiac abnormality 7 
Benign mass 10 
Malignant mass 1 
Peripheral arterial abnormality 6 
Anatomical variant/malformation 5 
Other finding 2 
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Table 4.3: Activity arising as a result of MRI incidental findings 
Activity Number of participants 
Investigations  
Abdominal/pelvic ultrasound scan 7 
Vascular ultrasound scan 2 
Plain x-ray 1 
Echocardiogram 6 
Other investigation* 3 
Review  
Review by study doctor 6 
Review by GP 9 
Referral and review to hospital specialist 17 
Intervention by study team  
Medication started on advice of study doctor 2 
*Other investigations include exercise tolerance tests, blood tests. 
 
 
Figure 4.1: A left lung mass (probably malignant) seen on a post contrast MRI scan in 
a female TASCFORCE participant 
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4.3. MRI derived left ventricular results 
 
4.3.1. Left ventricular measures 
1515 (n=574, 37.9% male) participants completed the cardiac MRI scan and produced 
images suitable for analysis. 15 participants did not have images suitable for analysis 
due to either motion artefacts or slices missing making reliable assessment of 
parameters impossible). The baseline clinical characteristics of those who underwent 
scanning are presented by gender in table 4.4. Summary statistics by gender for the 
baseline left ventricular measurements including left ventricular mass/end diastolic 
volume ratio (an indicator of cardiac remodelling) are given in table 4.5. All the 
measurements were significantly higher in men compared to women except ejection 
fraction which was slightly higher in women. Relationships of left ventricular mass with 
height, weight, BMI and body surface area (BSA) are shown in figures 4.2, 4.3 and 4.4.  
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Table 4.4: Descriptive characteristics of participants who underwent cardiac MRI 
imaging 
Variable Men (n=574) Women (n=941) 
Median (IQR) age (years) 53.3 (11.9) 53.9 (12.5) 
No (%) current smokers 51 (8.9) 113 (12.0) 
No (%) former smokers 162 (28.2) 251 (26.7) 
No (%) never smokers 359 (62.5) 573 (60.9) 
Mean (SD) systolic BP(mmHg)   125.1 (10.9) 120.9 (12.5) 
Mean (SD) diastolic BP(mmHg)   74.8 (8.8) 71.5 (9.3) 
Median (IQR) heart rate (beats per min) 60 (12) 63 (11) 
Median (IQR) body mass index 26.6 (4.4) 26.6 (5.6) 
Median (IQR) weight (kg) 83.1 (16.1) 68.1 (15.3) 
Mean (SD) height (cm) 176.1 (6.5) 162.5 (6.2) 
Mean (SD) waist circumference (cm) 92.4 (11.4) 82.9 (12.4) 
Mean (SD) BSA (m2) 2.02 (0.17) 1.78 (0.18) 
Median (IQR) CHD risk score 7.0 (6.0) 1.0 (2.0) 
Number (%) with family history of CV disease 131 (22.8) 256 (27.2) 
 
CHD=coronary heart disease, BP=blood pressure, BSA=body surface area (calculated using 
the Dubois formula), SD=standard deviation, IQR=inter-quartile range. 
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Table 4.5: Left ventricular characteristics by gender 
 Men 
(n=574) 
Women 
(n=941) 
p value* 
Mean SD Mean SD 
LV mass (g) 129.2 24.4 87.0 16.7 <0.001 
LV end diastolic volume (ml) 155.0 27.7 119.6 21.1 <0.001 
LV end systolic volume (ml) 50.2 14.8 37.1 12.0 <0.001 
LVM/LVEDV (g/ml) 0.85 0.16 0.74 0.13 <0.001 
Ejection fraction (%) 67.9 6.2 69.3 6.6 <0.001 
Stroke volume (ml) 104.8 19.0 82.5 14.2 <0.001 
Cardiac output (l/min) 6.46 1.20 5.47 1.13 <0.001 
 
*Comparison between men and women using independent samples t-test. LV=left ventricular, 
LVM=left ventricular mass, LVEDV=left ventricular end diastolic volume, SD=standard 
deviation. 
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Figure 4.2: Scatterplots of left ventricular mass and height (top left), weight (top right), 
body mass index (bottom left), body surface area (bottom right) for both men and 
women 
 
  
r=0.67, p<0.001 r=0.63, p<0.001 
  
r=0.29, p<0.001 r=0.71, p<0.001 
 
Statistics shown are Pearson correlation coefficients for association between the respective 
variables. Body surface area is calculated using the Dubois formula. 
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Figure 4.3: Scatterplots of left ventricular mass and height (top left), weight (top right), 
body mass index (bottom left), body surface area (bottom right) for men 
  
r=0.33, p<0.001 r=0.46, p<0.001 
  
r=0.33, p<0.001 r=0.47, p<0.001 
 
Statistics shown are Pearson correlation coefficients for association between the respective 
variables. Body surface area is calculated using the Dubois formula. 
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Figure 4.4: Scatterplots of left ventricular mass and height (top left), weight (top right), 
body mass index (bottom left), body surface area (bottom right) for women 
  
r=0.32, p<0.001 r=0.51, p<0.001 
  
r=0.40, p<0.001 r=0.54, p<0.001 
 
Statistics shown are Pearson correlation coefficients for association between the respective 
variables. Body surface area is calculated using the Dubois formula. 
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Left ventricular mass indexed (LVMI) for height, height1.7, height2.7, and BSA using 
DuBois and Mosteller formulae are given in table 4.6. LVMI using each of the methods 
was significantly higher in men than women. 
 
Table 4.6: Left ventricular mass index (LVMI) by height, height1.7, height2.7, and body 
surface area (BSA) using DuBois and Mosteller formulae 
 Men Women 
p value* Mean SD Mean SD 
LV mass/height (g/m) 73.2 13.11 53.5 9.82 <0.001 
LV mass/height1.7 (g/m1.7) 49.3 8.70 38.1 6.95 <0.001 
LV mass/height2.7 (g/m2.7) 28.0 5.03 23.5 4.41 <0.001 
LV mass/BSA (Dubois 
formula) (g/m2) 
64.3 10.6 49.5 8.1 <0.001 
LV mass/BSA (Mosteller 
formula) (g/m2) 
63.8 10.5 48.9 8.0 <0.001 
LV=left ventricular, BSA=body surface area, SD=standard deviation. *comparison is between 
men and women using independent samples t-test. 
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The distributions of LVM and LVMI using height, height1.7, height2.7, and BSA (using 
both Dubois and Mosteller formulae) for men and women are shown in figure 4.5. 
 
Figure 4.5: Boxplots of distribution of left ventricular mass and left ventricular mass 
index (LVMI) for men and women. From top left to bottom right: LVM, LVMI (height), 
LVMI (height1.7), LVMI (height2.7), LVMI (BSA using Dubois calculation) and LVM/end 
diastolic volume ratio 
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Correlations of LVMI using the different methods of indexing with height, weight, BSA 
and BMI are summarised in table 4.7 to give an indication if indexing has corrected for 
body size. The LVM (not indexed) is given for comparison. Indexing by height2.7 
reduces the correlation with height greater than height1.7 or height. Indexing my BSA 
reduces correlation with BMI the most whereas indexing for height increases the 
degree of correlation. 
 
Table 4.7: Correlations between left ventricular mass index and measures of body size 
Indexing 
method for 
LVMI 
Correlation 
Height Weight BSA (using 
Dubois) 
BMI 
LVM (not 
indexed) 
r=0.67, 
p<0.001 
r=0.63, 
p<0.001 
r=0.71, 
p<0.001 
r=0.29, 
p<0.001 
Height r=0.54, 
p<0.001 
r=0.59, 
p<0.001 
r=0.34, 
p<0.001 
r=0.64, 
p<0.001 
Height1.7 r=0.41, 
p<0.001 
r=0.55, 
p<0.001 
r=0.37, 
p<0.001 
r=0.56, 
p<0.001 
Height2.7 r=0.18, 
p<0.001 
r=0.44, 
p<0.001 
r=0.41, 
p<0.001 
r=0.40, 
p<0.001 
BSA (using 
Dubois) 
r=0.48, 
p<0.001 
r=0.35, 
p<0.001 
r=0.42, 
p<0.001 
r=0.08, 
p=0.002 
BSA (using 
Mosteller) 
r=0.48, 
p<0.001 
r=0.32, 
p<0.001 
r=0.40, 
p<0.001 
r=0.03, 
p=0.261 
 
Correlations are Pearson coefficients. LVM=left ventricular mass, LVMI=left ventricular mass 
indexed, BSA=body surface area, BMI=body mass index. 
 
 
The measures of left ventricular volume and function indexed for height, height1.7, 
height2.7, BSA (using Dubois formula) and BSA (using Mosteller formula) are 
summarised in table 4.8. Ejection fraction remained higher in women than men 
whichever indexing method was used. All the other measures were higher in men.  
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Table 4.8: Means and standard deviations of left ventricular measurements indexed for 
height, height1.7, height2.7, BSA (using Dubois formula) and BSA (using Mosteller 
formula) 
Indexed for height 
 Men Women  
Variable Mean SD Mean SD p value* 
LVEDV (ml) 87.8 14.9 73.5 12.1 <0.001 
LVESV (ml) 28.4 8.2 22.8 7.2 <0.001 
Ejection fraction (%) 38.6 3.8 42.7 4.5 <0.001 
Stroke volume (ml) 59.4 10.2 50.7 8.2 <0.001 
Cardiac output 
(l/min) 
3.66 0.65 3.37 0.67 <0.001 
Indexed for height1.7 
 Men Women  
Variable Mean SD Mean SD p value* 
LVEDV (ml) 59.1 9.9 52.3 8.4 <0.001 
LVESV (ml) 19.1 5.5 16.2 5.1 <0.001 
Ejection fraction (%) 26.0 2.9 30.5 3.7 <0.001 
Stroke volume (ml) 40.0 6.8 36.1 5.8 <0.001 
Cardiac output 
(l/min) 
2.46 0.43 2.40 0.48 0.005 
Indexed for height2.7 
 Men Women  
Variable Mean SD Mean SD p value* 
LVEDV (ml) 33.6 5.7 32.3 5.3 <0.001 
LVESV (ml) 10.9 3.1 10.0 3.1 <0.001 
Ejection fraction (%) 14.8 2.0 18.9 2.8 <0.001 
Stroke volume (ml) 22.7 3.9 22.3 3.7 0.027 
Cardiac output 
(l/min) 
1.40 0.25 1.48 0.30 <0.001 
 
Continued on next page 
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Table 4.8 continued 
Indexed for BSA (Dubois formula) 
 Men Women  
Variable Mean SD Mean SD p value* 
LVEDV (ml) 77.3 13.2 68.1 10.6 <0.001 
LVESV (ml) 25.0 7.4 21.1 6.6 <0.001 
Ejection fraction (%) 34.0 4.1 39.8 5.2 <0.001 
Stroke volume (ml) 52.2 8.9 47.0 7.2 <0.001 
Cardiac output 
(l/min) 
3.22 0.55 3.12 0.58 0.001 
Indexed for BSA (Mosteller formula) 
 Men Women  
Variable Mean SD Mean SD p value* 
LVEDV (ml) 76.7 13.3 67.4 10.6 <0.001 
LVESV (ml) 24.8 7.4 20.9 6.5 <0.001 
Ejection fraction (%) 33.8 4.1 39.4 5.4 <0.001 
Stroke volume (ml) 51.8 8.9 46.5 7.2 <0.001 
Cardiac output 
(l/min) 
3.19 0.55 3.08 0.58 <0.001 
*p values are for independent t test for difference in means between men and women. 
BSA=body surface area, LVEDV=Left ventricular end diastolic volume, LVESV=left ventricular 
end systolic volume, LVM=left ventricular mass, SD=standard deviation. 
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4.3.2. Correlation of left ventricular measures with BNP 
Correlations between BNP and MRI derived left ventricular measures are summarised 
in table 4.9. Left ventricular end diastolic volume (both raw and indexed) and stroke 
volume were weakly associated with BNP in men. The other measures in men and no 
measures in women were not correlated with BNP. Differences in left ventricular 
measures between those above and below 75th, 90th and 95th percentiles of BNP are 
shown in tables 4.10, 4.11 and 4.12 respectively. Mean left ventricular measures in 
those with a BNP above and below 100pg/ml (cut off used to diagnose heart failure) 
are shown in table 4.13. 
 
Differences in left ventricular measures between those above and below 75th, 90th and 
95th percentiles of BNP are shown in tables 4.10, 4.11 and 4.12 respectively. The only 
significant differences were a lower cardiac output in those with a BNP greater than the 
95th percentile. Women with a high BNP had higher LVMI (using all methods except 
BSA calculated using the Mosteller formula), higher end systolic volume and lower 
ejection fraction compared to those with a “normal” BNP. In men the only difference 
was a lower end diastolic volume. 
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Table 4.9: Correlations between BNP and MRI derived measures of left ventricular 
function and size 
 Men Women 
r p r p 
LV mass (g) 0.04 0.39 -0.08 0.82 
LVMI (height) (g/m) 0.03 0.46 -0.01 0.74 
LVMI (height1.7) (g/m1.7) 0.03 0.57 -0.02 0.64 
LVMI (height2.7) (g/m2.7) 0.03 0.48 -0.02 0.54 
LVMI (BSA using Dubois formula) (g/m2) 0.06 0.11 -0.02 0.59 
LVMI (BSA using Mosteller formula) (g/m2) 0.07 0.09 -0.02 0.67 
LVEDV (ml) 0.10 0.019 -0.01 0.74 
LVEDV/height (ml/m) 0.10 0.014 -0.02 0.60 
LVEDV/height1.7 (ml/m1.7) 0.11 0.011 -0.02 0.51 
LVEDV/height2.7 (ml/m2.7) 0.11 0.011 -0.02 0.48 
LVEDV/BSA (using Dubois formula) (ml/m2) 0.12 0.003 -0.01 0.72 
LVESV (ml) 0.05 0.27 -0.02 0.59 
LVESV/height (ml/m) 0.05 0.29 -0.02 0.51 
LVESV/height1.7 (ml/m1.7) 0.04 0.31 -0.03 0.45 
LVESV/height2.7 (ml/m2.7) 0.04 0.33 -0.03 0.39 
LVESV/BSA (using Dubois formula) (ml/m2) 0.06 0.12 -0.02 0.53 
LVM/LVEDV (g/ml) -0.07 0.08 -0.03 0.45 
Ejection fraction (%) 0.02 0.60 0.04 0.28 
Ejection fraction/height (%/m) 0.02 0.71 0.03 0.43 
Ejection fraction/height1.7 (%/m1.7) 0.01 0.91 0.02 0.50 
Ejection fraction/height2.7 (%/m2.7) -0.00 0.92 0.02 0.59 
Ejection fraction/BSA (using Dubois 
formula) (%/m2) 
0.06 0.19 0.02 0.60 
Stroke volume (ml) 0.11 0.009 0.04 0.90 
Stroke volume/height (ml/m) 0.11 0.007 0.00 0.92 
Stroke volume/height1.7 (ml/m1.7) 0.12 0.006 0.00 0.95 
Stroke volume/height2.7 (ml/m2.7) 0.11 0.009 0.00 0.94 
Stroke volume/BSA (using Dubois formula) 
(ml/m2) 
0.14 0.001 0.01 0.80 
Cardiac output (l/min) -0.03 0.43 -0.06 0.08 
Cardiac output/height (l/min/m) -0.04 0.35 -0.06 0.07 
Cardiac output/height1.7 (l/min/m1.7) -0.04 0.31 -0.06 0.08 
Cardiac output/height2.7 (l/min/m2.7) -0.05 0.28 -0.05 0.11 
Cardiac output/BSA (using Dubois formula) 
(l/min/m2) 
-0.02 0.72 -0.06 0.09 
 
Correlations are Spearman rank correlations. LV=left ventricular, LVMI=left ventricular mass 
index, BSA=body surface area, LVEDV=left ventricular end diastolic volume, LVESV=left 
ventricular end systolic volume. 
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Table 4.10: Comparison of left ventricular measures in different quartiles of BNP 
 Men Women 
3rd quartile 
(n= 232) 
4th quartile 
(n= 335) 
p 
value* 
3rd quartile 
(n= 431) 
4th quartile 
(n= 505) 
p 
value* 
LV mass (g) 127.9 
(21.1) 
130.5 
(26.3) 
0.21 87.3 (16.8) 86.9 (16.6) 0.78 
LVMI (height) (g/m) 72.5 (11.4) 73.8 (14.2) 0.25 53.6 (9.8) 53.5 (9.8) 0.87 
LVMI (height1.7) 
(g/m1.7) 
48.8 (7.7) 49.7 (9.4) 0.26 38.1 (6.9) 38.1 (7.0) 0.94 
LVMI (height2.7) 
(g/m2.7) 
27.7 (4.6) 28.2 (5.3) 0.30 23.5 (4.4) 23.5 (4.4) 0.96 
LVMI (BSA using 
Dubois formula) (g/m2) 
63.5 (9.4) 65.0 (11.3) 0.12 49.6 (8.0) 49.4 (8.1) 0.71 
LVMI (BSA using 
Mosteller formula) 
(g/m2) 
63.0 (9.3) 64.5 (11.2) 0.10 49.0 (7.9) 48.9 (8.0) 0.75 
LV end diastolic 
volume (ml) 
153.6 
(25.0) 
156.6 
(29.2) 
0.20 120.2 (21.3) 119.3 (20.8) 0.51 
LV end systolic volume 
(ml) 
49.6 (13.7) 50.8 (15.5) 0.33 37.7 (12.0) 36.7 (12.1) 0.20 
LVM/LVEDV (g/ml) 0.85 (0.16) 0.85 (0.16) 0.95 0.74 (0.13) 0.74 (0.13) 0.85 
Ejection fraction (%) 68.0 (6.2) 67.9 (6.3) 0.87 69.0 (6.4) 69.6 (6.8) 0.14 
Stroke volume (ml) 104.0 
(17.5) 
105.8 
(19.8) 
0.26 82.5 (14.2) 82.6 (14.1) 0.88 
Cardiac output (l/min) 6.51 (1.19) 6.44 (1.20) 0.58 5.53 (1.15) 5.44 (1.10) 0.24 
 
Figures given are mean (standard deviation). 1st and 2nd quartiles are not given as this 
population were not imaged (median BNP was used to determine if offered a scan). 
*comparison is between 3rd and 4th BNP quartiles using independent samples t-test. LV=left 
ventricular, LVMI=left ventricular mass index, BSA=body surface area, LVEDV=left ventricular 
end diastolic volume. 
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Table 4.11: Comparison of LV measures above and below 90th percentiles of BNP 
 Men Women 
≤90th 
percentile 
(n=432) 
>90th 
percentile 
(n=142) 
p value* ≤90th 
percentile 
(n=743) 
>90th 
percentile 
(n=198) 
p 
value* 
LV mass (g) 128.9 (23.0) 130.3 (28.1) 0.58 87.3 (16.6) 85.9 (17.2) 0.31 
LVMI (height) (g/m) 73.0 (12.4) 73.9 (15.1) 0.55 53.7 (9.8) 52.7 (10.0) 0.22 
LVMI (height1.7) (g/m1.7) 49.1 (8.3) 49.7 (9.9) 0.53 38.3 (6.9) 37.5 (7.0) 0.17 
LVMI (height2.7) (g/m2.7) 27.9 (4.9) 28.3 (5.6) 0.52 23.6 (4.4) 23.1 (4.4) 0.13 
LVMI (BSA using 
Dubois formula) (g/m2) 
63.9 (10.0) 65.6 (12.2) 0.10 49.6 (8.0) 49.0 (8.2) 0.27 
LVMI (BSA using 
Mosteller formula) 
(g/m2) 
63.4 (9.9) 65.2 (12.1) 0.07 49.0 (7.9) 48.4 (8.1) 0.34 
LV end diastolic volume 
(ml) 
153.7 (26.9) 158.9 (29.8) 0.06 119.8 (20.8) 119.0 (22.0) 0.67 
LV end systolic volume 
(ml) 
49.7 (14.3) 51.6 (16.1) 0.20 37.1 (11.6) 37.4 (13.5) 0.80 
LVM/LVEDV (g/ml) 0.85 (0.16) 0.83 (0.15) 0.14 0.74 (0.13) 0.73 (0.14) 0.62 
Ejection fraction (%) 67.9 (6.2) 67.9 (6.4) 0.90 69.4 (6.4) 69.1 (7.3) 0.68 
Stroke volume (ml) 104.0 (18.7) 107.3 (19.5) 0.08 82.7 (14.1) 81.7 (14.5) 0.38 
Cardiac output (l/min) 6.51 (1.21) 6.30 (1.15) 0.06 5.5 (1.13) 5.35 (1.11) 0.08 
 
Figures given are mean (standard deviation). *comparison using independent samples t-test. 
LV=left ventricular, LVMI=left ventricular mass index, BSA=body surface area, LVEDV=left 
ventricular end diastolic volume. 
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Table 4.12: Comparison of LV measures above and below 95th percentiles of BNP 
 Men Women 
≤95th 
percentile 
(n=507) 
>95th 
percentile 
(n=67) 
p 
value* 
≤95th 
percentile 
(n=840) 
>95th 
percentile 
(n=101) 
p 
value* 
LV mass (g) 129.2 
(23.9) 
129.5 
(27.7) 
0.92 87.1 (16.5) 86.2 (18.6) 0.62 
LVMI (height) (g/m) 73.2 (12.9) 73.8 (14.9) 0.73 53.6 (9.7) 52.7 (11.1) 0.44 
LVMI (height1.7) 
(g/m1.7) 
49.2 (8.6) 49.8 (9.8) 0.62 38.2 (6.8) 37.4 (7.9) 0.33 
LVMI (height2.7) 
(g/m2.7) 
27.9 (5.0) 28.5 (5.6) 0.48 23.6 (4.3) 23.0 (5.0) 0.21 
LVMI (BSA using 
Dubois formula) 
(g/m2) 
64.1 (10.4) 65.9 (12.1) 0.25 49.5 (7.9) 49.1 (9.2) 0.63 
LVMI (BSA using 
Mosteller formula) 
(g/m2) 
63.6 (10.2) 65.5 (12.0) 0.22 48.9 (7.8) 48.6 (9.2) 0.74 
LV end diastolic 
volume (ml) 
154.8 
(27.0) 
156.3 
(32.9) 
0.71 119.6 
(20.6) 
120.0 
(24.3) 
0.93 
LV end systolic 
volume (ml) 
50.1 (14.2) 50.8 (18.8) 0.71 37.0 (11.4) 38.6 (16.5) 0.21 
LVM/LVEDV (g/ml) 0.85 (0.16) 0.84 (0.16) 0.87 0.74 (0.13) 0.73 (0.15) 0.72 
Ejection fraction (%) 67.9 (6.1) 68.1 (7.4) 0.82 69.4 (6.3) 68.6 (8.9) 0.26 
Stroke volume (ml) 104.7 
(18.8) 
105.5 
(20.7) 
0.76 82.6 (14.1) 81.2 (15.33 0.39 
Cardiac output (l/min) 6.50 (1.20) 6.12 (1.07) 0.008 5.50 (1.13) 5.24 (1.05) 0.020 
 
Figures given are mean (standard deviation). *comparison using independent samples t-test. 
LV=left ventricular, LVM=left ventricular mass, LVMI=left ventricular mass index, BSA=body 
surface area, LVEDV=left ventricular end diastolic volume. 
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Left ventricular hypertrophy (LVH) was defined as an LVM greater than 2 standard 
deviations greater than the mean for each gender. This was 177.9g for men and 
120.4g for women. Using this definition of LVH 54 participants (20 men and 34 women) 
had LVH. The median BNP level for those with and without LVH is shown in table 4.13. 
There were no significant differences between the results. 
 
Concentric left ventricular hypertrophy was defined as an LVM/LVEDV greater than 2 
standard deviations greater than the mean for each gender. This was 1.16g/ml for men 
and 1.00g/ml in women. Using this definition 60 participants (22 men and 38 women) 
had concentric LVH. The median BNP level for those with and without concentric LVH 
is shown in table 4.14. There was no significant difference in BNP levels between 
those with and without concentric LVH. 
 
Table 4.13: Median BNP values for those with and without LVH 
 Men Women 
No LVH 
(n=553) 
LVH 
(n=20) 
p value* No LVH 
(n=906) 
LVH 
(n=34) 
p value* 
Median (IQR) BNP 
level (pg/ml) 
15.5 
(11.9) 
19.0 
(12.2) 
0.37 26.5 
(17.4) 
23.8 
(12.9) 
0.18 
 
*comparison is between those with and without LVH using the Mann-Whitney test. LVH=left 
ventricular hypertrophy and is defined as >mean+2xSD left ventricular mass for gender. 
IQR=inter-quartile range. 
 
Table 4.14: Median BNP values for those with and without concentric LVH 
 Men Women 
No cLVH 
(n=552) 
cLVH 
(n=22) 
p value* No cLVH 
(n=902) 
cLVH 
(n=39) 
p value* 
Median (IQR) BNP 
level pg/ml 
15.5 
(11.9) 
18.3 
(11.5) 
0.26 26.2 
(17.3) 
29.5 
(22.2) 
0.32 
 
*comparison is between those with and without concentric LVH using the Mann-Whitney test. 
cLVH=concentric left ventricular hypertrophy and is defined as >mean+2xSD left ventricular 
mass/ left ventricular end diastolic volume for gender. IQR=inter-quartile range. 
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4.3.3. Correlation of left ventricular measures with cardiovascular risk factors 
Univariate analysis of correlations between left ventricular mass and left ventricular 
mass index and baseline variables are presented for men and women in tables 4.15 
and 4.16. Age was weakly inversely correlated with LVM and LVMI (except when 
indexed for height2.7) in men but only with LVM and LVM indexed for height in women. 
Systolic BP was weakly correlated with LVM and LVMI and diastolic BP was weakly 
correlated with LVM and LVMI (except when indexed for MSA using the Mosteller 
formula) in men. Both systolic and diastolic BP were correlated with LVM and LVMI in 
women with a slightly stronger correlation than in men. Heart rate was negatively 
correlated with LVM and LVMI in men but only with LVM indexed for BSA in women. 
HDL was weakly inversely correlated and LDL and triglycerides were weakly positively 
correlated with LVMI in women but not in men. BMI was correlated with LVM and LVM 
indexed for height, height1.7 and height2.7 in both men and women (greater correlation 
in women). LVM or LVMI were not correlated with predicted CHD risk in men but they 
were weakly correlated in women. 
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Table 4.15: Univariate analysis of correlations between left ventricular mass and 
baseline variables in men 
Variable 
LV mass 
(g) 
LVMI 
(height) 
(g/m) 
LVMI 
(height1.7) 
(g/m1.7) 
LVMI 
(height2.7) 
(g/m2.7) 
LVMI 
(BSA 
using 
DuBois 
formula) 
(g/m2) 
LVMI 
(BSA 
using 
Mosteller 
formula) 
(g/m2) 
Age (years) -0.16 
(<0.001) 
-0.13 
(0.002) 
-0.10 
(0.015) 
-0.06 
(0.15) 
-0.11 
(0.007) 
-0.11 
(0.006) 
Systolic BP 
(mmHg) 
0.15 
(<0.001) 
0.16 
(<0.001) 
0.17 
(<0.001) 
0.17 
(<0.001) 
0.14 
(0.001) 
0.13 
(0.002) 
Diastolic BP 
(mmHg) 
0.14 
(0.001) 
0.14 
(0.001) 
0.14 
(0.001) 
0.14 
(0.001) 
0.08 
(0.045) 
0.07 
(0.08) 
Heart rate 
(beats/min) 
-0.16 
(<0.001) 
-0.16 
(<0.001) 
-0.14 
(0.001) 
-0.12 
(0.003) 
-0.20 
(<0.001) 
-0.20 
(<0.001) 
Total 
cholesterol 
(mmol/l) 
-0.03 
(0.51) 
-0.03 
(0.47) 
-0.03 
(0.50) 
-0.03 
(0.52) 
-0.06 
(0.13) 
-0.07 
(0.10) 
HDL (mmol/l) -0.05 
(0.24) 
-0.05 
(0.25) 
-0.04 
(0.30) 
-0.04 
(0.41) 
0.05 
(0.21) 
0.07 
(0.11) 
LDL (mmol/l) -0.02 
(0.57) 
-0.03 
(0.47) 
-0.03 
(0.44) 
-0.04 
(0.42) 
-0.06 
(0.14) 
-0.07 
(0.11) 
Triglycerides 
(mmol/l) 
0.03 
(0.51) 
0.03 
(0.49) 
0.03 
(0.52) 
0.02 
(0.61) 
-0.07 
(0.12) 
-0.08 
(0.05) 
BMI (kg/m2)  0.28 
(<0.001) 
0.31 
(<0.001) 
0.33 
(<0.001) 
0.33 
(<0.001) 
0.03 
(0.42) 
-0.02 
(0.65) 
Waist 
circumference 
(cm) 
0.18 
(<0.001) 
0.16 
(<0.001) 
0.15 
(<0.001) 
0.12 
(0.004) 
-0.07 
(0.89) 
-0.11 
(0.009) 
Predicted 
CHD risk 
score (%/10 
years)  
-0.07 
(0.12) 
-0.04 
(0.31) 
-0.02 
(0.67) 
-0.01 
(0.73) 
-0.05 
(0.24) 
-0.06 
(0.17) 
 
Spearman Rank correlations (ρ and (p) values are given) were used. LV=left ventricular, 
LVMI=left ventricular mass index, BSA=body surface area, LVEDV=left ventricular end diastolic 
volume, CHD=coronary heart disease, BMI=body mass index, LDL=low density lipoprotein, 
HDL=high density lipoprotein, BP=blood pressure. 
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Table 4.16: Univariate analysis of correlations between left ventricular mass and 
baseline variables in women 
Variable 
LV mass 
(g) 
LVMI 
(height) 
(g/m) 
LVMI 
(height1.7) 
(g/m1.7) 
LVMI 
(height2.7) 
(g/m2.7) 
LVMI 
(BSA 
using 
DuBois 
formula) 
(g/m2) 
LVMI 
(BSA 
using 
Mosteller 
formula) 
(g/m2) 
Age (years) -0.12 
(<0.001) 
-0.09 
(0.008) 
-0.06 
(0.07) 
-0.02 
(0.56) 
-0.03 
(0.30) 
-0.03 
(0.43) 
Systolic BP 
(mmHg) 
0.21 
(<0.001) 
0.24 
(<0.001) 
0.26 
(<0.001) 
0.27 
(<0.001) 
0.19 
(<0.001) 
0.18 
(<0.001) 
Diastolic BP 
(mmHg) 
0.25 
(<0.001) 
0.26 
(<0.001) 
0.26 
(<0.001) 
0.26 
(<0.001) 
0.19 
(<0.001) 
0.17 
(<0.001) 
Heart rate 
(beats/min) 
-0.03 
(0.41) 
-0.03 
(0.42) 
-0.03 
(0.47) 
-0.02 
(0.56) 
-0.10 
(0.003) 
-0.11 
(0.001) 
Total 
cholesterol 
(mmol/l) 
0.03 
(0.42) 
0.04 
(0.19) 
0.06 
(0.09) 
0.08 
(0.022) 
0.02 
(0.65) 
0.01 
(0.82) 
HDL (mmol/l) -0.14 
(<0.001) 
-0.15 
(<0.001) 
-0.15 
(<0.001) 
-0.14 
(<0.001) 
-0.04 
(0.18) 
-0.02 
(0.47) 
LDL (mmol/l) 0.07 
(0.06) 
0.08 
(0.017) 
0.09 
(0.007) 
0.11 
(0.002) 
0.04 
(0.23) 
0.03 
(0.37) 
Triglycerides 
(mmol/l) 
0.07 
(0.031) 
0.09 
(0.006) 
0.10 
(0.0031 
0.12 
(<0.001) 
0.06 
(0.85) 
-0.01 
(0.70) 
BMI (kg/m2) 0.37 
(<0.001) 
0.41 
(<0.001) 
0.43 
(<0.001) 
0.44 
(<0.001) 
0.05 
(0.11) 
-0.03 
(0.47) 
Waist 
circumference 
(cm) 
0.34 
(<0.001) 
0.35 
(<0.001) 
0.34 
(<0.001) 
0.32 
(<0.001) 
0.04 
(0.19) 
-0.02 
(0.64) 
Predicted 
CHD risk 
score (%/10 
years) 
0.08 
(0.018) 
0.11 
(0.001) 
0.13 
(<0.001) 
0.16 
(<0.001) 
0.10 
(0.002) 
0.09 
(0.005) 
 
Spearman Rank correlations (ρ and (p) values are given) were used. LV=left ventricular, 
LVMI=left ventricular mass index, BSA=body surface area, LVEDV=left ventricular end diastolic 
volume, CHD=coronary heart disease, BMI=body mass index, LDL=low density lipoprotein, 
HDL=high density lipoprotein, BP=blood pressure. 
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Univariate analysis of correlations between other left ventricular measures and 
baseline variables are presented for men and women in tables 4.17 and 4.18. Left 
ventricular volumes and cardiac output were weakly inversely correlated with age in 
men and women (stronger correlation in women). In men the volumes were inversely 
associated with heart rate, total cholesterol and LDL. Ejection fraction was correlated 
with age, systolic BP and total cholesterol, waist circumference and predicted CHD 
risk. LVM/LVEDV was correlated with systolic and diastolic BP, heart rate, total 
cholesterol, triglycerides, BMI, waist circumference and predicted CHD risk. None of 
the correlations were strong. In women ejection fraction was correlated with age, 
systolic and diastolic BP, total cholesterol, LDL, triglycerides and predicted CHD risk. 
LVM/LVEDV was correlated with age, systolic and diastolic BP, heart rate, total and 
LDL cholesterol, triglycerides, BMI, waist circumference and predicted CHD risk and 
inversely associated with HDL (weak). 
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Table 4.17: Univariate analysis of correlations between left ventricular measures and 
baseline variables in men 
Variable LVEDV 
(ml) 
LVESV 
(ml) 
Ejection 
fraction 
(%) 
Stroke 
volume 
(ml) 
Cardiac 
output 
(ml/min) 
LVM/LVE
DV (g/ml) 
Age (years) -0.23 
(<0.001) 
-0.20 
(<0.001) 
0.08 
(0.048) 
-0.19 
(<0.001) 
-0.15 
(<0.001) 
0.07 
(0.10) 
Systolic BP 
(mmHg) 
0.00 
(0.97) 
-0.07 
(0.10) 
0.09 
(0.038) 
0.05 
(0.25) 
0.11 
(0.006) 
0.15 
(<0.001) 
Diastolic BP 
(mmHg) 
0.01 
(0.91) 
-0.03 
(0.49) 
0.05 
(0.27) 
0.04 
(0.37) 
0.17 
(<0.001) 
0.13 
(0.002) 
Heart rate 
(beats/min) 
-0.34 
(<0.001) 
-0.19 
(<0.001) 
-0.03 
(0.43) 
-0.35 
(<0.001) 
0.17 
(<0.001) 
0.19 
(<0.001) 
Total 
cholesterol 
(mmol/l) 
-0.12 
(0.005) 
-0.14 
(0.001) 
0.10 
(0.017) 
-0.09 
(0.028) 
-0.01 
(0.90) 
0.10 
(0.021) 
HDL (mmol/l) 0.02 
(0.65) 
-0.02 
(0.60) 
0.05 
(0.20) 
0.04 
(0.31) 
-0.05 
(0.26) 
-0.06 
(0.16) 
LDL (mmol/l) -0.10 
(0.015) 
-0.10 
(0.027) 
0.05 
(0.30) 
-0.10 
(0.020) 
-0.03 
(0.46) 
0.08 
(0.08) 
Triglycerides 
(mmol/l) 
-0.07 
(0.09) 
-0.09 
(0.027) 
0.07 
(0.07) 
-0.04 
(0.41) 
0.08 
(0.06) 
0.10 
(0.014) 
BMI (kg/m2)  0.12 
(0.004) 
0.05 
(0.29) 
0.05 
(0.22) 
0.15 
(<0.001) 
0.20 
(<0.001) 
0.19 
(<0.001) 
Waist 
circumferenc
e (cm) 
0.03 
(0.47) 
-0.04 
(0.34) 
0.10 
(0.020) 
0.08 
(0.05) 
0.19 
(<0.001) 
0.16 
(<0.001) 
Predicted 
CHD risk 
score (%/10 
years)  
-0.23 
(<0.001) 
-0.20 
(<0.001) 
0.09 
(0.034) 
-0.19 
(<0.001) 
-0.05 
(0.22) 
0.17 
(<0.001) 
 
Spearman Rank correlations (ρ and (p) values are given) were used. LV=left ventricular, 
LVMI=left ventricular mass index, BSA=body surface area, LVEDV=left ventricular end diastolic 
volume, LVESV=left ventricular end systolic volume, CHD=coronary heart disease, BMI=body 
mass index, LDL=low density lipoprotein, HDL=high density lipoprotein, BP=blood pressure. 
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Table 4.18: Univariate analysis of correlations between left ventricular measures and 
baseline variables in women  
Variable LVEDV 
(ml) 
LVESV 
(ml) 
Ejection 
fraction 
(%) 
Stroke 
volume 
(ml) 
Cardiac 
output 
(ml/min) 
LVM/LVE
DV (g/ml) 
Age (years) -0.32 
(<0.001) 
-0.29 
(<0.001) 
0.17 
(<0.001) 
-0.25 
(<0.001) 
-0.23 
(<0.001) 
0.19 
(<0.001) 
Systolic BP 
(mmHg) 
-0.06 
(0.07) 
-0.18 
(<0.001) 
0.21 
(<0.001) 
0.04 
(0.29) 
0.15 
(<0.001) 
0.29 
(<0.001) 
Diastolic BP 
(mmHg) 
0.01 
(0.66) 
-0.08 
(0.018) 
0.13 
(<0.001) 
0.07 
(0.031) 
0.18 
(<0.001) 
0.26 
(<0.001) 
Heart rate 
(beats/min) 
-0.13 
(<0.001) 
-0.08 
(0.016) 
-0.01 
(0.84) 
-0.15 
(<0.001) 
0.23 
(<0.001) 
0.11 
(0.001) 
Total 
cholesterol 
(mmol/l) 
-0.18 
(<0.001) 
-0.19 
(<0.001) 
0.14 
(<0.001) 
-0.13 
(<0.001) 
-0.05 
(0.10) 
0.19 
(<0.001) 
HDL (mmol/l) -0.06 
(0.07) 
-0.03 
(0.40) 
0.00 
(0.99) 
-0.07 
(0.039) 
-0.06 
(0.07) 
-0.09 
(0.007) 
LDL (mmol/l) -0.14 
(<0.001) 
-0.15 
(<0.001) 
0.10 
(0.003) 
-0.10 
(0.004) 
-0.04 
(0.21) 
0.20 
(<0.001) 
Triglycerides 
(mmol/l) 
-0.13 
(<0.001) 
0.15 
(<0.001) 
0.11 
(0.001) 
-0.08 
(0.014) 
0.03 
(0.35) 
0.19 
(<0.001) 
BMI (kg/m2)  0.22 
(<0.001) 
0.09 
(0.008) 
0.05 
(0.13) 
0.24 
(<0.001) 
0.26 
(<0.001) 
0.17 
(<0.001) 
Waist 
circumferenc
e (cm) 
0.17 
(<0.001) 
0.06 
(0.06) 
0.05 
(0.17) 
0.18 
(<0.001) 
0.22 
(<0.001) 
0.21 
(<0.001) 
Predicted 
CHD risk 
score (%/10 
years)  
-0.23 
(<0.001) 
-0.24 
(<0.001) 
0.16 
(<0.001) 
0.17 
(<0.001) 
-0.09 
(0.007) 
0.30 
(<0.001) 
 
Spearman Rank correlations (ρ and (p) values are given) were used. LV=left ventricular, 
LVMI=left ventricular mass index, BSA=body surface area, LVEDV=left ventricular end diastolic 
volume, LVESV=left ventricular end systolic volume, CHD=coronary heart disease, BMI=body 
mass index, LDL=low density lipoprotein, HDL=high density lipoprotein, BP=blood pressure. 
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4.3.5. Multivariable analysis of left ventricular measures and risk factors and 
BNP 
For each gender multivariable linear regression analysis was performed to determine 
which baseline factors were independently associated with LVM, LVMI (using each 
correction method) and left ventricular end diastolic volume (LVEDV), left ventricular 
end systolic volume (LVESV), cardiac output, stroke volume, ejection fraction and 
LVM/LVEDV. The model included age, systolic BP, diastolic BP, heart rate, HDL 
cholesterol, LDL cholesterol, triglycerides, BMI, waist circumference, smoking status, 
family history of CVD, SIMD decile and BNP. All variables (including the left ventricular 
variables) with a positively skewed distribution were log transformed to produce a more 
normal distribution for the analysis. Results of the models are summarised in tables 
4.19, 4.20, 4.21 and 4.22. 
 
In men the strongest independent associations with LVM and/or LVMI were age, BMI 
and heart rate. Age was independently inversely associated with LVM and LVM 
indexed using all methods except height2.7. Heart rate was independently inversely 
associated with LVM and LVMI using all indexing methods. BMI was strongly 
associated with LVM and LVM indexed for height but not for BSA using the Mosteller 
formula. Systolic blood pressure was weakly associated with LVM and LVMI but 
diastolic blood pressure was not. Lipid profile (LDL, HDL and triglycerides) and FH 
were not associated with LVM or LVMI and current smoking status was weakly 
associated with LVM indexed for height2.7 or BSA. Notably BNP did not have any 
independent association with LVM or LVMI.  
 
In women the strongest independent associations with LVM and/or LVMI were heart 
rate, age, BMI and current smoking status. Age was independently inversely 
associated with LVM and LVM indexed for height and BSA but not for height1.7 or 
height2.7. Heart rate inversely associated with LVM and LVMI. The association with age 
and heart rate was weaker in women than in men. As in men BMI was strongly 
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positively associated with LVM and LVM indexed for height but not for BSA. Current 
smoking was more strongly associated with LVM and LVMI than in men. Again there 
was a weak association with systolic blood pressure but also with diastolic blood 
pressure in women. As in men there was no association with HDL or LDL or, notably, 
with BNP. Overall the models only accounted for 10-20% and 10-30% of the variability 
of LVM or LVMI in men and women respectively meaning much of the variability is 
probably due to unmeasured factors. 
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Table 4.19: Multivariable analysis of traditional cardiovascular risk factors, socio-
demographic factors and BNP in relation to left ventricular mass and left ventricular 
mass index in men 
Variable log LV mass log LVMI 
(height) (g/m) 
log LVMI 
(height1.7) 
(g/m1.7) 
log LVMI 
(height2.7) 
(g/m2.7) 
log LVMI (BSA 
using dubois 
formula) (g/m2) 
log LVMI (BSA 
using 
Mosteller 
formula) (g/m2) 
Proportion of 
variability 
explained by 
model$ 
20.3% 21.5% 22.2% 22.8% 11.8% 11.6% 
Risk factor coefficient (95% CI) 
Log Age 
(years) 
-0.26 
(-0.36,-0.15)* 
-0.18 
(-0.28,-0.09)* 
-0.13 
(-0.23,-0.04)* 
-0.06 
(-0.16,0.04) 
-0.16 
(-0.25,-0.06)* 
-0.16 
(-0.26,-0.06)* 
Log Heart 
rate (bpm) 
-0.31 
(-0.41,-0.22)* 
-0.30 
(-0.39,-0.21)* 
-0.29 
(-0.38,-0.20)* 
-0.27 
(-0.36,-0.18)* 
-0.29 
(-0.38,-0.20)* 
-0.29 
(-0.38,-0.20)* 
Log 
Triglycerides 
(mmol/l) 
-0.02 
(-0.05,0.02) 
-0.02 
(-0.05,0.02) 
-0.01 
(-0.05,0.02) 
-0.01 
(-0.05,0.02) 
-0.01 
(-0.04,0.02) 
-0.01 
(-0.04,0.02) 
log BMI 
(kg/m2) 
0.40 
(0.22,0.58)* 
0.54 
(0.37,0.71)* 
0.64 
(0.47,0.81)* 
0.78 
(0.61,0.95)* 
0.20 
(0.03,0.37)# 
0.12 
(-0.05,0.29) 
log BNP 
(pg/ml) 
0.01 
(-0.01,0.04) 
0.01 
(-0.02,0.04) 
0.01 
(-0.02,0.04) 
0.0078 
(-0.02,0.04) 
0.02 
(-0.01,0.04) 
0.02 
(-0.01,0.04) 
Systolic BP 
(mmHg) 
0.002 
(0.001, 0.004)* 
0.002 
(0,0.004)* 
0.002 
(0,0.004)# 
0.0018 
(0,0.003)# 
0.002 
(0.001,0.004)* 
0.002 
(0.001,0.004)* 
Diastolic BP 
(mmHg) 
0.00 
(-0.001, 0.003) 
0.001 
(-0.001,0.003) 
0.001 
(-0.001,0.003) 
0.001 
(-0.001,0.003) 
0.001 
(-0.001,0.003) 
0.001 
(-0.001,0.003) 
HDL (mmol/l) 0.02 
(-0.02,0.06) 
0.02 
(-0.03,0.06) 
0.017 
(-0.02,0.06) 
0.02 
(-0.02,0.06) 
0.02 
(-0.02,0.06) 
0.02 
(-0.03,0.06) 
LDL (mmol/l) -0.00 
(-0.02,0.01) 
-0.005 
(-0.02,0.01) 
-0.006 
(-0.02,0.01) 
-0.007 
(-0.02,0.01) 
-0.004 
(-0.021,0.012) 
-0.004 
(-0.021,0.012) 
Waist 
circumference 
(cm) 
0.00 
(-0.001,0.003) 
0.00 
(-0.003,0.001) 
-0.002 
(-0.004,0)# 
-0.004 
(-0.006, 
-0.002)* 
-0.002 
(-0.004,0) 
-0.002 
(-0.003,0) 
SIMD Decile 0.00 
(-0.006,0.006) 
-0.002 
(-0.007,0.004) 
-0.003 
(-0.008,0.003) 
0.00 
(-0.01,0.00) 
0.00 
(-0.01,0.00) 
0.00 
(-0.01,0.00) 
Ex smoker (v 
never 
smoked) 
0.01 
(-0.02,0.05) 
0.02 
(-0.02,0.05) 
0.02 
(-0.02,0.05) 
0.02 
(-0.02,0.05) 
0.02 
(-0.01,0.05) 
0.02 
(-0.02,0.05) 
Current 
smoking (v 
never 
smoked) 
0.04 
(-0.01,0.09) 
0.05 
(-0.002,0.1) 
0.05 
(0.01,0.10) 
0.06 
(0.01,0.11)# 
0.06 
(0.01,0.11)# 
0.06 
(0.01,0.11)# 
Family history 
of CVD (v no 
history of 
CVD) 
-0.01 
(-0.05,0.02) 
-0.009 
(-0.042,0.025) 
-0.006 
(-0.038,0.027) 
0.0 
(-0.03,0.03) 
-0.01 
(-0.04,0.03) 
-0.01 
(-0.04,0.03) 
*Test for significance of coefficient: p<0.01, #test for significance of coefficient: p<0.05. 
$Proportion of variability (adjusted r2) explained by the cardiovascular, demographic and blood 
markers included in model. CI=confidence interval, LV=left ventricular, LVMI=left ventricular 
mass index, BSA=body surface area, bpm=beats per minute, BMI=body mass index, BNP=B-
type natriuretic peptide, HDL=high density lipoprotein, LDL=low density lipoprotein, 
SIMD=Scottish index of multiple deprivation, CVD=cardiovascular disease. 
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Table 4.20: Multivariable analysis of traditional cardiovascular risk factors, socio-
demographic factors and BNP in relation to left ventricular mass and left ventricular 
mass index in women 
Variable log LV mass log LVMI 
(height) (g/m) 
log LVMI 
(height1.7) 
(g/m1.7) 
log LVMI 
(height2.7) 
(g/m2.7) 
log LVMI (BSA 
using DuBois 
formula) (g/m2) 
log LVMI (BSA 
using 
Mosteller 
formula) (g/m2) 
Proportion of 
variability 
explained by 
model$ 
25.7% 27.9% 29.0% 29.5% 11.0% 10.8% 
Risk factor coefficient (95% CI) 
log Age 
(years) 
-0.18 
(-0.27,-0.10)* 
-0.12 
(-0.20,-0.04)* 
-0.07 
(-0.15,0.01) 
-0.01 
(-0.09,0.07) 
-0.09 
(-0.17,-0.01)# 
-0.09 
(-0.17,-0.01)# 
log Heart rate 
(bpm) 
-0.20 
(-0.28,-0.13)* 
-0.19 
(-0.26,-0.12)* 
-0.18 
(-0.25,-0.12)* 
-0.17 
(-0.24,-0.10)* 
-0.18 
(-0.25,-0.11)* 
-0.18 
(-0.25,-0.11)* 
log 
Triglycerides 
(mmol/l) 
-0.03 
(-0.06,-0.003)# 
-0.03 
(-0.05,-0.001)# 
-0.02 
(-0.05,0.00) 
-0.02 
(-0.04,0.01) 
-0.02 
(-0.04,0.00) 
-0.02 
(-0.04,0.00) 
log BMI 
(kg/m2) 
0.18 
(0.06,0.30)* 
0.30 
(0.19,0.41)* 
0.38 
(0.27,0.49)* 
0.50 
(0.39,0.61)* 
-0.07 
(-0.18,0.04) 
-0.15 
(-0.26,-0.04)* 
log BNP 
(pg/ml) 
0.013 
(-0.01,0.04) 
0.01 
(-0.02,0.03) 
0.00 
(-0.02,0.03) 
0.00 
(-0.03,0.02) 
0.00 
(-0.02,0.03) 
0.01 
(-0.02,0.03) 
Systolic BP 
(mmHg) 
0.003 
(0.001,0.004)* 
0.003 
(0.001,0.004)* 
0.003 
(0.001,0.004)* 
0.003 
(0.001,0.004)* 
0.003 
(0.001,0.004)* 
0.003 
(0.001,0.004)* 
Diastolic BP 
(mmHg) 
0.003 
(0.001,0.004)* 
0.002 
(0.001,0.004)* 
0.002 
(0.001,0.004)* 
0.002 
(0.001,0.004)* 
0.002 
(0.001,0.004)* 
0.002 
(0.001,0.004)* 
HDL (mmol/l) -0.02 
(-0.05,0.02) 
-0.01 
(-0.04,0.02) 
-0.01 
(-0.04,0.02) 
-0.01 
(-0.04,0.02) 
-0.01 
(-0.04,0.02) 
-0.01 
(-0.04,0.02) 
LDL (mmol/l) 0.01 
(-0.01,0.02) 
0.01 
(-0.01,0.01) 
0.01 
(-0.01,0.02) 
0.00 
(-0.01,0.02) 
0.01 
(-0.01,0.02) 
0.00 
(-0.01,0.02) 
Waist 
circumference 
(cm) 
0.003 
(0.002,0.005)* 
0.00 
(0,0.00)# 
0.00 
(0.00,0.00) 
0.00 
(0.00,0.00) 
0.00 
(0.00,0.00) 
0.00 
(0.00,0.00) 
SIMD Decile 0.006 
(0.002,0.011)* 
0.00 
(0,0.01) 
0.00 
(0.00,0.01) 
0.00 
(0.00,0.00) 
0.00 
(0.00,0.01) 
0.00 
(0.00,0.01) 
Ex smoker (v 
never 
smoked) 
0.00 
(-0.03,0.03) 
-0.01 
(-0.03,0.02) 
-0.01 
(-0.03,0.01) 
-0.02 
(-0.04,0.01) 
0.00 
(-0.03,0.02) 
0.00 
(-0.03,0.02) 
Current 
smoking (v 
never 
smoked) 
0.08 
(0.05,0.12)* 
0.08 
(0.05,0.12)* 
0.09 
(0.05,0.12)* 
0.09 
(0.05,0.12)* 
0.09 
(0.05,0.12)* 
0.09 
(0.05,0.12)* 
Family history 
of CVD (v no 
family history) 
-0.01 
(-0.03,0.02) 
0.00 
(-0.02,0.02) 
0.00 
(-0.02,0.02) 
0.01 
(-0.01,0.03) 
0.00 
(-0.02,0.03) 
0.00 
(-0.02,0.03) 
*Test for significance of coefficient: p<0.01, #test for significance of coefficient: p<0.05. 
$Proportion of variability (adjusted r2) explained by the cardiovascular, demographic and blood 
markers included in model. CI=confidence interval, LV=left ventricular, LVMI=left ventricular 
mass index, BSA=body surface area, bpm=beats per minute, BMI=body mass index, BNP=B-
type natriuretic peptide, HDL=high density lipoprotein, LDL=low density lipoprotein, 
SIMD=Scottish index of multiple deprivation, CVD=cardiovascular disease. 
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Table 4.21: Multivariable analysis of traditional cardiovascular risk factors, socio-
demographic factors and BNP in relation to other left ventricular measures in men 
Variable log end 
diastolic 
volume (ml) 
log end 
systolic 
volume (ml) 
log stroke 
volume (ml) 
Ejection 
fraction (%) 
log cardiac 
output (l/min) 
log LV 
mass/LV end 
diastolic 
volume (g/ml) 
Proportion of 
variability 
explained by 
model$ 
27.5% 13.3% 24.4% 1.1% 28.2% 8.5% 
Risk factor coefficient (95% CI) 
log Age 
(years) 
-0.26 
(-0.36,-0.17)* 
-0.29 
(-0.47,-0.11)* 
-0.26 
(-0.36,-0.16)* 
0.50 
(-3.46,4.46) 
-0.26 
(-0.36,-0.16)* 
0.01 
(-0.10,0.11) 
log Heart rate 
(bpm) 
-0.48 
(-0.57,-0.39)* 
-0.51 
(-0.68,-0.35)* 
-0.46 
(-0.55,-0.37)* 
0.95 
(-2.66,4.57) 
0.54 
(0.45,0.63)* 
0.17 
(0.07,0.26)* 
log 
Triglycerides 
(mmol/l) 
-0.01 
(-0.04,0.02) 
-0.02 
(-0.08,0.03) 
-0.01 
(-0.04,0.02) 
0.33 
(-0.89,1.56) 
-0.01 
(-0.04,0.03) 
-0.01 
(-0.04,0.03) 
log BMI 
(kg/m2) 
0.26 
(0.09,0.43)* 
0.40 
(0.09,0.71)# 
0.22 
(0.05,0.39)# 
-3.49 
(-10.32,3.33) 
0.22 
(0.05,0.39)# 
0.14 
(-0.04,0.32) 
log BNP 
(pg/ml) 
0.02 
(0.00,0.05) 
0.02 
(-0.03,0.07) 
0.03 
(0.00,0.05) 
0.12 
(-0.96,1.10) 
0.03 
(0.00,0.05) 
-0.01 
(-0.04,0.02) 
Systolic BP 
(mmHg) 
0.00 
(0.00,0.00) 
0.00 
(0.00,0.00) 
0.00 
(0.00,0.00) 
0.03 
(-0.03,0.09) 
0.00 
(0.00,0.00) 
0.002 
(0.000,0.003)# 
Diastolic BP 
(mmHg) 
0.00 
(0.00,0.00) 
0.00 
(0.00,0.01) 
0.00 
(0.00,0.00) 
0.00 
(-0.08,0.08) 
0.00 
(0.00,0.00) 
0.00 
(0.00,0.00) 
HDL (mmol/l) 0.01 
(-0.03,0.05) 
-0.04 
(-0.11,0.04) 
0.03 
(-0.01,0.07) 
1.45 
(-0.22,3.12) 
0.03 
(-0.01,0.07) 
0.00 
(-0.04,0.05) 
LDL (mmol/l) -0.02 
(-0.04,-0.003)# 
-0.03 
(-0.06,-0.004)# 
-0.01 
(-0.03,0.00) 
0.42 
(-0.25,1.08) 
-0.01 
(-0.03,0.00) 
0.02 
(0.00,0.03) 
Waist 
circumference 
(cm) 
0.00 
(0.00,0.00) 
-0.00 
(-0.01,0.00) 
0.00 
(-0.00,0.00) 
0.07 
(-0.01,0.15) 
0.00 
(0.00,0.00) 
0.00 
(0.00,0.00) 
SIMD Decile 0.00 
(-0.01,0.00) 
-0.01 
(-0.02,0.00) 
0.00 
(-0.01,0.00) 
0.14 
(-0.08,0.37) 
0.00 
(0.00,0.00) 
0.00 
(0.00,0.01) 
Ex smoker (v 
never 
smoked) 
-0.03 
(-0.06,0.00) 
-0.07 
(-0.13,-0.02)# 
0.00 
(-0.03,0.03) 
1.50 
(0.26,2.74)# 
0.00 
(-0.04,0.03) 
0.04 
(0.01,0.07)# 
Current 
smoking (v 
never 
smoked) 
-0.03 
(-0.08,0.02) 
-0.05 
(-0.15,0.04) 
-0.01 
(-0.06,0.04) 
0.98 
(-1.04,3.00) 
-0.01 
(-0.06,0.04) 
0.07 
(0.02,0.12)# 
Family history 
of CVD (v no 
family history) 
-0.02 
(-0.06,0.01) 
-0.02 
(-0.08,0.04) 
-0.02 
(-0.06,0.01) 
-0.02 
(-1.36,1.33) 
-0.02 
(-0.06,0.01) 
0.01 
(-0.03,0.05) 
 
*Test for significance of coefficient: p<0.01, #test for significance of coefficient: p<0.05. 
$Proportion of variability (adjusted r2) explained by the cardiovascular, demographic and blood 
markers included in model. CI=confidence interval, LV=left ventricular, bpm=beats per minute, 
BMI=body mass index, BNP=B-type natriuretic peptide, HDL=high density lipoprotein, LDL=low 
density lipoprotein, SIMD=Scottish index of multiple deprivation, CVD=cardiovascular disease. 
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Table 4.22: Multivariable analysis of traditional cardiovascular risk factors, socio-
demographic factors and BNP in relation to other left ventricular measures in women 
 log end 
diastolic 
volume (ml) 
log end 
systolic volume 
(ml) 
log stroke 
volume (ml) 
Ejection 
fraction (%) 
log cardiac 
output (l/min) 
log LV 
mass/LV end 
diastolic 
volume (g/ml) 
Proportion of 
variability 
explained by 
model$ 
22.3% 13.3% 20.7 5.3% 42.1% 17.1% 
Risk factor coefficient (95% CI) 
log Age 
(years) 
-0.34 
(-0.42,-0.26)* 
-0.51 
(-0.67,-0.35)* 
-0.27 
(-0.36,-0.19)* 
4.61 
(1.29,7.94)* 
-0.28 
(-0.36,-0.19)* 
0.16 
(0.07,0.24)* 
log Heart rate 
(bpm) 
-0.28 
(-0.35,-0.21)* 
-0.30 
(-0.44,-0.17)* 
-0.30 
(-0.38,-0.23)* 
-0.68 
(-3.60,2.24) 
0.70 
(0.62,0.77)* 
0.08 
(0.008,0.15)# 
log 
Triglycerides 
(mmol/l) 
-0.04 
(-0.07,-0.02)* 
-0.06 
(-0.11,-0.01)# 
-0.04 
(-0.07,-0.02)* 
0.34 
(-0.69,1.37) 
-0.04 
(-0.07,-0.02)* 
0.02 
(-0.01,0.04) 
log BMI 
(kg/m2) 
0.25 
(0.13,0.36)* 
0.18 
(-0.04,0.40) 
0.28 
(0.17,0.40)* 
2.38 
(-2.27,7.04) 
0.28 
(0.17,0.40)* 
-0.06 
(-0.18,0.05) 
log BNP 
(pg/ml) 
0.02 
(-0.01,0.04) 
0.03 
(-0.01,0.08) 
0.01 
(-0.02,0.03) 
-0.68 
(-1.67,0.31) 
0.01 
(-0.02,0.03) 
-0.01 
(-0.03,0.02) 
Systolic BP 
(mmHg) 
0.00 
(0.00,0.00) 
0.00 
(0.00,0.00) 
0.002 
(0.001,0.003)* 
0.08 
(0.03,0.13)* 
0.002 
(0.001,0.003)* 
0.002 
(0.00,0.003)* 
Diastolic BP 
(mmHg) 
0.00 
(0.00,0.00) 
0.00 
(0.00,0.00) 
0.00 
(0.00,0.00) 
0.02 
(-0.05,0.08) 
0.00 
(0.00,0.00) 
0.003 
(0.001,0.004)* 
HDL (mmol/l) 0.00 
(-0.03,0.03) 
0.01 
(-0.05,0.06) 
-0.01 
(-0.04,0.02) 
-0.25 
(-1.41,0.92) 
-0.01 
(-0.04,0.02) 
-0.01 
(-0.04,0.02) 
LDL (mmol/l) -0.01 
(-0.03,-0.002)# 
-0.02 
(-0.05,0.00) 
-0.01 
(-0.03,0.00) 
0.25 
(-0.28,0.78) 
-0.01 
(-0.03,0.00) 
0.02 
(0.01,0.03)* 
Waist 
circumference 
(cm) 
0.00 
(0.00,0.00) 
0.00 
(0.00,0.01) 
0.00 
(0.00,0.00) 
-0.03 
(-0.10,0.03) 
0.00 
(0.00,0.00) 
0.002 
(0.001,0.004)* 
SIMD Decile 0.00 
(0.00,0.01) 
0.00 
(-0.01,0.01) 
0.01 
(0.002,0.01)* 
0.14 
(-0.04,0.31) 
0.01 
(0.002,0.01)* 
0.00 
(0.00,0.01) 
Ex smoker (v 
never 
smoked) 
0.01 
(-0.02,0.03) 
0.03 
(-0.02,0.07) 
-0.01 
(-0.03,0.02) 
-0.75 
(-1.77,0.27) 
-0.01 
(-0.03,0.02) 
-0.01 
(-0.03,0.02) 
Current 
smoking (v 
never 
smoked) 
0.02 
(-0.02,0.05) 
0.05 
(-0.02,0.11) 
0.00 
(-0.04,0.03) 
-1.16 
(-2.55,0.23) 
0.00 
(-0.03,0.03) 
0.06 
(0.03,0.10)* 
Family history 
of CVD (v no 
family history) 
-0.01 
(-0.03,0.02) 
-0.02 
(-0.07,0.02) 
0.00 
(-0.03,0.02) 
0.42 
(-0.55,1.39) 
-0.01 
(-0.03,0.02) 
0.00 
(-0.02,0.03) 
 
*Test for significance of coefficient: p<0.01, #test for significance of coefficient: p<0.05. 
$Proportion of variability (adjusted r2) explained by the cardiovascular, demographic and blood 
markers included in model. CI=confidence interval, LV=left ventricular, bpm=beats per minute, 
BMI=body mass index, BNP=b-type natriuretic peptide, HDL=high density lipoprotein, LDL=low 
density lipoprotein, SIMD=Scottish index of multiple deprivation, CVD=cardiovascular disease. 
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In men stroke volume, end diastolic volume and end systolic volume were 
independently inversely associated with age and heart rate and positively associated 
with BMI. End diastolic volume was also weakly inversely associated with LDL. Cardiac 
output was inversely associated with age and positively associated with heart rate and 
BMI. LVM/LVEDV was associated with heart rate, ex-smoking status or current 
smoking status and weakly with SBP. BNP was not independently associated with any 
of the measures of LV function in men. 
 
In women stroke volume, end diastolic volume and end systolic volume were 
independently inversely associated with age and heart rate as in men but also with 
triglyceride level. End diastolic volume and stroke volume (but not end systolic volume 
as in men) were associated with BMI and stroke volume was weakly associated with 
systolic blood pressure. As in men LDL was weakly inversely associated with end 
diastolic volume. Cardiac output was inversely associated with age and positively 
associated with heart rate and BMI as in men but was also inversely associated with 
triglycerides and positively weakly associated with systolic blood pressure. 
LVM/LVEDV was associated with heart rate, current smoking status and systolic blood 
pressure as in men but not with ex-smoking status. It was additionally associated with 
diastolic blood pressure (weakly) and LDL level. BNP was not independently 
associated with any of the measures of LV function in women. 
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4.4. Whole body MRI angiogram results 
 
4.4.1. Angiogram results 
1513 participants had all or some of their arterial tree imaged to allow assessment for 
arterial luminal stenosis. 1500 also had cardiac imaging available: the remaining 13 
had only MRA imaging because either their scan was abandoned partway through or 
the cardiac images were not suitable for analysis. A breakdown of the number and 
percentage of arterial segments with various degrees of luminal stenosis and other 
abnormalities is given in table 4.23 and is illustrated graphically in figure 4.7. The 
presence and degree of abnormality is given for each of the 31 segments analysed per 
patient to show the distribution of abnormality. The vast majority of segments (44435, 
94.6%) were assessed as normal. Of the vessel segments assessed to have some 
stenosis or aneurysm most had only a mild stenosis (<50%) however a reasonable 
number of segments had a more significant stenosis. 40 arterial segments were 
aneurysmal although only 7 of these were associated with a stenosis. Therefore the 
majority of contribution towards the standardised atheroma scores (SAS) greater than 
0 came from stenosis. 
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Figure 4.6: Example of bilateral carotid stenoses detected by WB CE-MRA in a 47 year 
old woman 
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Table 4.23: Individual arterial segment scores obtained from WB CE-MRA images 
 Norm
al 
<50%
 stenosis 
51-70%
 stenosis 
71-99%
 stenosis 
O
cclusion 
A
neurysm
 but no 
stenosis 
A
neurysm
 and 
<50%
 stenosis 
A
neurysm
 and 51-
70%
 stenosis 
A
neurysm
 and 71-
99%
 stenosis 
A
neurysm
 and 
occlusion 
U
ninterpretable/not 
im
aged 
Right Internal Carotid 1435 68 6 0 1 2 0 1 0 0 1 
Left Internal Carotid 1439 66 4 1 0 2 0 0 0 0 2 
Right Vertebral 1449 27 9 6 8 1 0 0 0 0 14 
Left Vertebral 1434 45 10 6 3 0 0 0 0 0 16 
Inominate 1482 14 2 1 0 0 0 0 0 0 14 
Right Common 
Carotid 
1468 31 1 0 0 0 0 0 0 0 14 
Left Common Carotid 1435 55 9 2 0 0 0 0 0 0 13 
Right Subclavian 1444 48 6 1 1 0 1 0 0 0 11 
Left Subclavian 1388 89 5 3 2 2 0 0 0 0 25 
Aortic Arch 1484 24 0 0 0 2 0 0 0 0 3 
Thoracic Aorta 1457 48 0 0 0 0 0 0 0 0 9 
Abdominal Aorta 1282 213 2 0 0 10 1 0 0 0 5 
Coeliac Trunk 1105 212 82 98 5 0 0 0 0 0 11 
Superior Mesenteric 1443 48 12 0 0 1 0 0 0 0 9 
Inferior Mesenteric 1471 15 2 0 6 0 0 0 0 0 18 
Right Renal 1416 65 19 1 1 0 0 0 0 0 11 
Left Renal 1439 50 4 5 1 0 1 0 0 0 12 
Right Iliac 1392 104 5 1 0 3 1 0 0 0 7 
Left Iliac 1408 80 6 2 1 7 2 0 0 0 6 
Right Femoral 1409 73 2 4 1 0 0 0 0 0 23 
Left Femoral 1435 48 5 2 1 0 0 0 0 0 22 
Right Profunda 
Femoris 
1497 4 1 0 0 0 0 0 0 0 10 
Left Profunda Femoris 1498 3 0 1 0 0 0 0 0 0 11 
Right Popliteal 1486 22 0 0 0 0 0 0 0 0 5 
Left Popliteal 1481 25 2 0 0 1 0 0 0 0 4 
Right Anterior Tibial 1461 30 6 6 8 0 0 0 0 0 2 
Left Anterior Tibial 1472 30 4 3 1 1 0 0 0 0 1 
Right Peroneal 1455 36 7 5 6 1 0 0 0 0 3 
Left Peroneal 1469 20 9 6 4 0 0 0 0 0 4 
Right Posterior Tibial 1454 28 5 6 12 0 0 0 0 0 8 
Left Posterior Tibial 1447 28 10 2 18 0 0 0 0 0 8 
All segments (total) 44435 1649 235 162 80 33 6 1 0 0 302 
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Figure 4.7: Distribution of abnormalities at arterial segment level 
 
1= less than 50% stenosis, 2= 51-70% stenosis, 3=71-99% stenosis, 4= occlusion, 
>4=presence of aneurysm with or without stenosis. L=left, R=right, ICA=internal carotid artery, 
VA=vertebral artery, IN AR=innominate artery, CCA=common carotid artery, SC=subclavian 
artery, AOR A=aortic arch, THOR AO=thoracic aorta, ABDO AO=abdominal aorta, 
COEL=coeliac trunk, SMA=superior mesenteric artery, IMA=inferior mesenteric artery, 
REN=renal artery, ILIAC=iliac artery, FEM=femoral artery, PROF=profunda femoris artery, 
POP=popliteal artery, AT=anterior tibial artery, PER=peroneal artery, PT=posterior tibial artery. 
 
The arterial segment most frequently assessed to have a stenosis was the coeliac 
trunk. As discussed later it is not clear if apparent stenosis is genuine or an artefact 
brought about by the anatomy of the artery. Therefore results for the whole body 
contrast enhanced magnetic resonance angiography (WB CE-MRA) looking at 
abnormalities in individual participants are presented both with and without the coeliac 
trunk included. 
 
At an individual participant level the number of segments affected are summarised in 
figures 4.8 and 4.9. 506 participants had multiple arterial segments (as opposed to a 
single arterial segment) affected by stenosis suggesting disease in more than one 
arterial territory. 
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Figure 4.8: Number of segments affected per individual participant (if coeliac artery 
included) 
 
 
Figure 4.9: Number of segments affected per individual participant (if coeliac artery 
excluded) 
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The standardised whole body atheroma scores (SAS) are illustrated in figure 4.10 and 
demonstrate a marked positive skew. The distribution of regional standardised 
atheroma scores is illustrated in figure 4.11. Summary values for the whole body and 
regional standardised atheroma scores are given in table 4.24 and for whole body SAS 
in men and women separately in table 4.25. 
 
Figure 4.10: Distribution of standardised atheroma scores with coeliac excluded (left) 
and included (right) 
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Figure 4.11: Distribution of regional atheroma scores. From top left to bottom right: 
head and neck, aorta, abdomen, iliofemoral, run-off 
 
 
 
 
 
 
Head and neck arteries = right and left internal carotid arteries, right and left common carotid 
arteries, innominate artery, right and left vertebral arteries, right and left subclavian arteries. 
Aorta = aortic arch, thoracic aorta, abdominal aorta. Abdominal = coeliac trunk, superior 
mesenteric artery, inferior mesenteric artery, right and left renal arteries. Ileofemoral = right and 
left iliac arteries, right and left femoral arteries, right and left profunda femoris. Run off = right 
and left popliteal arteries, right and left anterior tibial arteries, right and left posterior tibial 
arteries, right and left peroneal arteries. 
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Table 4.24: Regional standardised atheroma scores 
Region Median (IQR) 80th percentile 90th percentile 
Whole body 0 (1.67) 2.50 4.17 
Head and neck 0 (0.0) 2.80 3.96 
Aorta 0 (0.0) 0.0 8.3 
Abdominal 0 (0.0) 0.0 0.0 
Iliofemoral 0 (0.0) 0.0 4.20 
Run-off 0 (0.0) 0.0 3.10 
 
IQR=inter-quartile range. Head and neck arteries = right and left internal carotid arteries, right 
and left common carotid arteries, innominate artery, right and left vertebral arteries, right and left 
subclavian arteries. Aorta = aortic arch, thoracic aorta, abdominal aorta. Abdominal = coeliac 
trunk, superior mesenteric artery, inferior mesenteric artery, right and left renal arteries. 
Ileofemoral = right and left iliac arteries, right and left femoral arteries, right and left profunda 
femoris. Run off = right and left popliteal arteries, right and left anterior tibial arteries, right and 
left posterior tibial arteries, right and left peroneal arteries. 
 
 
Table 4.25: Standardised atheroma scores for men and women 
 Men (n=577) Women (n=936) p value* 
Median 0.00 0.83 0.08 
80th percentile 1.67 2.50 - 
90th percentile 3.33 4.17 - 
 
*Mann-Whitney test used to look for difference between men and women. 
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4.4.2. Correlation of angiogram results with risk factors and BNP 
The correlations between the whole body standardised atheroma score and the 
baseline demographic and risk factors were assessed by univariate analysis (table 
4.26). 
 
Table 4.26: Univariate analysis of correlations between baseline factors and 
standardised whole body atheroma score 
Variable 
Association with SAS 
Entire population 
(n=1513) 
Men 
(n=577) 
Women 
(n=936) 
Age (years) 0.25 (<0.001) 0.28 (<0.001) 0.23 (<0.001) 
Systolic BP (mmHg) 0.11 (<0.001) 0.10 (0.02) 0.13 (<0.001) 
Diastolic BP (mmHg) 0.03 (0.19) 0.04 (0.29) 0.04 (0.20) 
Heart rate (beats/min) 0.05 (0.05) 0.02 (0.64) 0.06 (0.06) 
Total cholesterol (mmol/l) 0.16 (<0.001) 0.13 (0.002) 0.17 (<0.001) 
HDL (mmol/l) 0.03 (0.28) 0.00 (0.93) 0.02 (0.49) 
LDL (mmol/l) 0.12 (<0.001) 0.10 (0.026) 0.14 (<0.001) 
Triglycerides (mmol/l) 0.06 (0.018) 0.05 (0.20) 0.09 (0.007) 
BMI (kg/m2) -0.03 (0.26) 0.00 (0.92) -0.03 (0.31) 
Waist circumference (cm) -0.02 (0.43) 0.05 (0.21) -0.02 (0.47) 
SIMD -0.08 (0.005) -0.08 (0.06) -0.01 (0.67) 
Predicted CHD risk score using 
ATPIII algorithm (%/10 years) 0.15 (<0.001) 0.28 (<0.001) 0.22 (<0.001) 
BNP (pg/ml) 0.03 (0.20) 0.06 (0.13) -0.02 (0.64) 
 
Spearman rank correlation test is used. ρ and (p) values are given. SAS=standardised 
atheroma score, HDL=high density lipoprotein, LDL=low density lipoprotein, BMI=body mass 
index, BNP=B-type natriuretic peptide, SIMD=Scottish index of multiple deprivation, 
CHD=coronary heart disease, ATPIII= Adult Treatment Panel III. 
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Linear multiple regression modelling demonstrated that age, heart rate, systolic BP, 
SIMD decile, ex-smoking status and current smoking status were independently 
associated with SAS (table 4.27). The original model included age, gender, smoking 
status, systolic BP, diastolic BP, heart rate, total cholesterol, HDL cholesterol, LDL 
cholesterol, triglycerides, BMI, waist circumference, family history of cardiovascular 
disease, SIMD decile and BNP level. Those variables with a positively skewed 
distribution were log transformed to create a near normal distribution. 
 
Table 4.27: Multivariable analysis of traditional cardiovascular risk factors, socio-
demographic factors and BNP in relation to standardised atheroma score 
Proportion of variability explained by 
model$ 
11.4% 
Risk factor coefficient (95% CI) 
log age (years) 3.40 (2.61,4.20)* 
log heart rate (bpm) 1.23 (0.51,1.95)* 
log triglycerides (mmol/l) 0.24 (-0.39,0.87) 
log BMI (kg/m2) -0.26 (-1.46,0.93) 
log BNP (pg/ml) 0.15 (-0.08,0.38) 
Systolic BP (mmHg) 0.02 (0.01,0.03)* 
Diastolic BP (mmHg) -0.01 (-0.03,0.01) 
Total cholesterol (mmol/l) -0.12 (-0.95,0.70) 
HDL (mmol/l) -0.01 (-0.87,0.86) 
LDL (mmol/l) 0.23 (-0.59,1.04) 
Waist circumference (cm) -0.01 (-0.02,0.01) 
SIMD Decile -0.06 (-0.10,-0.02)* 
Male gender (compared to female) 0.05 (-0.25,0.36) 
Ex smoker (v never smoked) 0.35 (0.10,0.60)* 
Current smoking (v never smoked) 0.79 (0.44,1.15)* 
Family history of CVD (v no family 
history) 
0.24 (-0.01,0.49) 
 
*Test for significance of coefficient: p<0.01, #test for significance of coefficient: p<0.05. 
$Proportion of variability (adjusted r2) explained by the cardiovascular, demographic and blood 
markers included in model. CI=confidence interval, bpm=beats per minute, BMI=body mass 
index, BNP=B-type natriuretic peptide, HDL=high density lipoprotein, LDL=low density 
lipoprotein, SIMD=Scottish index of multiple deprivation, CVD=cardiovascular disease. 
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Because the SAS is very positively skewed the baseline characteristics of those with a 
SAS above the 80th percentile are compared with those below the 80th percentile in 
table 4.28. Men and women with an SAS above the 80th percentile were older had a 
higher systolic blood pressure and had a higher predicted CHD risk when compared to 
those with an SAS below the 80th percentile. Additionally men were more likely to be 
current or ex-smokers and women had a higher total and LDL cholesterol and higher 
triglycerides. There were no significant differences in BNP levels. 
  
Univariate correlations between percentage of vessels with any abnormality and 
baseline risk factors are given in table 4.29. Percentage of vessels affected was 
associated with age, systolic BP, total cholesterol, LDL and predicted CHD risk score in 
both men and women and additionally (weakly) with heart rate and triglycerides in 
women. 
 
Baseline variables for those with no evidence of stenosis or aneurysm are compared 
with those with any presence of abnormality in table 4.30. Presence of any stenosis 
was associated with older age, higher total and LDL cholesterol and higher predicted 
CHD risk in both men and women, current or ex-smoking status in men and higher 
systolic BP in women. 
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Table 4.28: Baseline variables and BNP comparison between those with standardised 
atheroma score greater and less than 80th centile 
Variable 
Total population Men Women 
<80th 
centile 
SAS 
(n=1278) 
>80th 
centile 
SAS 
(n=235) 
p value <80th 
centile 
SAS 
(n=464) 
>80th 
centile 
SAS 
(n=113) 
p value <80th 
centile 
SAS 
(n=786) 
>80th 
centile 
SAS 
(n=150) 
p value 
Median (IQR) 
age (years) 
52.3 
(11.8) 
58.9 
(12.1) 
<0.001 51.8 
(10.8) 
59.9 
(10.8) 
<0.001 53.4 
(8.2) 
58.8 
(8.2) 
<0.001 
No (%) current 
smokers 
125 
(9.8) 
40 
(17.0) 
0.001 32 
(6.9) 
19 
(16.8) 
0.001 90 
(11.5) 
24 
(16.0) 
0.12 
No (%) former 
smokers 
332 
(26.0) 
78 
(33.2) 
0.022 118 
(25.4) 
45 
(39.8) 
0.003 205 
(26.1) 
42 
(28.0) 
0.61 
No (%) never 
smokers 
816 
(63.8) 
116 
(49.4) 
<0.001 312 
(67.2) 
49 
(43.4) 
<0.001 488 
(62.1) 
83 
(55.3) 
0.13 
Mean (SD) 
systolic BP 
(mmHg) 
122.0 
(12.1) 
125.3 
(12.1) 
<0.001 124.6 
(11.0) 
127.2 
(10.5) 
0.022 120.2 
(12.4) 
124.3 
(12.7) 
<0.001 
Mean (SD) 
diastolic BP 
(mmHg) 
72.7 
(9.3) 
73.5 
(9.0) 
0.23 74.9 
(8.9) 
74.8 
(8.4) 
0.95 71.3 
(9.2) 
72.8 
(9.2) 
0.08 
Median (IQR) 
heart rate 
(beats/min) 
62 
(12) 
63 
(13) 
0.40 60 
(11) 
60  
(14) 
0.73 65  
(10) 
65  
(9) 
0.55 
Mean (SD) total 
cholesterol 
(mmol/l) 
5.43 
(0.97) 
5.71 
(0.94) 
<0.001 5.38 
(0.94) 
5.52 
(0.78) 
0.12 5.46 
(1.02) 
5.81 
(1.02) 
<0.001 
Mean (SD) HDL 
(mmol/l) 
1.44 
(0.42) 
1.47 
(0.44) 
0.35 1.24 
(0.39) 
1.28 
(0.38) 
0.39 1.56 
(0.40) 
1.56 
(0.44) 
0.98 
Mean (SD) LDL 
(mmol/l) 
3.36 
(0.88) 
3.56 
(0.84) 
0.001 3.38 
(0.85) 
3.50 
(0.75) 
0.15 3.34 
(0.90) 
3.59 
(0.89) 
0.002 
Median (IQR) 
triglycerides 
(mmol/l)$ 
1.26 
(1.00) 
1.36 
(1.01) 
0.043 1.50 
(1.22) 
1.60 
(1.19) 
0.95 1.11 
(0.84) 
1.26 
(0.92) 
0.002 
Median (IQR) 
BMI (kg/m2) $ 
26.2 
(5.2) 
26.0 
(5.4) 
0.50 26.7 
(4.41) 
26.3 
(5.19) 
0.59 25.6 
(5.5) 
25.8 
(5.5) 
0.89 
Median (SD) 
waist 
circumference 
(cm) 
86.6 
(13.1) 
86.6 
(11.9) 
0.99 92.0 
(14.0) 
93.0 
(14.6) 
0.72 81.0 
(15.0) 
82.3 
(15.0) 
0.55 
Median (IQR) 
predicted CHD 
risk score using 
ATPIII algorithm 
(%/10 years) $ 
2 (5) 4 (9) <0.001 6 (6) 10 (5) <0.001 1 (2) 2 (3) <0.001 
Median (IQR) 
BNP (pg/ml) $ 
22.6 
(15.0) 
23.3 
(18.4) 
0.19 15.3 
(12.0) 
16.6 
(12.3) 
0.07 26.5 
(17.3) 
26.6 
(19.6) 
0.90 
No (%) with 
family history of 
CV disease 
323 
(25.3) 
66 
(28.1) 
0.37 108 
(23.3) 
25 0.79 209 
(26.6) 
47 
(31.3) 
0.23 
SIMD, 
Number (%) 
1 48 (3.8) 17 (7.2) 0.10 12 (2.6) 8 (7.1) 0.31 35 (4.5) 10 (6.7) 0.41 
2 66 (5.2) 13 (5.5) 21 (4.5) 4 (3.5) 44 (5.6) 10 (6.7) 
3 80 (6.3) 21 (8.9) 26 (5.6) 10 (8.8) 51 (6.5) 14 (9.3) 
4 66 (5.2) 10 (4.3) 28 (6.0) 6 (5.3) 37 (4.7) 5 (3.3) 
5 80 (6.3) 15 (6.4) 29 (6.3) 6 (5.3) 51 (6.5) 9 (6.0) 
6 143 (11.2) 
20 
(8.5) 
52 
(11.2) 
13 
(11.5) 
86 
(10.9) 
12 
(8.0) 
7 202 (15.8) 
45 
(19.1) 
67 
(14.4) 
21 
(18.6) 
126 
(16.0) 
33 
(22.0) 
8 254 (19.9) 
40 
(17.0) 
98 
(21.1) 
18 
(15.9) 
155 
(19.7) 
23 
(15.3) 
9 231 (18.1) 
43 
(18.3) 
88 
(19.0) 
20 
(17.7) 
140 
(17.8) 
26 
(17.3) 
10 105 (8.2) 11 (4.7) 43 (9.3) 7 (6.2) 58 (7.4) 8 (5.3) 
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[Notes for table 4.29] 
Unpaired t-test used to compare means for variables with a normal distribution. Mann-Whitney 
test used for variables with a skewed distribution (indicated by $). SAS=standardised atheroma 
score, SD=standard deviation, IQR=interquartile range, HDL=high density lipoprotein, LDL=low 
density lipoprotein, BMI=body mass index, CHD=coronary heart disease. 80th percentiles 1.67 
and 2.5 for men and women respectively. 
 
Table 4.29: Univariate correlations between percentage of arterial segments with any 
degree of stenosis or aneurysm and baseline risk factors 
Variable Association with percentage of vessels affected by stenosis 
and/or aneurysm 
Entire population 
(n=1513) 
Men 
(n=577) 
Women 
(n=936) 
Age (years) 0.26 (<0.001) 0.29 (<0.001) 0.24 (<0.001) 
Systolic BP (mmHg) 0.11 (<0.001) 0.10 (0.020) 0.14 (<0.001) 
Diastolic BP (mmHg) 0.04 (0.17) 0.03 (0.43) 0.05 (0.13) 
Heart rate (beats/min) 0.05 (0.041) 0.02 (0.67) 0.07 (0.043) 
Total cholesterol (mmol/l) 0.16 (<0.001) 0.13 (0.001) 0.18 (<0.001) 
HDL (mmol/l) 0.03 (0.20) 0.01 (0.82) 0.03 (0.38) 
LDL (mmol/l) 0.13 (<0.001) 0.10 (0.027) 0.15 (<0.001) 
Triglycerides (mmol/l) 0.06 (0.012) 0.06 (0.13) 0.09 (0.006) 
BMI (kg/m2) -0.03 (0.30) 0.003 (0.94) -0.03 (0.32) 
Waist circumference (cm) -0.02 (0.52) 0.06 (0.16) -0.02 (0.50) 
SIMD -0.04 (0.11) -0.08 (0.07) -0.02 (0.58) 
Predicted CHD risk score using 
ATPIII algorithm (%/10 years) 
0.15 (<0.001) 0.29 (<0.001) 0.22 (<0.001) 
BNP (pg/ml) 0.04 (0.13) 0.07 (0.09) -0.01 (0.70) 
 
Spearman rank correlation test is used. ρ and (p) values are given. HDL=high density 
lipoprotein, LDL=low density lipoprotein, BMI=body mass index, BNP=B-type natriuretic peptide, 
SIMD=Scottish index of multiple deprivation, CHD=coronary heart disease, ATPIII= Adult 
Treatment Panel III. 
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Table 4.30: Comparison of baseline characteristics between those with no atheroma 
and those with any atheroma 
 Total population Men Women 
Variable No 
stenosis 
(n=765) 
Any 
stenosis 
(n=748) 
p value* No 
stenosis 
(n=308) 
Any 
stenosis 
(n=269) 
p value* No 
stenosis 
(n=457) 
Any 
stenosis 
(n=479) 
p value* 
Median (IQR) age 
(years) 
51.7 
(11.6) 
55.3 
(13.0) 
<0.001 51.5 
(10.3) 
55.6 
(13.5) 
<0.001 51.9 
(12.3) 
55.3 
(12.9) 
<0.001 
No (%) current 
smokers 
68 
(8.9) 
97 
(13.0) 
0.010 20 
(6.5) 
31 
(11.5) 
0.034 48 
(10.5) 
66 
(13.8) 
0.12 
No (%) former 
smokers 
199  
(26.0) 
211  
(28.2) 
0.32 76 
(24.7) 
87 
(32.3) 
0.041 123 
(26.9) 
124 
(25.9) 
0.75 
No (%) never 
smokers 
496  
(64.8) 
436  
(58.3) 
0.011 211  
(68.5) 
150  
(55.8) 
0.002 285 
(62.4) 
286 
(59.7) 
0.45 
Mean (SD) systolic 
BP(mmHg)   
121.6 
(12.3) 
123.4 
(11.9) 
0.006 124.6 
(11.3) 
125.8 
(10.5) 
0.17 119.7 
(12.5) 
122.0 
(12.4) 
0.005 
Mean (SD) diastolic 
BP(mmHg)   
72.6  
(9.4) 
73.0  
(9.0) 
0.36 74.5 
(9.1) 
75.2  
(8.5) 
0.36 71.3  
(9.4) 
71.8  
(9.0) 
0.38 
Median (IQR) heart 
rate (bpm) 
61 (11) 63 (11) 0.08 60 (12) 61 (12) 0.51 63 (10) 64 (12) 0.14 
Mean (SD) total 
cholesterol 
(mmol/L) 
5.33 
(0.93) 
5.62 
(1.00) 
<0.001 5.31 
(0.91) 
5.52 
(0.91) 
0.006 5.35 
(0.94) 
5.67 
(1.04) 
<0.001 
Mean (SD) high 
density lipoprotein 
(mmol/l) 
1.43 
(0.42) 
1.45 
(0.43) 
0.25 1.26 
(0.39) 
1.24 
(0.38) 
0.61 1.54 
(0.40) 
1.57 
(0.41) 
0.27 
Mean (SD) low 
density lipoprotein 
(mmol/l) 
3.28 
(0.85) 
3.49 
(0.89) 
<0.001 3.33 
(0.84) 
3.48 
(0.82) 
0.040 3.25 
(0.85) 
3.51 
(0.93) 
<0.001 
Median (IQR) 
triglycerides 
(mmol/l) 
1.25 
(1.00) 
1.30 
(1.02) 
0.12 1.48 
(1.19) 
1.60 
(1.24) 
0.15 1.11 
(0.86) 
1.17 
(0.86) 
0.15 
Median (IQR) body 
mass index (kg/m2) 
26.4  
(5.3) 
26.0  
(5.1) 
0.16 26.7  
(4.3) 
26.7  
(4.7) 
0.80 25.7  
(6.0) 
25.5  
(5.4) 
0.10 
Mean (SD) waist 
circumference (cm) 
86.9 
(13.2) 
86.3 
(12.6) 
0.40 92.0 
(11.8) 
93.3 
(11.0) 
0.17 83.4 
(13.0) 
82.4 
(11.7) 
0.21 
Median (IQR) 10 
year CHD risk 
estimation (%) 
2 (4) 2 (5) <0.001 6 (6) 8 (7) <0.001 1 (2) 1↑ (2) <0.001 
No (%) with family 
history of CV 
disease 
188  
(24.6) 
201  
(26.9) 
0.31 69 
(22.4) 
64 
(23.8) 
0.69 119  
(26.0) 
137  
(28.6) 
0.38 
SIMD, Number 
(%) 
1 31 (4.1) 34 (4.5) 0.65 8 (2.6) 12 (4.5) 0.31 23 (5.0) 22 (4.6) 0.87 
2 37 (4.8) 42 (5.6) 12 (3.9) 13 (4.8) 25 (5.5) 29 (6.1) 
3 55 (7.2) 46 (6.1) 20 (6.5) 16 (5.9) 35 (7.7) 30 (6.3) 
4 37 (4.8) 39 (5.2) 18 (5.8) 16 (5.9) 19 (4.2) 23 (4.8) 
5 46 (6.0) 49 (6.6) 19 (6.2) 16 (5.9) 27 (5.9) 33 (6.9) 
6 90 (11.8) 73 (9.8) 38 (12.3) 27 (10.0) 52 (11.4) 46 (9.6) 
7 113 
(14.8) 
134 
(17.9) 
36  
(11.7) 
52  
(19.3) 
77  
(16.8) 
82  
(17.1) 
8 151 
(19.7) 
143 
(19.1) 
63 (20.5) 53 (19.7) 88 (19.3) 90 (18.8) 
9 145 
(19.0) 
129 
(17.2) 
63 (20.5) 45 (16.7) 82 (17.9) 84 (17.5) 
10 57 (7.5) 59 (7.9) 31 (10.1) 19 (7.1) 26 (5.7) 40 (8.4) 
 
*Unpaired t-test was used for normally distributed variables, Mann-Whitney test for skewed and 
ranked variables and Chi-square test for categorical variables. SIMD was treated as a 
continuous variable for the purpose of analysis. SD=standard deviation, IQR=inter-quartile 
range, bpm=beats per minute, CHD=coronary heart disease, BP=blood pressure, 
SIMD=Scottish Index of Multiple Deprivation. 
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BNP levels in men and women with and without arterial abnormality are shown in table 
4.31. There was no significant difference in BNP level between those with and without 
stenosis. 
 
Table 4.31: BNP levels in men and women with and without arterial abnormality on 
MRA 
 Median (IQR) of BNP pg/ml 
 No stenosis Presence of any 
stenosis 
p value* 
Men 15.2 (11.70) 16.1 (11.65) 0.31 
Women 26.7 (17.40) 26.2 (17.70) 0.59 
 
*comparison is between those with and without stenosis using Mann-Whitney test. BNP=B-type 
natriuretic peptide. IQR=inter-quartile range. 
 
 
4.4.3. Correlation of angiogram results with left ventricular measures 
The assessment of correlation between the standardised atheroma score (SAS) and 
left ventricular measures and between the percentage of vessels affected and left 
ventricular measures are summarised in tables 4.32 and 4.33 respectively. Only cases 
where both angiogram and cardiac imaging data were available were included in the 
analysis. End systolic and diastolic volumes and stroke volume were weakly inversely 
associated with both SAS and percentage of vessels affected, and LVM/LVEDV was 
weakly positively associated with both SAS and the percentage of vessels affected in 
both men and women. Ejection fraction was very weakly associated with SAS in 
women and percentage of vessels affected in both men and women. LVM indexed for 
height2.7 was associated with SAS and percentage of vessels affected in men. 
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Table 4.32: Univariate correlations between standardised atheroma score and left 
ventricular measures 
Left ventricular measure Men 
(n=572) 
Women 
(n=928) 
ρ p ρ p 
LV mass (g) 0.04 0.30 -0.06 0.08 
LVMI (height) (g/m) 0.06 0.15 -0.04 0.19 
LVMI (height1.7) (g/m1.7) 0.07 0.09 -0.03 0.37 
LVMI (height2.7) (g/m2.7) 0.09 0.040 -0.01 0.77 
LVMI (BSA using dubois formula) (g/m2) 0.06 0.12 -0.02 0.63 
LVMI (BSA using Mosteller fornula) (g/m2) 0.06 0.14 -0.01 0.71 
LV end diastolic volume (ml) -0.12 0.003 -0.15 <0.001 
LV end systolic volume (ml) -0.12 0.004 -0.14 <0.001 
LVM/LVEDV (g/ml) 0.16 <0.001 0.09 0.005 
Ejection fraction (%) 0.08 0.06 0.07 0.024 
Stroke volume (ml) -0. 9 0.030 -0.13 <0.001 
Cardiac output (l/min) -0.07 0.09 -0.02 0.48 
 
Spearman rank correlation test was used. LV=left ventricular, LVM=left ventricular mass, 
LVMI=left ventricular mass index, LVEDV=left ventricular end diastolic volume, 
SAS=standardised atheroma score. 
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Table 4.33: Univariate correlations between percentage of arterial segments affected 
and left ventricular measures 
Left ventricular measure Men 
(n=572) 
Women 
(n=928) 
ρ p ρ p 
LV mass (g) 0.04 0.40 -0.06 0.06 
LVMI (height) (g/m) 0.05 0.20 -0.05 0.15 
LVMI (height1.7) (g/m1.7) 0.07 0.11 -0.03 0.31 
LVMI (height2.7) (g/m2.7) 0.08 0.044 -0.01 0.69 
LVMI (BSA using dubois formula) (g/m2) 0.06 0.18 -0.02 0.56 
LVMI (BSA using Mosteller fornula) (g/m2) 0.05 0.20 -0.02 0.64 
LV end diastolic volume (ml) -0.12 0.004 -0.16 <0.001 
LV end systolic volume (ml) -0.12 0.004 -0.14 <0.001 
LVM/LVEDV (g/ml) 0.15 <0.001 0.09 0.004 
Ejection fraction (%) 0.08 0.049 0.07 0.024 
Stroke volume (ml) -0.09 0.040 -0.13 <0.001 
Cardiac output (l/min) -0.07 0.10 -0.03 0.45 
Spearman rank correlation test was used. LV=left ventricular, LVM=left ventricular mass, 
LVMI=left ventricular mass index, LVEDV=left ventricular end diastolic volume, 
SAS=standardised atheroma score. 
 
 
Because SAS is very positively skewed and the vast majority of participants have a 
score of zero LV measures in those above and below the 80th centile are compared in 
table 4.34 and between those with and without any arterial abnormality in table 4.35. 
An SAS >80th percentile was associated with lower end systolic end diastolic and 
stroke volumes and higher LVM/LVEDV in both men and women and with a slightly 
higher ejection fraction in women. Presence of any stenosis is associated with higher 
end systolic volume and LVM/LVEDV in both men and women and with lower end 
diastolic and stroke volumes and slightly higher ejection fraction in women. 
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Table 4.34: Comparison of left ventricular measures in those with standardised 
atheroma scores above and below 80th centile 
Left ventricular 
measure 
Men Women 
≤80th centile 
SAS 
(n=460) 
>80th centile 
SAS 
(n=112) 
p value* ≤80th centile 
SAS 
(n=778) 
>80th centile 
SAS 
(n=150) 
p value* 
Mean (SD) LV 
mass (g) 
129.2 (24.4) 129.5 (24.4) 0.91 87.2 (16.5) 86.8 (18.0) 0.92 
Mean (SD) 
LVMI (height) 
(g/m) 
73.1 (13.2) 73.8 (12.9) 0.64 53.4 (9.7) 53.9 (10.4) 0.63 
Mean (SD) 
LVMI (height1.7) 
(g/m1.7) 
49.1 (8.8) 49.9 (8.5) 0.41 38.0 (6.9) 38.6 (7.2) 0.36 
Mean (SD) 
LVMI (height2.7) 
(g/m2.7) 
27.9 (5.1) 28.6 (4.8) 0.19 23.4 (4.4) 24.0 (4.4) 0.13 
Mean (SD) 
LVMI (BSA 
using dubois 
formula) (g/m2) 
64.1 (10.7) 65.2 (10.3) 0.32 49.3 (8.0) 50.0 (8.3) 0.35 
Mean (SD) 
LVMI (BSA 
using Mosteller 
fornula) (g/m2) 
63.6 (10.5) 64.7 (10.1) 0.32 48.8 (7.9) 49.4 (8.3) 0.37 
Mean (SD) LV 
end diastolic 
volume (ml) 
156.5 (26.4) 148.3 (31.8) 0.005 120.8 (20.8) 113.7 (21.8) <0.001 
Mean (SD) LV 
end systolic 
volume (ml) 
50.9 (14.4) 47.1 (16.4) 0.028 37.8 (12.0) 34.2 (12.2) 0.001 
Mean (SD) 
LVM/LVEDV 
(g/ml) 
0.84 (0.14) 0.90 (0.20) <0.001 0.73 (0.12) 0.78 (0.16) <0.001 
Mean (SD) 
Ejection fraction 
(%) 
67.7 (6.2) 68.6 (6.1) 0.16 69.1 (6.5) 70.3 (7.0) 0.044 
Mean (SD) 
Stroke volume 
(ml) 
105.6 (18.5) 101.1 (20.4) 0.036 83.0 (14.0) 79.5 (14.9) 0.009 
Mean (SD) 
cardiac output 
(l/min) 
6.51 (1.17) 6.25 (1.26) 0.05 5.48 (1.09) 5.41 (1.21) 0.55 
 
*comparison was with independent samples t-test. LV=left ventricular, LVM=left ventricular 
mass, LVMI=left ventricular mass index, LVEDV=left ventricular end diastolic volume, 
SAS=standardised atheroma score, SD=standard deviation, IQR=inter-quartile range. 
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Table 4.35: Comparison of left ventricular measures between those with and without 
any abnormality on whole body angiography 
Left ventricular 
measure 
Men Women 
No stenosis 
(n=304) 
Presence of 
any 
stenosis 
(n=268) 
p value* No stenosis 
(n=454) 
Presence of 
any 
stenosis 
(n=474) 
p value* 
Mean (SD) LV 
mass (g) 
128.7 (24.2) 129.9 (24.5) 0.55 88.2 (17.6) 85.8 (15.8) 0.027 
Mean (SD) 
LVMI (height) 
(g/m) 
72.8 (13.2) 73.7 (13.0) 0.41 54.1 (10.4) 52.9 (9.3) 0.07 
Mean (SD) 
LVMI (height1.7) 
(g/m1.7) 
48.9 (8.8) 49.7 (8.6) 0.31 38.4 (7.4) 37.8 (6.6) 0.15 
Mean (SD) 
LVMI (height2.7) 
(g/m2.7) 
27.8 (5.1) 28.3 (4.9) 0.20 23.6 (4.6) 23.4 (4.2) 0.39 
Mean (SD) 
LVMI (BSA 
using dubois 
formula) (g/m2) 
64.1 (11.0) 64.6 (9.9) 0.56 49.7 (8.4) 48.7 (7.6) 0.41 
Mean (SD) 
LVMI (BSA 
using Mosteller 
fornula) (g/m2) 
63.6 (11.0) 64.1 (9.9) 0.60 49.1 (8.3) 48.7 (7.6) 0.48 
Mean (SD) LV 
end diastolic 
volume (ml) 
157.0 (26.3) 152.5 (29.1) 0.05 122.8 (20.7) 116.6 (21.0) <0.001 
Mean (SD) LV 
end systolic 
volume (ml) 
51.3 (14.3) 48.8 (15.4) 0.046 38.7 (12.1) 35.8 (11.9) <0.001 
Mean (SD) 
LVM/LVEDV 
(g/ml) 
0.83 (0.14) 0.87 (0.17) 0.003 0.73 (0.12) 0.75 (0.14) 0.010 
Mean (SD) 
Ejection fraction 
(%) 
67.5 (6.1) 68.3 (6.4) 0.15 68.8 (6.7) 69.8 (6.5) 0.020 
Mean (SD) 
Stroke volume 
(ml) 
105.6 (18.3) 103.6 (19.6) 0.20 84.1 (14.4) 80.9 (13.8) 0.001 
Mean (SD) 
cardiac output 
(l/min) 
6.48 (1.14) 6.42 (1.25) 0.58 5.48 (1.11) 5.45 (1.12) 0.68 
 
*comparison was with independent samples t-test. LV=left ventricular, LVM=left ventricular 
mass, LVMI=left ventricular mass index, LVEDV=left ventricular end diastolic volume, 
SAS=standardised atheroma score, SD=standard deviation, IQR=inter-quartile range. 
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4.5. MRI angiogram reproducibility 
 
4.5.1. Inter-observer reproducibility 
1488 arterial segments were evaluated (n=31 anatomical locations for n=48 
volunteers). A full breakdown of the individual arterial segments where disease was 
noted by consensus is summarised in table 4.36.  In 53 (3.6%) segments (involving 
n=29 of the 48 volunteers) there was some evidence of luminal stenosis. Of these 53 
segments, 34 were coded as 1 (minor stenosis 1-50%), 5 were coded as 2 (moderate 
stenosis 51-70%), 11 were coded as 3 (severe stenosis 70-99%) and 3 cases were 
coded as 4 (vessel occlusion).  However the vast majority of segments were 
interpreted as radiologically normal.  
 
The greatest frequency of stenosis was recorded at the coeliac trunk, where a stenosis 
score of 1 or more was noted in n=18 of the volunteers.  This was followed by the 
abdominal aorta (10 cases), and the right and left iliac arteries (4 cases each).  At all 
other segments, some degree of luminal narrowing was only ever noted in n=2 (or less) 
of the 48 volunteers. 
 
Independent single assessments of all n=48 volunteer datasets by each observer 
resulted in identical scoring between all four observers in 1277 (85.8%) of the 1488 
arterial segments evaluated.  Of those that were not scored identically, clear consensus 
agreement between three out of the four radiologists was recorded for 162 (10.9%) of 
the segments.  Radiological opinion was divided at the remaining 49 segments - which 
represented 3.3% of the total reviewed.  Fleiss’ kappa values are listed for each of the 
arterial segments under investigation as a measure of inter-observer agreement. The 
worst case agreement was found at the coeliac trunk (k=0.66) and best case perfect 
agreement was found at the innominate and left popliteal arteries (k=1.00). 
 
  
 
182 
The median total whole body atheroma (WBA) score by consensus was 0.8%, and 
ranged from 0% to 5.6%.  When the scores were evaluated between observers (using 
the Kruskal Wallis test), there was no significant difference detected between the 
means of those provided by each observer (p=0.14).   
 
Table 4.36: Number of abnormal arterial assessments within the cohort (from a possible 
n=48 for each location) identified by a consensus of four observers with cardiovascular 
MRI experience  
 
R=right, L=left, Int=Internal, Com=common, Sup=superior, Inf=inferior, Ant=anterior, 
Post=posterior.  Inter-observer agreement for each site is described by Fleiss’ kappa statistic. 
 
  
Arterial Segment Grade 1 Grade 2 Grade 3 Grade 4 Total (percent) Fleiss' kappa
R Int. Carotid 0 0 0 0 0 0.89
L Int. Carotid 2 0 0 0 2 (4.2%) 0.90
R Vertebral 0 0 0 0 0 (0%) 0.97
L Vertebral 0 0 0 0 0 (0%) 0.94
Aortic Arch 0 0 0 0 0 (0%) 0.99
Inominate 0 0 0 0 0 (0%) 1.00
R Com. Carotid 0 0 0 0 0 (0%) 0.99
L Com. Carotid 1 0 0 0 1 (2.1%) 0.93
R Subclavian 2 0 0 0 2 (4.2%) 0.88
L Subclavian 0 0 0 0 0 (0%) 0.90
Thoracic Aorta 1 0 0 0 1 (2.1%) 0.86
Abdominal Aorta 10 0 0 0 10 (21.0%) 0.81
Coeliac Trunk 6 5 6 1 18 (37.5%) 0.66
Sup. Mesenteric 1 0 0 0 1 (2.1%) 0.88
Inf. Mesenteric 0 0 1 0 1 (2.1%) 0.91
R Renal 1 0 0 0 1 (2.1%) 0.93
L Renal 0 0 0 0 0 (0%) 0.94
R Iliac 4 0 0 0 4 (8.4%) 0.90
L Iliac 3 0 1 0 4 (8.4%) 0.87
R Femoral 1 0 0 0 1 (2.1%) 0.91
L Femoral 2 0 0 0 2 (4.2%) 0.91
R Profundus 0 0 0 0 0 (0%) 0.96
L Profundus 0 0 0 0 0 (0%) 0.99
R Popliteal 0 0 0 0 0 (0%) 0.97
L Popliteal 0 0 0 0 0 (0%) 1.00
R Ant. Tibial 0 0 0 0 0 (0%) 0.93
L Ant. Tibial 0 0 0 0 0 (0%) 0.97
R Peroneal 0 0 1 0 1 (2.1%) 0.96
L Peroneal 0 0 2 0 2 (4.2%) 0.95
R Post. Tibial 0 0 0 1 1 (2.1%) 0.96
L Post. Tibial 0 0 0 1 1 (2.1%) 0.93
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4.5.2. Intra-observer reproducibility 
Intra-observer reproducibility (derived from four equal subsets of n=12 volunteers) 
resulted in observers 1 and 2 achieving consistent scoring in 356 (95.7%) of 372 arterial 
segments.  For observers 3 and 4, consistent scoring was achieved in 346 (93.0%) and 
350 (94.1%) of the segments respectively. 
When the WBA scores were compared on a per-observer basis (using the Wilcoxon 
signed rank test), there was no significant difference between the means of the first and 
second assessments (p=0.74, p=0.64, p=0.71, and p=0.71 for observers 1-4 
respectively). 
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5. Results part 3 – 2-year follow up 
 
5.1. CVD endpoints in eligible population 
Follow up data was extracted by the Health Informatics Centre, University of Dundee 
(HIC) 2 years following the end of recruitment. The data obtained gave follow up for a 
total of 18,364 person years at risk (9570 and 8794 years for the BNP and MRI/BNP 
groups respectively). The mean years at risk per person were 4.03 and 4.30 for the 
BNP and MRI/BNP groups respectively. 33 CV events of interest and 1 death occurred 
in the eligible population of the study. 17 events and 0 deaths were in the BNP group 
and 16 events and 1 death were in the MRI/BNP group. The details of the events are 
summarised in table 5.1. The death in the MRI/BNP group was due to acute 
myocardial infarction, unspecified (ICD code I21.9). No peripheral arterial disease 
events or diagnoses were recorded in any of the eligible participants at 2 year follow 
up. 
 
Survival from events in the BNP and MRI/BNP groups is illustrated in the Kaplan-Meier 
plot (figure 5.1). There was no significant difference in event rates between the BNP 
and MRI/BNP groups. The CV event rate (95% confidence interval) was 1.85 (1.28-
2.59), 1.78 (1.03-2.84) and 1.93 (1.13-3.10) per thousand person-years in the entire 
eligible population, BNP group and MRI/BNP group respectively. 
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Table 5.1: Cardiovascular events in the eligible population at 2 year follow up (following 
end of recruitment) 
Diagnosis or procedure Frequency 
BNP group 
(n=2376) 
MRI/BNP group 
(n=2047) 
Angina (ICD I20) 5 4 
Acute myocardial infarction (ICD I21) 9 5 
Percutaneous transluminal balloon 
angioplasty and insertion of 1-2 drug-
eluting stents into coronary artery (OPCS 
K75.1) 
1 1 
Cerebral infarction, unspecified (ICD 
I63.9) 
1 2 
Intracerebral haemorrhage (ICD I61) 0 1 
Stroke not specified as haemorrhage or 
infarction (ICD I64) 
1 3 
Total coronary events/procedures 15 10 
Total cerebral events 2 6 
Total events 17 16 
 
ICD = International Classification of Diseases, OPCS = Office of Population, Censuses and 
Surveys Classification. 
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Figure 5.1: Kaplan-Meier plot of survival to first cardiovascular event/procedure 
 
 
Of the 17 events (16 admissions and 1 death) that occurred in the MRI/BNP group 7 
were in participants who had CMR images available. The other 10 were in people who 
had either not completed an MRI scan or declined a scan. The event rates in those 
who had CMR images and those who did not were 1.10 (95% CI 0.44-2.26) and 4.15 
(2.0-7.6) events per 1000 patient years. The event rates in those with LVM, LVMI and 
LVM/LVEDV ratios in the upper and lower quartiles for their gender are shown in table 
5.2 and between those with LVM, LVMI and LVM/LVEDV ratios above and below the 
median for their gender in table 5.3. The event rates in those who had an SAS greater 
than 0 and those who had a score of 0 were 0.65 (95% confidence interval 0.08-2.35) 
and 1.52 (95% confidence interval 0.49-3.55) respectively. 
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Table 5.2: Combined cardiovascular event and all-cause mortality rates in those with 
upper and lower gender specific quartiles of LVM, LVMI and LVM/LVEDV 
Cardiac measure Event rate (95% CI) 
(Events/1000 participant 
years) 
Number of events 
Lower 
quartile for 
gender 
Upper 
quartile for 
gender 
Lower 
quartile for 
gender 
Upper 
quartile for 
gender 
Left ventricular mass 0.64 
(0.02-3.56) 
1.19 
(0.14-4.31) 
1 2 
Left ventricular mass 
(corrected for height) 
0.63 
(0.02-3.54) 
1.19 
(0.14-4.30) 
1 2 
Left ventricular mass 
(corrected for height1.7) 
0 
(0-2.38) 
1.20 
(0.14-4.32) 
0 2 
Left ventricular mass 
(corrected for height2.7) 
0 
(0-2.39) 
1.20 
(0.15-4.33) 
0 2 
Left ventricular mass 
(corrected for body 
surface area using 
Dubois formula) 
0.65 
(0.02-3.65) 
1.16 
(0.14-4.19) 
1 2 
Left ventricular mass 
(corrected for body 
surface area using 
Mosteller formula) 
0.65 
(0.02-3.65) 
0.58 
(0.01-3.22) 
1 1 
Left ventricular mass/left 
ventricular end diastolic 
volume 
0.67 
(0.02-3.71) 
1.17 
(0.14-4.24) 
1 2 
 
CI=confidence interval. 
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Table 5.3: Combined cardiovascular event and all-cause mortality rates in those with 
LVM, LVMI and LVM/LVEDV above and below gender specific median 
Cardiac measure Event rate (95% CI) 
(Events/1000 participant 
years) 
Number of events 
Below 
median for 
gender 
Above 
median for 
gender 
Below 
median for 
gender 
Above 
median for 
gender 
Left ventricular mass 1.61 
(0.52-3.75) 
0.61 
(0.07-2.21) 
5 2 
Left ventricular mass 
(corrected for height) 
0.61 
(0.07-2.21) 
1.61 
(0.52-3.75) 
2 5 
Left ventricular mass 
(corrected for height1.7) 
0.96 
(0.20-2.80) 
1.24 
(0.34-3.16) 
3 4 
Left ventricular mass 
(corrected for height2.7) 
0.95 
(0.20-2.77) 
1.25 
(0.34-3.20) 
3 4 
Left ventricular mass 
(corrected for body 
surface area using 
Dubois formula) 
1.29 
(0.35-3.31) 
0.91 
(0.19-2.66) 
4 3 
Left ventricular mass 
(corrected for body 
surface area using 
Mosteller formula) 
1.29 
(0.35-3.31) 
0.91 
(0.19-2.67) 
4 3 
Left ventricular mass/left 
ventricular end diastolic 
volume 
0.64 
(0.08-2.32) 
1.53 
(0.50-3.56) 
2 5 
 
CI=confidence interval. 
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5.2. CVD endpoints in screen fail population 
In the data obtained following the end of recruitment, total follow up was 1658 person-
years for those who failed screening due to hypertension, dyslipidaemia or high 
predicted CHD risk. 14 CV events of interest and 2 deaths occurred. 8 CV events and 
both deaths occurred in those who failed due to hypertension and 6 events and no 
deaths occurred in those who failed due to high predicted cardiovascular risk. The 
details of the events are summarised in table 5.4. One of the deaths in the 
hypertensive group was due to acute myocardial infarction and the other cannot be 
determined yet due to a lag in the detailed data being obtained from the general 
registrar office. The CV event rate was 8.4 (95% confidence interval 4.6-14.2) events 
per 1000 person-years. The death rate was 1.2 (95% confidence interval 0.14-4.2) 
deaths per 1000 person-years. Survival to events or death comparing the population 
who failed screening due to high cardiovascular with those who failed screening due to 
hypertension and the eligible population is shown in the Kaplan-Meier plot (figure 5.2). 
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Table 5.4: CV events in the population who failed screening due to high cardiovascular 
risk or hypertension at 2 year follow up 
Diagnosis or procedure Frequency 
Hypertensive group 
(n=291) 
High CHD risk group 
(n=146) 
Angina (ICD I20) 2 0 
Acute myocardial infarction (ICD 
I21) 
3 4 
Other forms of acute ischaemic 
heart disease (ICD I24.8) 
1 0 
Atherosclerotic heart disease (ICD 
I25.1) 
1 0 
Percutaneous transluminal balloon 
angioplasty of one coronary artery 
(OPCS K49.1) 
1 0 
Cerebral infarction, unspecified 
(ICD I63.9) 
0 2 
Total coronary 
events/procedures 
8 4 
Total cerebral events 0 2 
Total events 8 6 
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Figure 5.2: Kaplan-Meier plot of survival from CV events or all-cause death for those 
who failed screening due to high predicted cardiovascular risk, those who failed due to 
hypertension and the eligible study population 
  
BNP=BNP group, MRI/BNP=MRI/BNP group, SF1=failed screening due to high predicted CHD 
risk, SF2=failed screening due to hypertension. 
 
 
5.3. Prescribing changes following screening 
Medication prescribed before screening visit 
145 (33.1%) of the participants who failed screening due to high CHD risk or 
hypertension had been prescribed at least one of the classes of cardiovascular drugs 
of interest prior to the screening visit despite fully answering the questionnaire about 
medication at the screening visit. The analysis was performed with and without 
including aspirin as this is used for many non-cardiovascular indications. Even when 
aspirin was excluded 144 (32.9%) of the participants had been prescribed at least one 
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of the other classes of medication. For those with who failed screening and had pre-
visit prescriptions the time to visit from last prescription is summarised in table 5.5 and 
the drugs classes prescribed to them are summarised in table 5.6. 36 people had a 
prescription within 6 months before the screening visit. When aspirin was excluded 33 
people had a prescription in this time period. 
 
Table 5.5: Time from last prescription of cardiovascular medication to screening visit 
for participants who failed screening who had previously been prescribed medication 
 Time (days) 
Including aspirin Excluding aspirin 
Minimum 1 1 
1st quartile 197 222 
Median 1428 1488 
3rd Quartile 3820 3951 
Maximum 8416 8416 
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Table 5.6: Drug classes prescribed prior to screening visit 
Drug class Frequency (number of people prescribed each class 
of medication) 
High predicted CHD risk 
(n=146, 2.9% of those 
screened, 33.3% of 
screen fails) 
Hypertension (n=291, 
5.8% of those screened, 
66.4% of screen fails) 
Digoxin 1 1 
Lipid regulating drugs 9 9 
Thiazide and related diuretics 5 25 
Loop diuretics 4 13 
Potassium sparing diuretics 0 0 
Potassium sparing diuretics with 
other diuretics 3 6 
Diuretics with potassium 0 3 
Beta-adrenoceptor blocking 
drugs 17 51 
Centrally acting hypertensive 
drugs 0 1 
Alpha-adrenoceptor blocking 
drugs 1 2 
Angiotensin converting enzyme 
inhibitors 3 18 
Angiotensin-II receptor 
antagonists 0 4 
Nitrates 6 15 
Calcium-channel blockers 8 19 
Other anti-anginal drugs 1 0 
Peripheral vasodilators 0 3 
Oral anticoagulants 2 2 
Antiplatelet drugs 7 12 
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1159 (26.2%) of the eligible population had been prescribed one of the classes of drug 
prior to the screening visit. The analysis was also done without including aspirin as this 
is used for many non-cardiovascular indications. When aspirin was excluded 1130 
(25.6%) of the participants had been prescribed at least one of the other classes of 
medication. For those with pre-visit prescriptions the time to visit from last prescription 
is summarised in table 5.7 and the drugs classes prescribed to them are summarised 
in table 5.8. 167 had been prescribed medication within the 6 months before the 
screening visit (157 when aspirin was excluded). 
 
Table 5.7: Time from last prescription of cardiovascular medication to screening visit 
for participants who were eligible for the study but who had previously been prescribed 
medication 
 Time (days) 
 Including aspirin Excluding aspirin 
Minimum 1 1 
1st quartile 723 744 
Median 2407 2453 
3rd Quartile 4596 4623 
Maximum 8633 8633 
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Table 5.8: Drug classes prescribed to the eligible population prior to screening visit 
Drug class Frequency (number of people 
prescribed each class of medication) 
BNP (n=2376) MRI/BNP (n=2047) 
Digoxin 2 10 
Lipid regulating drugs 43 58 
Thiazide and related diuretics 110 90 
Loop diuretics 62 69 
Potassium sparing diuretics 4 8 
Potassium sparing diuretics with other 
diuretics 20 42 
Diuretics with potassium 12 14 
Beta-adrenoceptor blocking drugs 340 301 
Centrally acting hypertensive drugs 2 1 
Alpha-adrenoceptor blocking drugs 6 4 
Angiotensin converting enzyme inhibitors 22 26 
Angiotensin-II receptor antagonists 5 3 
Nitrates 48 54 
Calcium-channel blockers 75 58 
Other anti-anginal drugs 0 3 
Peripheral vasodilators 13 23 
Oral anticoagulants 14 28 
Antiplatelet drugs 59 80 
 
 
Medication prescribed after screening visit 
402 of those who failed screening had had no prescriptions of interest in the 6 months 
before screening and were therefore treated as not being on regular medication. Of 
these 171 participants had a drug prescription following screening (170 were 
prescribed prior to any CV event occurring and were therefore primary prevention and 
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1 was prescribed after a CV event so is likely to be for secondary prevention). Total 
follow up (until either first prescription, end of follow up or death) for this group was 
1045 person-years. The first prescription rate was 164 (95% confidence interval 140-
190) per 1000 person-years. The distribution of time to first prescription for these 171 
participants is shown in table 5.9. 
 
When aspirin was excluded from prescriptions either before or after screening 405 of 
those who failed screening had had no prescriptions of interest in the 6 months before 
screening and were therefore treated as not being on regular medication. Of these 172 
participants had a drug prescription following screening (171 were prescribed prior to 
any CV event occurring and were therefore primary prevention and 1 was prescribed 
after a CV event so is likely to be for secondary prevention). Total follow up (until either 
first prescription, end of follow up or death) for this group was 1045 person-years. The 
first prescription rate was 164 (95% confidence interval 141-191) per 1000 person-
years. The distribution of time to first prescription for these 171 participants is also 
shown in table 5.9. 
 
Table 5.9: Time to first prescription of cardiovascular medication from time of screening 
visit for those who failed screening due to high cardiovascular risk, hypertension or 
dyslipidaemia and were prescribed medication after screening visit 
 Time (days) 
Including aspirin Excluding aspirin 
Minimum 0 0 
1st quartile 62 59 
Median 204 192 
3rd Quartile 597 576 
Maximum 2339 2339 
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4240 of those eligible to enter the study had had no prescriptions of interest in the 6 
months before screening and were therefore treated as not being on regular 
medication. Of these 609 (14%) received at least one prescription between screening 
and the end of follow up. The total follow up (until either first prescription, end of follow 
up or death) for the eligible population was 16,424 person-years. The first prescription 
rate was 37 (95% confidence interval 34-40) per 1000 person-years. The distribution of 
time to first prescription for these 609 participants is shown in table 5.10. 
 
When aspirin was excluded from the analysis 4250 of those eligible to enter the study 
had had no prescriptions of interest in the 6 months before screening and were 
therefore treated as not being on regular medication. Of these 600 (14%) received at 
least one prescription between screening and the end of follow up. The total follow up 
(until either first prescription, end of follow up or death) for the eligible population was 
16433 person-years. The first prescription rate was 36 (95% confidence interval 34-39) 
per 1000 person-years. The distribution of time to first prescription for these 600 
participants is also shown in table 5.10. 
 
Table 5.10: Time to first prescription of cardiovascular medication from time of 
recruitment for those who were eligible to enter the study and were prescribed 
medication after recruitment 
 Time (days) 
Including aspirin Excluding aspirin 
Minimum 1 1 
1st quartile 321 320 
Median 680 690 
3rd Quartile 1217 1206 
Maximum 2293 2293 
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Figures 5.3 and 5.4 show time to prescription analysis (survival analysis) comparing 
those who failed due to hypertension and those who failed due to high CHD risk with 
the eligible BNP and MRI/BNP groups. Figure 5.3 includes aspirin and 5.4 excludes 
aspirin from the analysis. The classes of drugs prescribed to those who failed 
screening are summarised in table 5.11 and to the eligible population in figure 5.12. 
 
Figure 5.3: Time to prescription analysis for those who failed screening due to high 
predicted CHD risk or hypertension and those eligible for the study (including aspirin) 
 
SF1 is the group who failed screening due to high CHD risk score and SF2 is the group that 
failed screening due to hypertension. 
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Figure 5.4: Time to prescription analysis for those who failed screening due to high 
predicted CHD risk or hypertension and those eligible for the study (excluding aspirin) 
 
SF1 is the group who failed screening due to high CHD risk score and SF2 is the group that 
failed screening due to hypertension. 
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Table 5.11: Drug classes prescribed after screening visit to those who failed screening 
Drug class Frequency (number of participants 
prescribed each class of medication) 
High predicted CHD 
risk (n=146) 
Hypertension 
(n=291) 
Digoxin 0 1 
Lipid regulating drugs 43 49 
Thiazide and related diuretics 3 40 
Loop diuretics 6 12 
Potassium sparing diuretics 0 2 
Potassium sparing diuretics with other 
diuretics 2 5 
Diuretics with potassium 0 2 
Beta-adrenoceptor blocking drugs 20 53 
Centrally acting hypertensive drugs 0 1 
Alpha-adrenoceptor blocking drugs 1 4 
Angiotensin converting enzyme inhibitors 12 92 
Angiotensin-II receptor antagonists 1 24 
Nitrates 10 19 
Calcium-channel blockers 17 61 
Other anti-anginal drugs 1 1 
Peripheral vasodilators 1 5 
Oral anticoagulants 3 1 
Antiplatelet drugs 14 20 
 
CHD=coronary heart disease. 
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Table 5.12: Drug classes prescribed after screening visit to those who were eligible for 
the study 
Drug class Frequency (number of participants 
prescribed each class of medication) 
BNP (n=2376) MRI/BNP (n=2047) 
Digoxin 1 9 
Lipid regulating drugs 154 158 
Thiazide and related diuretics 119 97 
Loop diuretics 61 67 
Potassium sparing diuretics 5 6 
Potassium sparing diuretics with other 
diuretics 19 36 
Diuretics with potassium 10 10 
Beta-adrenoceptor blocking drugs 371 321 
Centrally acting hypertensive drugs 4 2 
Alpha-adrenoceptor blocking drugs 8 7 
Angiotensin converting enzyme inhibitors 87 85 
Angiotensin-II receptor antagonists 15 23 
Nitrates 65 68 
Calcium-channel blockers 104 99 
Other anti-anginal drugs 1 6 
Peripheral vasodilators 11 20 
Oral anticoagulants 16 30 
Antiplatelet drugs 89 125 
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Effect of medication prescription on CV event rate 
1534 person years of follow up occurred for those who had failed screening due to high 
CHD risk, hypertension or dyslipidaemia and had not previously had a prescription for 
CV medication in the preceding 6 months. 24% of the follow up time occurred during 
exposure to one or more of the drugs of interest. A time updated Cox proportional 
hazards model including current exposure status, current age and sex showed no 
significant effect of exposure status on time to CV event (hazard ratio 2.8, 95% 
confidence interval 0.76-10.1, p=0.12). 
 
When aspirin was excluded from the analysis 1545 person years of follow up occurred 
for those who had failed screening due to high CHD risk, hypertension or dyslipidaemia 
and had not previously had a prescription for CV medication in the preceding 6 months. 
24% of the follow up time occurred during exposure to one or more of the drugs of 
interest. A time updated Cox proportional hazards model including current exposure 
status, current age and sex showed no significant effect of exposure status on time to 
CV event (hazard ratio 2.7, 95% confidence interval 0.75-10, p=0.13). 
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6. Discussion 
 
6.1. Summary of main findings 
The TASCFORCE study is a prospectively recruited observational study and was 
designed to assess the ability of a range of biomarkers (B-type natriuretic peptide, MRI 
derived left ventricular mass and stenosis burden detected by whole body contrast 
enhanced angiography) in addition to “traditional” risk factors to predict future 
cardiovascular disease in a low or intermediate risk group. The use of such research 
methodology for this aim is well established and forms the basis of the large 
epidemiological studies that have given us understanding of the aetiology of 
cardiovascular disease. Our use of this combination of biomarkers, using MRI and 
recruiting a population at low (<10% risk at 10 years) or intermediate (10-20% risk at 
10 years) predicted risk of CVD at baseline makes this study unique. The intermediate 
and low risk groups are of particular interest as there is debate about how this group 
should be advised and treated in terms of primary prevention for cardiovascular risk. 
This study allows investigation of this difficult clinical group to help direct how they are 
managed.  
 
We recruited 4423 individuals across Tayside to produce a cohort of volunteers free 
from cardiovascular disease and at low or intermediate predicted 10 year risk of 
cardiovascular disease. The study achieved its target recruitment by recruiting using a 
range of methods. The recruitment strategies ensured we recruited people from areas 
with different levels of social deprivation and from ethnic minorities to ensure it closely 
matched the local population. The recruitment involved screening over 5000 people so 
recruitment itself was a major success. All agreed to be re-contacted for future studies, 
for their data to be used over a number of years and for their data to be linked and 
followed up over time. We have established a large database of genotypic phenotypic 
and blood measures. It is one of the largest prospective studies of cardiovascular 
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disease using MRI globally. The well-characterised cohort and stored blood samples 
will also facilitate other observational studies of the development of cardiovascular 
diseases and novel biomarkers as events unfold in this Scottish population. 
Additionally it has provided opportunity to investigate associations of a wide range of 
baseline clinical, demographic, imaging and blood biomarker variables to help 
understand and generate hypotheses about the aetiology and development of CV 
disease. This represents a “Scottish Framingham” that will be a major resource for the 
study of cardiovascular disease for Scotland for years to come. 
 
Originally it was intended that the study would be an intervention study investigating 
the effect of statins on those found to have evidence of subclinical disease however as 
the use of statins has become more widespread with an expanded evidence base the 
study was changed to an observational one. 
 
The primary aim of the recruiting this cohort was to study the ability of a number of 
imaging and blood biomarkers to identify which individuals develop cardiovascular 
disease. Individuals with a left ventricular mass (both absolute and indexed for body 
size) and left ventricular mass/left ventricular end diastolic volume (a marker of 
concentric hypertrophy) in the upper quartile for their gender had a trend towards a 
higher rate of cardiovascular events and death compared to those in the lower quartile. 
However this did not reach statistical significance. This probably reflects the low 
number of events at this early stage in follow up and it is not possible to draw any firm 
conclusions about the ability of left ventricular parameters to predict CV disease until 
more follow up time has elapsed. Preplanned analyses at 5,10 and 20 years have been 
planned. There was also no significant difference in the rates of events between those 
with BNP levels above and below their gender median. There was a trend towards 
more cerebral (stroke) events in those with a higher BNP level and more coronary 
events in those with lower BNP levels. Again the low number of events so far makes it 
hard to draw any firm conclusions at this stage. 
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In addition to analysing the ability of the biomarkers to predict events the wealth of data 
collected allowed the analysis of normal values and associations of a wide variety of 
variables in a low and intermediate risk population. The main findings are summarised 
here and the reasons for the findings are discussed in more detail later. 
 
At a preplanned review of BNP levels after the recruitment of about 1500 participants it 
became apparent that BNP levels in this healthy group were different between men 
and women. This resulted in gender specific medians having to be recalculated during 
recruitment and the recall of some participants for a scan. A number of studies 
published before the start of TASCFORCE had demonstrated a gender difference in 
BNP levels in healthy populations.[139-141] However as BNP levels in the healthy 
Tayside population were not known it was decided to determine these from the study 
population. In retrospect it may have been better to do a pilot study in a healthy 
population to determine normal BNP levels before the study started rather than have to 
retrospectively invite people for a scan. Increasing age, female sex, ex-smoking status, 
lower heart rate, lower total cholesterol and higher HDL were independently associated 
with higher BNP levels. The possible reasons for these associations are discussed in 
more detail later. Higher BNP levels were also associated with predicted CHD and 
CVD risk using ATPIII and ASSIGN algorithms respectively. This lends weight to the 
argument that BNP is a marker of vascular risk: as expected those with a higher 
predicted cardiovascular risk calculated using their risk factor profile have a higher 
BNP.  
 
Left ventricular mass and left ventricular mass index was significantly higher in men 
than women reflecting their usually larger body habitus. Left ventricular end diastolic 
volume, end systolic volume, stroke volume and cardiac output were all significantly 
higher in men compared to women and ejection fraction was higher in women. 
However these differences remained when indexed for body size suggesting that 
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gender differences in cardiac size and function are not solely due to differences in body 
size but may reflect other differences such as metabolic rates, body shape (rather than 
size or surface area), physical activity, genetics and sex related anatomy. BNP was 
weakly correlated with end diastolic volume and stroke volume (both raw and indexed 
for body size) in men but not with any other left ventricular measures. The correlation 
with end diastolic volume may be expected as increased end diastolic volume may 
result in increased cardiac stretch which is known to stimulate BNP release. BNP was 
not correlated with any left ventricular measures in women. The weak or non-existent 
correlations with BNP may be because the vast majority of BNP levels were within a 
“normal” clinical range and because only those with a greater than median BNP were 
imaged thus reducing the range of BNP levels. Stronger correlations may have been 
seen if those with all BNP levels were imaged. Age was weakly, but significantly, 
inversely associated with LVM and LVMI (except when indexed by height2.7) in men but 
only with LVM and LVM indexed by height in women. These associations persisted in a 
multivariable regression model suggesting that the association may be independent of 
other changes in CV risk that accompany age. Age was also associated with 
decreasing LV volumes, stroke volume and cardiac output in both men and women 
which persisted when corrected for other variables in the multiple regression models. 
These age related changes may reflect a combination of genuine myocardial atrophy 
with age (it is known that sarcopenia of systemic muscle is associated with age) and a 
biased population of older participants who are healthier and less likely to have LVH. 
Because age is a major determinant of cardiovascular risk older people may have a 
slightly more favourable risk factor profile of other factors to compensate for their age 
and result in a predicted score low enough to still allow eligibility. Systolic BP was 
positively associated with LVM and LVMI in both men and women as would be 
expected: a higher blood pressure increases cardiac work and can induce increase in 
cardiac muscle mass. 
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The vast majority of arterial segments in the angiograms were normal with no stenosis 
and of those that were abnormal most only had a mild stenosis which means we did 
recruit a truly low risk population in our study as planned. This is helpful as in future 
biomarker studies carried out when event rates are higher we will be able to 
hypothesise that with such a low atheroma score newly detected risk 
factors/biomarkers might be more likely to be considered aetiological rather than a 
secondary effect of atherosclerosis, which is a problem in secondary prevention 
studies which also aim to evaluate biomarkers. However the finding also demonstrates 
that a significant number of individuals at low predicted risk of CVD have evidence of 
possible disease. As follow up the significance, or otherwise, of this will become 
apparent. The standardised atheroma score was positively associated with predicted 
10-year CHD risk in men and women. Age, systolic BP, ex-smoking status, heart rate, 
current smoking status and SIMD decile were independently associated with SAS. As 
above with LVM this suggests that the presence of subclinical stenosis is related to 
cardiovascular risk factors so is likely to reflect subclinical disease. The strongest 
association was with age suggesting this is the greatest driver of the association with 
predicted CHD risk. No other researchers have looked at this marker of subclinical 
disease in such a large population of people at low or intermediate risk of CVD and its 
prognostic capabilities are so far not reported. Follow up of the TASCFORCE cohort 
will allow us to investigate the relevance and implications of these findings. 
 
 
6.2. Trial methodology 
 
6.2.1. Recruitment 
The study screened over 5000 individuals. Recruitment was assisted by study staff 
going to large employers and engaging at public events such as football matches and 
in supermarkets in addition to advertising and recruiting through primary care. 
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Additionally advertising through radio and regular press releases increased public 
awareness further. The multiple approaches to recruiting made it easier to reach a 
wider variety of people from different backgrounds ensuring we recruited a balanced 
population in terms of gender, race and social deprivation to reflect the local 
population. Actively going to people made it easier for members of the public to engage 
with the study as it required less active intent on their part. If recruitment had relied 
solely on recruitment through GP surgeries or hospitals it is likely that it would have 
been more difficult to reach so many people. A similar albeit less “one-to-one” method 
of approaching the population for screening has been adopted with success by 
programmes such as the Scottish bowel cancer screening programme which sends 
faecal occult blood sample cards in the post to men and women aged 50-74 years 
old.[238] However it has also been shown that people are more likely to participate in a 
screening programme if it is endorsed by the GP[239] so a mixed approach of 
approaching individuals, advertising and using primary care is likely to be best and 
helped recruit a large number of individuals. However despite recruiting a significant 
number of people the study did not quite reach its aim, based on the power calculation, 
of recruiting 5000 people at low or intermediate risk of cardiovascular disease because 
of the numbers found to have a CV risk score of ≥20% or hypertension (n=438) and 
these could not be replaced due to the booking requirements of the MRI scanner being 
allocated to other trials at the projected end of our study. The slightly smaller number of 
participants may result in the number of events at 5 year follow up is too small to draw 
any significant results. However the follow up in later years (e.g. at 10 years) is still 
likely to yield the required number of events to give sufficient power. The small under-
target recruitment is therefore not likely to affect the eventual results but may just result 
in a longer time of follow up being needed to reach a significant number of events. 
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6.2.2. Ensuring representation of a cross section Scottish population 
The study team aimed to recruit a population that represented as closely as possible 
the local population in Tayside. This would not only help assess the ability of a 
screening programme to enrol people from different ethnic and socioeconomic 
backgrounds but mean that any conclusions drawn by the study would be more likely 
to represent the population of Tayside as a whole and therefore be generalizable to 
this wider population. Therefore effort was made to recruit men, people from areas of 
social deprivation (using the Scottish Index of Multiple deprivation) and people from 
non-white-European ethnicity. These are groups that are recognised as being difficult 
to engage in screening programmes[240-244] and are often under-represented in 
studies.[245] They are also all groups that are recognised as being at increased risk of 
cardiovascular disease and therefore have potentially more to gain from screening and 
recruitment to clinical trials. 
 
Despite aiming to recruit a representative sample men were still under-represented 
compared to women (1740 v. 2683, 39.3% v. 60.7%) compared to the Tayside 
population (48.4% v. 51.6%)[246] echoing the findings of other studies of screening 
programmes. The recruitment of participants from areas of social deprivation as 
indicated by Scottish Index of Multiple Deprivation (SIMD) was not markedly dissimilar 
to the local working age and total populations although those from areas of multiple 
deprivation were slightly under-represented (32% of the TASCFORCE population were 
below the median SIMD compared to 41% of the local population). Of those who were 
screened (i.e. before potential volunteers were excluded) only 41.2% were men 
suggesting even despite targeting recruitment at men they were still less likely to 
volunteer than women.  Additionally the majority of those who failed screening due to 
high predicted cardiovascular risk or hypertension were men and more were from 
areas of multiple deprivation than the eligible population. Therefore the skewing of the 
population to women and those from areas with less deprivation is partly due to the 
screen failed population being skewed in the opposite direction. Therefore despite 
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targeting recruitment at these groups this may have needed to have been done more 
aggressively to account for the greater number of people from these groups who failed 
screening. The higher proportion of women may have an effect on the outcome data as 
men tend to have CV events at a younger age than women[247]: the over-
representation of women may therefore mean that events take longer to accrue than 
has been predicted. The slight under-representation of those from areas of social 
deprivation may have a similar effect. It is known that living in areas of social 
deprivation is associated with a lower life expectancy and healthy life expectancy.[248] 
Except for those recruited as part of the South Asian substudy we did not collect 
ethnicity data on all participants. Therefore it is not possible to determine if the ethnic 
make up of the study population reflects the local population. However Asian and other 
ethnic groups are only a small percentage of the local Tayside population. 96.8% of the 
Tayside population is white with 2.1% of Asian origin and 1.1% from other ethnic 
groups.[246] 
 
The reasons for underrepresentation of certain hard to reach groups has been 
investigated previously; fear of screening programmes (particularly of finding 
abnormality or disease), past negative experiences with healthcare, lack of motivation 
and dissuasion by peers have been shown to influence uptake.[249, 250] The social 
and demographic environment has an influence on screening engagement beyond 
individual characteristics such as gender and ethnicity.[251] A large qualitative study 
into engagement with cancer screening found that those with a lower socioeconomic 
status rated the benefits of screening lower, and had more fear and a more fatalistic 
attitude to cancer.[252] Therefore it is likely that attitudes and beliefs in hard to reach 
groups may need to be better understood and addressed to improve uptake further 
rather than just targeting existing screening programmes at these groups. However we 
have shown that this targeted approach is still worthwhile. This is particularly important 
as those from areas of deprivation and men are at increased risk of CV disease so are 
more likely to benefit from intervention. 
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Those from areas of social deprivation and ethnic minorities are also under-
represented in clinical trials.[245] The reasons for under-representation in socially 
deprived groups is not fully understood and motivation for participation in clinical trials 
remains elusive however there is likely to be some overlap of the reasons for poor 
engagement in screening programmes described above. Different people are likely to 
volunteer for different reasons and this may depend on the aims of each individual 
study: some will volunteer purely for altruistic purposes whereas at the other end of the 
spectrum others will only volunteer if they personally see some benefit. This will be 
influenced by what the study involves. This personal gain motivation may be reflected 
in the number of people who enrolled in TASCFORCE but did not consent or attend for 
their MRI scan: the ability to get a health check and blood test including lipid profile 
may have been seen as advantageous to that individual at relatively little personal cost 
whereas attending for an MRI scan may not have been perceived as bringing any 
personal benefit. Financial incentives to participate in trials have been investigated and 
were found not to increase recruitment of those from lower socioeconomic 
backgrounds.[253] We believed that access was also important and thus actively 
sought out this population in areas near to their locale, and at venues most people 
attend (for example football grounds, supermarkets and workplaces). 
 
An area that has been covered more in the literature is that of reasons for 
underrepresentation of ethnic minorities in research. TASCFORCE specifically 
recruited participants of South Asian ethnicity as part of the South Asian sub-study. 
They were matched with white European participants to facilitate comparison of 
baseline parameters and CV outcomes between the two ethnic groups and therefore 
better understand the differences between them. 38 (0.9%) of the total recruited 
population was of South Asian origin compared with 2.1% of the local population being 
from Asian origin.[246] However the ethnicity of the rest of the study population was 
not fully determined and documented thus preventing accurate description of the 
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population in terms of ethnicity. No black participants were recruited and although 
some of East Asian origin were they accounted for less than 1% of participants, which 
is very close to the local population proportion. This lack of characterisation is common 
particularly in the UK although it may be marginally better in the USA.[254] A review of 
recruitment of ethnic minority groups describes some of the barriers to recruiting 
representative populations in trials.[245] Although TASCFORCE did not explicitly 
exclude participants from ethnic minorities it is possible that their involvement could be 
indirectly hindered. For example for some English may not be their first language which 
could provide barriers to understanding recruitment material, participant information 
sheets and the consent process. Because of the extra work (and therefore cost) 
involved many studies do not routinely translate study materials into different 
languages or provide interpreters. Cultural beliefs (for example modesty and reluctance 
to be examined by study staff) may also inhibit some from participating. Additionally the 
concept of clinical trials is a “Westernised” one so it has been suggested that it may not 
yet be part of the “cultural repertoire” of ethnic minority communities. Therefore extra 
effort may need to be made to make trial participation more appealing and easier for 
ethnic minorities. Additionally more effort should be made to describe the ethnic make-
up of study populations such as the TASCFORCE cohort so that it can be determined if 
findings can be extrapolated to other populations. 
 
6.2.3. Screening method 
The screening process for recruitment to TASCFORCE involved the comprehensive 
collection of a range of “traditional” risk factor and demographic data. This has enabled 
the study population to be well characterised and described, has facilitated the analysis 
of associations of these data with the blood and imaging biomarkers and formed the 
basis of the CV risk estimation. It also allowed targeted advice to be given to 
participants to improve modifiable risk factors through lifestyle and diet modification. 
  
 
213 
The use of leaflets produced by the British Heart Foundation re-enforced the verbal 
information given. 
 
Where the initial BP reading was elevated (>145/90mmHg) and would have therefore 
led to exclusion of the participant up to a further two readings were taken. If more than 
one measurement was taken the lowest of the readings was used in analysis which is 
in keeping with current guidelines from the British Hypertension Society (BHS).[10] The 
use of a cut-off of 145/90mmHg is slightly higher than that which diagnoses stage 1 
hypertension and according to the BHS guidelines should lead to an assessment for 
end organ damage and overall assessment of cardiovascular risk. Participants found to 
have such a blood pressure were referred to their GP for further assessment and 
management. The screening process therefore identified a significant number of 
people who had hypertension who were unaware of their diagnosis potentially allowing 
treatment and full assessment earlier than would have been the case if they had not 
participated. This shows that despite the quality outcomes framework (QOF) driving the 
checking of blood pressure by GPs a significant number of people had undiagnosed 
hypertension. This may reflect the reluctance of some fit and healthy people to attend 
their GP for screening. The sole use of one-off BP readings may have led to the 
exclusion of some individuals with white coat hypertension who may have been eligible 
if they had undergone ambulatory or home blood pressure monitoring as advised by 
the BHS guidelines. However this would not have been practically possible within the 
resources available for the trial so follow up was left to the discretion of the participants’ 
GPs. 
 
All those recruited had their predicted 10-year coronary heart disease risk calculated 
using the algorithm in the bedside cholesterol analyser. This used the ATPIII algorithm 
based on the Framingham cohort.[229] Around the time of design and start of 
recruitment for TASCFORCE the ASSIGN score was developed[41] and is now 
recommended for use in Scotland[5] to estimate people’s cardiovascular risk. The use 
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of ATPIII in TASCFORCE has resulted in a difference between the method used for 
risk estimation in the study and in clinical practice. The two scoring methods have 
some significant differences and are therefore not interchangeable. ATPIII predicts 
coronary heart disease whereas ASSIGN also includes prediction of non-coronary 
cardiovascular disease particularly stroke. SIGN, ECS and AHA guidelines now all 
recommend that risk estimation includes this broader range of CV disease. The two 
scores were strongly correlated but the ASSIGN score on average was higher than the 
ATPIII score. This would be expected due to the broader outcomes predicted by the 
ASSIGN score. ASSIGN also includes additional variables (family history of CV 
disease, measure of social deprivation and history of rheumatoid arthritis) and treats 
variables as continuous rather than grouping them in brackets. The ASSIGN score was 
derived from a Scottish study population more similar to our study population whereas 
the ATPIII score was derived from a study population in the United States. As may be 
expected the different methods and meaning of their results led to the reclassification 
of some individuals in terms of their risk category and we demonstrated differences 
between individuals’ ATPIII and ASSIGN derived scores. More people were “up-
classified” to a higher risk group using the ASSIGN score than were “down-classified” 
and on average ASSIGN scores were greater than ATPIII scores. This suggests that if 
the ASSIGN score had been used in the study a significant number of those recruited 
(258) would have failed screening and should be considered for starting on cholesterol 
lowering medication and 52 of those who failed screening due to high predicted CV risk 
would actually have been eligible for the study. This means that more people were 
recruited than may have been possible if the ASSIGN score had been used to assess 
eligibility. Additionally those recruited may have a higher rate of events than would 
otherwise be predicted. This could result in a higher than expected number of events 
as follow up continues. It will also allow us to determine in 10 years time which scoring 
method is most accurate in this population. 
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Random blood glucose measurement was introduced approximately halfway through 
recruitment for the study. It had been excluded due to the difficulty of asking volunteers 
to fast as previous normal volunteer studies had shown potential recruits were put off 
by a fast. However we decided to measure random samples in the latter half of the 
population giving us sufficient data to investigate links in later data linkages. As this 
was not measured for all participants an elevated level was not used to exclude people 
from the study - it is not possible to ascertain that those who did not have a level 
checked did not have diabetes. Additionally even if the random blood glucose level was 
>11mmol/l this would not be sufficient to diagnose diabetes in the absence of 
symptoms without a second confirmatory plasma determination[255] making diagnosis 
of diabetes at a one off visit impossible. Therefore if the level was >7mmol/l 
participants were informed of the result and asked to have a fasting sample rechecked 
at their GP to determine if they had diabetes. Glucose measurement was therefore 
used more to flag up the need for further investigation rather than an exclusion criteria. 
Currently stored samples are being used to check blood glucose levels for those who 
did not originally have a level checked, which will allow a more robust usage of the 
data, but these data are not yet available for analysis in this thesis. 
 
In addition to the opportunistic education about modifiable cardiovascular risk factors 
offered to all those who were screened all individuals who were found to be at high risk 
of cardiovascular disease or were hypertensive were referred to their GP for further 
assessment and consideration of treatment. The use of such a proactive screening 
programme therefore helped identify a large number of people at increased risk of 
cardiovascular disease who may not otherwise have had this risk recognised. This 
potentially has allowed monitoring and/or interventions to be put in place to reduce the 
incidence of CVD. Prescription of cardiovascular medication following screening is 
discussed later in section 6.3.1. The opportunistic education may in fact have an effect 
and lower the event rate as follow up continues but it was not considered ethical to do 
otherwise.  
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Those who failed screening due to high predicted CHD risk were older, mostly men 
(97%), mostly smokers (58%), had a slightly higher blood pressure, total cholesterol, 
lower LDL and higher HDL showing the increased risk is due to a combination of risk 
factors. The fact that almost all were men shows the power of male gender on 
cardiovascular risk. This contributed to the eligible population containing fewer men as 
discussed earlier in section 6.2.2. Despite the CHD score not directly using SIMD data 
more of those excluded due to high CV risk were from areas of multiple deprivation 
(33.5% of those who failed due to high predicted risk compared to 24.3% of the eligible 
population were from SIMD deciles 1-4). This shows that traditional cardiovascular risk 
factors are associated with social deprivation although this has also been shown to be 
an independent factor hence it’s inclusion in the ASSIGN score as discussed 
earlier.[41] Those who failed screening due to hypertension were older than the eligible 
population probably reflecting the association of increasing BP with increasing age. 
This will again have resulted in the exclusion of older people and contributed to an 
eligible population that is skewed towards younger participants. 
 
As only those with a cardiovascular risk of less than 20% in 10 years were recruited 
into the main study those imaged and with BNP levels are likely to have a narrower 
range of BNP levels and less variation in MRI findings than if a more diverse population 
was studied in more detail. However this low/intermediate risk group were those of 
most interest as there is uncertainty as to how best treat them so the limited resources 
for the study were targeted at this group. It is recognised however that this may have 
limited the ability of the study to find significant differences in imaging and biomarker 
parameters. With more financial resource it would have been preferable to investigate 
a wider range of participants. 
 
We used BNP to determine who should be offered an MRI scan. As described in detail 
in the literature search there is a large body of evidence showing that natriuretic 
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peptides are associated with impaired vascular function, calcification and presence of 
subclinical disease and importantly is able to detect individuals with subclinical 
cardiovascular disease. Levels are also associated with increased estimated and 
actual cardiovascular risk in a variety of populations. BNP measurements from different 
assays may not be interchangeable[139] so median values and distribution obtained in 
TASCFORCE cannot routinely be used in other populations unless the same assay is 
used. Assays for both BNP and NT-proBNP are available. NT-proBNP has a longer 
half life and is more stable over a period of time so may have been a better test to use. 
However at the time of the study initiation the BNP assay was cheaper and the aim 
was to screen a large number of people. Therefore a pragmatic decision was made to 
use BNP rather than NT-proBNP. 
 
Interestingly, if puzzling, using data linkage through the Health Informatics Centre in 
Tayside, it has subsequently been found that a proportion of people who were deemed 
eligible to enter the study based on their negative history for CVD or high risk, had 
apparently previously been prescribed cardiovascular medication. This comprised lipid 
regulating medication, antihypertensives, antiplatelets and antianginals. Many had not 
received a prescription for a considerable amount of time (median time from last 
prescription was 2407 days) however some (167, 3.8%) had been prescribed 
medication in the 6 months prior to being enrolled in the study and at least one 
participant had received a cardiovascular medication the day before recruitment. This 
may suggest that either these people were not taking medication they had been 
prescribed, did not declare they were taking them at time of recruitment or that there 
are errors in the linkage programme and we are following up on all of these to 
ascertain which is the case. Alternatively they may have received the medication for 
indications other than for cardiovascular disease. For example aspirin may have been 
prescribed as an analgesic (e.g. for migraine), anticoagulants for venous 
thromboembolic disease, calcium channel blockers for cluster headache or Raynauds 
prevention or beta blockers for essential tremor. However even when analysis was 
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done excluding aspirin 1130 (25.6%) of the eligible population had been prescribed 
cardiovascular medication compared to 1159 (26.2%) when aspirin was included. The 
difference between the two analyses is not large suggesting the issue of medications 
being used for other purposes may not be that great a problem. Further analysis is 
ongoing looking at whether prescriptions were acute or repeat prescriptions and what 
the indications may be using the GP coding data. However this illustrates one of the 
difficulties of interpreting linked follow up data without direct access to clinical notes. 
 
6.2.4. Imaging method 
As MRI scanners become more widely available and scanning techniques have been 
refined it is becoming increasingly feasible to use them to screen for cardiovascular 
disease. The lack of ionising radiation also makes the modality more acceptable for 
use in mass screening compared to other modalities which have an evidence base for 
detecting subclinical disease such as CT for calculating coronary artery calcium 
scores. The MRI used in in TASCFORCE also images a wide range of parameters 
(both arterial and cardiac) thus potentially increases the sensitivity for detecting 
abnormality compared to more targeted imaging such as coronary artery calcium 
scores or carotid intima media thickness measurement. Therefore MRI was chosen for 
this screening study. The TASCFORCE study is unique in combining cardiac and 
whole body angiography in a large cohort of truly low risk people. The technique has 
been refined by the study team and uses what would otherwise be “deadtime” in the 
scan protocol to gain further images. In this way comprehensive imaging of the heart 
and arterial tree is possible in an acceptable scan time. Other studies have used 
individual components of the imaging protocol but have either not combined it with 
whole body angiography or have imaged people with a variety of baseline 
cardiovascular risk profiles. For example the MESA study[174] has used MRI cardiac 
imaging but not whole body angiography in individuals free from CVD and the Dallas 
Heart study[175] included a thoracic MRI scan but did not specifically exclude those at 
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high risk of cardiovascular disease and again did not include MRI angiography. Those 
who have used contrast enhanced MRI angiography to quantify whole body atheroma 
burden (some along with cardiac imaging have used populations who are either much 
smaller, diabetic, older, had pre-existing or suspected CV disease and/or had mixed 
background cardiovascular risk (i.e. those at increased risk were not excluded)[207-
209] Therefore the TASCFORCE population and its imaging data is unique and permits 
characterisation and determination of normal values and correlations between the 
variables for this a normal low risk group. The coronary arteries were not imaged in this 
study. This would have entailed a longer imaging time which would have impacted on 
participant acceptability and had an implication for resource utilisation. Atherosclerosis 
is a systemic disease and atheroma in peripheral arteries has been associated with 
coronary artery disease (209). Therefore the pragmatic decision was made to image 
the wider arterial tree and look for a wider range of cardiovascular abnormalities whilst 
limiting the scan time to a reasonable one. There is also local expertise in performing 
and interpreting cardiac MRI and whole body MRA. 
 
25.5% of those eligible for a scan did not complete a scan which may limit the imaging 
technique’s acceptability as a screening tool. 4.0% were due to claustrophobia but 
significantly 18.9% either did not consent for an MRI scan or did not attend for their 
appointment. This compares to a 16.3% “did not attend” rate for colonoscopy in the UK 
bowel screening programme[238] so is not dissimilar. It is possible that potential 
recruits were keen to get their blood pressure and cholesterol checked (if this was at 
their place of work it will have taken very little of their time) but were not prepared to 
attend for the scan. As they were identified as not being at increased risk of CV 
disease individuals’ perception of the need for or value of an MRI scan may have been 
reduced. Interestingly those who declined or were unable to have an MRI scan had a 
small but statistically significantly higher resting heart rate which may reflect a degree 
of anxiety in those who declined a scan. They also had a marginally higher systolic 
blood pressure, which may support this theory. This may have produced a skewed 
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population of people who completed a scan who were potentially “healthy responders” 
or “worried well”. It would be interesting to have explored the views of those who did 
not attend for or declined an MRI scan to understand factors influencing the decision to 
attend. This would allow factors that prevent or dissuade people undergoing scanning 
to be tackled in a potential future screening programme.  
 
The cardiac imaging protocol is similar to other groups who have used cardiac MRI to 
image healthy populations using a steady state free precision (SSFP) sequence. 
However TASCFORCE used a 3.0T scanner whereas all the other the other groups 
have used 1.5T scanners[177, 256-258] making TASCFORCE the only study to use 3T 
SSFP cardiac imaging in a healthy population. The TASCFORCE population is also 
much larger (1515) than any of the other three studies who studied 1140 people 
between[177, 259] them with the most in one study being 852.[258] Other groups have 
studied cardiac volumes and mass in larger populations using MRI but have used turbo 
gradient echo (TGE) sequences.[182, 183, 260-262] Such protocols have been shown 
to give different values for mass and volume compared to SSFP[256] which is thought 
to be due to improved delineation of the endocardial border because of better definition 
with SSFP. Therefore values from the 2 protocols are not interchangeable. Other larger 
cardiac imaging studies have also studied populations of mixed cardiovascular risk. 
 
As with other groups ECG gated breath-hold images were acquired. There is some 
variation between studies in the thickness of slices. TASCFORCE acquired 6mm slices 
with a 4mm gap whereas others using SSFP have used slices of 7mm with gaps 
ranging from 0 to 4mm. The method we used for determining cardiac volumes and 
masses is similar to those used by other groups. We used manual placing of epicardial 
and endocardial contours as did all the groups using SSFP MRI protocols. One 
difference between studies is the inclusion or exclusion of papillary muscles in the left 
ventricular mass. In TASCFORCE papillary muscles were excluded from the left 
ventricular muscles mass and were ascribed to the blood pool unless they were 
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indistinguishable from the myocardial wall whereas all but one[177] of the other SSFP 
studies included them in the left ventricular mass.[259] For groups using TGE protocols 
there has been some variability in inclusion of papillary muscles as there appears to be 
lack of agreement about the best method. The MESA group excluded papillary 
muscles from the LV mass as they found it resulted in greater reproducibility[191] as 
did the Framingham Offspring study[183] whereas the Dallas Heart Study group[262] 
included them in the left ventricular mass. 
 
TASCFORCE used a specific gravity for myocardium of 1.05g/ml identical to that used 
by the Dallas Heart study group and Lorenz et al whereas the MESA study group used 
a slightly different specific gravity of 1.04g/ml which could account for other differences 
(albeit small) in calculations of left ventricular mass. 
 
The differences in methodology both for image acquisition and analysis need to be 
considered when comparing findings between groups. Calculation of LV volumes and 
mass is well used by the different groups and is similar to the methodology in 
TASCFORCE however the different acquisition protocols, slice and gap sizes and 
attribution of papillary muscles could potentially introduce different levels of calculation 
error.  
 
Left ventricular mass and other variables are commonly indexed to account for body 
size. Scaling of cardiovascular parameters is rarely performed in clinical practice 
whereas it is routine in paediatric medicine despite adults having a wide range of body 
sizes. Therefore it seems justified to account for this natural variation in body size. 
Various different methods of indexing left ventricular mass to correct for body mass, 
size and height have been described and used by different research groups. We have 
used a variety of methods (dividing by height, height1.7, height2.7, body surface area 
(using 2 different calculations for estimating body surface area)). This will allow us to 
see which method of indexation may best predict future cardiovascular disease. 
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A review of different methods of indexing cardiovascular parameters explains in detail 
the strengths and limitations of various methods of indexing.[263] The authors argue 
that ratiometric scaling methods (simply dividing a left ventricular parameter by a 
measure of body size) are problematic as they rely on the relationship between the two 
being linear and that dividing a 3 dimensional LV measure by a 2 dimensional body 
size measure (eg BSA) is theoretically flawed. They support this theoretical 
shortcoming with evidence from studies. They give evidence that allometric scaling (LV 
measure/body size measurex) is superior at indicating the normality of cardiovascular 
function and size for a given patient size. For this reason the use of allometrically 
derived indexing (for example use of height1.7 and height2.7) may be preferable to the 
other ratiometric indexes. 
 
It is also important to consider which measure of body size is best to use. Obesity and 
therefore body surface area are associated with CV disease. However height and CV 
are also associated.[264] For the purpose of predicting CV disease indexing for height 
may seem reasonable as this is a non-modifiable factor. Those who are taller are also 
likely to have larger hearts. However correcting for body surface area which increases 
with body mass or BMI may not necessarily be desirable if the results are to be used 
for this purpose. Increased body mass (and therefore body surface area) is associated 
with increased risk of cardiovascular disease so correcting for this may remove or 
attenuate an important prognostic indicator. The review of indexing[263] supports this 
view. Body surface area does not take account of how much mass is metabolically 
active tissue (which the heart’s aim is to supply with nutrients and oxygen). For 
example an athlete will have more tissue with greater metabolic potential than a non-
athletic obese person despite potentially having the same BMI. Body surface area and 
body mass index do not account for these important morphological differences. The 
validity of the Dubois calculation is also questionable as this was derived from a study 
of only 9 cadavers about 100 years ago.[235] The allometric associations between fat 
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free mass and LV structure and function are better than using BSA or total body 
mass[263] however as fat free mass determination is difficult the use of height (as we 
have used as one indexing method) is a reasonable alternative. In TASCFORCE 
indexing by height2.7 reduced correlation with height and weight more than indexing by 
height1.7 or height. When we indexed by BSA correlation of LVMI with weight reduced 
further but not with height. The lack of complete removal of correlation with height 
and/or weight led the MESA group to index by dividing actual LV mass and volumes by 
predicted LV mass and volumes respectively calculated using an allometric regression 
model of non-obese, normotensive sub-population to predict LV mass based on height, 
weight and sex.[191] The Dallas Heart study group have indexed LV mass by fat free 
mass (albeit ratiometrically) as well as for BSA and height2.7 to account for body 
compensation.[184, 262] The Framingham heart Study Offspring study have indexed 
left ventricular measurements for height, height1.7, height 2.7, BSA and fat-free 
mass.[177] 
 
We also calculated LV mass/LV end diastolic volume (LVM/LVEDV) as a marker of 
concentric remodelling. In concentric remodelling the left ventricular mass increases to 
a greater degree than the left ventricular volume so this ratio increases. Concentric 
remodelling has been associated with decreased systolic function.[265] Importantly LV 
mass/volume ratio has been positively associated with incident coronary heart disease 
and stroke[181, 191] showing the potential importance of this measure in predicting 
disease. 
 
The protocol for whole body angiography was developed locally on a subset of the 
TASCFORCE participants to optimise the contrast dose and delivery rate to maximise 
image quality.[203] The reduction in total contrast dose and the use of an asymmetric 
bolus regime (10ml and 15ml) reduced the level of venous contamination during the 
second bolus injection. The term “whole body” MRI angiography is commonly used 
although as in the case of TASCFORCE does not usually image every artery but just 
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the aorta and main branches. For example we did not image coronary arteries. This 
would require ECG gating and is therefore technically much more difficult. 
 
A locally developed scoring system for whole body angiography was used in 
TASCFORCE. This assessed the presence of luminal stenosis in a range of arterial 
segments ranging from the carotid arteries to the leg vessels. Increasing scores are 
given for increasing degrees of stenosis and the score is then standardised and takes 
account of segments that cannot be scored due to technical problems with the imaging 
or lack of tolerability of the scan meaning not all segments were imaged. This gives a 
standardised atheroma score that reflects the whole-body burden of stenosis. As well 
as being used by the same research team locally in different study populations similar 
scoring systems have been devised by other research groups. Various atheroma 
scoring systems are in use by different research groups. The systems in use are subtly 
different in both the way that degrees of stenosis are scored and how these are 
combined to give a total body atheroma burden. They have also been performed in 
different populations of patients. For comparison the scoring systems used by different 
groups are summarised in table 6.1. 
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Table 6.1: Whole body atheroma scores reported in the literature 
Study 
group/lead 
author 
Patient group Vessel scoring system Method of combing scores 
TASCFORCE Over 40s free 
from CV 
disease and 
with predicted 
risk <20% 
over 10 years 
31 arterial segments 
0=no stenosis or wall 
irregularity 
1=<50% stenosis 
2=50-69% stenosis 
3=70-99% stenosis 
4=occlusion 
Point added for 
aneurysm 
Standardised atheroma score 
(SAS) derived by summing 
segment scores, dividing by 
number of interpretable 
segments divided by 4 
(maximum score for 
segment) multiplied by 100. 
PIVUS[208] 70 year olds 
with mixed 
vascular risk 
profile 
26 arterial segments 
0=no stenosis or wall 
irregularity 
1=<50% stenosis 
2=50-99% stenosis or 
occlusion 
Segments summed in 5 
territories (carotids, aorta, 
renal arteries, pelvic/upper 
leg, lower leg) divided by 
maximum possible score in 
that territory multiplied by 
100. 5 territory scores 
summed to give a total 
atheroma score (TAS). 
Findiesen[207] Patients with 
diabetes 
22 arterial segments 
1=normal or mild wall 
irregularity 
2=no significant 
stenosis 
3=single stenosis>50% 
4=multisegmental 
stenosis >50% 
5=fading vessel 
6=occlusion 
Mean of segment scores. 
Lehrke[209] Patients 
suspected of 
having 
coronary 
artery disease 
40 arterial segments 
1=normal 
2=<25% stenosis 
3=26-50% stenosis 
4=51-75% stenosis 
5=76-99% stenosis 
6=occlusion 
Segment scores summed 
and divided by number of 
analysable segments to give 
atherosclerosis score index. 
Ruehm[205] Patients with 
peripheral 
arterial 
disease 
15 arterial segments 
(only from aorta and 
inferiorly) 
0=normal 
1=irregularity and <10% 
stenosis 
2=<50% stenosis 
3=≥50% stenosis 
4=occlusion 
Not combined into a total 
score. 
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The scoring systems in use differ in 2 key ways: the cut off between different degrees 
of stenosis and how the segment scores are combined to give a total score. The first of 
these differences means that some give more weight to lesser degrees of stenosis or 
wall irregularity than others. Therefore those using lower cut-offs would be expected to 
give higher total scores for lots of subclinical disease. The cut offs used may depend 
on what the score is being used for. If being used to screen for early stage disease (as 
with TASCFORCE) building in the sensitivity to detect early changes is important and 
distinction between more severe stenosis may be less important (for example between 
our scores 2, 3 and 4). It is significant that we included wall irregularity in the “<50% 
stenosis” group to detect very early stage disease; not all groups have done this. For 
screening for early disease the total number of vessels affected may be more important 
than the degree of stenosis found. 
 
The second difference means that different arterial territories may be given greater 
weighting than others. For example the system used in the PIVUS group results in 
segments in territories that have less segments (such as the aorta and renal arteries, 2 
segments each) contribute more to the overall total atheroma score than segments in 
territories with more segments (such as the pelvic/lower limb with 10 segments). 
TASCFORCE like most of the other scores have given equal weight to each arterial 
segment in the total body score. Weighting may be appropriate if it was shown that 
some segments are more important prognostically than others however this is not yet 
clear in this asymptomatic group. The data is still available at individual segment level 
to allow future analysis of different weightings to produce total scores and the impact 
this may have on predicting cardiovascular events. Ongoing follow up in TASCFORCE 
will allow this to be investigated. 
 
One limitation is due to the different width and length of the segments. By measuring 
stenosis in terms of percentage luminal narrowing larger arteries such as the aorta 
require a much greater thickness of plaque to produce a greater than 50% stenosis 
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than a narrower distal leg artery. The aorta could therefore have quite extensive 
atheromatous disease which may have serious clinical implications but still have a less 
than 50% narrowing and therefore score lowly. Conversely a small atheromatous 
plaque in a narrow distal artery will cause a potentially greater percentage narrowing 
and therefore score much higher. The length of arteries will also have an effect. Some 
segments are short (for example the innominate artery) and so have a theoretically 
smaller chance of having a stenosis compared to a much longer arterial segment. This 
may explain why the rate of abnormality detected in the innominate artery was so low. 
However it still contributes the same to the overall score as longer arteries. This may 
not be as important when the method is being used to detect subclinical disease as the 
presence of rather than the degree of atheromatous may be more important. 
 
The use of “luminography” rather than looking at wall thickness could be criticised as 
not theoretically detecting atherosclerosis. However as discussed later, the correlation 
with predicted cardiovascular risk that we have demonstrated lends support to its 
suitability to detect subclinical disease. 
 
All the arterial segments in the MRAs were assessed for the presence of aneurysms. 
Aneurysms and atherosclerosis have overlapping risk factors and some commonality in 
their pathology and aetiology so it is conceivable that they could represent an 
increased risk of cardiovascular disease. The presence and increasing diameter of 
abdominal aortic aneurysm is associated with increased risk of non-aneurysm related 
mortality and cardiovascular mortality suggesting it may be a marker of cardiovascular 
risk.[266] However it is less clear how significant the presence of aneurysm is for 
predicting cardiovascular risk or what the significance of aneurysms in other arteries is. 
None of the other groups using scoring systems for WB CE-MRA have included 
aneurysms in their whole body score. Currently in our score the presence of aneurysm 
adds one to a score for the segment affected so contributes the same as minor luminal 
narrowing and significantly less than the presence of significant stenosis. The presence 
  
 
228 
of aneurysms affected only 40 out of 46601 (0.09%) total segments analysed whereas 
atheroma affected 2133 (4.6%) of segments affected so contributed significantly more 
to standardised atheroma scores. 
 
Initially the coeliac trunk was assessed for stenosis however standardised atheroma 
scores have been calculated both including and excluding this segment because of 
concerns about significant artefact in this segment. This illustrated by the 
disproportionately high level of recorded stenosis in this artery compared to other 
segments. This phenomenon on MRI had been described previously where stenosis 
appeared significantly more prevalent on MRI images obtained at end expiration 
compared to inspiration.[267] It is likely this artefact is due to compression of the 
coeliac artery by the median arcuate ligament which is a well-recognised anatomical 
variant. For this reason it is not clear whether the stenoses we observed in the 
segment are genuine. It is notable that the majority of those using scoring systems 
have not included the coeliac artery in their analyses. 
 
We demonstrated almost perfect inter-observer agreement (Fleiss kappa values>0.80) 
in all the arterial segments except the coeliac artery demonstrating that the technique 
is reproducible. The reduced (but still substantial) agreement for the coeliac trunk is 
most likely to reflect the difficulties in interpretation due to artefact outlined above. 
 
6.2.5. Strengths and limitations 
Strengths 
We have recruited a large cohort of people from a variety of socioeconomic 
backgrounds. Our gender split is similar for the population of Tayside despite a non-
significant slight female bias. We ensured at least a 0.9% ethnic minority population in 
a population where this is at 2.8%.[246] Comprehensive collection of baseline clinical 
and demographic variables has allowed the cohort to be well characterised and will 
permit investigation of associations of baseline variables with each other and future 
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events and disease. It also assists characterisation and investigation of a large Scottish 
population. This will help generate hypotheses about possible aetiology of 
cardiovascular disease and cardiovascular risk. Other cardiovascular cohort studies 
such as Framingham have sampled or studied populations with different ethnic mixes 
or in different cultural, political and healthcare backgrounds from where findings may 
not be directly transferable to the Scottish populations. 
 
The imaging and blood biomarkers being investigated have an evidence base showing 
association with clinically relevant outcomes. Rather than using entirely new 
techniques and or markers TASCFORCE is building on this evidence to investigate 
whether incremental value is added using the unique combination of biomarkers. 
However blood from each participant has been stored and will be available for analysis 
of emerging or new biomarkers in the future allowing the study to remain contemporary 
as the research in the field develops as the study follow up progresses. Additionally 
DNA has been stored and can be duplicated using polymerase chain reaction to 
investigate genetic determinants of cardiovascular disease. 
 
TASCFORCE is assessing the ability of a screening programme incorporating MRI 
derived left ventricular mass and BNP to predict future cardiovascular events thus 
potentially allowing targeted intervention to be improved. The UK National Screening 
Committee has produced criteria for appraising screening programmes (see below in 
table 6.2).[268] The programme being investigated in TASCFORCE either fulfils or is 
seeking to answer a number of these criteria and therefore the method is a potential 
viable screening technique. 
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Table 6.2: Criteria for screening programme and how TASCFORCE fits these 
Criteria TASCFORCE 
The condition should be an important health 
problem. 
CV is a leading cause of death. 
The epidemiology and natural history of the 
condition, including development from latent to 
declared disease, should be adequately 
understood and there should be a detectable risk 
factor, disease marker, latent period or early 
symptomatic stage. 
Well understood for CV disease. 
All the cost-effective primary prevention 
interventions should have been implemented as 
far as practicable. 
Extensive public health 
initiatives are already in place to 
reduce incidence. 
There should be a simple, safe, precise and 
validated screening test. 
TASCFORCE is investigating 
this. BNP is simple, safe and 
cheap and is being assessed as 
a stratifier to determine who 
would undergo more intensive 
imaging. 
The distribution of test values in the target 
population should be known and a suitable cut-off 
level defined and agreed. 
TASCFORCE will help answer 
these questions for BNP and 
imaging parameters. 
Additionally biomarkers 
discovered in the future can be 
validated using stored samples. 
The test should be acceptable to the population. Acceptability of MRI being 
assessed by TASCFORCE. 
There should be an agreed policy on the further 
diagnostic investigation of individuals with a 
positive test result and on the choices available to 
those individuals. 
Would be decided depending on 
study findings. 
There should be an effective treatment or 
intervention for patients identified through early 
detection, with evidence of early treatment leading 
to better outcomes than late treatment. 
Established evidence base for 
primary prevention (eg with 
statins). 
There should be agreed evidence based policies 
covering which individuals should be offered 
treatment and the appropriate treatment to be 
offered. 
Would be decided following 
study findings. 
Clinical management of the condition and patient 
outcomes should be optimised in all health care 
providers prior to participation in a screening 
programme. 
There already exists a 
framework to treat those at 
increased risk of CV with 
primary prevention. A screening 
programme aims to improve 
how those at increased risk are 
identified. 
 
Continued on next page. 
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Table 6.2 continued 
There should be evidence from high quality 
Randomised Controlled Trials that the screening 
programme is effective in reducing mortality or 
morbidity. Where screening is aimed solely at 
providing information to allow the person being 
screened to make an “informed choice” (eg. Down’s 
syndrome, cystic fibrosis carrier screening), there 
must be evidence from high quality trials that the 
test accurately measures risk. The information that 
is provided about the test and its outcome must be 
of value and readily understood by the individual 
being screened. 
Evidence that the programme 
reduces mortality would need to 
be assessed at a later stage if it 
was shown to be effective in 
determining risk. The concept 
of CV risk is widely used in 
clinical practice already. 
There should be evidence that the complete 
screening programme (test, diagnostic procedures, 
treatment/ intervention) is clinically, socially and 
ethically acceptable to health professionals and the 
public. 
Would need to be assessed if 
the method/blood test is shown 
to be efficacious. 
The benefit from the screening programme should 
outweigh the physical and psychological harm 
(caused by the test, diagnostic procedures and 
treatment). 
The opportunity cost of the screening programme 
(including testing, diagnosis and treatment, 
administration, training and quality assurance) 
should be economically balanced in relation to 
expenditure on medical care as a whole (ie. value 
for money). Assessment against this criteria should 
have regard to evidence from cost benefit and/or 
cost effectiveness analyses and have regard to the 
effective use of available resource. 
Would need to be assessed if is 
shown to be efficacious. 
All other options for managing the condition should 
have been considered (eg. improving treatment, 
providing other services), to ensure that no more 
cost effective intervention could be introduced or 
current interventions increased within the resources 
available. 
There should be a plan for managing and 
monitoring the screening programme and an 
agreed set of quality assurance standards. 
Adequate staffing and facilities for testing, 
diagnosis, treatment and programme management 
should be available prior to the commencement of 
the screening 
programme. 
Evidence-based information, explaining the 
consequences of testing, investigation and 
treatment, should be made available to potential 
participants to assist them in making an informed 
choice. 
Public pressure for widening the eligibility criteria for 
reducing the screening interval, and for increasing 
the sensitivity of the testing process, should be 
anticipated. Decisions about these parameters 
should be scientifically justifiable to the public. 
Criteria relating to genetic mutations have not been included. 
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Follow up for events is by record linkage. This has the dual strengths of cost-
effectiveness and potentially reduced attrition. Data on a wide range of clinical activity 
(such as hospital attendances (including diagnoses), procedures, prescribing and 
deaths is routinely collected across Scotland, whereas in England such a wealth of 
information is not as easily available. This data has been (and will continue to be) 
anonymously linked using their unique community health index (CHI) number for all 
participants at regular time intervals allowing investigation of a wide variety of 
outcomes to be followed prospectively. As the vast majority of healthcare is provided 
by the NHS and almost every participant has a registered GP (who provides the 
majority of prescriptions) follow up data is likely to be complete, although in England it 
will be difficult to obtain any data bar death. However Tayside Scots tend to stay in 
Scotland so it is hoped this will not impact too greatly on follow up. It also does not rely 
on recurrent study team contacts with participants. This latter approach would be more 
costly (in terms of both time and finance) and has greater potential to lead to attrition 
as participants lose contact with the study team. 
 
Weaknesses 
The use of the ATPIII score to predict risk means the study has lagged behind 
developments in clinical practice: the ASSIGN score and inclusion of total 
cardiovascular risk (beyond coronary heart disease) became the recommended tool 
during the course of recruitment. Although this difference in practice has resulted in 
some participants being recruited who would otherwise be excluded and vice versa 
reclassification only affects a minority of the total participants. The comprehensive 
collection of baseline data has also facilitated calculation of ASSIGN scores so 
correlations and predictions can also be analysed with respect to this risk prediction 
tool. This will allow us to compare efficacy of the respective scores as events occur. 
 
The introduction of glucose testing partway through recruitment meant that it could not 
be used to exclude those with undiagnosed diabetes. Additionally because a single 
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elevated random glucose level in the absence of symptoms of diabetes was not 
sufficient to diagnose diabetes it was not possible to exclude diabetes at the single 
recruitment visit. Therefore it is possible that a small number of people with 
undiagnosed diabetes (which is associated with increased CV risk) were recruited to 
the study as the condition was not recognised and incorporated in the CHD risk 
prediction. However with the analyses of the blood sugar of the whole population we 
will have all the random glucose results in due course, and will be able to determine if a 
formal diagnosis of diabetes is ever made, using record linkage. Additionally analysis 
of HbA1C from frozen blood samples could now be used to exclude diabetes 
retrospectively. 
 
Funding and scanner time resource constraints meant that only those with a higher 
than median BNP were scanned. Although this is in keeping with the hypothesis that a 
higher BNP identifies a group with an increased CV risk who merit further investigation 
and assessment of cardiovascular parameters it would have been helpful to image 
those with a lower BNP. This would have allowed comparison of the imaging markers 
between those with higher and lower BNP levels and would have led to accurate 
determination of normal ranges and distributions of cardiac and angiographic 
parameters for a normal “low risk” population. Imaging of only those with a higher BNP 
may have led to a biased population being imaged particularly if the hypothesis that 
increased BNP reflects cardiovascular disease. As a result determination of “normal” 
imaging parameters from this population has to be interpreted with caution. Any 
correlations between imaging variables and BNP are likely to be attenuated as the 
distribution of BNP in the imaged population has been artificially narrowed. Additionally 
the ability of LVM to predict cardiovascular disease was used as the primary endpoint 
but less than half of the recruited participants had an MRI scan. This will have resulted 
in decreased ability to demonstrate the endpoint but it is anticipated that with time as 
more events occur the potential to show any association will increase. 
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Although a sub-population of participants of South Asian ethnicity was recruited the 
remainder of the population were not fully characterised in terms of ethnicity. The 
ethnically heterogeneous population will limit the assessment of the effect of ethnicity 
on cardiovascular risk and normal imaging parameters. However with the positive 
enrolment of people of South Asian origin we believe the population better represents 
the Scottish population as a whole than other studies which did not make this effort to 
positively recruit. Other studies have demonstrated significant differences in cardiac 
structure[182, 184] and remodelling[269] but not function[180] between different ethnic 
groups. Better characterisation of ethnicity would have allowed normal values to be 
accurately described for different ethnic groups allowing results to be personalised. 
This is particularly important for LV mass as this is a parameter that has been shown to 
be different in different ethnic groups and is the primary outcome of the study. The 
collection of data about ethnicity would also have allowed investigation of behaviour 
patterns with screening programmes: for example are those from different ethnic 
groups more or less likely to engage in screening programmes or undergo MRI scans. 
However as the main aim of this study is to determine if imaging biomarkers and BNP 
are able to predict CV events the behaviour aspect is a secondary issue and could be 
investigated in future studies if MRI is found to be efficacious. 
 
The blood tests for cholesterol were random rather than fasting samples. Additionally 
323 (7.3%) of cases had LDL measurements missing, the majority of which were 
because the level could not be calculated because of a triglyceride level above 4.51 
mmol/l or less than the assay’s lowest threshold of 0.51mmol/l. This means the data is 
not missing at random, but is related to the level of triglycerides. Because the reason 
for missing data is that it could not be calculated it was decided that replacement with 
multiple imputation would not be appropriate as the best predictors of the values would 
be the same values that are either not characterised fully (i.e. below the assay 
detection threshold) or at a higher level which is known to not correlate as well with 
LDL. It must be recognised however that this means the unavailability of LDL values is 
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in a population biased by having either very high or very low triglyceride levels. This will 
have had an impact on multiple regression analyses. It is possible that LDL analyses 
could be performed on the stored samples using newer assays that are not limited by 
triglyceride levels but as a great deal is already known about the association of LDL 
with CVD this is unlikely to add a great deal to the literature. 
 
Although follow up by electronic record linkage is comprehensive and has the strengths 
outlined above it could also lead to false conclusions. This is particularly the case with 
prescribing data. Many medications have multiple indications as discussed earlier. For 
example a prescription for aspirin could be as secondary or primary prevention for 
cardiovascular disease or as an analgesic. Therefore prescription of many medications 
that can be used for cardiovascular disease does not necessarily mean they are 
prescribed for this reason. It can be difficult to determine the reason for prescriptions in 
all cases which limits the use of this data to draw firm conclusions. However further 
analysis including the doses of medications could help differentiate use for 
cardiovascular disease from other indications. 
 
There are also limitations to using the wide range of cardiovascular events some of 
which are often poorly coded or can be “diagnosed” without any hard clinical evidence 
to support them (such as “angina”). The aim was to capture all events however it is 
accepted that this will increase sensitivity for events at the expense of specificity. This 
is one of the drawbacks of electronic record linkage follow up where it can sometimes 
be difficult to get further confirmatory information to corroborate diagnoses. However 
the follow up information is in the form that can be filtered to only include major 
adverse cardiovascular events. 
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6.3. Usefulness of screening for incidental findings 
 
6.3.1. Increased cardiovascular risk 
The screening process for recruitment to the study identified a significant number of 
people who had previously unidentified increased cardiovascular risk or hypertension 
that would merit further investigation or treatment. 146 (2.9%) and 291 (5.8%) of the 
5015 people screened were found to have a high predicted cardiovascular risk or 
hypertension respectively. This compares to positive faecal occult blood test rates in 
the pilot bowel cancer screening programme of 1.6% to 2.1%[240] and a recall for 
assessment rate following mammography of approximately 4% in the breast cancer 
screening programme.[270] This highlights the importance and usefulness of screening 
for increased cardiovascular risk to allow early intervention to reduce the risk of future 
cardiovascular disease. This is encouraged via the quality outcomes framework (QOF) 
embedded in GPs’ contracts. The section on primary prevention of CVD currently 
requires those with a new diagnosis of hypertension and who have a CVD risk 
assessment score greater than 20% in the previous 12 months be on a statin and 
those with hypertension to be given lifestyle advice (increasing physical activity, 
smoking cessation, safe alcohol consumption and healthy diet).[271] Compliance with 
this standard in Tayside in 2013/14 was 96.3%[272] suggesting that of those identified 
to be at risk appropriate management was being instigated. However the QOF does 
not drive the routine assessment of CV risk in those at a younger age and relies on 
them attending their GP practice to have risk factors measured. Our finding of a large 
number of people with previously unrecognised increased risk shows there is room for 
improvement and opportunity to improve how screening for risk is performed. For 
example our method of proactively going to screen people may augment practice 
based screening. 
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Of those who failed screening 171 (42.5%) (172 (42.5%) when aspirin excluded) 
received a new prescription for cardiovascular medication following their screening visit 
and during the follow up period. The rate of prescription and odds ratio of receiving a 
prescription in those who failed screening was significantly higher than the eligible 
study population. This probably reflects the increased cardiovascular risk in this group 
and it would be expected that they may be prescribed medication at some point during 
follow up if the increased risk was detected by their GP. However significant number of 
these were in the first few months after screening (the lines on the Kaplan Meier 
analysis are steeper initially) suggesting that the screening visit may have prompted 
the new prescription and suggests pro-actively screening people may be beneficial in 
improving treatment rates for cardiovascular risk factors compared to opportunistic 
screening at GP surgeries. The median time to receiving a prescription was 204 days 
so half those who failed screening and received cardiovascular medication had 
received a prescription in just over 6 months.  
 
Those who failed due to hypertension had a shorter time to first prescription on Kaplan 
Meier analysis than those who failed due to high cardiovascular risk. Because BP was 
checked before cardiovascular risk was calculated some who failed screening due to 
hypertension may also have had a high overall CV risk but they were recorded as 
being hypertensive in preference. High cardiovascular risk is often due to a 
combination factors (for example smoking, blood pressure and lipid profile) potentially 
without one measure being significantly elevated. Therefore people with high predicted 
risk but not hypertensive may have elected to try lifestyle changes initially (eg smoking 
cessation, exercise or dietary modification) rather than start on medication. Those with 
just hypertension may perceive this risk as being something that is not as amenable to 
lifestyle modification and as a single risk factor may start medication for it instead. Lipid 
modifying drugs were prescribed to proportionately more people who failed screening 
due to high cardiovascular risk compared to those who were hypertensive as would be 
appropriate clinically. Also as would be expected antihypertensives (particularly 
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angiotensin converting enzyme inhibitors, calcium channel blockers, beta blockers and 
thiazide diuretics) were prescribed more to the hypertensive group. This would largely 
be in keeping with guidelines. Despite this only half of those we found to be 
hypertensive were subsequently prescribed antihypertensives. This may be because 
BP was not found to be elevated when rechecked by the GP or with ambulatory 
monitoring, or because lifestyle measures such as exercise or weight loss were used 
instead of medication in others. The fact that they had previously undetected 
hypertension may also reflect a reticence in some to attend their GP and be reviewed. 
 
There was no statistically significant effect of exposure to CV medication on the 
cardiovascular event rate. This is probably due to the relatively low incidence of 
cardiovascular events in the follow up so far meaning power was not great enough to 
show any effect. As follow up for events continues this difference may become 
significant in the future. The evidence for primary prevention for CV disease shows that 
the benefit accrues with time therefore emphasising the need for a longer follow up 
time.  
 
6.3.2. Non-cardiovascular findings 
A small number of incidental findings of anatomical abnormalities and masses were 
picked up by MRI scan (n=32, 2.1% of those scanned). This generated an increase in 
clinical activity in the form of supplementary imaging and or clinical review however is 
necessary to either investigate if further action or treatment is necessary or to reassure 
the participant and staff of the benign nature of a finding. One participant was found to 
have a malignancy. Although the detection of an otherwise unknown malignancy is 
potentially beneficial by allowing earlier detection of a cancer, participants in the study 
weren’t routinely counselled pre-scan about this possible finding. Despite the low rate 
of incidental malignancy (only one participant), 32 (2.1% of those imaged) required 
further investigation or assessment (including imaging in some cases) to investigate 
the initial incidental finding further which may have caused distress or anxiety to 
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participants. It would therefore be important in clinical practice or in future trials to 
discuss the potential for such incidental findings when obtaining consent for imaging in 
clinical practice. 
 
6.4. Baseline results 
 
6.4.1. Risk factors and BNP 
The BNP levels in our population were not dissimilar to those found and proposed to 
be reference ranges in a sub-population of the Framingham offspring cohort free from 
cardiovascular disease, hypertension and diabetes although they only quote mean 
values so direct comparison is impossible.[140] BNP levels were significantly higher in 
women compared to men as demonstrated in previous studies (using both BNP and 
NT-proBNP)[92, 139-141, 146] justifying our use of gender specific medians for 
deciding whether participants were offered an MRI scan. The median results for men 
and women were also close to the cut-offs used (determined earlier in the study) for 
allocating to the MRI/BNP group. Notably the vast majority of participants had a BNP 
level below the threshold of 100pg/ml used for the potential diagnosis of heart failure. 
Only 2 men and 14 women had a BNP reading above this level and the 99th percentile 
for both genders was below this level. The women with a BNP greater than 100pg/ml 
were older and had a slightly higher predicted risk using the ATPIII and ASSIGN 
scores (although they all still had a predicted CHD risk less than 10%). Apart from age 
there was no significant difference in any individual CV risk factor measured. The 2 
men with a BNP >100pg/ml had a higher predicted risk using both the ATPIII and 
ASSIGN scoring algorithms but due to the small numbers the differences were not as 
statistically significant and no individual risk factor measured was significantly different. 
These findings may suggest that because women on average have a higher BNP level 
the same threshold is less able to identify those at increased risk than in men. The 
findings also suggest that the increased level may just be a marker of age (which is a 
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risk factor for CVD). This provides evidence for the need for age and gender specific 
thresholds and normal values for BNP as discussed in more detail below. 
 
The reasons for women having higher BNP levels have been explored in a study of a 
population free from cardiovascular and cardiovascular medication and in who LV 
failure (including diastolic dysfunction) had been excluded by echocardiogram.[139] 
Higher BNP levels were not explained by gender related differences in blood pressure, 
renal function or cardiac structure; although there were associations between gender 
and renal function and blood pressure these were confounders and did not remain 
associated when age and gender were corrected for. The higher BNP level may be 
related to oestrogen status as BNP levels were higher in women using HRT.[139] The 
differences in BNP between genders may also be due to a greater degree of stretch in 
the hearts of women because they have smaller hearts (both mass and volumes). 
However as the stroke volumes and cardiac output are also lower in women there is 
little to support his theory in our findings. 
 
Those allocated to the MRI/BNP group (i.e. those with a greater than median BNP) 
were older, had a slightly higher systolic BP, lower heart rate, higher HDL, lower 
triglycerides, lower BMI, greater height, lower waist circumference, contained fewer 
current smokers and higher ASSIGN score and more people with an intermediate 10 
year CHD risk score (calculated using the ATPIII algorithm). These latter two findings 
are reassuring as they indicate that BNP level may be a marker of an individual’s risk 
and support our use of it for this purpose. Men with a BNP reading in the 4th quartile 
were older, had a lower diastolic BP, lower heart rate, higher HDL, lower triglycerides, 
lower BMI and higher 10 year cardiovascular risk compared to those with a lower BNP. 
Women with a BNP in the 4th quartile were also older, had a lower heart rate, higher 
HDL, and higher 10 year CHD risk but also had a lower proportion of current smokers 
(probably driving the lower numbers of current smokers in the MRI/BNP group as a 
whole as mentioned above), higher proportion of never smokers, higher systolic BP but 
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no significant difference in triglycerides, diastolic BP or BMI. The differences in the 
variables between groups noted above from the univariate analysis could be due to 
genuine physiological effects, the statistical effect of performing a large number of 
univariate analyses and therefore “finding” differences by chance that do not exist in 
reality (type 1 error) or because some risk factors dominate cardiovascular risk leading 
to biases in other risk factors to counter the dominant ones while still ensuring overall 
cardiovascular risk is low enough for people to be eligible for the study. Possible 
reasons for the differences we found are discussed further below. Using a stepwise 
multivariable linear regression analysis age and female sex along with ex-smoking 
status, lower heart rate, lower total cholesterol and higher HDL remained independent 
predictors of log10BNP level suggesting these correlations are genuine after correcting 
for confounders. It is likely therefore that current smoking status is not an independent 
predictor od BNP level as suggested by the univariate analysis but more likely due to 
confounding from other variables. We did not include CHD risk in the multivariable 
analysis as it is derived from the other CV risk factors that were included. Of note BMI, 
triglycerides and lower waste circumference were not correlated in this analysis. This 
may be because body size (measured either by BMI or by waist circumference) is 
associated with other cardiovascular risk factors (such as lipid profile and blood 
pressure) so the effect of these is reflected in those other factors. Triglycerides were 
within “normal” range for most people so the range of values recorded may have been 
too small to allow any correlation to be seen. 
 
Increasing levels of BNP with age are well recognised.[139-141] The exact mechanism 
for this association remains unclear; although renal function and age related changes 
in cardiac size could have some influence on levels, the effect of age on BNP is 
independent of renal function, atrial volume, LV dimension and LV mass.[139] Age 
related alterations in production, secretion or degradation may be responsible. 
Decreasing cyclic guanine monophosphate (cGMP) to BNP ratio with increasing age 
has been demonstrated[273] suggesting an attenuated biological effect of BNP with 
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increasing age requiring higher levels of BNP to have the same effect. Natriuretic 
peptide C receptor levels, involved with clearance of BNP, are also reduced with 
ageing[274] suggesting a reduced rate of clearance of BNP. The large combined 
impact of gender and age has led to suggestions that age and gender specific BNP 
levels should be adopted if BNP or NT-proBNP is being used for screening.[141] Our 
findings very much support this and could be used to derive “normal” age and gender 
specific BNP parameters. 
 
The inverse association between heart rate and BNP could be caused by the increased 
filling time that results from a lower heart rate causing increased myocardial stretch 
which stimulates release of BNP. Those with a higher BNP could paradoxically be fitter 
and therefore have a lower resting heart rate. This is supported by the fact that a 
higher BNP was associated with lower waist circumference in men and lower BMI in 
men and women. It could also reflect a physiologically increased LVM due to exercise: 
a lower heart rate may be a marker of exercise participation which could increase LVM. 
However as discussed later BNP was not independently associated with LVM which 
makes this explanation less likely. It may be that BNP within this “physiologically 
normal” range reflects differences in healthy physiology rather than pathology. 
 
The higher ASSIGN scores and greater proportion of people with intermediate CV risk 
in those in the MRI/BNP group is in keeping with results from a study of patients with 
diabetes but no pre-existing CVD where log10 BNP was positively correlated with 
Framingham risk score.[134] This lends more support to BNP being a marker for global 
CV risk even though association with individual risk factors is less marked. It is likely 
that age and gender are the greatest drivers of the predicted cardiovascular risk (and 
therefore potentially BNP level) in our population therefore overshadowing the other 
differences in the individual contributors to cardiovascular risk. The fact that cholesterol 
and triglyceride levels were not significantly elevated above clinical “normal” values in 
either the MRI/BNP or MRI group supports the theory that they are unlikely to be 
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contributing significantly to the cardiovascular risk profile and potentially BNP level in 
this low and intermediate risk group. Although statistically significant differences in the 
HDL and triglyceride levels do exist between those with higher and lower levels of BNP 
the magnitude of differences is small and therefore unlikely to have a large effect on 
cardiovascular risk when compared to age and gender. The lower triglyceride and 
higher HDL levels in those with higher BNP results (the opposite to what would be 
expected in those at higher risk) may be due to a biased population brought about by 
effect of age. Because age is a variable used in the CHD prediction those who are 
older were more likely to be excluded due to high CHD risk (see earlier discussion) 
meaning those older people who were eligible may have had more favourable other 
risk factors to “compensate” for their increased age. As BNP is also increased with age 
the group with higher BNP includes a skewed higher age group with this more 
favourable (other than age) risk factor profile. 
 
The reasons for lower BMI, lower waist circumference and lower proportion of smokers 
in the MRI/BNP group is less clear as these findings may be expected to be associated 
with a lower cardiovascular risk. Lower BNP levels in obese compared to non-obese 
people have been demonstrated in both heart failure[275] and heart failure free[276] 
populations. The reasons for this are not fully understood but an abundance of 
natriuretic peptide clearance receptors in adipose tissue[277] may increase the rate of 
removal of BNP in those who are overweight or obese and therefore have a higher BMI 
and waist circumference. As the multivariable regression analysis did not show that 
BMI or waist circumference were independently associated with BNP, it is possible that 
body size is merely a marker for other cardiovascular risk factors.  
 
In summary, higher BNP levels appear to be associated with female gender, older age, 
and increased predicted CHD risk although associations with other individual risk 
factors such as BP, lipid profile and obesity are conflicting or in the opposite direction 
to what would be expected possibly because of unintentionally skewed populations 
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caused by the effect of age on both cardiovascular risk and BNP level. As the main aim 
of the study is to determine if BNP aids prediction of future cardiovascular events 
beyond the measurement of traditional cardiovascular risk factors the association and 
exploration if BNP is associated with actual future events is more important in terms of 
clinical applicability. As follow up continues and cardiovascular events accumulate to a 
significant level investigation of whether BNP predicts CV events will be possible. As 
the vast majority of people have “normal” levels of BNP it may be that there is a 
threshold above which BNP may be predictive of events as shown in other studies 
albeit with different study populations.[133] Our findings support the results of other 
studies that gender specific BNP levels should be used as age seems to be an 
independent predictor of its level. However as CV risk increases with age means it may 
not be desirable to correct completely for this risk factor. It is also possible that BNP is 
acting as a surrogate marker for age and may not add any further prognostic value 
within a normal range. 
 
6.4.2. Cardiac imaging baseline results 
Left ventricular mass (LVM) was significantly higher in men than women supporting the 
results of other studies that have measured LVM using MRI.[177, 183, 185, 187, 256-
258, 260, 261] There was a strong correlation of LVM with height, weight and body 
surface area. All these measures of body size were different between men and women 
but the gender differences in LVM persisted even after indexing by each of these 
parameters. This also supports the findings of the other studies where LVMI is different 
between men and women when corrected for either height or body surface area. The 
persistence of differences when corrected for body size suggest that gender 
differences are not solely due to different body sizes and height but are genuine 
gender differences. These could be due to different metabolism, hormonal effects or 
genetic differences. 
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The mean LVM and LVMI values in our cohort are similar to those reported by other 
studies that have used steady state free precision (SSFP) imaging sequence MRI to 
determine LVM in a healthy population without cardiovascular disease and free from 
hypertension, high cholesterol or treatment.[177, 259] The mean LVM in TASCFORCE 
was 128.9g and 87.1g for men and women respectively compared to 134g and 98g for 
20-80 year old men and women in the pooled estimate of LVM from three studies that 
have used SSFP sequences with a 1.5T scanner. So far no-one has published normal 
values for SSFP using a 3T scanner (as used for TASCFORCE). The four studies 
combined have only studied 1140 people (493 men and 647 women) compared to the 
1515 (577 men and 938 women) imaged in TASCFORCE making our population 
significantly larger than any other single study. Our values for LVM indexed for body 
surface area are also similar for men but slightly lower for women compared to the 
pooled results. Alfakih et al quote normal values for a subgroup aged 40-65 (more 
similar to our population than the pooled results) which are very similar to our results 
for both LVM and LVM indexed for BSA for both men and women.[256] This suggests 
that the difference in women may be caused by the inclusion of younger people in the 
pooled results. Our results for LVM and LVMI (for BSA) were also similar to the 
subgroup of those aged 35 or older in Hudsmith et al’s population.[257] 
 
We also found that LV end diastolic volume, end systolic volume, stroke volume and 
cardiac output were all significantly higher in men compared to women and ejection 
fraction was higher in women. These differences remained when the parameters were 
indexed for height, height1.7, height2.7 or BSA except for stroke volume corrected for 
height2.7. Similar gender differences have been reported previously. End diastolic and 
end systolic ventricular volumes, stroke volumes and ejection fractions are similar to 
the pooled results[259] and particularly those of a similar age and when indexed for 
BSA.[256, 257] There are some differences between TASCFORCE and the other 
SSFP MRI studies quoting normal values. They all included papillary muscles in the left 
ventricular mass whereas we excluded it and included it in the LV cavity volume. 
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Papillary muscle has been noted to account for about 9% of total LV mass[278] so it 
would be expected that our volumes would be slightly higher and masses slightly lower 
than others. We also only imaged those with a BNP greater than the gender specific 
mean so do not truly represent the whole population. However the vast majority of 
participants had a “normal” BNP and the only significant difference in LV parameters 
with a higher BNP was slightly decreased cardiac output as discussed below. 
Therefore the results LV are likely to represent the population as a whole. 
 
Other studies have used turbo gradient echo (TGE) MRI sequences for cardiac 
imaging. When directly comparing the TGE with SSFP sequences in the same patients 
TGE has been shown to produce higher values for mass and lower values for LV cavity 
volumes compared to SSFP.[256] Improved border definition is possible with SSFP 
which could lead to differences in endocardial border definition between the 2 
sequences. This explains why the values for LVM and LVMI are higher and left 
ventricular volumes (both raw and indexed for body size) are lower in a low risk group 
of the MESA study,[182] in the Framingham Heart Study offspring cohort[183] and in 
Marcus et al’s study of “healthy” volunteers in the Netherlands[260] compared to 
TASCFORCE. 
 
The differences in parameters obtained by the different imaging methods mean that 
measurements using the two techniques are not interchangeable and reference values 
for each technique are required. As well as for the mass and volume measurements 
this also has implications for the calculation of LVM/LVEDSV which is used to 
determine concentric LV remodelling. 
 
In addition to the techniques there are also differences in the populations between the 
various studies. Marcus et al’s population was younger (mean age was 22.9 and 21.9 
years for men and women respectively) and was taller and leaner whereas the 
Framingham cohort had a similar age range and body composition to TASCFORCE. 
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Ethnicity may also play a role. Although we did not collect detailed ethnicity data for the 
TASCFORCE participants the local population is predominantly white European with 
some of South Asian ethnicity so the study population is likely to reflect that.  In 
comparison the MESA study included a significant number of African-American, 
Hispanic and Asian-American people.[182] Although they did not find a statistically 
significant difference in LVM or LVMI (for BSA) between the different ethnic groups 
except between Asians and the other groups the mean values for African-Americans 
were higher than for other groups and for Asians were lower which will have influenced 
the results. The three main studies that have used SSFP were all European[256-258] 
but ethnicity was not reported so it is not possible to explore ethnic differences. 
Another factor that may influence LVM in different populations are exercise: increased 
level of exercise produces physiological increase in LVM rather than a pathological 
increase due to hypertension or intrinsic cardiac disease. From the data available it is 
not possible to compare exercise levels between the different study groups to 
determine if this is a factor contributing to the different results between studies. 
 
We have used a variety of measures of body size to index left ventricular measures. 
Although still significantly different between genders the magnitude of difference is less 
when allometric indices are used (height1.7, height2.7) compared to ratiometric indices. 
As discussed earlier use of allometric indices is theoretically superior. 
 
The higher LVM and LVMI in men compared to women is opposite to the difference in 
BNP results where women had higher levels. For this reason associations between LV 
measures and BNP and baseline factors were analysed separately for men and 
women. As raised BNP is associated with left ventricular hypertrophy and left 
ventricular failure it may have been expected that either BNP would be correlated with 
LVM or a raised BNP (for example above a certain threshold) would be associated with 
either higher LVM, decreased LV function or both. This was not the case. BNP was 
weakly correlated with end diastolic volume and stroke volume (both raw and indexed 
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for body size) in men but not with any other left ventricular measures. BNP was not 
correlated with any measures in women. The correlations with end diastolic volume 
and stroke volume in men could be due to increased stretch brought about increased 
ventricular filling. This in turn may be due to a decreased heart rate leading to 
increased filling time. Our finding of an inverse correlation between heart rate and left 
ventricular mass and left ventricular volumes in men supports this. The lack of 
correlation between LVM or LVMI and BNP may be because LVM and BNP levels are 
“normal” in the vast majority of participants as this is a healthy population. However 
even when we performed analyses looking at different thresholds for “abnormal” BNP 
levels we did not demonstrate significant associations with increased left ventricular 
mass. When thresholds of 90th and 95th percentiles of BNP were investigated to identify 
those with a higher BNP compared to the rest of the normal population the differences 
in LV parameters were still not significant between those with a higher and lower BNP 
except for a decreased cardiac output with higher BNP. As the ejection fractions and 
stroke volumes were not different the lower cardiac output is probably a product of a 
decreased heart rate with higher higher BNP rather than cardiac function. There was 
no significant difference in BNP level when LVH in our healthy population was defined 
as an LVM greater than 2 standard deviations above the mean (gender specific). BNP 
was also not different between those with and without concentric LVH defined as 
LVM/LVEDV greater than 2 standard deviations above the mean. As LVM mass was 
negatively correlated with age in men whereas BNP increases with age any increase in 
BNP with increased LVM may be hidden by the age related decrease in LVM. An 
alternative method may be to use age and gender specific reference ranges for BNP to 
see if that identifies LVH. However in a multivariable regression analysis BNP was not 
an independent predictor of any LV parameters suggesting that in this healthy 
population, where BNP is within the normal range, BNP is not genuinely not associated 
with LVM or LVMI. This supports evidence from the Dallas Heart Study where BNP 
was not able to accurately identify people with LVH or LV systolic dysfunction in a 
young and healthy population.[262] A limiting factor in our analyses is that the range of 
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BNP levels is relatively narrow as only those with a higher than median BNP were 
imaged. If those with a lower BNP had been imaged a wider range of BNPs would 
have been included. 
 
Age was weakly but significantly inversely associated with LVM and LVMI (except 
when indexed by height2.7) in men but only with LVM and LVM indexed by height in 
women. These associations persisted in a multivariable regression model suggesting 
that the association may be independent of other changes in CV risk that accompany 
age. Age was also associated with decreasing LV volumes, stroke volume and cardiac 
output in both men and women which persisted when corrected for other variables in 
the multiple regression models. Ejection fraction was weakly positively correlated with 
age in both sexes but only in women when corrected for other variables. Natori et al 
report an inverse association between age and LVM (but not LVM indexed for BSA) 
and LV volumes in men.[182] They however found no association between LVM or 
LVMI with age but an inverse association of left ventricular volumes with age in 
women. Maceira et al also reported that mass and volumes (both raw and corrected for 
BSA) decrease with age in men but only volumes and not mass do in women.[258] The 
reduction in myocardial mass with age could reflect genuine reduction in mass due to 
decreased activity as people age. This could also account for the decreased stroke 
volume and left ventricular volumes. It could also reflect the increasing likelihood of 
having cardiovascular disease or increased cardiovascular risk with increasing age. 
Those with higher LVM or volumes may have been excluded from the study due to 
increased cardiovascular risk or hypertension so the older participants who were 
imaged were a biased sub-population of relatively healthy older people. Because age 
plays a significant part in the CHD risk prediction those who were older and eligible 
may be a population with a lower BP to compensate for an increased age. 
 
Systolic BP was positively associated with LVM and LVMI in both men and women and 
the association remained when adjusted for other covariates in the regression model 
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(although the association was only weak). Diastolic BP was also associated with LVM 
and LVMI in both sexes on univariate analysis but only in women on multivariate 
analysis. The association of systolic BP and smoking with LVM supports the findings of 
the MESA study[187] although they found a stronger association between LVM and BP 
in men whereas we found a marginally stronger correlation in women. The association 
with systolic BP would be expected as increased BP results in increased cardiac work 
and is known to lead to hypertrophy although the strength of association we 
demonstrated was not as large as may be expected. Current smoking was 
independently associated with LVM and LVMI in women but not men. The association 
with smoking is also expected as smoking increases myocardial work, increases BP 
and acutely increases the stiffness of peripheral arteries.[279] BMI was moderately 
associated with LVM and LVM indexed for height in both univariable and multivariable 
anaylsis. The lack of or reduced association with LVM indexed for BSA is likely to be 
due to the association of BSA with BMI meaning the increased BMI is corrected for 
when indexed for BSA. The association of BMI with LVM would be expected as 
increased weight results in increased metabolic demand and therefore cardiac demand 
and is known to be a risk factor for cardiovascular disease. The stronger association of 
smoking and blood pressure in women compared to men may again reflect the 
different risk factor profile in the male population caused by the effect of male gender 
on risk discussed previously. 
 
In univariate analysis heart rate was negatively associated with LVM and LVMI in men 
but only LVM indexed for BSA in women. However in the multivariable models heart 
rate was independently associated with LVM and all LVMIs in both genders. The 
reason for this is unclear as decreased resting heart rate would be expected to be 
associated with better cardiovascular health and therefore decreased LVM. It is 
possible that the correlation is due to the presence of physiologically increased LVM 
due to exercise (which would be associated with a lower heart rate) rather than 
pathologically increased LVM. This is particularly the case as the study population was 
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a low CV risk group therefore likely to be a healthier fitter group where pathological 
changes are less prevalent. Lower heart rate could be acting as a surrogate marker for 
exercise. Heart rate was also inversely associated with end diastolic and end systolic 
volumes in both men and women. This hypothesis would be in keeping with a previous 
study where higher levels of intentional exercise were associated with greater left 
ventricular mass, end diastolic volume and lower resting heart rate.[280]  
 
The presence of exercise related physiological changes in LVM may explain why LVM 
and LVMI were not correlated with predicted CHD risk in men. However in women LVM 
and LVMI were associated with CHD risk which may suggest increased LVM was more 
pathological in women compared to men in our study. However the association was 
only weak. The MESA and Dallas Heart study groups have previously reported that 
LVM is more strongly associated with the incidence or risk of heart failure than CHD or 
stroke.[181, 191, 281] However greater left ventricular mass has been associated with 
low short term/high lifetime risk compared to low short term/low lifetime risk[186] so it 
may reflect lifetime risk (that we have not calculated) rather than short term risk. 
 
LV mass/left ventricular end diastolic volume (LVM/LVEDV) ratio is commonly used as 
a marker of concentric cardiac remodelling which is a pathological change. This was 
correlated with 10-year CHD risk in men and women. In women the correlation was 
stronger than for LVM or LVMI. In multivariable analysis LVM/LVEDV showed a 
positive association with systolic BP, and current smoking status in both men and 
women and additionally age, heart rate, diastolic BP, LDL and waist circumference in 
women only lending further support to the argument that this may be a better index of 
pathological changes to the myocardium. The positive association of heart rate with 
LVM/LEDV (compared to the inverse correlation seen with LVM and LVMI) suggests 
this measure may differentiate those with pathologically increased LVM from those with 
a physiologically increased LVM. The MESA study reported that LVM/LVEDV after 
adjustment for risk factors was associated with incident stroke and incident CHD[181, 
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191] again showing this may be a better measure of cardiovascular risk than LVM or 
LVMI and suggests that remodelling is a more important factor than mass alone.  
 
Cardiac volumes (end diastolic, end systolic and stroke) all decreased with age in both 
men and women. Age remained independently inversely associated with volumes on 
multivariable analysis. This may reflect decreasing physical activity with increasing 
age. Volumes were also inversely independently associated with heart rate in both men 
and women possibly reflecting a healthier lifestyle (causing a lower resting pulse). End 
diastolic volume, stroke volume and cardiac output was independently associated with 
BMI in both men and women (plus end systolic volume in men). This was most likely 
driven by the increased metabolic and circulatory demands in those who have a 
greater body mass. Ejection fraction was only independently associated with ex 
smoking status in men but with age (strongly) and systolic BP in women. The lack of 
independent associations in men may be caused by the relative healthy condition of 
men due to the biased population as discussed previously. Additionally the men appear 
to have more physiologically affected hearts (eg due to exercise) than the women as 
demonstrated by the differences in concentric remodelling discussed earlier. The 
associations with age and systolic BP in women would be expected as these are both 
cardiovascular risk factors. Women with a BNP >100pg/ml (the diagnostic threshold for 
heart failure) had a lower ejection fraction than those with lower BNP. This is in 
keeping with the diagnostic use of BNP for heart failure and shows a significantly 
elevated level can detect decreased cardiac function. Interestingly ejection fraction was 
weakly associated with predicted CHD risk in both men and women. This is the 
opposite direction of association to what would be expected as cardiovascular risk 
would be expected to be associated with impaired cardiac function. This may be a 
“statistical anomaly” due to looking for multiple associations or could again be due to 
the prominent effect of age on cardiovascular risk resulting in a population where older 
people are actually healthier (including having healthier hearts) to compensate for their 
age and still allow inclusion in the study. 
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6.4.3. MRA baseline results 
The vast majority of arterial segments scanned produced images suitable for analysis 
with only 0.6% of the images unsuitable. This provides further evidence that the 
technique is technically suitable to be used in screening. As would be expected in a 
healthy population the vast majority of segments were normal with no stenosis and of 
those that were abnormal most only had a mild stenosis (<50% of lumen). Only a very 
small number had an aneurysm. The highest abnormality rate was found in the coeliac 
artery with an abnormality rate about 75% higher than the next most affected segment 
(the abdominal aorta). The coeliac artery also had a higher proportion of more severe 
luminal stenosis (50-70% and 70-99%) than any other segment. This is likely to be due 
to an anatomical variant as the artery runs under the median arcuate ligament in a 
significant number of people which can result in compression of the artery particularly 
during expiration and can produce arterial narrowing.[267] This is a limitation of 
luminography where the vessel wall is not imaged as it is not possible to distinguish the 
anatomical variant from atherosclerotic disease. The coeliac artery also had the worst 
inter-observer correlation possibly reflecting the difficulty interpreting the images due to 
the anatomical abnormalities described above. For this reason whole body atheroma 
scores were calculated both including and excluding the coeliac arteries for illustrative 
purposes but all correlations with baseline risk factors and other imaging variables 
have used the scores without the segment included. 
 
When the coeliac artery was excluded 766 (50.6%) of people had normal standardised 
atheroma scores. Of those with abnormal scores 45% had just one segment affected 
although many people did have stenosis affecting more than one segment suggesting 
possible widespread subclinical disease. With the coeliac artery excluded the most 
commonly affected segment was the abdominal aorta where most of the abnormality 
was minor (less than 50%) followed by the left subclavian and right and left iliac 
arteries. As these are all vessels with a relatively large lumen and large flow it is 
possible that subclinical disease develops here before it does in smaller vessels. 
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However because they are larger vessels atheroma would have to be become quite 
thick before it caused significant stenosis and therefore clinically evident disease (a 
similar sized plaque in a small artery would cause proportionally more luminal 
stenosis). As follow up continues it will be interesting to see if such abnormality in large 
vessels is prognostically important. The standardised atheroma scores were very 
positively skewed as would be expected for a disease free and low risk population 
where the majority of people have normal vessels and only a minority have more 
extensive disease.  
 
The standardised atheroma score was positively associated with age, systolic blood 
pressure, total cholesterol, LDL and predicted 10-year CHD risk in men and women 
and additionally with triglycerides in women and inversely with SIMD in men. When 
adjusted for other baseline factors in a multivariable model there was an independent 
association with age, systolic BP, ex-smoking status, heart rate, current smoking status 
and inversely with SIMD decile. The strongest association was with age suggesting this 
is the greatest driver of the association with predicted CHD risk although the 
independent association with blood pressure, smoking status and SIMD in the 
regression model suggests that age is not the only factor driving the association with 
CV risk. Resting heart rate may be a surrogate marker for exercise which could explain 
its positive association with SAS. When those with a greater than 80th percentile of 
SAS were compared with those with a lower SAS age, systolic blood pressure, total 
cholesterol, LDL and predicted CV risk score were all higher in those with the greater 
SAS. This lends further support to the hypothesis that cardiovascular health is reflected 
in the stenosis seen on MR in the TASCFORCE study and is supported by findings 
from other studies. In the PIVUS study of 70 year-olds a similar atheroma score was 
associated with Framingham risk score, male gender, cigarette pack years, HDL, 
systolic and diastolic blood pressure and cigarette pack years.[208] Their participants 
were all aged 70 so it was not possible to examine correlation with age however this 
showed that in that age group atheroma burden was still associated with 
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cardiovascular risk independent of age. Their participants were of mixed risk factor 
profile (for example including people with hypertension). The older age and different 
risk factor profile is likely to be the cause for the higher level of atheroma detected in 
the PIVUS study (they detected atherosclerotic changes in 68% of participants)[211] 
compared to TASCFORCE. A whole body magnetic resonance angiography based 
score has also been associated with age, male sex and coronary artery disease status 
in a population of patients with long-standing diabetes.[282] 
 
The PIVUS group’s scoring system was subtly different as outlined above in section 
6.2.4. In particular they did not differentiate the degree of stenosis beyond greater or 
less than 50% (greater included occlusion). In a screening population such as ours the 
presence or absence of atherosclerosis may be more important than the exact degree 
of stenosis so a scoring system more similar to the PIVUS score may be more 
appropriate. This was explored by investigating the percentage of segments per 
participant with any abnormality. The percentage of abnormal segments was still 
associated with age, systolic BP, heart rate (women only), total cholesterol, LDL, 
triglycerides (women only) and predicted CHD risk score suggesting that the more 
intricate scoring system may not be required. When those with normal arteries were 
compared with those with any abnormality in any artery those with abnormality were 
older, had a higher systolic BP, higher total cholesterol, higher LDL, and higher CV risk 
than those without abnormality giving further weight to the argument that the presence 
of any stenosis may be as important as the degree of stenosis. 
 
There was no correlation with SAS score or number of affected arterial segments and 
BNP or any differences in BNP level between those with any arterial abnormality. 
Because the degree and amount of stenosis in this population is so low it is possible 
that any stenosis present is not sufficient to increase strain on the heart to stimulate 
release of the hormone. As with the BNP association with left ventricular measures our 
analysis is limited by the fact that only those with an above median BNP were imaged. 
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Therefore the range of BNP in those with SASs is narrower than would be the case in 
the general population which may have limited the ability to detect significant 
differences. 
 
Those with an SAS greater than the 80th percentile had a higher LVM/LVEDV than 
those with a SAS less than the 80th percentile indicating that those with more atheroma 
burden have greater presence of ventricular remodelling. They also had lower end 
diastolic and end systolic LV volumes and these cardiac measures were also inversely 
associated with the SAS. The lower LV end diastolic volume and end systolic volumes 
in those with higher SASs could reflect early abnormal cardiac remodelling. The 
increased LVM/LVEDV could be due to increased strain on the heart by the presence 
of atheroma (or poor vascular health predating the atheroma) or could be due to the 
shared risk factors for both. However the associations are likely to be affected by age 
which is independently associated with increased LVM/LVEDV and also the SAS. 
There is therefore likely to be some co-linearity. There are no published studies 
examining associations between MRA derived whole body atheroma burden and 
cardiac MRI derived LV measures making the combination of these techniques unique. 
 
6.5. Primary outcome – ability of BNP and left ventricular mass to predict 
cardiovascular events and death 
At 2 year follow up an equal number of combined cardiovascular events and deaths 
occurred in both the BNP and MRI/BNP groups with no significant difference in the 
event rates. The total person years at risk was slightly higher in the BNP group but this 
group also contained more people so the average years at risk per person was similar 
between the groups. More cerebral events occurred in the MRI/BNP group whereas 
more coronary events occurred in the BNP group. The small number of events in the 
short follow up time so far would be as expected in this population who are predicted to 
be at low risk of CVD. As a result of the small number of events it is not surprising that 
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there is no statistically significant difference in event rates between those with higher 
and lower BNP levels even though the event rate is marginally higher in the MRI/BNP 
group. As we would expect it is therefore unclear at this stage if BNP is a useful 
predictor of CV events in this low risk group. As the first projected follow up analyses is 
at 5 years hopefully the event rate will be sufficient for a meaningful analysis at that 
time. 
 
The numbers and rates of CV events in those with LVMI (using height, height1.7, 
height2.7 and BSA) and LVM/LVEDV ratio were slightly higher in those with 
measurements above the median compared to those below the median and in the top 
quartile compare to the lower quartile. However the confidence intervals for the rates 
are quite wide and overlap. Again this probably represents the small number of events 
at this stage of follow up. This is exacerbated by the fact that of the 17 events in the 
MRI/BNP group 10 occurred in people who were not able to tolerate or refused an MRI 
scan therefore only 7 occurred in people who had scan images. As follow up continues 
it will be interesting to see if the confidence intervals narrow and the differences 
between those with higher and lower LVMI become significant. It may be that any 
increase in CV event rate in those with higher LVM, LVMI and LVM/LVEDV reflects 
increased CV risk and may not add any further information: LVM and LVMI are 
associated with increased predicted CHD risk in women however not in men and 
LVM/LVEDV is associated with increased CHD risk in both men and women. Once 
more events have occurred as follow up continues multivariable statistical models will 
need to be used to determine if LVM or LVMI independently adds to the prognostic 
ability of existing clinical prediction tools. 
 
As discussed above more than half of the events in those who were eligible for an MRI 
scan (the MRI/BNP group) occurred in those who either declined, were unsafe to scan 
or were unable to complete a scan due to claustrophobia or technical reasons despite 
this group being smaller than those who underwent a scan. In a subgroup analysis of 
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those who were eligible for a scan (MRI/BNP group) comparing those who did and did 
not complete a scan there was a trend of a higher rate in those who did not have a 
scan compared to those who did although the low numbers of events make it difficult to 
draw any firm conclusions. The subgroup (of the MRI/BNP group) who did have a scan 
had less men, a small but statistically significant lower heart rate, systolic and diastolic 
blood pressure, and higher HDL compared to those who completed a scan. However 
the median predicted risks (using both ATPIII and ASSIGN) were not different between 
the groups. Any difference in rates could reflect the health behaviour of those who 
were willing to have a scan which would not be picked up directly by the risk scores: 
were people willing to have a scan more “health conscious” and therefore took a 
greater interest in their health than those who did not have a scan?  
 
6.6. Ability of whole body MRI angiogram to predict cardiovascular 
events 
The cardiovascular event rate in those with any presence of atheroma had a trend 
towards being higher compared to those who had no evidence of atheroma however 
the confidence intervals were wide and overlapping. As discussed above in relation to 
cardiac parameters this probably reflects the relatively small numbers of events that 
have occurred so far particularly in those who completed a scan and as follow up 
continues it will be observed if differences are significant when further analysis is 
performed at 10 and 15 years follow up. Again it may be that any increased CVE rates 
associated with presence of atheroma merely reflects the association of increased CV 
risk associated with atheroma and modelling will need to account for confounding 
factors to see if the atheroma score adds to the predictive ability of the clinical scores. 
As follow up continues this will be become apparent. 
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6.7. Conclusions 
The main short term aim of this study was to establish recruitment strategies, and to 
recruit a population of sufficient size such that defined end points could be used at 5, 
10 and 15 years to evaluate their strengths or otherwise to predict CV events. This has 
been achieved. The phenotypic and genotypic data has been recorded, and tissue 
samples sored for future analyses. MRI data has also been recorded in detail. Data 
linkage of the population has been established. 
 
As expected we have not demonstrated the ability of left ventricular mass determined 
using magnetic resonance imaging to predict cardiovascular disease so early in follow 
up in a population at low or intermediate risk of CHD. Although those with a left 
ventricular mass in the upper quartile for their gender had a trend towards a higher rate 
of cardiovascular events this did not reach statistical significance. This may be due to 
the low number of events that have occurred so far at this early stage of follow up. As 
follow up using electronic record linkage continues and further events occur we will 
establish whether increased left ventricular mass or concentric remodelling predicts or 
not cardiovascular events in future analyses. 
 
Again as expected we have not demonstrated the ability of presence of subclinical 
arterial stenosis detected using whole body contrast enhanced magnetic resonance 
angiography to predict clinical CV disease in the low or intermediate risk population. As 
with the left ventricular results above it is possible that the low number of events so far 
has led to a non-significant result and further follow up may show a significant ability to 
predict events. 
 
We have also not demonstrated the ability of BNP to identify those at low or 
intermediate risk of CHD who will develop clinical CV disease. Again the low number of 
events so far makes it hard to draw any firm conclusions. There was a trend towards 
more cerebral (stroke) events in those with a higher BNP level and more coronary 
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events in those with lower BNP levels. Interestingly BNP levels were associated with 
predicted CHD and CVD risk and increasing age, female sex, ex-smoking status, lower 
heart rate, lower total cholesterol and higher HDL were all independently associated 
with BNP levels. This association with traditional risk factors gives some support to 
evidence from other studies that BNP is associated with CV risk however at this stage 
it is not clear if BNP is a suitable initial screening test for CV disease particularly to 
exclude those who will not develop clinical disease who we would aim to reassure that 
they are truly low risk. As CV events accumulate during continued follow up it may be 
that a benefit of measuring BNP in predicting CV disease is demonstrated. 
 
We have characterised the normal values and distribution of a range of left ventricular 
structural and functional parameters derived using a steady state free precision 
sequence MRI in a population at low or intermediate risk of CHD. Left ventricular mass 
(LVM) and left ventricular mass index (LVMI) was significantly higher in men than 
women. Left ventricular end diastolic volume, end systolic volume, stroke volume and 
cardiac output (including when indexed for body size) were all significantly higher in 
men compared to women and ejection fraction was higher in women. Age was weakly 
but significantly inversely associated with LVM and LVMI (except when indexed by 
height2.7) in men but only with LVM and LVM indexed by height in women. These 
associations persisted in a multivariable regression model suggesting that the 
association may be independent of other changes in CV risk that accompany age. Age 
was also associated with decreasing LV volumes, stroke volume and cardiac output in 
both men and women which persisted when corrected for other variables in the 
multiple regression models. This may suggest that age specific normal values for MRI 
derived cardiac measurements may be required. 
 
LVM/LVEDV ratio (a measurement of concentric remodelling) was much more strongly 
correlated with predicted CHD risk than LVM or LVMI suggesting that concentric 
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remodelling may be a more important determinant of CV risk than mass alone by 
differentiating pathologically from physiologically increased LVM. 
 
The vast majority of arterial segments imaged using whole body contrast enhanced 
magnetic resonance angiography in participants at low or intermediate predicted risk of 
CHD were normal with no stenosis. Of those that were abnormal most only had a mild 
stenosis. The standardised atheroma score was positively associated with predicted 
10-year CHD risk in men and women. Age, systolic BP, ex-smoking status, heart rate, 
current smoking status and SIMD decile were independently associated with SAS. The 
strongest association was with age suggesting this is the greatest driver of the 
association with predicted CHD risk.  
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7. Further work 
 
7.1. Further follow up to 20 years 
It is planned to continue to obtain further follow up data on hospital admissions and 
diagnoses, deaths and prescribing at regular intervals with planned analyses at 5, 10 
and 20 years from recruitment. As this data becomes available and more CVEs and 
deaths occur in the cohort it will be possible to determine whether the screening 
programme using BNP and MRI imaging is able to improve our prediction of CVEs and 
death. 
 
A number of possible challenges could influence the follow up period. There is an 
increasing drive to treat more patients in the community and avoid hospital admissions. 
As the events and diagnoses are detected by contact with hospitals the change in 
policy could potentially affect the sensitivity of the follow up method. However the 
nature of cardiac and stroke disease is likely to continue to require contact with hospital 
at least in the acute phase the change in focus of locus of care is unlikely to 
significantly affect the accuracy of follow up. Electronic access to GP data would be 
useful in the future, to ensure complete follow up in this population. 
 
Another possible challenge is that of potential changes in policy about primary 
prevention. It is possible that offering statins to a wider range of the population (for 
example over a certain age or those at intermediate risk) may be advised at some point 
in the near future. This could modulate the effect of a prediction model and reduce the 
overall event and death rate in the cohort. We may have to repeatedly reanalyse risk 
as more becomes known providing shrinkage in the truly ‘low risk’ group over time. 
However the acquisition of prescribing data for the follow up will allow this factor to be 
incorporated in the data analysis. It may also bring an opportunity to look at the effect 
of medication on risk. It is likely that a proportion of people who are offered medication 
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may not take it allowing observational comparisons to be made between those who 
take medication and those who do not. As this would be observational data and the 
taking or not taking of CV drugs may be associated with other health behaviours such 
data would have to be interpreted cautiously. 
 
7.2. Health economics of the technique as a screening programme 
If follow up shows that the screening method is efficacious at improving risk detection 
and therefore potentially improving how we target primary preventive medication the 
economics of the approach would need to be investigated. MRI scans are a relatively 
expensive investigation and would need resources that would either need to be 
increased or diverted from other uses. Analysis of the efficacy once more end points 
have occurred will help determine how many scans would be required on a population 
basis to improve risk prediction. The cost of the scanning and blood tests could then be 
calculated. The comprehensive follow up data including data of all hospital admissions 
and prescriptions will allow future analyses of hospital usage costs (including 
investigations) and prescriptions to be modelled. 
 
7.3. A “Scottish Framingham” 
The recruitment of a well characterised cohort of the Tayside population including the 
ability to follow up for future health events and prescriptions gives potential to further 
investigate the aetiology and progression of cardiovascular diseases. Additionally the 
development of other diseases which have a vascular component such as dementia 
can be studied. This makes the study cohort an excellent research resource similar to 
the Framingham cohort.  
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8. Publications and Presentations 
 
8.1. Publications 
Gandy SJ, Lambert M, Belch JJF, Cavin ID, Crowe E, Littleford R, MacFarlane JA, 
Matthew SZ, Martin P, Nicholas RS, Struthers AD, Sullivan F, Waugh SA, White RD, 
Wier-McCall JR, Houston JG.  Technical assessment of whole body angiography and 
cardiac function within a single MRI examination. Clinical Radiology 2015; 70: 595-603. 
 
8.2. Oral presentations 
Magnetic resonance imaging derived left ventricular parameters and association with 
cardiovascular risk factors – University of Dundee Annual Student symposium, 
Dundee, 12th June 2015. Awarded prize. 
 
Screening for asymptomatic cardiovascular disease with contrast enhanced MRI: 
association of left ventricular mass with whole body atheroma burden, cardiovascular 
risk and B type natriuretic peptide – European Congress of Radiology, Vienna, March 
2015. 
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Appendix 2 – Participant information sheet (Cardiovascular risk assessment by BNP) 
THE TASCFORCE PROJECT 
Tayside Screening for risk of Cardiac Events  
 
Participant Information Leaflet No 1 (PIL 1 Version 9)  
Cardiovascular Risk assessment by BNP 
 
 
You have been sent this information sheet because you have expressed an interest in 
taking part in the TASCFORCE Project. We aim to enroll 5,000 Tayside and Fife men 
and women into this study. Since you are aged 40 years or over and are not known to 
have diabetes, hypertension, stroke, heart or blood vessel disease, you may be 
suitable to take part. Before you decide whether to take part, it is important for you to 
understand why this research is being done and what it will involve. Please take time to 
read the following information and discuss it with others if you wish. Ask us if there is 
anything that is not clear or if you would like more information.  
 
 
PURPOSE OF THE TASCFORCE PROJECT 
Heart attack and stroke are still amongst the most common causes of illness and death 
in Scotland, despite major advances in preventive medicine.  National guidelines are in 
place to assess whether an individual is at risk of heart and blood vessel disease, and 
thus requires treatment.  We believe, however, that some people may still be at risk, 
but that the current methods of assessments fail to detect this. The project has been 
designed to identify these people, to screen for early signs of heart disease and to find 
out how effective new screening techniques are in predicting the risk of heart disease 
so that it can be prevented or treated at an early stage. 
  
The project will be carried forward in two stages:  
 
1. Assessment of cardiovascular (heart and blood vessel) risk. 
 
2. Screening for early signs of cardiovascular disease by Magnetic Resonance 
Imaging (MRI, heart and blood vessel scan) in those found to be at risk. 
 
At the first stage of the project, we wish to identify those who may be at, as yet 
undetected, cardiovascular risk by measuring a blood chemical called BNP. The level 
of BNP in the blood shows how well the heart is working and helps us to assess risk.  
This information sheet tells you about this first stage of the TASCFORCE project.  If 
you are selected to continue to a further stage a separate information sheet and 
explanation will be given at the time before asking for your consent for further 
participation.  
 
How will you know that I may be at risk? 
Your blood pressure, weight, height, and levels of blood glucose and cholesterol will be 
measured. These measurements, along with whether you smoke and have a family 
history of heart or stroke disease will be used to calculate your risk of developing heart 
disease. If you are found to be at risk using the standard methods of assessment, we 
will advise you and discuss what next to do to ensure you receive treatment. If you do 
not seem to be at risk using standard methods, then we will take a blood sample to 
measure a substance called BNP which measures risk.   
 
 
Version 9 (14th November 2012) 
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What will I be required to do? 
You will be asked to attend for one visit to Ninewells Hospital, or to your GP’s surgery, 
or other suitable place. Your travelling expenses can be reimbursed You will have the 
opportunity to discuss the study and to receive answers to any questions you may 
have before being asked to sign a form consenting to take part. This visit is to find out if 
you are suitable to take part in the study and to assess your risk of developing heart 
disease. 
The study nurse will: 
• Ask you about your present and past illnesses and what medicines you are taking. 
• Ask you whether you smoke and whether any members of your family have had 
heart disease. 
• Carry out an ECG (this is a tracing of your heart activity). 
• Measure your blood pressure, weight, height and waist circumference. 
• Take some blood (20 ml - about 4 teaspoons) for various tests. This blood will be 
used to check your blood glucose and cholesterol level, and your level of BNP. 
These tests will be done right away at the bedside.  The rest of the blood will be 
stored for future research into heart and blood vessel disease as part of a Bio-
bank in the Institute of Cardiovascular Research. 
• Give you advice and leaflets on how to change your lifestyle to reduce your risks. 
• Take a separate blood sample 9ml for genetic study (optional) if you agree to it.   
A separate information sheet is attached for the genetic sub-study. 
 
If you need treatment under the current recommendations, we will advise you of this, 
and arrange for you to see your General Practitioner. 
 
If your level of BNP is raised you will be offered a MRI scan of your heart and blood 
vessels.  This will be explained to you at the time and a separate information sheet will 
be given to you before asking for your consent. If your level of BNP is low then you will 
be informed, your participation will be gratefully acknowledged but will not be required 
beyond this first visit. 
 
We will ask your permission to allow us to receive from or pass on any relevant 
information to your GP for the duration of the study at 2, 5, and 10 years and for a 
period up to twenty years beyond the study end. We will ask your permission to receive 
information on any hospital admissions you may have and their diagnoses and to be 
notified in the unlikely event of your death for a period of up to 20 years. We would also 
ask you to allow us to receive information regarding any health problems relating to 
your heart or blood vessels. This will allow us to assess how effective our screening 
techniques are in predicting and in preventing heart and blood vessel disease and help 
increase our understanding of these diseases. This information is gathered from the 
Scottish Office’s Information and Statistics Division (ISD) via the Health Informatics 
Centre (HIC), University of Dundee. All your information is anonymised.  
Will I be given the results of any tests that you do? 
If you have given a blood sample for DNA, neither you nor your GP will be given the 
result. You will be informed of your blood pressure, cholesterol levels, and whether 
your BNP is high or low. 
 
What are the potential advantages of taking part in the study? 
You will have the opportunity to reduce your cardiovascular risk by receiving lifestyle 
management advice and leaflets on any modifiable risks that you may have. If from any 
of the tests that we do, we feel you should have further investigation, the results will be 
sent to your GP so you can be treated according to current clinical practice. There is no 
guaranteed benefit from taking part in the study but your participation contributes to 
medical science and possible future benefits. 
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What are the potential disadvantages of taking part in the study? 
Blood sampling: Taking blood can be briefly uncomfortable and can on occasion 
cause some bruising. 
 
 
 
 
How will my information be stored? 
Any information we obtain from you and your health records will remain strictly 
confidential.  Information will be stored securely under conditions in keeping with the 
Data Protection Act 1998. To ensure confidentiality we will allocate a code (not your 
name) to your records and to your blood samples. We will keep your personal details 
(name and address) separate from the information collected but linked by your code.  
Only individuals directly involved with the study will have access to this information. 
Reports or publications of research findings will not contain information through which 
you can be identified. We may be required to allow regulatory authorities, who ensure 
that research is being carried out in the correct manner, to inspect your records but 
they will not have access to your name or address.   
 
What if anything goes wrong? 
Indemnity is provided by the NHS. The University of Dundee covers any non-negligent 
harm that occurs due to the design of the clinical trial 
 
What are my rights? 
Participation in this study is voluntary and you are free to withdraw from the study at 
any time without having to give a reason. This will not affect your medical care.  If you 
decide to take part you will be given this Information Sheet to keep along with a copy of 
the Consent Form that you would be required to sign. If you should ever have any 
concerns about this study or the way it has been carried out, you should contact: 
 
Dr Roberta Littleford, Trial Manager    01382 383231/633963 
Professor Jill JF Belch, Principal Investigator 01382 383092 
The East of Scotland Research Ethics Service REC 1 has examined this proposal and 
has raised no objections from the point of view of medical ethics. 
 
Thank you for taking time to read this information sheet. 
One of the study nurses will telephone you in the next week to answer any questions 
that you may have and to make an appointment for you if you decide to take part. 
 
Roberta Littleford  
Trial Manager,  
The TASCFORCE Project 
The Institute of Cardiovascular Research 
Vascular & Inflammatory Diseases Unit 
Ninewells Hospital & Medical School, Dundee DD1 9SY 
Telephone 01382 383231/633963 
E- mail: tascforce@dundee.ac.uk 
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Appendix 3 – Participant consent form (BNP study) 
THE TASCFORCE PROJECT 
Tayside Screening for risk of Cardiac Events  
Consent Form - BNP Study / PIL No.1 (Version 7) 
This form must be completed and signed by the research participant in the presence of 
someone with knowledge of the research designated by the Principal Investigator. 
   Initials 
I have read and understood the patient information sheet PIL 1 (Version 
6). 
Yes □ No □  
I have had the opportunity to discuss the study and to ask questions. All 
my questions have been answered to my satisfaction. 
 
Yes □ No □ 
 
I understand that my participation in the study is voluntary and that I am 
free to leave the study at any time without having to give a reason and 
that this will not affect my medical care in any way. 
 
Yes □ No □ 
 
I have spoken to Dr, Mr. Mrs, Miss _________________________________  
I agree that members of the research team and the regulatory 
authorities can access my medical records and any information collected 
during the research project. 
Yes □ No □  
I agree that members of the research team can contact both me and my 
GP about any relevant information pertaining to the study now, and in 
the future, even if at any point I decide not to continue with the study. 
Also, 
 
Yes □ No □ 
 
I agree that you may receive information on any hospital admissions that 
I may have now, and in the future, even if at any point I decide not to 
continue with the study or if you find that I am not suitable to take part. 
 
Yes □ No □ 
 
I agree that the information or blood samples that I provide can be used 
for future medical research into health, illness and medical treatment. 
This research will be approved by an Ethics committee. 
 
Yes □ No □ 
 
I agree for the storage of my blood sample as part of the Bio-bank study 
for up to 10 years. 
Yes □ No □  
If eligible, I agree to be informed of a future intervention study.  Yes □ No □  
I agree to give a sample of blood for DNA which can be stored for up to 
10 years. 
Yes □ No □  
I have read and understood the HEALTHFORCE patient information 
sheet PIL (Version 2) and if eligible would like to take part.  
Yes □ No □  
I agree to the research team contacting me in the future about other 
research projects. 
Yes □ No □  
I agree to take part in the above study. Yes □ No □  
Participant Name: (Block Letters) 
_____________________________________________________ 
Signature: _______________________________________________  Date: 
_________________ 
Tel Contact Numbers: Home ________________________________  Work: 
_________________ 
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Study Nurse Signature: _______________________________ Date: _________________ 
Appendix 4 – Case report form (CRF) 
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Appendix 5 – Participant information leaflet (MRI scan) 
 
THE TASCFORCE PROJECT 
Tayside Screening for risk of Cardiac Events  
Participant Information Leaflet No 2 (PIL 2 Version 3) - MRI study 
You have already agreed to participate in the TASCFORCE study. You are now being 
invited to have a scan of your heart and blood vessels using Magnetic Resonance 
Imaging (MRI) because at the first stage of the project you were found to have an 
increased blood level of BNP and may be more at risk of cardiovascular disease than 
those with a lower level. Before you decide whether to take part, it is important for you 
to understand why this research is being done and what it will involve. Please take time 
to read the following information. Ask us if there is anything that is not clear or if you 
would like more information. 
We believe that detection of early signs of heart disease would allow for early 
treatment and ultimately prevent cardiovascular events (heart attack and stroke). We 
aim to establish that MRI is an effective screening technique for detecting early signs of 
heart disease. 
The cardiac MRI scan creates 'pictures' of the heart and blood vessels which can be 
examined for any signs of disease. We have chosen this method of screening because 
it does not use radiation (like x-rays) and is safe and non-invasive. To ensure that the 
pictures are clear and to provide information about blood supply to the heart tissues, an 
injection contrast agent (gadolinium) is given. Gadolinium looks clear like water and is 
non-radioactive and has been used for many years without serious complications in 
thousands of patients. A specialist will examine the scans for any signs of disease. 
What will I be required to do? 
You will receive an appointment either by telephone call, letter or e-mail and be sent 
directions to attend the MRI department of the Clinical Research Centre, Ninewells 
Hospital, Dundee. If you are a woman of child bearing potential you will be asked to 
provide a urine specimen which you can either bring with you (a specimen bottle will be 
provided) or you could provide a sample at the beginning of your MRI clinic visit. A 
pregnancy test will be performed to ensure your safety. A positive result will exclude 
you from having an MRI scan (and eye x-ray if applicable.) 
Before your scan you will meet one of the research team who will conduct a quick 
  
 
310 
check that you are still eligible to have the scan and to consent you.  You will then be 
seen by the radiographer, the person taking your scan, and she/he will help you to 
complete a checklist about pieces of metal or other objects that might stop you having 
the scan.  
If at Visit 1 you are found to have a history of a penetrative eye injury or exposure to 
metal fragments in your eye(s) you will be asked to consider having an eye x-ray prior 
to your MRI scan to establish safety. This can be performed at the main x-ray 
department at the same visit prior to your MRI scan. You will be taken or directed to the 
x-ray department. If the radiology staff establishes that you are unsafe to scan you will 
not have your MRI and you will be free to go. With your consent, we will write to your 
GP informing them of your MRI safety status, as this information may be of benefit for 
your future health care needs.  
You will then be asked to change into a gown for the scan. After being prepared for 
your scan, which will involve placing a cannula or small tube into your arm, to give the 
contrast agent, you will be asked to lie up on the scanning table and then will be moved 
into the centre of the scanner (the scanner is shaped like a big doughnut). During the 
scan, which takes around 45 minutes, you will be able to speak to the radiographer. 
The scan will take pictures of your heart and blood vessels. As the scan is noisy you 
will be wearing hearing protection.  After you have completed the scan you are free to 
go home. You can drive if you need to. A specialist will examine your scan at a later 
date for any signs of disease and will measure your left ventricular mass. 
This visit should take no longer than one and half hours. . 
Will I be given the results of the scan? 
Your scan will be examined by a radiologist. Prior to your scan you will be asked to 
give consent to be informed of any incidental finding found during your scan and agree 
that members of the research team can contact your GP and make any referral 
required for further investigation. The necessary steps would be taken for you to be 
treated according to current clinical practice.  If no abnormalities requiring treatment 
are found, we will send you a standard results letter.  
What are the potential advantages of taking part in this stage of the project? 
By having an MRI scan, the potential is there to detect established heart and blood 
vessel disease which may otherwise not have been detected and allows for early 
management. This project may introduce a treatment phase and we will ask for your 
permission to be invited into this next phase. There is no guaranteed benefit from 
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taking part in the study but your participation contributes to medical science and 
possible future benefits. 
What are the potential disadvantages of taking part in the study? 
1. Eye (orbital) x-ray: (If this required and you give consent). This x-ray will 
be taken when you are either sitting or lying down and will take about 5 minutes 
to perform. This procedure will involve you being exposed to radiation, but it is 
low and is calculated to be equivalent to a chest x-ray.  
2. MRI scanning: This type of scan is very safe and does not use radiation. Some 
people, when being scanned, may feel a bit closed in but you will be in constant 
contact with the person performing the scan and you can come out at any time. 
The scanner is a bit noisy but you will be given ear protection which also plays 
music.  The insertion of the cannula (needle) for the contrast medium can be 
briefly uncomfortable and can on occasion cause some bruising. 
3. Contrast Medium: Gadolinium is the contrast agent used in the cardiac MRI; it 
provides greater contrast between normal tissue and abnormal tissue in the 
heart. Gadolinium looks clear like water and is non-radioactive. In a cardiac MRI 
scan, a contrast agent injected into the bloodstream can provide information 
about blood supply to the heart tissues. Usually, several scans are taken: one 
before the contrast agent is injected and at least one after. The pre-contrast and 
post-contrast images are compared and areas of difference are highlighted. 
Gadolinium has been used for years without any serious complications in 
thousands of patients. The FDA declared Gadolinium safe for use in MRI in 1988. 
A few side effects, such as mild headache, nausea and local burning, and on 
occasion a slight local skin rash can occur.  Very rarely (less than one in a 
thousand), patients are allergic to Gadolinium. The Gadolinium used in MRI is 
many times safer than the iodine type contrast used in CT scans. 
How will my information be stored? 
Any information we obtain from you and your health records will remain strictly 
confidential.  Information will be stored securely under conditions in keeping with the 
Data Protection Act 1998.  
There will be two sets of information obtained after you have had your MRI scan. One 
set will be the MRI scan images (and/or eye x-ray, if applicable) and the other, the 
research data obtained from those images The MRI images (eye x-ray) obtained will be 
stored indefinitely using your name and unique hospital record number within the NHS 
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clinical system and can be made available to specialist doctors for your future health 
care needs. Your research data will be stored using a unique study code which is non-
identifiable and held on password protected University of Dundee secure databases.  
Only individuals directly involved with the study will have access to this information.  
Reports or publications of research findings will not contain information through which 
you can be identified.  We may be required to allow regulatory authorities, who ensure 
that research is being carried out in the correct manner, to inspect your records but 
they will not have access to your name or address.  
The company who is providing the MRI scanner (Siemens Ltd) may be sent the images 
in an anonymised form to help them in the future development of the MRI imaging. 
What if anything goes wrong? 
Indemnity is provided by the NHS. The University of Dundee covers any non negligent 
harm that occurs due to the design of the clinical trial.  Any harm that may occur by the 
use of medication is covered by the manufacturer under the Consumer Protection Act. 
What are my rights? 
Participation in this study is voluntary and you are free to withdraw from the study at 
any time without having to give a reason. This will not affect your medical care.  If you 
decide to take part you will be given this Information Sheet to keep along with a copy of 
the Consent Form that you would be required to sign. If you should ever have any 
concerns about this study or the way it has been carried out, you should contact: 
Dr Roberta Littleford, Trial Manager     01382 633963 
Professor Jill JF Belch, Principal Investigator    01382 
632457 
Professor  Graeme Houston, Consultant Radiologist  01382 632651 
The Tayside Committee on Medical Research Ethics has examined this proposal and 
has raised no objections from the point of view of medical ethics. 
Thank you for taking time to read this information sheet. 
Roberta Littleford  
Trial Manager, the TASCFORCE Project 
The Institute of Cardiovascular Research 
Vascular & Inflammatory Diseases Unit 
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Ninewells Hospital & Medical School, Dundee DD1 9SY 
Telephone 01382 633963 
Appendix 6 – Participant consent form (MRI scan) 
THE TASCFORCE PROJECT 
Tayside Screening for risk of Cardiac Events  
Consent Form - MRI Study / PIL No. 2 (Version4) 
 
This form must be completed and signed by the research participant in the presence of 
someone with knowledge of the research designated by the Principal Investigator. 
  Initials 
I have read and understood the participant information leaflet 
PIL 2 (Version 4). 
Yes No  
   
I have spoken to Dr, Mr. Mrs, Miss _________________________________  
   
I have had the opportunity to discuss the study and to ask 
questions.  
All my questions have been answered to my satisfaction. 
 
Yes No 
 
   
I agree to have MRI with contrast. Yes No  
 
I agree, if required, to have an x-ray of my eyes prior to MRI 
scan for MRI safety reasons.  
 
Yes No 
 
 
I understand that by undergoing an eye x-ray, the results may 
exclude me from having an MRI for safety reasons.  
 
I agree that my GP be informed of MRI safety status. 
    
 
 
Yes        No 
 
 
Yes No 
 
 
I understand that my participation in the study is voluntary and 
that I am free to leave the study at any time without having to 
give a reason and that this will not affect my medical care in any 
way. 
 
Yes No 
 
 
I understand that my identifiable MRI images of my heart and 
blood vessels will be stored within the NHS clinical system and 
will be available to specialist doctors looking after me in the 
future.  
 
 
Yes        No 
 
   
I agree (if applicable) to supply a urine sample for pregnancy 
testing. I understand that a positive result will exclude me from 
having eye x-ray and MRI scan.  
N/A  
Yes No 
 
I agree to be informed of any incidental finding found during my 
MRI scan and agree that members of the research team can 
contact both me and my GP and inform any referral specialist 
required to carry out further investigations.  
 
 
Yes No 
 
   
I agree that the images of my heart and blood vessels may be 
sent to Siemens Ltd in fully anonymised form to aid future 
development of MRI Imaging. 
 
Yes No 
 
   
I agree to take part in the above study. Yes No  
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Participant Name: (Block-Letters) 
__________________________________________________________ 
Signature: ___________________________________________ Date: __________________ 
Tel Contact Numbers: Home _____________________________ Work: _________________ 
Study Nurse Signature: _________________________________ Date: __________________ 
  
 
 
